{"meta":{"query_hash":"60e1f68fa11d","filters":{"venue":"Lung Cancer"},"cohort_total":361,"direct_labels_cover":0,"predictions_cover":361,"exported":361,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/60e1f68fa11d","api":"https://metacan.xera.ac/api/v1/cohort?venue=Lung+Cancer"},"results":[{"id":"W1499085340","doi":"10.1002/9781118468791.ch12","title":"Staging of the Mediastinum","year":2014,"lang":"en","type":"other","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mediastinoscopy; Mediastinum; Medicine; Lung cancer staging; Radiology; Lung cancer; Stage (stratigraphy); Mediastinal lymph node; Lymph node; Modalities; Cancer; Pathology; Metastasis; Internal medicine","score_opus":0.00740995929479451,"score_gpt":0.29900963663890606,"score_spread":0.2915996773441116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1499085340","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05340255,0.12537394,0.026976727,0.0054347613,0.002461304,0.0005112601,0.0047276756,0.000895645,0.78021616],"genre_scores_gemma":[0.52470315,0.15549572,0.06777944,0.0052898685,0.0032192299,0.0004068663,0.008674754,0.00053818594,0.23389275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981374,0.000049009766,0.000021200589,0.000023655295,0.00006760226,0.00002484848],"domain_scores_gemma":[0.99976546,0.00003734824,0.000040290022,0.000025254747,0.00008075062,0.00005087257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054385647,0.00040553222,0.00021378908,0.0012743396,0.00037139287,0.00078033627,0.00036502478,0.00035608216,0.015999272],"category_scores_gemma":[0.0012471017,0.00008536457,0.00029238244,0.00082914555,0.00037771263,0.0005454024,0.00057866477,0.00051969656,0.0068392935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002027918,0.000078637844,0.03819189,0.0009353374,0.00003956981,0.0016930008,0.00028492042,0.00064816617,0.0086983135,0.010996773,0.1084567,0.82977384],"study_design_scores_gemma":[0.000031015017,0.00015848319,0.04600255,0.0013958276,0.000060871036,0.014093254,0.00024404787,0.0007690605,0.0041508484,0.006067954,0.9270014,0.000024709885],"about_ca_topic_score_codex":0.0020731713,"about_ca_topic_score_gemma":0.004163857,"teacher_disagreement_score":0.015999272,"about_ca_system_score_codex":0.0005656583,"about_ca_system_score_gemma":0.00086378725,"threshold_uncertainty_score":0.053522944},"labels":[],"label_agreement":null},{"id":"W1500680442","doi":"10.1002/9781118468791.ch7","title":"Detection and Treatment of Preneoplastic Lesions","year":2014,"lang":"en","type":"other","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung cancer; Medicine; Radiology; Natural history; Lung; Biopsy; Cancer; Disease; Pathology; Internal medicine","score_opus":0.010573428309209548,"score_gpt":0.29656285781861874,"score_spread":0.2859894295094092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1500680442","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082345754,0.38630906,0.0329,0.013561438,0.0021973343,0.00081200793,0.003472996,0.0013807919,0.47702068],"genre_scores_gemma":[0.47911718,0.31553602,0.03439624,0.0063345353,0.0026868333,0.00043301904,0.0053589204,0.00030985955,0.15582742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997341,0.00004875651,0.000024729674,0.000041060623,0.000119841134,0.000031402178],"domain_scores_gemma":[0.99975747,0.000040624323,0.000056539157,0.000025704212,0.00006719225,0.000052455198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039035187,0.00030954924,0.00030317684,0.0011268196,0.00038361896,0.00066770666,0.00033425787,0.0004413554,0.0114235785],"category_scores_gemma":[0.0010094484,0.00008872934,0.0004090569,0.0005944485,0.00036541073,0.00045326215,0.00056095666,0.00069704896,0.0045915595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019858204,0.00020204272,0.01297604,0.0012849845,0.000040975152,0.0015871262,0.00009702319,0.00036386563,0.014486224,0.0056045963,0.038052898,0.92510563],"study_design_scores_gemma":[0.000049912414,0.00034831508,0.026891211,0.0008351542,0.00007371696,0.014079164,0.00016156978,0.00055838097,0.017861808,0.005183163,0.93393046,0.000027234886],"about_ca_topic_score_codex":0.0014462493,"about_ca_topic_score_gemma":0.0030970518,"teacher_disagreement_score":0.0114235785,"about_ca_system_score_codex":0.0005609454,"about_ca_system_score_gemma":0.0007811744,"threshold_uncertainty_score":0.038215697},"labels":[],"label_agreement":null},{"id":"W1529488333","doi":"10.1016/j.lungcan.2013.11.006","title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; Chemotherapy; Odds ratio; Meta-analysis; Randomized controlled trial; Proportional hazards model; Confidence interval; Cancer; Colorectal cancer","score_opus":0.10246975773111995,"score_gpt":0.409869584780272,"score_spread":0.3073998270491521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529488333","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29605213,0.67185724,0.018359574,0.001219847,0.0027251816,0.0009276373,0.0059060846,0.0006405512,0.002311761],"genre_scores_gemma":[0.96966434,0.021120511,0.004400049,0.0009038673,0.00033005132,0.0005190424,0.002097746,0.00016034654,0.0008040704],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96582454,0.025105547,0.0036639057,0.0034191539,0.0012971023,0.00068976154],"domain_scores_gemma":[0.9616249,0.028694881,0.0040811566,0.0041675,0.0008903402,0.00054117915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028857801,0.003851668,0.014920913,0.0022445428,0.0007111904,0.0030779673,0.0024902958,0.0025936645,0.004171007],"category_scores_gemma":[0.05808326,0.0023395715,0.05849677,0.002808215,0.0009345494,0.002112453,0.0017401594,0.0041192556,0.0005378428],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019733973,0.000021306207,0.004312175,0.00499086,0.96786124,0.000046380366,0.000019144496,0.0010167134,0.00022266143,0.00007074569,0.00024373039,0.0014611367],"study_design_scores_gemma":[0.0054335645,0.00054914935,0.0041314363,0.0002647295,0.9879615,0.000061188955,0.00001624928,0.0006110286,0.00014127781,0.00032597297,0.00048343852,0.000020457985],"about_ca_topic_score_codex":0.0046113753,"about_ca_topic_score_gemma":0.006807564,"teacher_disagreement_score":0.028857801,"about_ca_system_score_codex":0.0018405766,"about_ca_system_score_gemma":0.001216841,"threshold_uncertainty_score":0.15261644},"labels":[],"label_agreement":null},{"id":"W1550684373","doi":"10.1016/j.lungcan.2015.04.007","title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Spinal cord compression; Internal medicine; Incidence (geometry); Bone metastasis; Oncology; Retrospective cohort study; Cohort; Radiation therapy; Surgery; Cancer; Metastasis; Spinal cord","score_opus":0.03881720652294452,"score_gpt":0.42509689147911367,"score_spread":0.38627968495616916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550684373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95624787,0.029261481,0.00037716056,0.0020416882,0.00008791036,0.00002543008,0.0023059782,0.000022976157,0.009629553],"genre_scores_gemma":[0.9964405,0.0025001008,0.00004331822,0.00007016311,0.00008164142,0.0000029748012,0.000525308,0.000002349615,0.0003336675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904865,0.00032943062,0.00010315405,0.0000883348,0.00029720736,0.00013319675],"domain_scores_gemma":[0.9976718,0.0008283848,0.0008761005,0.00009101906,0.00028003857,0.0002527003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008252191,0.00018894441,0.00029580985,0.0009642555,0.00024577946,0.0008742098,0.0004731125,0.0006610457,0.0029337187],"category_scores_gemma":[0.006459317,0.00020126383,0.00054836425,0.0015340721,0.00044106116,0.0005752024,0.0004814388,0.00078312564,0.00026670637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060981675,0.000060448103,0.9816041,0.0000901942,0.00013326267,0.00035796495,0.00003392219,0.0003486762,0.00041990707,0.0002245003,0.0005055959,0.015611576],"study_design_scores_gemma":[0.0000087943645,0.00010910649,0.9978137,0.000015713438,0.00006585138,0.0007262471,0.00013854167,0.0003066581,0.0000631837,0.00020011642,0.0005473037,0.000004729901],"about_ca_topic_score_codex":0.008001693,"about_ca_topic_score_gemma":0.012794896,"teacher_disagreement_score":0.008001693,"about_ca_system_score_codex":0.000618378,"about_ca_system_score_gemma":0.0005400255,"threshold_uncertainty_score":0.015910208},"labels":[],"label_agreement":null},{"id":"W1679349094","doi":"10.1016/j.lungcan.2015.07.001","title":"Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gemcitabine; Vinorelbine; Toxicity; Common Terminology Criteria for Adverse Events; Chemotherapy; Lung cancer; Internal medicine; Lean body mass; Chemotherapy regimen; Regimen; Oncology; Gastroenterology; Surgery; Urology; Cisplatin","score_opus":0.03323948792599945,"score_gpt":0.3422419903377314,"score_spread":0.30900250241173194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1679349094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982651,0.0010050103,0.0000742969,0.00007630741,0.000010457371,0.000004411866,0.000093329174,0.000003802276,0.00046719625],"genre_scores_gemma":[0.9994349,0.00020924798,0.000058760008,0.000021914293,0.00001835116,0.0000027144895,0.00011486146,0.0000014207079,0.00013788475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997805,0.00006232049,0.000034882036,0.000040812392,0.000043153326,0.000038368846],"domain_scores_gemma":[0.99799454,0.00031886456,0.0013178457,0.000057295238,0.00012047688,0.00019095516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032385983,0.00025359893,0.0003043085,0.0007129867,0.00029501252,0.00052067457,0.00034723358,0.00043182576,0.0014396405],"category_scores_gemma":[0.0020440842,0.00019644546,0.0003118811,0.0013003319,0.00026707738,0.00027094915,0.00035766914,0.000513647,0.00014636287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028903427,0.000029892373,0.9967244,0.00001961858,0.00006512683,0.00024360977,0.000015268302,0.000044236203,0.0008310318,0.000014046676,0.00004901098,0.0016746353],"study_design_scores_gemma":[0.0000037601715,0.00009033246,0.9989839,0.000005007381,0.000037132024,0.00050565356,0.000037121084,0.00016211736,0.00006636274,0.000026643236,0.000079937905,0.000001919517],"about_ca_topic_score_codex":0.0018073027,"about_ca_topic_score_gemma":0.0026879471,"teacher_disagreement_score":0.0018073027,"about_ca_system_score_codex":0.00024354568,"about_ca_system_score_gemma":0.00019944254,"threshold_uncertainty_score":0.0048160553},"labels":[],"label_agreement":null},{"id":"W177387553","doi":"10.1016/j.lungcan.2012.10.017","title":"18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Mesothelioma; Positron emission tomography; Radiology; Peritoneal mesothelioma; Extrapleural Pneumonectomy; Pleural disease; PET-CT; Positron emission; Thoracoscopy; Nuclear medicine; Lung cancer; Pneumonectomy; Respiratory disease; Pathology; Lung; Internal medicine","score_opus":0.005173032213293872,"score_gpt":0.25715114180126025,"score_spread":0.2519781095879664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W177387553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754214,0.00090675725,0.00007240059,0.00014557107,0.000015911566,0.0000058807427,0.0001403055,0.000007703303,0.0011632373],"genre_scores_gemma":[0.9994925,0.00020559164,0.0000540043,0.00003727009,0.000017434753,0.000002997792,0.00010363324,0.000001564757,0.000084919135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997743,0.00004132785,0.000034974753,0.0000403297,0.000034907243,0.000074257514],"domain_scores_gemma":[0.9995659,0.000120936274,0.00009699429,0.000022376444,0.000058102163,0.00013562755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033217994,0.00038371896,0.00039262822,0.00092638173,0.000448403,0.00068657566,0.00032380517,0.00096027146,0.0009528442],"category_scores_gemma":[0.0017852512,0.00027851277,0.0004307909,0.0005413391,0.00034745823,0.00059298426,0.00030668484,0.00039278733,0.00024767406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013308782,0.000057516285,0.98187166,0.00002292,0.000037503523,0.008531192,0.00009194512,0.00018043024,0.0038850144,0.00002663347,0.00021713355,0.0037471722],"study_design_scores_gemma":[0.000046150435,0.0004132547,0.97725654,0.000016932972,0.00018397624,0.017731572,0.00040776705,0.0012374731,0.0020330609,0.00009212002,0.00056627474,0.000014865774],"about_ca_topic_score_codex":0.004111567,"about_ca_topic_score_gemma":0.005279115,"teacher_disagreement_score":0.004111567,"about_ca_system_score_codex":0.00054229173,"about_ca_system_score_gemma":0.00038154554,"threshold_uncertainty_score":0.008175254},"labels":[],"label_agreement":null},{"id":"W1881422607","doi":"10.1016/j.lungcan.2015.06.009","title":"IL1B gene polymorphisms, age and the risk of non-small cell lung cancer in a Chinese population","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Technology; Ministry of Health, British Columbia; Fudan University; Research and Development; National Natural Science Foundation of China; National Science Foundation","keywords":"Medicine; Lung cancer; Oncology; Chinese population; Internal medicine; Gene; Genetics; Genotype; Biology","score_opus":0.006080338920320681,"score_gpt":0.25174813654559786,"score_spread":0.24566779762527718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1881422607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99944144,0.0001990762,0.00004595297,0.00003870381,0.0000072604357,0.0000032510522,0.00005542283,0.0000017910613,0.00020710306],"genre_scores_gemma":[0.9993926,0.0001097036,0.000042711803,0.000029494184,0.000016186761,0.0000048213365,0.00006122672,0.0000017402373,0.0003415527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980456,0.000036117257,0.000020937381,0.000057476715,0.00002833019,0.000052517833],"domain_scores_gemma":[0.9996947,0.00006277167,0.00007038749,0.00003349451,0.000038471004,0.0001001457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041217997,0.00045388713,0.0004759437,0.0006851393,0.0009536435,0.000514567,0.00032369964,0.0005359253,0.0020301223],"category_scores_gemma":[0.00064736494,0.0005250423,0.0006837209,0.0009520611,0.0004293916,0.0003743307,0.00024082145,0.0006463274,0.00021232096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006026261,0.0001313864,0.9945662,0.000017789003,0.00017172436,0.0004102102,0.0003778035,0.00007495152,0.0021930968,0.0000632494,0.00009790496,0.001292928],"study_design_scores_gemma":[0.00002291352,0.00016067381,0.9983584,0.0000039319552,0.00015712762,0.00025699264,0.0002988206,0.00038254596,0.00013373749,0.000063353145,0.00015442347,0.0000070364463],"about_ca_topic_score_codex":0.025362192,"about_ca_topic_score_gemma":0.013903687,"teacher_disagreement_score":0.025362192,"about_ca_system_score_codex":0.0004374063,"about_ca_system_score_gemma":0.0006601083,"threshold_uncertainty_score":0.050429165},"labels":[],"label_agreement":null},{"id":"W1920342986","doi":"10.1016/j.lungcan.2015.07.004","title":"Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Lung cancer; Relative survival; Population; Cancer; Demography; Oncology; Internal medicine; Cancer registry; Environmental health","score_opus":0.021763515646647368,"score_gpt":0.34458078962022687,"score_spread":0.3228172739735795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920342986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98118263,0.0016928707,0.00018514322,0.0005869425,0.000020430289,0.000039229726,0.0143495975,0.00002916293,0.0019139348],"genre_scores_gemma":[0.99412113,0.00071845547,0.00017940844,0.00010979764,0.000009990864,0.00001389798,0.0041996357,0.000007812509,0.0006399482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986872,0.00007501436,0.00012192533,0.00025701744,0.00041746983,0.00044130287],"domain_scores_gemma":[0.99656063,0.00013294665,0.0005951237,0.00012430327,0.0020005994,0.0005864388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073066767,0.00036593992,0.0005659223,0.0019398107,0.0017530893,0.0013629438,0.0014555681,0.00079576025,0.0017217622],"category_scores_gemma":[0.0026285644,0.00041920348,0.0010484388,0.008020263,0.0006495973,0.00064404245,0.00076690025,0.0011722272,0.00021353218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008455278,0.000020448664,0.9969199,0.000020217873,0.000100000856,0.00004699859,0.00018214194,0.00012162649,0.00009102291,0.00007168419,0.0007435825,0.0015977655],"study_design_scores_gemma":[0.0000054466373,0.000016281527,0.9985343,0.000010597846,0.00004660949,0.000063296364,0.00042919375,0.00032382074,0.000027399235,0.000018131026,0.00051530957,0.000009552304],"about_ca_topic_score_codex":0.9924831,"about_ca_topic_score_gemma":0.9924229,"teacher_disagreement_score":0.025572034,"about_ca_system_score_codex":0.025572034,"about_ca_system_score_gemma":0.028283529,"threshold_uncertainty_score":0.18553895},"labels":[],"label_agreement":null},{"id":"W1934286911","doi":"10.1016/j.lungcan.2015.09.004","title":"Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Queen's University; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute; Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Biomarker; Oncology; Proportional hazards model; Vascular endothelial growth factor; Gastroenterology; VEGF receptors","score_opus":0.07367530118651305,"score_gpt":0.4186572175267875,"score_spread":0.3449819163402744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934286911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902721,0.0044685267,0.0002649362,0.00036032646,0.00008839881,0.00044638413,0.0013878304,0.00003600132,0.0026753654],"genre_scores_gemma":[0.9952619,0.00071180565,0.0004479109,0.00026718233,0.00008752433,0.00049921183,0.0016996089,0.0000092586915,0.0010155493],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99839956,0.0008952002,0.00011218306,0.00017196096,0.0002542061,0.00016686926],"domain_scores_gemma":[0.998374,0.00052520644,0.00051412545,0.00012633333,0.00014123558,0.00031899216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033727523,0.0007153848,0.002120613,0.00039593832,0.00027627006,0.0012397913,0.00053468114,0.0009047411,0.0016013759],"category_scores_gemma":[0.0036305648,0.00024541767,0.0010326672,0.0005514412,0.0004345773,0.00052442733,0.00019179049,0.0017484939,0.0004238603],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81897396,0.0031203858,0.090096235,0.00051856023,0.0035003016,0.00022938872,0.00009653275,0.0018717378,0.027527481,0.00033149085,0.0030112565,0.05072263],"study_design_scores_gemma":[0.1813506,0.19405493,0.5858188,0.00016811004,0.005803739,0.000665124,0.00012875462,0.0045244633,0.016168917,0.00074619765,0.010446022,0.00012433412],"about_ca_topic_score_codex":0.00077762303,"about_ca_topic_score_gemma":0.0014417034,"teacher_disagreement_score":0.0033727523,"about_ca_system_score_codex":0.0009542634,"about_ca_system_score_gemma":0.0008130407,"threshold_uncertainty_score":0.017837048},"labels":[],"label_agreement":null},{"id":"W1944068990","doi":"10.1016/j.lungcan.2014.07.013","title":"Interval lung cancers not detected on screening chest X-rays: How are they different?","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Cancer; National Lung Screening Trial; Stage (stratigraphy); Lung; Internal medicine; Oncology; Radiology; Lung cancer screening","score_opus":0.019618729451306795,"score_gpt":0.291492737576781,"score_spread":0.27187400812547424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944068990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46180665,0.3527165,0.004426444,0.12169934,0.013849786,0.00025300062,0.0024666635,0.00012953143,0.04265208],"genre_scores_gemma":[0.9020829,0.058610145,0.0020188072,0.019896641,0.013940169,0.00009905891,0.0016867669,0.00008811574,0.0015773075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874007,0.0036515014,0.0021712952,0.0017712709,0.0033184704,0.001686592],"domain_scores_gemma":[0.96119565,0.02240877,0.0066406564,0.0012063953,0.005564782,0.0029837294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011272879,0.00075244164,0.0036026924,0.0035015948,0.0012323017,0.006106871,0.0022534227,0.005633339,0.0054252376],"category_scores_gemma":[0.07081752,0.0008027917,0.0031504403,0.0036418925,0.0028781742,0.010006624,0.0017647503,0.0065019806,0.0013041054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043260427,0.00049228023,0.7324596,0.001971292,0.0018931875,0.0048244484,0.00179112,0.00030920742,0.0005165462,0.007155313,0.018512158,0.22574879],"study_design_scores_gemma":[0.0006296553,0.00065520545,0.91568863,0.0037753603,0.0024980644,0.017523963,0.011746588,0.0010364004,0.00024049052,0.023328671,0.022536384,0.00034069843],"about_ca_topic_score_codex":0.0037190877,"about_ca_topic_score_gemma":0.004773872,"teacher_disagreement_score":0.011272879,"about_ca_system_score_codex":0.0016926102,"about_ca_system_score_gemma":0.0014616534,"threshold_uncertainty_score":0.0596174},"labels":[],"label_agreement":null},{"id":"W1964109435","doi":"10.1016/j.lungcan.2008.06.017","title":"Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Phase (matter); Lung cancer","score_opus":0.05241453114756632,"score_gpt":0.41515913076825106,"score_spread":0.3627445996206847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964109435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211276,0.0017002629,0.0006701216,0.0004894646,0.00023601657,0.0021698144,0.0009944381,0.00013907738,0.0014880192],"genre_scores_gemma":[0.9851216,0.0021000325,0.0013361739,0.00069109217,0.0003066633,0.003126677,0.0021276472,0.0000604591,0.005129738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992805,0.000332525,0.000025610194,0.000112602786,0.000047372265,0.0002013451],"domain_scores_gemma":[0.9988996,0.0001968829,0.00014163008,0.00013837272,0.000055535013,0.00056803675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018530778,0.0024901894,0.0040590656,0.001108576,0.00085939176,0.0014065123,0.0019611863,0.0026590026,0.0049315533],"category_scores_gemma":[0.0011235704,0.0011087023,0.0018470795,0.00069402397,0.0016636186,0.001421663,0.0004962135,0.005309558,0.0013895902],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74894565,0.13823904,0.0025421442,0.00053758535,0.0009857503,0.00024615735,0.00031160444,0.0025845373,0.04365346,0.00031074503,0.0032697264,0.05837364],"study_design_scores_gemma":[0.4699133,0.5185177,0.0041347025,0.00001763844,0.00028510008,0.00014093451,0.00007587723,0.00072013034,0.0045965677,0.00011725696,0.0014552923,0.000025565678],"about_ca_topic_score_codex":0.0030550908,"about_ca_topic_score_gemma":0.004677507,"teacher_disagreement_score":0.0049315533,"about_ca_system_score_codex":0.0014105197,"about_ca_system_score_gemma":0.0024324663,"threshold_uncertainty_score":0.016497672},"labels":[],"label_agreement":null},{"id":"W1965250671","doi":"10.1016/j.lungcan.2012.05.091","title":"Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Subtyping; Medicine; Lung cancer; Immunohistochemistry; Pathology; Carcinoma; Lung; Targeted therapy; Oncology; Internal medicine; Cancer","score_opus":0.02731344183904456,"score_gpt":0.30117816090950206,"score_spread":0.2738647190704575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965250671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98083055,0.015457472,0.0009110593,0.00012581842,0.00007195164,0.000035093963,0.00057609286,0.000015441248,0.0019766428],"genre_scores_gemma":[0.9975237,0.0017676494,0.0002521443,0.00003061221,0.000017381206,0.00000889658,0.00030686354,0.0000052742025,0.000087404565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948059,0.001434694,0.0013181317,0.0005936646,0.0016357304,0.00021190365],"domain_scores_gemma":[0.95738876,0.022261543,0.0054697837,0.0023846882,0.0118253855,0.0006697224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012873517,0.00019417796,0.0005167183,0.00442706,0.0006071913,0.00094690063,0.00090950995,0.00040804292,0.0003936439],"category_scores_gemma":[0.029066779,0.00032162844,0.00045406222,0.003158501,0.0011652901,0.00088108506,0.000747894,0.00027808186,0.00018668818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023976997,0.0000111098925,0.98859125,0.00011241555,0.00008649956,0.0003754534,0.0005952763,0.00006164348,0.001378406,0.000026636562,0.00011973365,0.00840181],"study_design_scores_gemma":[0.0000058318283,0.0000985999,0.99460286,0.000045182893,0.0001432087,0.0015784057,0.0011884121,0.00019604145,0.001196613,0.000021410244,0.0009174776,0.0000060120515],"about_ca_topic_score_codex":0.008389791,"about_ca_topic_score_gemma":0.012296638,"teacher_disagreement_score":0.012873517,"about_ca_system_score_codex":0.00077977247,"about_ca_system_score_gemma":0.00072777574,"threshold_uncertainty_score":0.06808245},"labels":[],"label_agreement":null},{"id":"W1965527358","doi":"10.1016/s0169-5002(01)00397-x","title":"Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer","year":2001,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Decitabine; Epigenetics; DNA methylation; Lung cancer; Medicine; Carcinogenesis; Deoxycytidine; Cancer research; Methylation; Epigenetic therapy; Cancer; Oncology; Gene; Biology; Internal medicine; Gene expression; Genetics; Gemcitabine","score_opus":0.008718673126525666,"score_gpt":0.2836352383365898,"score_spread":0.27491656521006413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965527358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88569427,0.08911331,0.005931928,0.0009842068,0.00031160738,0.00029942906,0.0008123398,0.0002110028,0.016641943],"genre_scores_gemma":[0.97062355,0.020863509,0.0016091935,0.00015504187,0.000059148217,0.00008079739,0.00043058812,0.000023135553,0.006155048],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99993277,0.000021825907,0.0000043260097,0.000010193388,0.000009134045,0.000021691525],"domain_scores_gemma":[0.9999558,0.000013919856,0.0000055366304,0.000006083739,0.000006848219,0.000011989737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002447188,0.0002541845,0.00068021,0.00024253142,0.00019466534,0.00032153676,0.00033689692,0.0002836945,0.0015997279],"category_scores_gemma":[0.00014156921,0.00011818125,0.0001718235,0.00020161935,0.00014887936,0.00012811419,0.00014395248,0.00066964875,0.00034722165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038833949,0.00048298846,0.00079635513,0.00038250626,0.00007377218,0.00044327092,0.00008946564,0.0013802022,0.8906045,0.0025918337,0.0011777489,0.09809398],"study_design_scores_gemma":[0.0012313443,0.008029193,0.0074848584,0.000041325853,0.00024643808,0.0014916235,0.00005302293,0.0024779805,0.92060083,0.00038004178,0.05794281,0.000020413288],"about_ca_topic_score_codex":0.0018777087,"about_ca_topic_score_gemma":0.0052628415,"teacher_disagreement_score":0.0018777087,"about_ca_system_score_codex":0.00042135554,"about_ca_system_score_gemma":0.00038555622,"threshold_uncertainty_score":0.005351603},"labels":[],"label_agreement":null},{"id":"W1966226479","doi":"10.1016/s0169-5002(00)80174-9","title":"Is there a role for maintenance chemotherapy in patients treated for non-small cell lung cancer (NSCLC) stage IIIB and IV?","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer","score_opus":0.0073079127568988255,"score_gpt":0.29998126115390294,"score_spread":0.2926733483970041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966226479","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4239827,0.36413908,0.00067984266,0.18808803,0.0039784424,0.00014573896,0.0011292889,0.00009148431,0.017765421],"genre_scores_gemma":[0.8939778,0.06595148,0.0019790616,0.027505506,0.0049782223,0.00016155349,0.0011244791,0.00003634127,0.0042855167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966645,0.00011081517,0.000037593814,0.000056212728,0.000052120828,0.00007695983],"domain_scores_gemma":[0.9962853,0.0017550854,0.0007576035,0.0001235718,0.00028764288,0.0007907377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011197339,0.00022983058,0.0013778716,0.00022459298,0.00043249005,0.0010290296,0.0010373732,0.001824679,0.006946916],"category_scores_gemma":[0.0063967225,0.00017633205,0.0012918512,0.00045436813,0.0004987015,0.0019264871,0.00030406984,0.0017434359,0.00045557556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027255507,0.0014696646,0.20633553,0.0025751633,0.0012676255,0.0005464876,0.00024582073,0.0011699612,0.003916942,0.003522558,0.03165162,0.7200431],"study_design_scores_gemma":[0.009580749,0.017846003,0.776665,0.007928182,0.0059536016,0.002812942,0.0014169756,0.0028720547,0.0016517985,0.008763037,0.16435368,0.00015607712],"about_ca_topic_score_codex":0.0034040194,"about_ca_topic_score_gemma":0.011921541,"teacher_disagreement_score":0.006946916,"about_ca_system_score_codex":0.00094907515,"about_ca_system_score_gemma":0.0023635982,"threshold_uncertainty_score":0.023239791},"labels":[],"label_agreement":null},{"id":"W1966804257","doi":"10.1016/j.lungcan.2003.08.024","title":"Women’s susceptibility to tobacco carcinogens","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Odds ratio; Lung cancer; Confidence interval; Demography; Logistic regression; Smoking history; Incidence (geometry); Cohort; Tobacco control; Cohort study; Relative risk; Public health; Internal medicine; Pathology","score_opus":0.024848849269004603,"score_gpt":0.3287624544172703,"score_spread":0.3039136051482657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966804257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741037,0.0012347684,0.000045999088,0.00129883,0.000033066528,0.000007161225,0.0002460972,0.0000043678274,0.009719354],"genre_scores_gemma":[0.99820983,0.0003289965,0.000022750388,0.00008025094,0.000016054595,0.0000024376143,0.000061090774,0.000001364392,0.001277143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997173,0.000118314485,0.000014358597,0.000032039046,0.00004239557,0.00007556162],"domain_scores_gemma":[0.99920243,0.00033410612,0.00016465137,0.000052418676,0.000078933575,0.00016753511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038527075,0.00011054043,0.00016726521,0.00048358281,0.00038971435,0.00044341624,0.00015208653,0.00037851502,0.006243599],"category_scores_gemma":[0.0030367002,0.00017005067,0.00024268546,0.00037167536,0.0002642414,0.00024462643,0.00029646515,0.00033147386,0.00041076884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044512542,0.00012705226,0.98540676,0.000025008057,0.00009498776,0.00037321204,0.0013220503,0.000050326136,0.0013230108,0.00028417908,0.0005844494,0.009964035],"study_design_scores_gemma":[0.000016980726,0.0002904226,0.99265456,0.000019863617,0.00007160446,0.00084789505,0.0017842306,0.0000764744,0.00042621625,0.00033378444,0.0034710409,0.0000069816083],"about_ca_topic_score_codex":0.007771354,"about_ca_topic_score_gemma":0.0066647595,"teacher_disagreement_score":0.007771354,"about_ca_system_score_codex":0.00022814094,"about_ca_system_score_gemma":0.0003209503,"threshold_uncertainty_score":0.020886898},"labels":[],"label_agreement":null},{"id":"W1966930108","doi":"10.1016/s0169-5002(03)00283-6","title":"Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Health Canada","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Radiation therapy; Stage (stratigraphy); Internal medicine; Survival rate; Relative survival; Oncology; Cancer; Carcinoma; Small-cell carcinoma; Surgery; Cancer registry","score_opus":0.005651231004388065,"score_gpt":0.23508689627475934,"score_spread":0.2294356652703713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966930108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923632,0.0011706288,0.00015780477,0.0008913815,0.000029113464,0.00002123472,0.0027825155,0.000017742239,0.0025663623],"genre_scores_gemma":[0.9982236,0.00033378805,0.000051256196,0.000085927095,0.0000074514805,0.0000036661368,0.000728336,0.000008275638,0.0005577656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988991,0.00013108506,0.000091352915,0.00019708625,0.00025295085,0.000428505],"domain_scores_gemma":[0.996203,0.00035301535,0.00084422034,0.0001266115,0.0013798313,0.0010932714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051155745,0.00020141568,0.00043849385,0.0012966642,0.0017651282,0.00097171863,0.0013079403,0.0006842372,0.0030485522],"category_scores_gemma":[0.00310781,0.00033572392,0.0006859256,0.0038037552,0.0008574733,0.00025963678,0.0006321652,0.0008530095,0.00021170724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010854934,0.000012554527,0.99698883,0.000008290521,0.000054337208,0.00007794171,0.00020006909,0.00019926093,0.00017381822,0.00009490325,0.0004762885,0.001605234],"study_design_scores_gemma":[0.0000062648473,0.000011845281,0.9987727,0.000008006529,0.000024558694,0.000079228215,0.00043423465,0.00020806878,0.00004394509,0.000030208546,0.00037252824,0.0000083494615],"about_ca_topic_score_codex":0.9848237,"about_ca_topic_score_gemma":0.9904047,"teacher_disagreement_score":0.021578556,"about_ca_system_score_codex":0.021578556,"about_ca_system_score_gemma":0.019998424,"threshold_uncertainty_score":0.15656412},"labels":[],"label_agreement":null},{"id":"W1968673033","doi":"10.1016/s0169-5002(99)00132-4","title":"An estimate of the cost of conducting phase II trials in lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Gemcitabine; Docetaxel; Clinical trial; Lung cancer; Pharmacy; Oncology; Cancer; Internal medicine; Intensive care medicine; Family medicine","score_opus":0.10718475209156585,"score_gpt":0.5220729525916058,"score_spread":0.41488820050003994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968673033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32890764,0.24384879,0.13917376,0.07510102,0.0056527737,0.009839037,0.04954138,0.0011004104,0.14683512],"genre_scores_gemma":[0.9070904,0.02679334,0.041088916,0.006618161,0.00096259604,0.0033722827,0.0057410323,0.00011267334,0.00822056],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9758213,0.019980561,0.001038405,0.00042000334,0.00217233,0.0005673296],"domain_scores_gemma":[0.894513,0.087633766,0.0068126502,0.0032725662,0.0059353197,0.0018326478],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.023964554,0.0011022168,0.0015262899,0.0026590328,0.00040432785,0.002203674,0.0010453146,0.002282852,0.0054516015],"category_scores_gemma":[0.095319964,0.000631485,0.0033908484,0.0022807666,0.0006461315,0.0018664746,0.0010898302,0.002140199,0.0007003079],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045190167,0.0011887522,0.08606417,0.010917112,0.015691038,0.0012778445,0.00048966875,0.07816786,0.0052652084,0.034958456,0.04547041,0.6753194],"study_design_scores_gemma":[0.024458518,0.021098992,0.41855967,0.0098501155,0.063606426,0.011593865,0.0021215777,0.10830892,0.012753678,0.051030844,0.2759864,0.0006309402],"about_ca_topic_score_codex":0.009079822,"about_ca_topic_score_gemma":0.007991812,"teacher_disagreement_score":0.9760355,"about_ca_system_score_codex":0.004429322,"about_ca_system_score_gemma":0.0045835725,"threshold_uncertainty_score":0.12673819},"labels":[],"label_agreement":null},{"id":"W1969713662","doi":"10.1016/j.lungcan.2011.05.012","title":"Mesothelioma at era of helical tomotherapy: Results of two institutions in combining chemotherapy, surgery and radiotherapy","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Tomotherapy; Medicine; Radiation therapy; Chemotherapy; Mesothelioma; Oncology; General surgery; Radiology; Internal medicine; Pathology","score_opus":0.03445576827368732,"score_gpt":0.32202801683707605,"score_spread":0.2875722485633887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969713662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999064,0.00027510792,0.00015556574,0.000039243558,0.000014108574,0.0000278906,0.000071542054,0.000008417194,0.000344171],"genre_scores_gemma":[0.9986981,0.00034508138,0.00025507898,0.000049012542,0.00005066863,0.000017166227,0.00021551395,0.000007652307,0.00036151474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991799,0.00023020912,0.000071051116,0.00016690542,0.000100206154,0.0002517362],"domain_scores_gemma":[0.99900395,0.00019909385,0.000112132424,0.0001644252,0.00012363208,0.00039674708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010734138,0.0007102875,0.001038782,0.00068866974,0.0013811832,0.0006754871,0.00044355742,0.0010856646,0.0009175578],"category_scores_gemma":[0.0016074895,0.0003290137,0.0015086088,0.00090193475,0.00075553014,0.0004923175,0.0009254594,0.00096896786,0.00036298553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11197299,0.03819866,0.6408239,0.00035834347,0.0019391337,0.0150518045,0.0051088273,0.009150599,0.057861138,0.00019786389,0.0010156507,0.11832114],"study_design_scores_gemma":[0.0017905061,0.10160807,0.85790765,0.000057062254,0.0022532023,0.0064215492,0.0019324608,0.0021181032,0.02302023,0.00019997153,0.0025219764,0.00016913326],"about_ca_topic_score_codex":0.0043408363,"about_ca_topic_score_gemma":0.0041343863,"teacher_disagreement_score":0.0043408363,"about_ca_system_score_codex":0.0009981156,"about_ca_system_score_gemma":0.0007440552,"threshold_uncertainty_score":0.00863111},"labels":[],"label_agreement":null},{"id":"W1970151900","doi":"10.1016/s0169-5002(00)80603-0","title":"Prognostic significance of BAG-1 expression in non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Expression (computer science)","score_opus":0.008902687794944778,"score_gpt":0.298233672332086,"score_spread":0.2893309845371412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970151900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960212,0.0014518062,0.00028888573,0.00021862106,0.00005030385,0.0000065733684,0.0005055499,0.000021856862,0.0014351411],"genre_scores_gemma":[0.999151,0.000150072,0.00007578888,0.000022793043,0.0000461393,0.0000050304575,0.0002971239,0.0000032517262,0.0002487618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997578,0.00007261851,0.000019446077,0.000034923716,0.000036638503,0.00007859754],"domain_scores_gemma":[0.99873596,0.0003944253,0.00031291033,0.0000709825,0.0001286216,0.000357177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045738523,0.00025104746,0.00031058682,0.000777453,0.00041263722,0.00062466227,0.00036602054,0.0005065089,0.0020288397],"category_scores_gemma":[0.0017294885,0.00015377397,0.00019295026,0.00084677106,0.00039168465,0.0005128163,0.00037119875,0.0005936179,0.0005130676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010003513,0.000028743932,0.98538774,0.000028940434,0.00004672636,0.00022814228,0.000037564452,0.00016517597,0.0070606098,0.000089583074,0.00034369074,0.005582651],"study_design_scores_gemma":[0.000017574439,0.00014838911,0.99568284,0.0000062619984,0.00008418292,0.00076726574,0.00010997588,0.000885199,0.0013180051,0.00024779243,0.0007250422,0.000007491215],"about_ca_topic_score_codex":0.000520063,"about_ca_topic_score_gemma":0.0007594744,"teacher_disagreement_score":0.0020288397,"about_ca_system_score_codex":0.00025887968,"about_ca_system_score_gemma":0.00018063515,"threshold_uncertainty_score":0.006787181},"labels":[],"label_agreement":null},{"id":"W1970574485","doi":"10.1016/j.lungcan.2015.04.006","title":"Prophylactic cranial irradiation (PCI). Still a no-brainer?","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"Sunnybrook Foundation","keywords":"Prophylactic cranial irradiation; Conventional PCI; Medicine; Intensive care medicine; Medical physics; Surgery; Radiology; Internal medicine","score_opus":0.03641837392901453,"score_gpt":0.38552492142454425,"score_spread":0.3491065474955297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970574485","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017009322,0.93809396,0.00074101094,0.053844158,0.0016589755,0.000012264073,0.000052096297,0.0000168198,0.0038796677],"genre_scores_gemma":[0.026953448,0.9339675,0.001638019,0.029755589,0.005194765,0.000035749996,0.0000736197,0.000029902678,0.0023514838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989172,0.00051807566,0.0001598111,0.00015824656,0.00018799826,0.000058660164],"domain_scores_gemma":[0.9957973,0.0029978184,0.0005122428,0.0001302699,0.00036061546,0.00020182447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028395893,0.00029901852,0.0012716085,0.00040738026,0.00040102433,0.0017548833,0.0006989161,0.0016126857,0.0058355024],"category_scores_gemma":[0.0059776832,0.00014045574,0.00050728634,0.00079890655,0.0017931481,0.002783555,0.00066077267,0.0029021462,0.0016927965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068058097,0.00010157792,0.0016888711,0.0077815014,0.00023527743,0.00020318771,0.00019194599,0.00013565678,0.0007687218,0.016275687,0.036310695,0.9356264],"study_design_scores_gemma":[0.00048643682,0.0018404871,0.008505527,0.028910981,0.00097318727,0.00369273,0.0018408672,0.00015336514,0.0014598637,0.037871696,0.91417015,0.00009478091],"about_ca_topic_score_codex":0.0013875425,"about_ca_topic_score_gemma":0.004044538,"teacher_disagreement_score":0.0058355024,"about_ca_system_score_codex":0.0007769605,"about_ca_system_score_gemma":0.0019912878,"threshold_uncertainty_score":0.019521713},"labels":[],"label_agreement":null},{"id":"W1971754811","doi":"10.1016/j.lungcan.2005.05.028","title":"Acquisition of fluorescence and reflectance spectra during routine bronchoscopy examinations using the ClearVu Elite™ device: Pilot study","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bronchoscopy; Lung cancer; Carcinoma in situ; Radiology; Lung; Population; Pathology; Carcinoma; Nuclear medicine; Internal medicine","score_opus":0.029500268182809507,"score_gpt":0.38617791242534527,"score_spread":0.3566776442425358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971754811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99834895,0.00011160777,0.0010943707,0.000013051972,0.000005433855,0.00009487814,0.00005077332,0.000013711575,0.00026716766],"genre_scores_gemma":[0.99658954,0.00016347764,0.0022727654,0.00004622908,0.000022125434,0.00007820358,0.00014969168,0.00001904558,0.00065890735],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99959725,0.00014792061,0.000015993352,0.00009255135,0.000071039045,0.000075250246],"domain_scores_gemma":[0.99905664,0.00044466325,0.000064720705,0.00014213003,0.00017209581,0.00011974896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008606255,0.0004551666,0.000544599,0.000357307,0.0005245121,0.00030771256,0.0003739462,0.0006940521,0.0014388943],"category_scores_gemma":[0.0014594496,0.0003458755,0.0003614098,0.00024551246,0.0006587662,0.00058280164,0.0003668318,0.00059266674,0.00031081846],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03629722,0.008911127,0.037452072,0.00031057376,0.00010379155,0.0010982103,0.0024296134,0.00048043052,0.8632388,0.000118607844,0.00037738783,0.049182083],"study_design_scores_gemma":[0.0013157496,0.1206851,0.5167087,0.000030786738,0.00048554747,0.0045881276,0.0021005739,0.0033758988,0.34783238,0.00016305968,0.0025699795,0.00014409014],"about_ca_topic_score_codex":0.0017853158,"about_ca_topic_score_gemma":0.0016817052,"teacher_disagreement_score":0.0017853158,"about_ca_system_score_codex":0.00024225385,"about_ca_system_score_gemma":0.0003867873,"threshold_uncertainty_score":0.004813552},"labels":[],"label_agreement":null},{"id":"W1972272153","doi":"10.1016/j.lungcan.2014.04.014","title":"Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mach-Gaensslen Foundation of Canada","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Bevacizumab; Clinical endpoint; Lung cancer; Chemotherapy; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.003084220057585393,"score_gpt":0.25172074226016494,"score_spread":0.24863652220257956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972272153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989097,0.00026683148,0.000062649575,0.000039648745,0.000014089427,0.000007746307,0.0003012424,0.0000057974185,0.00039239123],"genre_scores_gemma":[0.9987949,0.000081119004,0.00011784648,0.00007161123,0.000012969661,0.000014452374,0.00047233183,0.0000035622206,0.00043110934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998216,0.000029452358,0.00001793542,0.000053368676,0.000036010704,0.000041682295],"domain_scores_gemma":[0.9997304,0.00006488454,0.000083859755,0.000014066539,0.000034315555,0.00007242909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017420249,0.0001513545,0.00042791283,0.00020574378,0.00021505212,0.0005284028,0.00017022816,0.00037084345,0.0010202408],"category_scores_gemma":[0.0007385999,0.00014226491,0.0002565056,0.0003169097,0.00011618791,0.0002149111,0.0001312545,0.00041800793,0.00026404418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013957411,0.00034783967,0.9281372,0.000070569484,0.00024823527,0.0011049084,0.00022411437,0.00025197974,0.031528052,0.000093262664,0.0009845711,0.023051824],"study_design_scores_gemma":[0.00013876149,0.001900861,0.9924265,0.000009195153,0.00016529456,0.001205989,0.00016320156,0.0006480075,0.0022619097,0.000064964355,0.0010027968,0.000012598467],"about_ca_topic_score_codex":0.0009727636,"about_ca_topic_score_gemma":0.0016624137,"teacher_disagreement_score":0.0010202408,"about_ca_system_score_codex":0.00025466917,"about_ca_system_score_gemma":0.00023810202,"threshold_uncertainty_score":0.0034130812},"labels":[],"label_agreement":null},{"id":"W1974498632","doi":"10.1016/s0169-5002(03)00300-3","title":"Induction treatment before surgery for non-small cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Induction chemotherapy; Radiation therapy; Clinical trial; Disease; Chemotherapy; Randomized controlled trial; Lung cancer; Surgery; Standard of care; Oncology; Cancer; Internal medicine","score_opus":0.04540205712742559,"score_gpt":0.36755930025658906,"score_spread":0.3221572431291635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974498632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006062152,0.99783486,0.00010723667,0.00010309301,0.00017470641,0.000014671143,0.0000389619,0.000007457044,0.0011128779],"genre_scores_gemma":[0.003230618,0.9951585,0.00023130953,0.00032296433,0.00017493777,0.00002154563,0.000082299244,0.0000024941257,0.0007753169],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998516,0.0000335937,0.000035714027,0.00003296028,0.000034144927,0.000011975735],"domain_scores_gemma":[0.999582,0.0002450245,0.000107202555,0.0000118740345,0.0000327056,0.000021165495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003712313,0.000571292,0.0018016907,0.0011090339,0.0001730509,0.00041595846,0.00071413454,0.00053110934,0.0054573156],"category_scores_gemma":[0.0008524529,0.00021276416,0.00069732533,0.0012296477,0.00023261097,0.00051528163,0.00026532135,0.0012201658,0.0012103682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040548883,0.00015087197,0.00036768243,0.035991047,0.000230652,0.00023931988,0.000030571187,0.00018063915,0.0013850125,0.00030903288,0.012203387,0.94850624],"study_design_scores_gemma":[0.00085997,0.0019136799,0.016966783,0.02675522,0.0024703927,0.0068864096,0.00012239101,0.00015348288,0.0030236423,0.0006315457,0.94016224,0.00005427476],"about_ca_topic_score_codex":0.0009858683,"about_ca_topic_score_gemma":0.003539736,"teacher_disagreement_score":0.0054573156,"about_ca_system_score_codex":0.000475171,"about_ca_system_score_gemma":0.00088108465,"threshold_uncertainty_score":0.018256545},"labels":[],"label_agreement":null},{"id":"W1976487567","doi":"10.1016/j.lungcan.2012.02.019","title":"Emphysema detected on computed tomography and risk of lung cancer: A systematic review and meta-analysis","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Meta-analysis; Odds ratio; Cochrane Library; Lung cancer screening; Internal medicine; Lung; Radiology","score_opus":0.04412811388537274,"score_gpt":0.38101351988535676,"score_spread":0.336885405999984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976487567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007686502,0.99107134,0.00040324905,0.00009194126,0.00012672064,0.00012684312,0.00033218216,0.000018655039,0.00014255766],"genre_scores_gemma":[0.19319297,0.8028399,0.0018474526,0.0006256677,0.00022786346,0.00035765333,0.00052421365,0.00001998992,0.00036433025],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963983,0.0013032125,0.0011085997,0.000588134,0.00042059607,0.00018111293],"domain_scores_gemma":[0.9919676,0.005833876,0.0011615498,0.0003030627,0.00057385355,0.0001599844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005543376,0.002622365,0.015075459,0.004406654,0.00068490754,0.0021054768,0.0021137896,0.0023102039,0.003148636],"category_scores_gemma":[0.015115913,0.0018873967,0.028869543,0.006000842,0.00063905894,0.0014837699,0.0015766323,0.0018140873,0.000311567],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022166478,0.00004743426,0.009140421,0.29240128,0.683522,0.00024971843,0.00011030383,0.00045849656,0.00037046036,0.00009213841,0.0006415569,0.010749484],"study_design_scores_gemma":[0.00044076884,0.00014350346,0.004702528,0.008278892,0.98519367,0.00012216461,0.000050101746,0.00009588198,0.00008007664,0.000084717045,0.0007831389,0.000024534376],"about_ca_topic_score_codex":0.010051604,"about_ca_topic_score_gemma":0.028062126,"teacher_disagreement_score":0.015075459,"about_ca_system_score_codex":0.0017295781,"about_ca_system_score_gemma":0.0025021571,"threshold_uncertainty_score":0.029316545},"labels":[],"label_agreement":null},{"id":"W1977749101","doi":"10.1016/j.lungcan.2004.07.040","title":"Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Stage (stratigraphy); Univariate analysis; Carboplatin; Multivariate analysis; Performance status; Chemotherapy; Population; Histology; Cancer; Gastroenterology; Oncology; Cisplatin","score_opus":0.015688345930696318,"score_gpt":0.3198114188996633,"score_spread":0.304123072968967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977749101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99730873,0.00043956673,0.000077905774,0.00037333288,0.000024069128,0.000006959683,0.00020793545,0.0000063282214,0.0015553016],"genre_scores_gemma":[0.99930835,0.00008163322,0.00005454508,0.00006044359,0.000045613033,0.0000036986373,0.00014378114,0.0000021521378,0.00029977428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996307,0.000103080565,0.000041516418,0.00005545606,0.00007832762,0.00009104847],"domain_scores_gemma":[0.99400276,0.002060853,0.0021056705,0.00018243282,0.00028268064,0.0013655336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004420063,0.00019930111,0.00033961586,0.00043285504,0.00043230975,0.0006999616,0.00033128177,0.0011094661,0.005557707],"category_scores_gemma":[0.0049655307,0.00017635005,0.0006826642,0.00060128723,0.00033376398,0.0004144672,0.00023382306,0.0015386334,0.00034762605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003053018,0.0000915384,0.99786985,0.0000059021404,0.00004255665,0.00018378416,0.000016258144,0.00012076976,0.00033713368,0.000023351322,0.00013855845,0.0008649631],"study_design_scores_gemma":[0.000013369203,0.00019878332,0.997834,0.000004532862,0.00004901466,0.0007979972,0.00008918903,0.00067328324,0.00009830527,0.000048115522,0.00018813087,0.000005163014],"about_ca_topic_score_codex":0.0029697134,"about_ca_topic_score_gemma":0.0031928078,"teacher_disagreement_score":0.005557707,"about_ca_system_score_codex":0.00028274162,"about_ca_system_score_gemma":0.00052985153,"threshold_uncertainty_score":0.018592417},"labels":[],"label_agreement":null},{"id":"W1982407179","doi":"10.1016/s0169-5002(03)00355-6","title":"Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Carboplatin; Medicine; Lung cancer; Metastasis; Matrix metalloproteinase inhibitor; Chemotherapy; Matrix metalloproteinase; Internal medicine; Cancer; Combination therapy; Oncology; Cisplatin","score_opus":0.008950563754020943,"score_gpt":0.2611626431329394,"score_spread":0.2522120793789185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982407179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942215,0.0022093311,0.0016581137,0.0001628977,0.00008532092,0.000042966134,0.00029812832,0.00022431632,0.0010972733],"genre_scores_gemma":[0.9948095,0.0009850125,0.0013812737,0.000036220707,0.00002438064,0.000041238083,0.00050666905,0.000027348831,0.0021882653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986756,0.000013854135,0.0000067256683,0.000022046015,0.000032004406,0.00005777111],"domain_scores_gemma":[0.999902,0.000011819123,0.000024463907,0.000012992163,0.0000051675993,0.000043569722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116734416,0.0005843939,0.00083700183,0.00034253192,0.00019475167,0.00037178554,0.00032547585,0.00029686795,0.00070958585],"category_scores_gemma":[0.000090114816,0.00018831006,0.0004144842,0.00026062317,0.00029193173,0.00026883144,0.00017567001,0.0012494714,0.00024612676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022300908,0.00062386895,0.0005163347,0.00005005786,0.000033454213,0.00009175056,0.000019079751,0.0002904146,0.98932797,0.00010007396,0.0004003424,0.006316614],"study_design_scores_gemma":[0.00033901847,0.0065928013,0.009709833,0.0000064393325,0.00008320692,0.00048204188,0.000029147297,0.0014722274,0.9787143,0.000080500366,0.0024753474,0.000015060053],"about_ca_topic_score_codex":0.0013031116,"about_ca_topic_score_gemma":0.004057568,"teacher_disagreement_score":0.0013031116,"about_ca_system_score_codex":0.00037208005,"about_ca_system_score_gemma":0.00048532116,"threshold_uncertainty_score":0.0026996732},"labels":[],"label_agreement":null},{"id":"W1983913656","doi":"10.1016/j.lungcan.2005.02.011","title":"Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gefitinib; Medicine; Histology; Adenocarcinoma; Ethnic group; Internal medicine; Oncology; Carcinoma; Lung; Cancer; Epidermal growth factor receptor; Anthropology","score_opus":0.0075751153579548735,"score_gpt":0.28768857319094115,"score_spread":0.2801134578329863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983913656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972066,0.00089299923,0.000044306256,0.0005355443,0.00002986434,0.0000024652793,0.000120394965,0.000004642651,0.0011632021],"genre_scores_gemma":[0.9992143,0.00021917972,0.00003592539,0.000096568256,0.00003168742,0.0000016844949,0.00010015151,0.0000034859604,0.00029705456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996828,0.00010438227,0.000035973644,0.00004208453,0.000058999052,0.00007573352],"domain_scores_gemma":[0.99822015,0.0004943237,0.00061683304,0.00006955658,0.00016008597,0.00043900844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004920695,0.00021360222,0.0005522978,0.000389341,0.00045258543,0.0006932004,0.00026033333,0.00048210195,0.0020288068],"category_scores_gemma":[0.0018342608,0.00020819572,0.00077559275,0.00074390875,0.0002870352,0.000445145,0.00022781643,0.0007262183,0.00026985529],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011812355,0.000015875677,0.9981059,0.0000040968634,0.000059161186,0.00007137848,0.000029990268,0.000029564786,0.00020178255,0.000011088169,0.00012769192,0.0012254048],"study_design_scores_gemma":[0.000005546737,0.000043780932,0.99883527,0.0000045420124,0.00012298905,0.00024296253,0.0001784909,0.00021245153,0.000088893816,0.000028671027,0.00023328295,0.0000031251468],"about_ca_topic_score_codex":0.01236485,"about_ca_topic_score_gemma":0.026310137,"teacher_disagreement_score":0.01236485,"about_ca_system_score_codex":0.0004553083,"about_ca_system_score_gemma":0.0007346048,"threshold_uncertainty_score":0.024585783},"labels":[],"label_agreement":null},{"id":"W1983936911","doi":"10.1016/j.lungcan.2004.12.004","title":"Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Prophylactic cranial irradiation; Chemotherapy; Incidence (geometry); Lung cancer; Stage (stratigraphy); Surgery; Oncology; Brain metastasis; Internal medicine; Cancer; Metastasis","score_opus":0.010715695218175135,"score_gpt":0.311923990686607,"score_spread":0.30120829546843186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983936911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83141196,0.08811013,0.0012887435,0.056752298,0.0012982333,0.00003594351,0.00097038737,0.00003490429,0.020097323],"genre_scores_gemma":[0.9832667,0.009325855,0.0002889504,0.0033019937,0.0027387778,0.000010587637,0.00040237987,0.000015669062,0.00064900203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998473,0.00060894573,0.00015885223,0.00014627386,0.00030961775,0.0003033126],"domain_scores_gemma":[0.98831767,0.006025382,0.003246645,0.00045978307,0.0008341645,0.00111641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030621209,0.00025939455,0.001240188,0.0005393606,0.0003533525,0.0011565032,0.0010621606,0.003499625,0.0036547417],"category_scores_gemma":[0.021068323,0.00017360588,0.00097265607,0.0013212797,0.0012109845,0.0016979697,0.00039544585,0.0016478945,0.0007775612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012128215,0.0003814289,0.8030559,0.00067392463,0.0009777047,0.002688593,0.000097983895,0.002161289,0.0017614736,0.004736633,0.0058332244,0.16550356],"study_design_scores_gemma":[0.0004403195,0.0022599658,0.96636957,0.00032795305,0.0012060032,0.007363532,0.00071834546,0.0016467132,0.0005087193,0.012176043,0.0069208858,0.000061914674],"about_ca_topic_score_codex":0.004583148,"about_ca_topic_score_gemma":0.0084637515,"teacher_disagreement_score":0.004583148,"about_ca_system_score_codex":0.0012477612,"about_ca_system_score_gemma":0.0015289686,"threshold_uncertainty_score":0.016194224},"labels":[],"label_agreement":null},{"id":"W1984146948","doi":"10.1016/j.lungcan.2012.04.014","title":"National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; National Comprehensive Cancer Network","keywords":"Medicine; Docetaxel; Gefitinib; Erlotinib; Pemetrexed; Oncology; Internal medicine; Gemcitabine; Lung cancer; Guideline; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Pathology","score_opus":0.02256977514883364,"score_gpt":0.37233941694808714,"score_spread":0.3497696417992535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984146948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107474,0.0003296306,0.00009365809,0.00016819626,0.0000139664435,0.00003009921,0.0069254697,0.000009800958,0.001354517],"genre_scores_gemma":[0.9949373,0.00018323654,0.000084051964,0.00011251386,0.000008640656,0.000033536067,0.0041071246,0.0000018257421,0.0005317237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921703,0.000114889335,0.00016062897,0.00015427984,0.00020392967,0.0001491829],"domain_scores_gemma":[0.99849784,0.00015220667,0.0004429539,0.000095341115,0.0003676888,0.00044399346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000752446,0.00024550053,0.000389761,0.001314103,0.0005177544,0.00029980892,0.00045660135,0.000379407,0.0013388915],"category_scores_gemma":[0.0012397919,0.00034550313,0.00044731374,0.0031142416,0.00024849176,0.00037928837,0.00041097408,0.0003391611,0.00020332924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018413288,0.000013106554,0.9984603,0.000023029608,0.00003996284,0.00003269829,0.000074122094,0.000042908763,0.00019452305,0.000024401763,0.00039793455,0.00067855115],"study_design_scores_gemma":[0.0000017305642,0.000009469186,0.9995272,0.0000028227994,0.000009710628,0.0000255869,0.00008253199,0.000080846025,0.000019100482,0.0000056994227,0.00023347484,0.0000019026224],"about_ca_topic_score_codex":0.15911135,"about_ca_topic_score_gemma":0.17919387,"teacher_disagreement_score":0.15911135,"about_ca_system_score_codex":0.0015036009,"about_ca_system_score_gemma":0.0028482354,"threshold_uncertainty_score":0.31637043},"labels":[],"label_agreement":null},{"id":"W1986187845","doi":"10.1016/j.lungcan.2012.10.006","title":"VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Universitair Medisch Centrum Groningen; Maastricht Universitair Medisch Centrum; Institute for Oil Sands Innovation, University of Alberta; Universiteit Maastricht; Inselspital, Universitätsspital Bern","keywords":"Erlotinib; Medicine; Bevacizumab; Internal medicine; Lung cancer; Oncology; Hazard ratio; Gefitinib; Confidence interval; Proportional hazards model; Chemotherapy; Log-rank test; Cancer; Epidermal growth factor receptor","score_opus":0.00779591278885484,"score_gpt":0.28823118241143075,"score_spread":0.2804352696225759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986187845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798696,0.016170753,0.00053919404,0.0003166685,0.00011909945,0.000019371211,0.0020169402,0.000048839454,0.00089938927],"genre_scores_gemma":[0.99649894,0.0010234554,0.00019561808,0.00011985672,0.000099220015,0.000008242877,0.0015714832,0.000011750826,0.0004713227],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9984321,0.00059983373,0.00014159622,0.00042387226,0.00024404112,0.00015855815],"domain_scores_gemma":[0.99693847,0.0012693482,0.0010666887,0.00031049812,0.00016731341,0.0002475816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002528617,0.00068290695,0.0021092822,0.00052318914,0.00018242748,0.0010712097,0.00057682884,0.0007196698,0.001953852],"category_scores_gemma":[0.0035198794,0.0003810837,0.0046046283,0.0007930388,0.00030264832,0.00089313963,0.00051693607,0.0010498166,0.00030556705],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06787682,0.00017315931,0.82315147,0.0004658727,0.053575356,0.00023271596,0.000058214122,0.0018034497,0.0052196393,0.000118103984,0.0019664748,0.045358755],"study_design_scores_gemma":[0.0018805525,0.0049472703,0.951684,0.000061024977,0.033126537,0.0006610268,0.0000926496,0.0034898303,0.0015332644,0.0002587917,0.0022004554,0.00006449936],"about_ca_topic_score_codex":0.0017936784,"about_ca_topic_score_gemma":0.0039629797,"teacher_disagreement_score":0.002528617,"about_ca_system_score_codex":0.00042525557,"about_ca_system_score_gemma":0.0003561504,"threshold_uncertainty_score":0.013372779},"labels":[],"label_agreement":null},{"id":"W1986783484","doi":"10.1016/s0169-5002(00)00240-3","title":"Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control","year":2001,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Epirubicin; Toxicity; Population; Gastroenterology; Cyclophosphamide; Radiation therapy; Chemotherapy; Mucositis; Vincristine; Progressive disease; Cancer; Oncology; Surgery; Urology","score_opus":0.08057751619949674,"score_gpt":0.4081317458969609,"score_spread":0.32755422969746417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986783484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726288,0.019400332,0.001147983,0.0010813732,0.00028289412,0.0002020192,0.0002712023,0.000084311854,0.0049010306],"genre_scores_gemma":[0.9907336,0.0055007716,0.0011898153,0.00040104086,0.00025070016,0.00017052218,0.0002858221,0.000021918577,0.0014457786],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99941456,0.00026853263,0.00005797962,0.00007290564,0.00011293301,0.000073010924],"domain_scores_gemma":[0.99659014,0.0017767332,0.0008653855,0.0003383812,0.00010945274,0.0003199567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013595684,0.0002833839,0.00075398915,0.00022285238,0.00038731899,0.0002724498,0.00042128225,0.00053549383,0.0030436188],"category_scores_gemma":[0.004839318,0.0001271275,0.0006695406,0.00051219953,0.0002319335,0.0004157424,0.00016907381,0.0016444902,0.000250234],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057511277,0.014465255,0.06442072,0.0018088521,0.0016708627,0.00021214454,0.0005812666,0.0023953696,0.027148234,0.001304937,0.0050200173,0.8234611],"study_design_scores_gemma":[0.019786423,0.14889449,0.74914354,0.00052578765,0.004148348,0.0011978894,0.00055403897,0.0027758067,0.018664509,0.0021572027,0.05208577,0.00006613178],"about_ca_topic_score_codex":0.0018435513,"about_ca_topic_score_gemma":0.003916801,"teacher_disagreement_score":0.0030436188,"about_ca_system_score_codex":0.0004533516,"about_ca_system_score_gemma":0.0006973403,"threshold_uncertainty_score":0.010181904},"labels":[],"label_agreement":null},{"id":"W1987622504","doi":"10.1016/j.lungcan.2011.05.027","title":"ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"Pfizer","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Internal medicine; Oncology; Chemotherapy; Fluorescence in situ hybridization; Adenocarcinoma; Tyrosine-kinase inhibitor; Fusion gene; Cancer; Cancer research; Gene; Biology","score_opus":0.02078302751036611,"score_gpt":0.3394637568106692,"score_spread":0.3186807293003031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987622504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716669,0.00419944,0.0014799392,0.0032901373,0.0005240846,0.00028732207,0.00067285233,0.00010714552,0.01777202],"genre_scores_gemma":[0.9916325,0.0010229701,0.00063835684,0.0012420983,0.0007559944,0.00006324592,0.00041254878,0.0000390409,0.0041932934],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999198,0.000048669524,0.000072445626,0.00016367952,0.00013827105,0.00037887873],"domain_scores_gemma":[0.9990539,0.0002573456,0.00017328323,0.00006555398,0.000059986138,0.00038984156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003296049,0.0013186327,0.0014033574,0.002465457,0.0029995893,0.0008495059,0.0014860026,0.0051760506,0.005217499],"category_scores_gemma":[0.0017575326,0.0010322217,0.002991277,0.0010753144,0.0018690286,0.00067990576,0.0011150833,0.0021585987,0.0011238562],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005963384,0.00033208643,0.03656957,0.000049872597,0.000055108198,0.9572011,0.00016656778,0.00017551235,0.0015196799,0.00014219484,0.0003800932,0.002811872],"study_design_scores_gemma":[0.00014612687,0.001094899,0.0875783,0.000017378557,0.00015269239,0.90489954,0.00038227413,0.00048194817,0.002777561,0.00026874742,0.0021546604,0.00004581645],"about_ca_topic_score_codex":0.005847335,"about_ca_topic_score_gemma":0.00798942,"teacher_disagreement_score":0.005847335,"about_ca_system_score_codex":0.0019438306,"about_ca_system_score_gemma":0.0010573047,"threshold_uncertainty_score":0.017454267},"labels":[],"label_agreement":null},{"id":"W1987756569","doi":"10.1016/s0169-5002(03)00148-x","title":"Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Observational study; Lung cancer; Population; General surgery; Demography; Intensive care medicine; Oncology; Internal medicine; Environmental health","score_opus":0.043261292114015505,"score_gpt":0.41295802667273485,"score_spread":0.3696967345587193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987756569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845695,0.00010628557,0.000068760564,0.00009104413,0.0000058307014,0.000020189076,0.0008292763,0.000004781024,0.0004168171],"genre_scores_gemma":[0.99909115,0.000044780696,0.000053108703,0.000058166574,0.000005798184,0.000021273008,0.0005746116,0.000004136455,0.00014693405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973459,0.000724842,0.00037518656,0.0006286759,0.00032372453,0.0006016113],"domain_scores_gemma":[0.99468476,0.0005789491,0.0026040538,0.00053005666,0.0006677387,0.00093450653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014247164,0.00036204915,0.0009979568,0.0009091894,0.00064853794,0.00129078,0.0014214463,0.001118208,0.0014574121],"category_scores_gemma":[0.0051652067,0.0007388798,0.001349126,0.0020426102,0.00069239223,0.0009971116,0.0013388513,0.0013621586,0.00040963327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018435527,0.00006133234,0.9987348,0.000009022053,0.0000704258,0.00006977798,0.00013992666,0.00003872952,0.00010061435,0.000010586466,0.00017358623,0.00040688898],"study_design_scores_gemma":[0.00001224732,0.000096743985,0.99893934,0.0000072719463,0.000028333385,0.00014759757,0.00049497,0.0000970779,0.000023258846,0.000008652501,0.00013601388,0.000008492367],"about_ca_topic_score_codex":0.062510416,"about_ca_topic_score_gemma":0.060779564,"teacher_disagreement_score":0.062510416,"about_ca_system_score_codex":0.0030350867,"about_ca_system_score_gemma":0.0019336251,"threshold_uncertainty_score":0.12429315},"labels":[],"label_agreement":null},{"id":"W1988539479","doi":"10.1016/j.lungcan.2007.01.007","title":"Lung cancer in systemic lupus erythematosus","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; McGill University; McGill University Health Centre","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Medicine; Cancer; Lung cancer; Lung; Systemic lupus erythematosus; Lupus erythematosus; Dermatology; Oncology; Internal medicine; Immunology; Antibody; Disease","score_opus":0.01606062311865448,"score_gpt":0.3507504158093458,"score_spread":0.3346897926906913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988539479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6093749,0.32007965,0.00038720312,0.03109659,0.0017092514,0.00008701786,0.0005461038,0.00004828133,0.036670968],"genre_scores_gemma":[0.92386264,0.063638315,0.0002444736,0.002258324,0.0056358315,0.000040043953,0.00032345435,0.0000041722496,0.0039927093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944407,0.00023840935,0.00007617753,0.00003703014,0.0001071337,0.000097207296],"domain_scores_gemma":[0.9986008,0.0005366786,0.00028225564,0.0000371868,0.00019942728,0.00034372695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010651469,0.00015898829,0.00054569234,0.0016130328,0.0006121688,0.000847462,0.00027165664,0.0012180244,0.0033526185],"category_scores_gemma":[0.002321819,0.00015697937,0.0002923183,0.0013637455,0.00052210735,0.0006625225,0.00048046414,0.0007190082,0.00032431708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097557926,0.00038889513,0.8754153,0.00077942724,0.00009877763,0.0048907828,0.0004407684,0.00017491438,0.0010923032,0.0015698735,0.01392782,0.10024552],"study_design_scores_gemma":[0.00013540905,0.0005508104,0.96771026,0.00038529336,0.00019655959,0.012451046,0.0010072946,0.0002716118,0.00022337445,0.00070930185,0.016345214,0.000013792701],"about_ca_topic_score_codex":0.007561981,"about_ca_topic_score_gemma":0.011296491,"teacher_disagreement_score":0.007561981,"about_ca_system_score_codex":0.0008886513,"about_ca_system_score_gemma":0.0013627406,"threshold_uncertainty_score":0.015035927},"labels":[],"label_agreement":null},{"id":"W1989531033","doi":"10.1016/j.lungcan.2011.05.009","title":"Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"China Academy of Building Research","keywords":"Medicine; Internal medicine; Adiponectin; Cachexia; Leptin; Gastroenterology; Lung cancer; Cancer; Ghrelin; Context (archaeology); Oncology; Insulin; Obesity; Insulin resistance; Hormone","score_opus":0.03305584892285819,"score_gpt":0.3659825178433134,"score_spread":0.33292666892045525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989531033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99790394,0.0012665162,0.00007547054,0.000079252815,0.000009824473,0.000004644506,0.00020587126,0.000003604803,0.00045081638],"genre_scores_gemma":[0.99931884,0.0002736978,0.000104464656,0.000016747483,0.00001060061,0.0000038990956,0.00016306281,8.062969e-7,0.00010781145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999838,0.00005527271,0.000021181135,0.000024374827,0.00003649348,0.00002463878],"domain_scores_gemma":[0.9989838,0.0002606237,0.0004331907,0.000040307998,0.00009573145,0.00018623182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000391303,0.0003309866,0.00051251624,0.00067739433,0.00031418295,0.00053815177,0.00027444368,0.00046295277,0.00080410123],"category_scores_gemma":[0.0024198869,0.0002014224,0.0003280706,0.0010993211,0.00019352089,0.00041040074,0.00037153062,0.000713474,0.00013344431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002041296,0.000024691097,0.99832124,0.00000689696,0.000047024056,0.000028283224,0.000017489217,0.0000406166,0.00014867225,0.0000072922735,0.00002739621,0.0011261974],"study_design_scores_gemma":[0.0000050070903,0.00013083692,0.99911743,0.0000040644245,0.00004460686,0.00013481197,0.000058033962,0.00035288985,0.0000589006,0.000029216868,0.000060998787,0.0000032442697],"about_ca_topic_score_codex":0.0034609213,"about_ca_topic_score_gemma":0.005871737,"teacher_disagreement_score":0.0034609213,"about_ca_system_score_codex":0.0002526965,"about_ca_system_score_gemma":0.0002739927,"threshold_uncertainty_score":0.006881535},"labels":[],"label_agreement":null},{"id":"W1991781559","doi":"10.1016/j.lungcan.2011.05.004","title":"Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Nausea; Maintenance therapy; Chemotherapy; Adverse effect; Carboplatin; Phases of clinical research; Surgery; Cancer; Clinical trial; Cisplatin","score_opus":0.02031515920557238,"score_gpt":0.3429522428959205,"score_spread":0.32263708369034816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991781559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938606,0.0019682483,0.00035892933,0.00046058878,0.0001930393,0.0011709695,0.0007837884,0.00009549516,0.0011083022],"genre_scores_gemma":[0.99188614,0.0014209085,0.0006926029,0.00046005,0.00016693815,0.0014745417,0.0014765933,0.000036085454,0.0023861884],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995524,0.00017955036,0.000018744386,0.00009026939,0.000029350344,0.00012968689],"domain_scores_gemma":[0.999328,0.00010834284,0.00010566789,0.00006519454,0.00003680524,0.00035597605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013470524,0.0018293661,0.0042659347,0.0005608,0.0006232959,0.0012884659,0.0010430048,0.0015029967,0.004311727],"category_scores_gemma":[0.00079343305,0.0007237356,0.0021589592,0.00048111173,0.0012224924,0.0012149278,0.00036283195,0.0037830488,0.0009918021],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8576464,0.041326035,0.005088786,0.00067181425,0.0014285492,0.00018965735,0.00028124166,0.0031039014,0.0279233,0.0002623264,0.003267151,0.058810726],"study_design_scores_gemma":[0.615056,0.36888772,0.009949392,0.000024725921,0.00047199833,0.00019725457,0.000084080675,0.0011897017,0.0024401306,0.000167567,0.0015001056,0.000031289237],"about_ca_topic_score_codex":0.0017484032,"about_ca_topic_score_gemma":0.003949918,"teacher_disagreement_score":0.004311727,"about_ca_system_score_codex":0.0012583834,"about_ca_system_score_gemma":0.0016904048,"threshold_uncertainty_score":0.014424205},"labels":[],"label_agreement":null},{"id":"W1993982225","doi":"10.1016/j.lungcan.2008.10.002","title":"Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Proportional hazards model; Multivariate analysis; Life expectancy; Surgery; Confidence interval; Population","score_opus":0.016353814824862152,"score_gpt":0.32141116587109064,"score_spread":0.3050573510462285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993982225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8729017,0.026151601,0.00018407701,0.07129244,0.0013309435,0.000027080016,0.008797772,0.00007268971,0.01924182],"genre_scores_gemma":[0.98308337,0.0046084025,0.00014513211,0.0073901773,0.00043470124,0.000012898429,0.0024821758,0.00005255615,0.001790599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99613273,0.0006031507,0.00028569074,0.00038659375,0.00096871605,0.0016230553],"domain_scores_gemma":[0.99061817,0.0014728534,0.002011072,0.00061970984,0.002804011,0.002474102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026665675,0.00030033189,0.0012727374,0.0019311502,0.0016442094,0.0028098966,0.0013159591,0.0021088698,0.008179221],"category_scores_gemma":[0.011373076,0.00028824675,0.001158031,0.0047448687,0.0013335244,0.0015442902,0.0017105434,0.0021959583,0.0007934062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035444736,0.00014534521,0.8532128,0.00044086072,0.0010628519,0.0008157776,0.0018215465,0.0005184463,0.0010627282,0.0022814977,0.04102628,0.09406738],"study_design_scores_gemma":[0.00005856173,0.00007780745,0.9913024,0.00011379847,0.0001921169,0.0001300914,0.002015835,0.00006405653,0.000077576,0.00027256247,0.005651567,0.0000435954],"about_ca_topic_score_codex":0.81824446,"about_ca_topic_score_gemma":0.8835326,"teacher_disagreement_score":0.18175554,"about_ca_system_score_codex":0.00878257,"about_ca_system_score_gemma":0.012050116,"threshold_uncertainty_score":0.36565185},"labels":[],"label_agreement":null},{"id":"W1998005130","doi":"10.1016/j.lungcan.2014.09.016","title":"Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Cohort; Referral; Oncology; Lung cancer; Population; Internal medicine; Cohort study; Cancer; Gerontology; Family medicine; Environmental health","score_opus":0.018891360673866275,"score_gpt":0.32253025293221255,"score_spread":0.3036388922583463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998005130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929404,0.00011699887,0.000030003814,0.00014008261,0.000004515109,0.0000032877483,0.00020722463,0.0000019459324,0.00020190082],"genre_scores_gemma":[0.9993967,0.000099704135,0.000025874593,0.000044690616,0.000009855152,0.000003945154,0.00028647596,0.0000024567441,0.00013021939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992268,0.00019642989,0.00007330017,0.00020792213,0.00010065912,0.00019493638],"domain_scores_gemma":[0.9984629,0.00024162672,0.0006387039,0.00008756233,0.0001670467,0.00040220018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005179264,0.00022945442,0.0004315266,0.0008124998,0.00081881555,0.001236336,0.00063441106,0.0008307556,0.0024344493],"category_scores_gemma":[0.0031377487,0.00038325528,0.00070456107,0.0021265682,0.00044177863,0.0011072378,0.00095271214,0.0009890245,0.00035624838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003884943,0.000033640143,0.9991621,0.0000020729428,0.000023488861,0.000068907626,0.00011883368,0.0000229361,0.000053930253,0.000015835501,0.00007055033,0.00038886574],"study_design_scores_gemma":[0.0000032770815,0.000045177796,0.99872667,0.000002963992,0.00001225802,0.0001517263,0.0008282533,0.00012668587,0.000009403571,0.00002623057,0.00006374718,0.0000036591728],"about_ca_topic_score_codex":0.0359784,"about_ca_topic_score_gemma":0.039603576,"teacher_disagreement_score":0.0359784,"about_ca_system_score_codex":0.0010833549,"about_ca_system_score_gemma":0.0009841683,"threshold_uncertainty_score":0.07153797},"labels":[],"label_agreement":null},{"id":"W1998447850","doi":"10.1016/j.lungcan.2009.03.030","title":"Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience","year":2009,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Nodule (geology); Stage (stratigraphy); Radiology; Cancer; Nuclear medicine; Internal medicine","score_opus":0.017731119485595973,"score_gpt":0.3445140233105349,"score_spread":0.3267829038249389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998447850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677759,0.0027090234,0.00025418564,0.0054861023,0.00007277326,0.000049527956,0.0006726353,0.000020060514,0.022959752],"genre_scores_gemma":[0.9923969,0.00295978,0.00037416423,0.00067751424,0.00006258,0.000011927508,0.00024182223,0.000016506601,0.0032588053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946874,0.0000949362,0.00003264876,0.00006040442,0.00021857147,0.00012480853],"domain_scores_gemma":[0.9979164,0.00017781521,0.00022093399,0.000059932183,0.00045028084,0.001174691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043639887,0.00029750343,0.0002393078,0.0003884792,0.0021500394,0.0010205198,0.0004813872,0.0005768085,0.0030578908],"category_scores_gemma":[0.0018983705,0.0002835209,0.00023118903,0.0013026871,0.00077117013,0.000530372,0.000970398,0.00086177967,0.00027379737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049762754,0.00037866607,0.9092773,0.00015840889,0.00008261199,0.0067288475,0.009818677,0.00069027464,0.0023492693,0.0011698945,0.011017553,0.057830874],"study_design_scores_gemma":[0.00004015688,0.00034219556,0.9754519,0.000088286724,0.0000757466,0.0031751278,0.0075619277,0.00049737387,0.000280818,0.00015258435,0.01228435,0.000049545062],"about_ca_topic_score_codex":0.81727296,"about_ca_topic_score_gemma":0.9466068,"teacher_disagreement_score":0.18272704,"about_ca_system_score_codex":0.011105023,"about_ca_system_score_gemma":0.009795566,"threshold_uncertainty_score":0.36760628},"labels":[],"label_agreement":null},{"id":"W1998469340","doi":"10.1016/j.lungcan.2014.01.020","title":"Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients","year":2014,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Body Composition Measurement Techniques","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Medicine; Bioelectrical impedance analysis; Sarcopenia; Cachexia; Lung cancer; Intensive care medicine; Malnutrition; Quality of life (healthcare); Anthropometry; Clinical Practice; Cancer; Physical therapy; Internal medicine; Body mass index","score_opus":0.03263241219288492,"score_gpt":0.4028540895371105,"score_spread":0.37022167734422556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998469340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011914291,0.9983005,0.00008210409,0.0001453968,0.00004659249,0.0000046259515,0.00004265032,0.0000023935831,0.00018433222],"genre_scores_gemma":[0.008607759,0.99046093,0.00039060728,0.00016162098,0.00015159215,0.000012404898,0.00010146705,9.5310645e-7,0.000112603026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997056,0.00006411821,0.000058812257,0.00005996811,0.0000953269,0.000016162887],"domain_scores_gemma":[0.99914193,0.00054137525,0.00016281968,0.000012416964,0.000116186,0.000025273801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089003716,0.00068795733,0.001993753,0.0011466356,0.0001398322,0.00083674025,0.000694888,0.00059764856,0.00091960403],"category_scores_gemma":[0.0019140927,0.00021638657,0.00096119964,0.0016550653,0.0003101341,0.00055260374,0.0004568593,0.0011611041,0.00022084858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034083886,0.00018446714,0.025887333,0.022163339,0.0017501188,0.000102643426,0.00006632178,0.00045781213,0.00043325254,0.0006901802,0.0059821308,0.9419416],"study_design_scores_gemma":[0.00046661863,0.0015446045,0.43295452,0.06582696,0.025335252,0.005035679,0.0011127321,0.002936246,0.0026918133,0.008002697,0.4537104,0.0003824769],"about_ca_topic_score_codex":0.0021444734,"about_ca_topic_score_gemma":0.0037613146,"teacher_disagreement_score":0.0021444734,"about_ca_system_score_codex":0.0003122792,"about_ca_system_score_gemma":0.0009895015,"threshold_uncertainty_score":0.004706979},"labels":[],"label_agreement":null},{"id":"W1999448758","doi":"10.1016/j.lungcan.2012.06.002","title":"Rising incidence of adenocarcinoma of the lung in Canada","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Adenocarcinoma; Medicine; Incidence (geometry); Lung cancer; Cohort; Small-cell carcinoma; Cancer; Oncology; Internal medicine; Adenocarcinoma of the lung; Cohort study; Carcinoma; Demography","score_opus":0.02995053333884998,"score_gpt":0.32370334262935885,"score_spread":0.29375280929050884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999448758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099278,0.022009637,0.00047544666,0.019759858,0.00042500955,0.00006170568,0.016109245,0.00015405523,0.031077262],"genre_scores_gemma":[0.98813057,0.0058912677,0.00025591854,0.00085343653,0.00007459852,0.0000048654965,0.0016253998,0.0000148630825,0.0031490906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999252,0.000033779164,0.00004178273,0.00007485978,0.00033180244,0.00026579865],"domain_scores_gemma":[0.99734986,0.00008657393,0.0003296583,0.00003928716,0.0015394927,0.000655058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026921363,0.00020131757,0.00033374457,0.002492424,0.0014873482,0.0014948922,0.00087228563,0.000833542,0.004745006],"category_scores_gemma":[0.0022278256,0.00022991342,0.0006660917,0.006437923,0.000592366,0.0005069937,0.0005573924,0.0011978687,0.00032218883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012435584,0.000029264902,0.96767575,0.00013431335,0.00008073612,0.0005111866,0.00035007822,0.00047838996,0.00043255073,0.0007285159,0.0087362565,0.02071854],"study_design_scores_gemma":[0.000009096189,0.000018029772,0.9911829,0.000060046303,0.00006139604,0.00036097114,0.0011413525,0.0005786554,0.00012826343,0.000103963655,0.006338269,0.000016968686],"about_ca_topic_score_codex":0.9948144,"about_ca_topic_score_gemma":0.99748296,"teacher_disagreement_score":0.031928103,"about_ca_system_score_codex":0.031928103,"about_ca_system_score_gemma":0.047010366,"threshold_uncertainty_score":0.23165572},"labels":[],"label_agreement":null},{"id":"W2000030988","doi":"10.1016/j.lungcan.2010.07.005","title":"Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Stage (stratigraphy); Lung cancer; Clinical trial; Cancer; Population; Oncology; Surgery","score_opus":0.004274299695362077,"score_gpt":0.2545818721247282,"score_spread":0.25030757242936613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000030988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489695,0.00083364866,0.00004446306,0.00055756705,0.000016683507,0.00001573864,0.00080799224,0.000005660072,0.0028211223],"genre_scores_gemma":[0.9975746,0.00048878865,0.00006151061,0.00015622505,0.00000888463,0.000004499146,0.00044546244,0.0000050154945,0.0012549373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994875,0.00005384307,0.000031278185,0.000055386867,0.00016043267,0.00021157129],"domain_scores_gemma":[0.9983499,0.00014707954,0.00028866614,0.000028719309,0.0006657007,0.00051980524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004052387,0.00016643379,0.00034499724,0.0008038032,0.0013319979,0.0010846102,0.00088531256,0.00046701566,0.0018091723],"category_scores_gemma":[0.0017965322,0.00021117018,0.00033471963,0.002280375,0.0005641322,0.00024655656,0.0004464771,0.00066131697,0.00017725652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024174037,0.000049802853,0.9937749,0.000018944465,0.000025986934,0.00016728505,0.0004762943,0.00021573647,0.00024118678,0.00009747987,0.0006478288,0.0040429514],"study_design_scores_gemma":[0.000013667112,0.00004707711,0.9976544,0.000018710823,0.00001948838,0.00011168562,0.0011094707,0.00020495206,0.00005658894,0.00002565501,0.00072963734,0.000008618721],"about_ca_topic_score_codex":0.9876204,"about_ca_topic_score_gemma":0.9934042,"teacher_disagreement_score":0.0213063,"about_ca_system_score_codex":0.0213063,"about_ca_system_score_gemma":0.017818045,"threshold_uncertainty_score":0.15458876},"labels":[],"label_agreement":null},{"id":"W2000715692","doi":"10.1016/s0169-5002(05)80908-0","title":"P-415 Occupational distribution, incidence and survival rates of malignant mesothelioma in Nova Scotia, Canada 1990–2002","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova scotia; Medicine; Mesothelioma; Incidence (geometry); Nova (rocket); Distribution (mathematics); Demography; Geography; Pathology; Archaeology","score_opus":0.01148010091261293,"score_gpt":0.2924919957574463,"score_spread":0.28101189484483335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000715692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500043,0.0016629144,0.00015346061,0.0003516905,0.000034998928,0.000059948525,0.04261395,0.00003832884,0.0050805244],"genre_scores_gemma":[0.9854269,0.00071355863,0.00016118168,0.00009396553,0.000009718172,0.00002342952,0.009579303,0.000009289184,0.0039826916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944097,0.00003616291,0.00006902158,0.00007501101,0.00018552996,0.00019332915],"domain_scores_gemma":[0.997405,0.00010835362,0.00045998514,0.000064095235,0.0015287327,0.0004338102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000360566,0.00032183854,0.00029056144,0.0025996803,0.0012064013,0.00068224146,0.00095038454,0.00044080793,0.0019939248],"category_scores_gemma":[0.001646425,0.00033064157,0.00063003384,0.0040319855,0.0004008229,0.00025829437,0.00055075885,0.00041007338,0.00041660786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001278016,0.000013779885,0.99369353,0.0000603707,0.00006797863,0.00013085279,0.00020239702,0.0002719625,0.0003005276,0.00006024698,0.0024548487,0.0026156225],"study_design_scores_gemma":[0.0000045229663,0.000007813078,0.99877304,0.000014272914,0.000013873115,0.00005715709,0.00017112667,0.00016621966,0.000038733993,0.0000049706814,0.00074463943,0.000003628854],"about_ca_topic_score_codex":0.9952852,"about_ca_topic_score_gemma":0.9967899,"teacher_disagreement_score":0.014834101,"about_ca_system_score_codex":0.014834101,"about_ca_system_score_gemma":0.018019332,"threshold_uncertainty_score":0.10762942},"labels":[],"label_agreement":null},{"id":"W2000856265","doi":"10.1016/s0169-5002(99)00093-8","title":"Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis","year":2000,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique; McGill University","funders":"Health Canada","keywords":"Medicine; Relative risk; Lung cancer; Meta-analysis; Tobacco smoke; Confidence interval; Confounding; Cohort study; Cohort; Cancer; Demography; Internal medicine; Environmental health","score_opus":0.056858556199907685,"score_gpt":0.37662433203467754,"score_spread":0.31976577583476984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000856265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010391279,0.98814315,0.0006951145,0.000115054594,0.0001374546,0.000058477905,0.00025535157,0.000022437842,0.00018181074],"genre_scores_gemma":[0.16237111,0.83417755,0.0017738292,0.0003878843,0.00021274465,0.0001486719,0.00039727817,0.00001588258,0.00051503774],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9981426,0.00087718037,0.00036908896,0.00027947527,0.00024589652,0.000085681684],"domain_scores_gemma":[0.99617237,0.002878487,0.00047334444,0.0001318257,0.00026002905,0.000083941326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004121899,0.0023283185,0.009163628,0.002277802,0.00036290236,0.0012921946,0.001458427,0.0014127708,0.0022448837],"category_scores_gemma":[0.007621762,0.0011270897,0.018301386,0.0034802558,0.00027521403,0.0006683319,0.0007205901,0.00103445,0.0002319262],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008681597,0.000114871444,0.010440748,0.105042495,0.8378041,0.00037751457,0.0000621745,0.0014313138,0.00089879945,0.00013078508,0.001135376,0.033880167],"study_design_scores_gemma":[0.00092472945,0.0003539207,0.005846042,0.0025791829,0.98785144,0.00019559269,0.000023245964,0.00024857325,0.000186512,0.00015831953,0.001609563,0.000022865846],"about_ca_topic_score_codex":0.0067917267,"about_ca_topic_score_gemma":0.015612465,"teacher_disagreement_score":0.009163628,"about_ca_system_score_codex":0.0010803754,"about_ca_system_score_gemma":0.0017039347,"threshold_uncertainty_score":0.021798968},"labels":[],"label_agreement":null},{"id":"W2001550450","doi":"10.1016/j.lungcan.2011.07.004","title":"Lung cancer associated venous thromboembolic disease: A comprehensive review","year":2011,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Lung cancer; Cancer; Thrombosis; Disease; Venous thrombosis; Risk factor; Internal medicine; Incidence (geometry); Oncology; Intensive care medicine","score_opus":0.056645546334832146,"score_gpt":0.397982378862458,"score_spread":0.34133683252762587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001550450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009290981,0.99942505,0.000025719128,0.0001190584,0.00008715983,0.000005449937,0.00002937435,0.0000026280034,0.00021271264],"genre_scores_gemma":[0.0005801216,0.99897027,0.000077385776,0.00014184625,0.00009675879,0.0000049660903,0.000029489536,4.9911193e-7,0.000098702105],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99962544,0.000061876766,0.0001305774,0.000055078654,0.00010181713,0.000025247262],"domain_scores_gemma":[0.99881977,0.0005554104,0.00036792786,0.000017716338,0.00017788367,0.00006131266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006482404,0.000868707,0.0023650762,0.004873093,0.00025318004,0.0010968883,0.0007750593,0.0009411402,0.004131423],"category_scores_gemma":[0.0021445774,0.0004242421,0.0009231986,0.005136679,0.00035185026,0.0014580507,0.00076007645,0.0009344091,0.0006879491],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012567353,0.00008965838,0.0013076264,0.13447264,0.00079718453,0.0004888592,0.000094237126,0.0003039109,0.00075895386,0.00056829903,0.04232225,0.81867075],"study_design_scores_gemma":[0.00018484608,0.00041068366,0.010588278,0.10473652,0.007007704,0.0065795705,0.00030183137,0.00022774152,0.00055676093,0.00084396865,0.86847734,0.00008480224],"about_ca_topic_score_codex":0.0029093497,"about_ca_topic_score_gemma":0.009047724,"teacher_disagreement_score":0.004873093,"about_ca_system_score_codex":0.0007184336,"about_ca_system_score_gemma":0.0025608672,"threshold_uncertainty_score":0.013821006},"labels":[],"label_agreement":null},{"id":"W2004018927","doi":"10.1016/j.lungcan.2011.12.003","title":"Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ministry of Health; Canadian Centre for Applied Research in Cancer Control","funders":"BC Cancer Agency","keywords":"Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Cost-effectiveness analysis; Cohort; Survival analysis; Erlotinib Hydrochloride; Cost effectiveness; Univariate analysis; Population; Cancer; Multivariate analysis; Epidermal growth factor receptor","score_opus":0.028621419008751803,"score_gpt":0.41023038328219824,"score_spread":0.3816089642734464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004018927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9339724,0.035317626,0.0059061097,0.0018309243,0.00029069395,0.0011804629,0.015462524,0.00012788734,0.0059114355],"genre_scores_gemma":[0.99105084,0.0035293403,0.0016791405,0.00026739386,0.000061264735,0.00018705809,0.0027946485,0.000020483421,0.0004097182],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99353117,0.00492757,0.00034203738,0.00036350795,0.00040803294,0.00042765582],"domain_scores_gemma":[0.9876744,0.010057343,0.0012731872,0.0002869696,0.0002763726,0.00043169552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0078101633,0.0018831777,0.0043801256,0.0024897605,0.00029947696,0.0024549575,0.0014364026,0.0017456689,0.0057937554],"category_scores_gemma":[0.016350677,0.0009517714,0.012292974,0.003031362,0.000722226,0.0029055122,0.0009421563,0.0024447122,0.0002612481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33948776,0.0040330295,0.06510842,0.011535594,0.093376026,0.0011471509,0.00021395995,0.3442,0.0018272311,0.0057952884,0.0065296046,0.12674592],"study_design_scores_gemma":[0.094863,0.06618287,0.1791199,0.0030260812,0.2222313,0.0038339773,0.0014643448,0.40160093,0.0027591016,0.010181798,0.013884724,0.00085189304],"about_ca_topic_score_codex":0.011300352,"about_ca_topic_score_gemma":0.00843124,"teacher_disagreement_score":0.011300352,"about_ca_system_score_codex":0.0048597045,"about_ca_system_score_gemma":0.0019406418,"threshold_uncertainty_score":0.04130459},"labels":[],"label_agreement":null},{"id":"W2004298772","doi":"10.1016/j.lungcan.2011.09.003","title":"Lung cancer histologies associated with emphysema on computed tomography","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Jewish General Hospital","keywords":"Medicine; Lung cancer; COPD; Adenocarcinoma; Odds ratio; Internal medicine; Squamous carcinoma; Lung cancer screening; Pulmonology; Small-cell carcinoma; Cancer; Radiology; Carcinoma; Oncology","score_opus":0.022944144480351387,"score_gpt":0.29865045225307646,"score_spread":0.2757063077727251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004298772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968169,0.0040052286,0.0007791212,0.00040877433,0.00009345785,0.000081096216,0.00028786607,0.000031331012,0.02614413],"genre_scores_gemma":[0.99814665,0.0006273003,0.00028620087,0.00007777629,0.00010023322,0.000006515396,0.0001291318,0.000003650932,0.0006224934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996772,0.00006643376,0.000052875825,0.00003156923,0.000083769126,0.00008815188],"domain_scores_gemma":[0.9989761,0.00031729953,0.0003269608,0.00009332264,0.00013235466,0.00015399147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037093874,0.00034201244,0.00030792443,0.0018056175,0.0006073548,0.0005641967,0.0003279693,0.00048324437,0.004400414],"category_scores_gemma":[0.0017862865,0.00022062109,0.000287004,0.0009770436,0.0006388504,0.00049506477,0.00036970485,0.0003989175,0.00049374404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021218277,0.000037066347,0.96340144,0.000047850404,0.000031740045,0.02888875,0.00005820421,0.00007731688,0.0031777695,0.00027208144,0.00032464723,0.0034708653],"study_design_scores_gemma":[0.000021150194,0.00010754064,0.8237954,0.000042008785,0.00008566311,0.17054892,0.00039305605,0.00044852102,0.002272333,0.00045068914,0.0018228686,0.000011900626],"about_ca_topic_score_codex":0.0010688697,"about_ca_topic_score_gemma":0.0023925013,"teacher_disagreement_score":0.004400414,"about_ca_system_score_codex":0.0003541491,"about_ca_system_score_gemma":0.0003894635,"threshold_uncertainty_score":0.014720798},"labels":[],"label_agreement":null},{"id":"W2004469331","doi":"10.1016/j.lungcan.2008.02.002","title":"Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Docetaxel; Gefitinib; Oncology; Chemotherapy; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Epidermal growth factor receptor","score_opus":0.02022896833383872,"score_gpt":0.35836567103033284,"score_spread":0.3381367026964941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004469331","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42430326,0.5607175,0.00085687434,0.001156273,0.00065192813,0.0003619948,0.008521571,0.000037261565,0.0033932533],"genre_scores_gemma":[0.8119695,0.17567362,0.0013615907,0.0023436355,0.0015869709,0.00019515301,0.0058567016,0.00005075275,0.0009619968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972451,0.00070390303,0.001404704,0.00025417111,0.00031565718,0.00007655269],"domain_scores_gemma":[0.98299295,0.0069854357,0.007505998,0.00046520165,0.0017528145,0.00029763437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026868517,0.0002052453,0.0011387554,0.0016620781,0.00017747078,0.0008046785,0.00039242933,0.0005292459,0.0013117016],"category_scores_gemma":[0.009486251,0.00023590244,0.0015446703,0.0029345793,0.00032307408,0.0004948694,0.00026736248,0.00029645412,0.00032916272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028719727,0.0006127011,0.54233867,0.076629035,0.022353435,0.0072368244,0.0009024695,0.0007893553,0.010009997,0.00048820223,0.016067613,0.29385197],"study_design_scores_gemma":[0.0020969373,0.014083541,0.8005792,0.011892263,0.059102956,0.0333407,0.00070763024,0.00036658967,0.0055556814,0.00015969346,0.07197391,0.00014091152],"about_ca_topic_score_codex":0.001448685,"about_ca_topic_score_gemma":0.0024455506,"teacher_disagreement_score":0.0026868517,"about_ca_system_score_codex":0.0006920934,"about_ca_system_score_gemma":0.00091930135,"threshold_uncertainty_score":0.014209628},"labels":[],"label_agreement":null},{"id":"W2006129790","doi":"10.1016/j.lungcan.2006.05.009","title":"Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with limited stage small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Vanderbilt University","keywords":"Medicine; Stage (stratigraphy); Antidiuretic; Syndrome of inappropriate antidiuretic hormone secretion; Internal medicine; Performance status; Gastroenterology; Cancer; Statistical significance; Pleural effusion; Lung cancer; Surgery; Hormone","score_opus":0.007191848446745408,"score_gpt":0.26870471296888465,"score_spread":0.26151286452213923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006129790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618137,0.0012247618,0.00019041747,0.00026207307,0.000036854806,0.000015528598,0.0001400584,0.000015897847,0.0019330574],"genre_scores_gemma":[0.99940443,0.00024249892,0.000057736364,0.00006667945,0.000044702898,0.000003897285,0.00008887139,0.0000013473036,0.000089846115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979836,0.000034627374,0.000044122735,0.00003490605,0.000048453243,0.000039469673],"domain_scores_gemma":[0.9989213,0.00042354056,0.00025135826,0.00004101253,0.0000677945,0.00029505743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019685703,0.00046159705,0.00061898056,0.0011186337,0.000602566,0.00047319417,0.00036614932,0.00070963963,0.0014626837],"category_scores_gemma":[0.0024322176,0.00023284195,0.0003908674,0.0009682223,0.00056533254,0.0006434835,0.00040642123,0.0006285267,0.0001623878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006692087,0.000056547742,0.92774886,0.00004363849,0.00004300818,0.06598945,0.0001344355,0.0001208187,0.0016202235,0.00007991289,0.00028109466,0.0032126396],"study_design_scores_gemma":[0.00006887483,0.00055955077,0.8034482,0.0000239634,0.00010649298,0.1931826,0.0005495194,0.0008234667,0.00047119078,0.00022181353,0.00052058743,0.00002376456],"about_ca_topic_score_codex":0.0029443507,"about_ca_topic_score_gemma":0.002707376,"teacher_disagreement_score":0.0029443507,"about_ca_system_score_codex":0.00031700396,"about_ca_system_score_gemma":0.0005251159,"threshold_uncertainty_score":0.005854428},"labels":[],"label_agreement":null},{"id":"W2006472996","doi":"10.1016/j.lungcan.2010.01.012","title":"Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Medical prescription; Population; Cancer registry; Total cost; Average cost; Cancer; Emergency medicine; Medical record; Intensive care medicine; Internal medicine","score_opus":0.010535648217525272,"score_gpt":0.3217445640135893,"score_spread":0.311208915796064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006472996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967578,0.0007124134,0.00009907566,0.0003911335,0.000009254523,0.000007114248,0.0011321348,0.00000899749,0.0008819635],"genre_scores_gemma":[0.9991491,0.00018432469,0.000042284275,0.00003663715,0.000011086546,0.000003781238,0.00047063633,0.0000022251447,0.000099988756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999209,0.00025926527,0.00009283375,0.00013688991,0.0000943492,0.00020770042],"domain_scores_gemma":[0.9964371,0.0006413956,0.0020886352,0.00015210781,0.00022578052,0.00045505512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050470483,0.0001441144,0.00028591158,0.00070057693,0.00028327506,0.00057941535,0.00062751304,0.0006332675,0.0027924771],"category_scores_gemma":[0.0052676415,0.00024328643,0.0010439706,0.0015237565,0.00025807015,0.0006081554,0.0004959572,0.00078653824,0.00015086475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053131813,0.000051332077,0.9941168,0.000016588752,0.00020728378,0.00011563682,0.000031791693,0.0009504848,0.00012521459,0.00018022048,0.0004242195,0.0032491283],"study_design_scores_gemma":[0.000012535841,0.000109726614,0.99783176,0.0000072497237,0.00005973789,0.00032677565,0.00010205246,0.0012130056,0.000033225242,0.00013877002,0.00015971586,0.0000054416428],"about_ca_topic_score_codex":0.020962808,"about_ca_topic_score_gemma":0.028345255,"teacher_disagreement_score":0.020962808,"about_ca_system_score_codex":0.0016952681,"about_ca_system_score_gemma":0.0007122006,"threshold_uncertainty_score":0.041681588},"labels":[],"label_agreement":null},{"id":"W2006888413","doi":"10.1016/j.lungcan.2005.11.006","title":"Targeting colloidal particulates to thoracic lymph nodes","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"University of Toronto","keywords":"Lymphatic system; Lymph; Medicine; Pathology; Clearance; Anatomy","score_opus":0.00886427457805322,"score_gpt":0.32012398770829753,"score_spread":0.3112597131302443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006888413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9335909,0.017560054,0.03335364,0.0011424572,0.0009055055,0.00021959028,0.00013016423,0.0002633066,0.0128343515],"genre_scores_gemma":[0.9767616,0.004577932,0.007642175,0.0002948481,0.00019384951,0.00007614516,0.0000652931,0.0000520416,0.010336141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998907,0.000023250623,0.000004756133,0.000021436621,0.000030503896,0.000029280975],"domain_scores_gemma":[0.9998772,0.00005046682,0.000020971016,0.000015610978,0.000014430953,0.000021305894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002632943,0.00020420138,0.00028505884,0.00033390117,0.0002766494,0.0005681815,0.00023490234,0.00053373404,0.0021299082],"category_scores_gemma":[0.000358027,0.00016385561,0.00032493484,0.00017994357,0.00038716543,0.00036463214,0.0003615568,0.00047697985,0.00081292883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084445666,0.00022420025,0.0013538916,0.0006139752,0.00007054263,0.0009256839,0.00019179973,0.0015213875,0.9198179,0.0017133631,0.0015969577,0.07112581],"study_design_scores_gemma":[0.00036580212,0.006973608,0.0042636674,0.000118825745,0.00022152918,0.0025993846,0.00027527666,0.0062485654,0.94158983,0.0010063594,0.036309905,0.000027158154],"about_ca_topic_score_codex":0.0008583917,"about_ca_topic_score_gemma":0.0012816241,"teacher_disagreement_score":0.0021299082,"about_ca_system_score_codex":0.00028642503,"about_ca_system_score_gemma":0.00032644108,"threshold_uncertainty_score":0.0071252584},"labels":[],"label_agreement":null},{"id":"W2007240877","doi":"10.1016/j.lungcan.2013.05.007","title":"Clinical evaluation of microRNA expression profiling in non small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National and Kapodistrian University of Athens","keywords":"microRNA; Lung cancer; Pathogenesis; Gene expression profiling; Medicine; Cancer; Fold change; Gene expression; Cancer research; Pathological; Molecular biology; Pathology; Gene; Biology; Internal medicine; Genetics","score_opus":0.019094468253357384,"score_gpt":0.34699834123570766,"score_spread":0.3279038729823503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007240877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789012,0.007183018,0.0032800667,0.00061910384,0.00015299734,0.00020449462,0.00047346763,0.00013487761,0.009050722],"genre_scores_gemma":[0.99645483,0.00063909014,0.0013998065,0.00022887428,0.000054399075,0.000086890854,0.0003140932,0.000022954328,0.00079903414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998514,0.0005624581,0.00017274948,0.0002840053,0.00036085898,0.00010592503],"domain_scores_gemma":[0.9981699,0.0008703439,0.00023014098,0.00010234996,0.0004506135,0.00017669887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002220373,0.00037936214,0.00068156753,0.0007584268,0.0004877813,0.0010696698,0.00032891365,0.00067031186,0.0010852504],"category_scores_gemma":[0.004944139,0.00020209071,0.0002417695,0.00077148696,0.000627157,0.00048732266,0.0002821516,0.00049246347,0.00049492816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065129115,0.0002267417,0.86018467,0.00027574273,0.00014456299,0.0024005945,0.00036635323,0.00046483506,0.05815341,0.0004278402,0.0015699066,0.0692724],"study_design_scores_gemma":[0.00019933759,0.004943546,0.9016284,0.000096314514,0.0003941088,0.00953617,0.00073105714,0.007852694,0.062910564,0.00066274544,0.010995477,0.00004961588],"about_ca_topic_score_codex":0.00039966125,"about_ca_topic_score_gemma":0.0007375256,"teacher_disagreement_score":0.002220373,"about_ca_system_score_codex":0.0004014016,"about_ca_system_score_gemma":0.00040121854,"threshold_uncertainty_score":0.011742592},"labels":[],"label_agreement":null},{"id":"W2009395127","doi":"10.1016/j.lungcan.2012.06.011","title":"Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Regimen; Gastroenterology; Progressive disease; Dosing; Chemotherapy; Phases of clinical research; Oncology; Surgery; Randomized controlled trial","score_opus":0.009072014609089915,"score_gpt":0.26735822757912303,"score_spread":0.2582862129700331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009395127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98166007,0.010412361,0.0003585243,0.00229786,0.000331645,0.0010638561,0.00090811774,0.0001058285,0.0028618025],"genre_scores_gemma":[0.98077446,0.0070433076,0.0017214832,0.0026202062,0.0003732238,0.0013914198,0.002496943,0.000043206837,0.0035357845],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994535,0.00034084212,0.00001715043,0.00006322473,0.000043107055,0.000082212384],"domain_scores_gemma":[0.99904865,0.00020524436,0.00015040906,0.00006305537,0.00006425114,0.00046838194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023678557,0.0013050665,0.0016203922,0.0004528739,0.00061583245,0.0011708724,0.00083551806,0.0013979904,0.0024770563],"category_scores_gemma":[0.0012186042,0.00045066193,0.0013174615,0.00042902294,0.00089925237,0.00074393256,0.00038870017,0.003411198,0.00052846404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7628722,0.021598024,0.013836032,0.0015030855,0.0033432385,0.00025963635,0.0003303942,0.0032241896,0.024656426,0.000733578,0.015755335,0.1518878],"study_design_scores_gemma":[0.8548035,0.120417625,0.014728268,0.00008775322,0.0009510794,0.00022594059,0.00008841239,0.0010210358,0.0019595504,0.0002481361,0.0054293713,0.000039451723],"about_ca_topic_score_codex":0.0020346863,"about_ca_topic_score_gemma":0.006122944,"teacher_disagreement_score":0.0024770563,"about_ca_system_score_codex":0.0011459875,"about_ca_system_score_gemma":0.0015696626,"threshold_uncertainty_score":0.012522578},"labels":[],"label_agreement":null},{"id":"W2009482902","doi":"10.1016/j.lungcan.2006.04.007","title":"Risk of lung cancer following nonmalignant respiratory conditions: Evidence from two case-control studies in Montreal, Canada","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Institut National de la Recherche Scientifique; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Odds ratio; Context (archaeology); Respiratory disease; Asthma; Internal medicine; Pneumonia; Case-control study; Cancer; Confounding; Population; Risk factor; Lung; Environmental health","score_opus":0.024214358865067356,"score_gpt":0.36603021768674476,"score_spread":0.3418158588216774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009482902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647946,0.021361712,0.00087940873,0.0008434461,0.00009600483,0.0002854165,0.007242271,0.00003511049,0.0044620316],"genre_scores_gemma":[0.99368036,0.0032624782,0.00049805216,0.00022265565,0.000025194904,0.000059871716,0.0012996453,0.000009704972,0.00094193715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964005,0.0010577266,0.0003670878,0.0006701197,0.0008562081,0.0006485067],"domain_scores_gemma":[0.9920866,0.0013194613,0.0018004816,0.0005094021,0.0033941197,0.0008899712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031353363,0.0009620141,0.0010399801,0.0030597884,0.0031945913,0.0021151206,0.002618286,0.0010332838,0.0027595481],"category_scores_gemma":[0.009270816,0.0008567721,0.0018714498,0.0059257834,0.0017235129,0.00044883514,0.0009836776,0.0008119889,0.00014811968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056019454,0.00006627326,0.99185,0.00020556134,0.0011687163,0.00022299282,0.00062155485,0.00015874523,0.0002627415,0.00022056268,0.0010037486,0.0036589904],"study_design_scores_gemma":[0.000113778624,0.00006073832,0.997829,0.00007516723,0.00060137484,0.000080717364,0.00023730626,0.00012008011,0.00006189725,0.000026984437,0.0007737606,0.000019075233],"about_ca_topic_score_codex":0.9943954,"about_ca_topic_score_gemma":0.99482226,"teacher_disagreement_score":0.026193935,"about_ca_system_score_codex":0.026193935,"about_ca_system_score_gemma":0.019894121,"threshold_uncertainty_score":0.19005114},"labels":[],"label_agreement":null},{"id":"W2012290550","doi":"10.1016/s0169-5002(00)80349-9","title":"Concurrent chemo- (cisplatin and etoposide) radiation for stage III non-small cell lung cancer: Lack of correlation of p53 expression to treatment response","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Etoposide; Oncology; Cisplatin; Lung cancer; Internal medicine; Stage (stratigraphy); Radiation therapy; Correlation; Cancer research; Chemotherapy; Biology","score_opus":0.028126937392692876,"score_gpt":0.391023161995535,"score_spread":0.3628962246028421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012290550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978212,0.0009688813,0.00010078909,0.000057753747,0.000008750183,0.000017146755,0.00006011284,0.000003867551,0.0009612928],"genre_scores_gemma":[0.99966586,0.000108288245,0.000033944314,0.000016885808,0.00000804319,0.0000048224792,0.000046562203,0.0000010817057,0.000114578244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991942,0.0003947267,0.000093852344,0.00008763782,0.00016403657,0.00006554518],"domain_scores_gemma":[0.9943487,0.0036949955,0.00060942606,0.00047259938,0.00044261446,0.00043167511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017258173,0.00012453135,0.00038785083,0.00040402522,0.00020747143,0.00041375015,0.00027792124,0.00033530986,0.001639998],"category_scores_gemma":[0.004951948,0.00013153379,0.0003432969,0.0004731829,0.00037138828,0.00030449947,0.00019594727,0.00048780453,0.00021072426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029107535,0.0009152425,0.8457627,0.00017803007,0.0005299827,0.00046193038,0.00047089224,0.0005215191,0.07307673,0.00018338239,0.0003053202,0.048486773],"study_design_scores_gemma":[0.00022777022,0.007015596,0.98261815,0.000016428477,0.00028385065,0.0008032742,0.00014991825,0.0004478601,0.007535625,0.00006790731,0.00082805514,0.0000056066824],"about_ca_topic_score_codex":0.0017504118,"about_ca_topic_score_gemma":0.0025303988,"teacher_disagreement_score":0.0017504118,"about_ca_system_score_codex":0.00042427387,"about_ca_system_score_gemma":0.00052237464,"threshold_uncertainty_score":0.00912714},"labels":[],"label_agreement":null},{"id":"W2015739947","doi":"10.1016/j.lungcan.2013.07.012","title":"Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"National Cancer Institute; Eli Lilly and Company","keywords":"Vinorelbine; Gemcitabine; Medicine; Cisplatin; Oncology; Lung cancer; Internal medicine; Randomized controlled trial; Chemotherapy","score_opus":0.014542369910559483,"score_gpt":0.34099801955339265,"score_spread":0.3264556496428332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015739947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483486,0.0141578,0.0060594096,0.005914025,0.0016148981,0.007595931,0.0068039373,0.00030688915,0.009198521],"genre_scores_gemma":[0.988139,0.0012650035,0.002218899,0.0014634508,0.0002999001,0.0020448316,0.002119939,0.00005069775,0.0023982844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99432063,0.004637226,0.0001432563,0.00034051173,0.00018493309,0.00037339132],"domain_scores_gemma":[0.99263144,0.0048646335,0.0010889426,0.00037803352,0.0001959208,0.00084100274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008505462,0.003534062,0.0033689796,0.00077590614,0.00039527682,0.0017330254,0.0017413717,0.0025318868,0.013201157],"category_scores_gemma":[0.013733508,0.0010635741,0.006981502,0.00050142274,0.0016119995,0.0014878941,0.0010185213,0.005546307,0.00092091184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9848275,0.0010534781,0.00038083942,0.0004368753,0.0030196633,0.00005081073,0.000019191877,0.0035945964,0.00033455112,0.0003248497,0.0008640234,0.0050935857],"study_design_scores_gemma":[0.9534574,0.028368756,0.0019227111,0.00013399178,0.0051917336,0.00010221136,0.00004502563,0.007862224,0.00034712674,0.0013735219,0.0011516107,0.000043808133],"about_ca_topic_score_codex":0.003479123,"about_ca_topic_score_gemma":0.0029003902,"teacher_disagreement_score":0.013201157,"about_ca_system_score_codex":0.0033948873,"about_ca_system_score_gemma":0.0023046131,"threshold_uncertainty_score":0.044981718},"labels":[],"label_agreement":null},{"id":"W2017143209","doi":"10.1016/j.lungcan.2012.11.018","title":"Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Human papilloma virus; Lung; Carcinoma; Virus; Genome; Oncology; Pathology; Cancer research; Internal medicine; Virology; Cancer; Gene; Biology; Cervical cancer; Genetics","score_opus":0.017812179469169135,"score_gpt":0.31493750048465374,"score_spread":0.2971253210154846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017143209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962553,0.00073647447,0.0000701694,0.00019954777,0.000026280071,0.0000066640364,0.00034104267,0.0000106221705,0.0023540494],"genre_scores_gemma":[0.9990589,0.00032480079,0.0000347588,0.00007866764,0.00003101576,0.0000042201927,0.00016071677,0.0000037737284,0.00030323802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995466,0.00009809409,0.000045640707,0.00009569846,0.00010491772,0.00010898268],"domain_scores_gemma":[0.9983375,0.0006660836,0.00053238514,0.000097429795,0.0001362542,0.00023038671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026692235,0.00019509625,0.00030528838,0.0012389744,0.0007921178,0.0009306746,0.00041745385,0.0007162733,0.00523874],"category_scores_gemma":[0.0029289688,0.00030229596,0.00020931993,0.0011171327,0.00045328637,0.00061487296,0.0002849493,0.00048910594,0.000464644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014503209,0.000037791975,0.99378127,0.000021050035,0.000019185823,0.0015717506,0.00018236366,0.00001535535,0.0011135394,0.000064600914,0.00042159655,0.0026264098],"study_design_scores_gemma":[0.000010436384,0.000093019284,0.9845844,0.000021532313,0.000048134538,0.01224387,0.0012098645,0.00012232215,0.00025660676,0.0001490353,0.0012519571,0.000008845519],"about_ca_topic_score_codex":0.0050529647,"about_ca_topic_score_gemma":0.006033748,"teacher_disagreement_score":0.00523874,"about_ca_system_score_codex":0.00023350825,"about_ca_system_score_gemma":0.00041461166,"threshold_uncertainty_score":0.017525315},"labels":[],"label_agreement":null},{"id":"W2017922297","doi":"10.1016/s0169-5002(03)00138-7","title":"Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Plant Disease Resistance and Genetics","field":"Agricultural and Biological Sciences","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adenocarcinoma; Lung cancer; Medicine; Lung; Oncology; Incidence (geometry); Ethnic group; Internal medicine; Adenocarcinoma of the lung; Pathology; Cancer","score_opus":0.014958719896782387,"score_gpt":0.2580034833160323,"score_spread":0.2430447634192499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017922297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99846244,0.0003193918,0.00016511448,0.000056151934,0.00000881141,0.000003895665,0.00012888928,0.0000076153133,0.00084771815],"genre_scores_gemma":[0.999373,0.0000733155,0.00004901382,0.000012250324,0.000007566029,0.0000024569274,0.00005593157,0.000004536218,0.00042183124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994386,0.00023045194,0.00006372045,0.00010319707,0.000065834625,0.00009807124],"domain_scores_gemma":[0.99770004,0.0008849754,0.00052713626,0.00023444663,0.00015844371,0.0004949846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006656326,0.00027661218,0.00047001027,0.0014113428,0.0006229126,0.0005983393,0.0004524543,0.0006387794,0.0041684546],"category_scores_gemma":[0.0025084862,0.0003148294,0.0007282068,0.0011145232,0.0005825909,0.0003101353,0.00049069436,0.00064851815,0.0004042716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020997908,0.00007625458,0.9810698,0.000014458596,0.00024293333,0.00077721797,0.00018623077,0.00010123434,0.013421569,0.00012509573,0.000053864715,0.0018315488],"study_design_scores_gemma":[0.000010293781,0.00016982594,0.99731535,0.000003308623,0.00010386421,0.0010365245,0.00017729522,0.00022924,0.00068192254,0.000109590685,0.00015676882,0.0000059926792],"about_ca_topic_score_codex":0.0041636494,"about_ca_topic_score_gemma":0.0038649936,"teacher_disagreement_score":0.0041684546,"about_ca_system_score_codex":0.00021635335,"about_ca_system_score_gemma":0.00027378535,"threshold_uncertainty_score":0.013944864},"labels":[],"label_agreement":null},{"id":"W2019407271","doi":"10.1016/j.lungcan.2004.08.016","title":"Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer","year":2004,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Vinorelbine; Chemotherapy; Lung cancer; Internal medicine; Surgery; Cohort; Cancer; Oncology; Cisplatin","score_opus":0.02556108665151988,"score_gpt":0.36827560822227706,"score_spread":0.34271452157075716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019407271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048564473,0.9989748,0.000030206045,0.000120439014,0.00005783717,0.0000026901257,0.000016623968,0.0000014328631,0.0003103908],"genre_scores_gemma":[0.003923986,0.99558985,0.00009270628,0.00012988059,0.000071280425,0.000006051363,0.000023188972,5.3473593e-7,0.00016255352],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997036,0.00008060253,0.000078496654,0.00004282042,0.00008219078,0.000012206427],"domain_scores_gemma":[0.9989039,0.0006617378,0.0003066417,0.000013153043,0.00008879656,0.000025805562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063875783,0.00033679625,0.0013945205,0.0010592747,0.00011220243,0.00045701064,0.00046044326,0.0004656874,0.0015356592],"category_scores_gemma":[0.0021668184,0.00017883364,0.00052077183,0.0018654678,0.00018593532,0.00047294842,0.00023824736,0.00056584383,0.00018622719],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015406914,0.00008096211,0.0028363487,0.043101102,0.0004489446,0.00012649607,0.00006156906,0.00024981837,0.00034251044,0.00035812688,0.007264377,0.9449756],"study_design_scores_gemma":[0.0003749611,0.0016066699,0.09430264,0.09408626,0.00781738,0.007339145,0.0005621941,0.00074698246,0.0014327142,0.0014115192,0.79022163,0.000097897915],"about_ca_topic_score_codex":0.0020874427,"about_ca_topic_score_gemma":0.0061899065,"teacher_disagreement_score":0.0020874427,"about_ca_system_score_codex":0.00046798112,"about_ca_system_score_gemma":0.0009458159,"threshold_uncertainty_score":0.0051372647},"labels":[],"label_agreement":null},{"id":"W2022580888","doi":"10.1016/s0169-5002(03)00228-9","title":"The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Red Cross Society","funders":"","keywords":"Medicine; Radiation therapy; Hilum (anatomy); NODAL; Lung cancer; Cancer; Oncology; Internal medicine; Radiology","score_opus":0.028996414512802944,"score_gpt":0.3789804832824597,"score_spread":0.34998406876965676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022580888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937452,0.002259136,0.00037232507,0.000108779815,0.000008001183,0.00001557528,0.002477095,0.000017800714,0.0009960925],"genre_scores_gemma":[0.99740076,0.0003751797,0.00015123092,0.00002963058,0.000011281154,0.000007061532,0.0017593442,0.000027141947,0.00023839161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764687,0.0014026818,0.00018117877,0.0002366273,0.00039523034,0.00013743818],"domain_scores_gemma":[0.98753536,0.009404336,0.0017066112,0.00072752347,0.0003205802,0.00030558894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003962112,0.00030249805,0.000980054,0.0011473289,0.00015257836,0.0006902293,0.0007205736,0.00037315814,0.0015978211],"category_scores_gemma":[0.00803614,0.00020893269,0.0018856281,0.0014781042,0.00041565025,0.00054765097,0.00040461743,0.00058575626,0.00024231646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010009085,0.00011682526,0.9528175,0.00016571567,0.0026429906,0.0001699005,0.000094762385,0.012002663,0.0016765147,0.00011443527,0.0006225807,0.019567087],"study_design_scores_gemma":[0.00007235545,0.00064065884,0.9940142,0.000011197074,0.0008445196,0.00028906373,0.000058289133,0.0027428614,0.00051115244,0.00006497701,0.00073810475,0.0000126181285],"about_ca_topic_score_codex":0.008793129,"about_ca_topic_score_gemma":0.014451757,"teacher_disagreement_score":0.008793129,"about_ca_system_score_codex":0.00087595626,"about_ca_system_score_gemma":0.00048614855,"threshold_uncertainty_score":0.020953894},"labels":[],"label_agreement":null},{"id":"W2022747660","doi":"10.1016/j.lungcan.2006.10.021","title":"Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Adverse effect; Anemia; Adjuvant; Lung cancer; Oncology; Chemotherapy; Hemoglobin; Cisplatin; Gastroenterology","score_opus":0.017849420176140628,"score_gpt":0.3537547577835715,"score_spread":0.3359053376074309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022747660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897057,0.0052432697,0.0002639869,0.0010129308,0.0001544826,0.00016084987,0.00107593,0.000025467625,0.0023574433],"genre_scores_gemma":[0.99335104,0.0024778934,0.00043449106,0.0005692457,0.00017616189,0.00025850374,0.0016024808,0.00002066347,0.0011094292],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99886847,0.00083688064,0.000045395976,0.000087106055,0.00007438421,0.00008776873],"domain_scores_gemma":[0.9982589,0.000848172,0.0003209984,0.00015661887,0.00008212235,0.00033322003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035720398,0.0006834815,0.0015466838,0.000124353,0.00021565745,0.00071214564,0.00047334237,0.00060660945,0.0011989367],"category_scores_gemma":[0.0028278385,0.00021876623,0.001438373,0.0003237703,0.0005992128,0.0005950525,0.00027804766,0.0025065825,0.00022241869],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87493724,0.006382289,0.020984408,0.0007764042,0.0044493647,0.00012486058,0.00015929055,0.0037751803,0.006518374,0.00054610765,0.0057807816,0.07556564],"study_design_scores_gemma":[0.5848818,0.27728742,0.11644625,0.0002583016,0.007467657,0.00024898147,0.00015220323,0.0030462937,0.003014439,0.0011455605,0.00597349,0.00007762461],"about_ca_topic_score_codex":0.0013399759,"about_ca_topic_score_gemma":0.0027476298,"teacher_disagreement_score":0.0035720398,"about_ca_system_score_codex":0.0007867369,"about_ca_system_score_gemma":0.000952341,"threshold_uncertainty_score":0.018891037},"labels":[],"label_agreement":null},{"id":"W2025267040","doi":"10.1016/j.lungcan.2013.06.023","title":"What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Cancer; Disease; Internal medicine; Physical therapy","score_opus":0.020265612033253267,"score_gpt":0.37654256354529836,"score_spread":0.3562769515120451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025267040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94259596,0.0417786,0.00025125174,0.006494976,0.00015887117,0.00011212352,0.005414837,0.00001155716,0.0031818314],"genre_scores_gemma":[0.9912641,0.0052001686,0.00025199197,0.00092689716,0.00017433728,0.00004370482,0.0019173756,0.000006426316,0.00021500903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99628925,0.0026214686,0.000264813,0.0002529479,0.0003213577,0.00025016005],"domain_scores_gemma":[0.98907065,0.0060353056,0.003658277,0.00027806708,0.00025788514,0.00069983903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039200503,0.00028261496,0.0014795391,0.00052180066,0.00024009764,0.001242502,0.0009173122,0.0011479127,0.0020893288],"category_scores_gemma":[0.016344758,0.00023307963,0.003409553,0.0012207167,0.00040112468,0.0014190833,0.0007696126,0.0016298331,0.00019646794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14518373,0.0044717835,0.6555287,0.0048243636,0.018789904,0.00016267003,0.00029014942,0.00596935,0.00040606526,0.002141511,0.011416709,0.15081516],"study_design_scores_gemma":[0.022515679,0.009635692,0.9340005,0.002139134,0.017355714,0.0002398907,0.00080287515,0.0036872306,0.00036633908,0.002241975,0.006917188,0.000097762604],"about_ca_topic_score_codex":0.008587515,"about_ca_topic_score_gemma":0.014736595,"teacher_disagreement_score":0.008587515,"about_ca_system_score_codex":0.0019017399,"about_ca_system_score_gemma":0.0015631149,"threshold_uncertainty_score":0.02073145},"labels":[],"label_agreement":null},{"id":"W2025575316","doi":"10.1016/j.lungcan.2007.07.006","title":"Systematic review of baseline low-dose CT lung cancer screening","year":2007,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Stage (stratigraphy); Predictive value; Clinical trial; Randomized controlled trial; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.037610699726108913,"score_gpt":0.41769251457685586,"score_spread":0.38008181485074694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025575316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010752439,0.99771845,0.000117263095,0.00013268464,0.00009578159,0.00019658335,0.00039775154,0.0000097254815,0.00025659215],"genre_scores_gemma":[0.023196433,0.9745122,0.0007395467,0.0006755622,0.00006638538,0.0003031657,0.00029445934,0.0000072975913,0.0002049335],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99617356,0.001320999,0.0014853007,0.00036766945,0.0005291391,0.00012344462],"domain_scores_gemma":[0.99052,0.0058462946,0.002460823,0.00014846113,0.00085207145,0.00017240855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00432476,0.0013839258,0.009296494,0.0041760528,0.0004080822,0.001531224,0.001559648,0.0012128731,0.0054194382],"category_scores_gemma":[0.019874869,0.0009913996,0.0066504464,0.0048928335,0.00061206846,0.001297759,0.0011948318,0.0012945826,0.00036868383],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000517127,0.000023473636,0.0006997986,0.9465382,0.022354383,0.0000913159,0.0000936354,0.00014095618,0.00019436152,0.00007976017,0.0018860591,0.027380923],"study_design_scores_gemma":[0.002350789,0.00079863245,0.010711315,0.5849907,0.36862436,0.0007100796,0.00020285895,0.00015949215,0.00032396414,0.00028619633,0.030769454,0.00007223173],"about_ca_topic_score_codex":0.01610997,"about_ca_topic_score_gemma":0.056378588,"teacher_disagreement_score":0.01610997,"about_ca_system_score_codex":0.0035235204,"about_ca_system_score_gemma":0.008263258,"threshold_uncertainty_score":0.03203243},"labels":[],"label_agreement":null},{"id":"W2026319709","doi":"10.1016/s0169-5002(00)00135-5","title":"The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Proportional hazards model; Lung cancer; Internal medicine; Oncology; Retrospective cohort study; Carboplatin; Logistic regression; Chemotherapy; Toxicity","score_opus":0.005698174636181947,"score_gpt":0.3125502786399122,"score_spread":0.30685210400373025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026319709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971312,0.0017472346,0.00014488758,0.00012951472,0.000049219743,0.000032251064,0.00008687349,0.000010613984,0.00066816236],"genre_scores_gemma":[0.99885225,0.00046365318,0.00012850172,0.00005190508,0.000046542944,0.000018045206,0.00008364526,0.000009021471,0.00034643224],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995065,0.00029675147,0.000030757714,0.000049179947,0.00005299491,0.00006379428],"domain_scores_gemma":[0.99885595,0.00067780964,0.00010566372,0.00007952348,0.00003827324,0.00024283529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010191124,0.00020960113,0.00081170426,0.0002569954,0.00017846689,0.00037664038,0.00029292062,0.0003819513,0.0011210329],"category_scores_gemma":[0.0022363276,0.00011735093,0.00040816254,0.00032912163,0.00025297084,0.00042295497,0.000194255,0.0006705269,0.00013288256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44987667,0.006341537,0.083313435,0.00039181067,0.0011596928,0.00052704883,0.0004285214,0.0109069105,0.11626836,0.0005364736,0.001962728,0.32828686],"study_design_scores_gemma":[0.013468484,0.23891088,0.6837608,0.00008412967,0.0016791278,0.0014779678,0.00048105384,0.01209269,0.038131002,0.0010783097,0.008756529,0.00007902045],"about_ca_topic_score_codex":0.00075455266,"about_ca_topic_score_gemma":0.0019736907,"teacher_disagreement_score":0.0011210329,"about_ca_system_score_codex":0.00048349638,"about_ca_system_score_gemma":0.000449822,"threshold_uncertainty_score":0.005389631},"labels":[],"label_agreement":null},{"id":"W2030607022","doi":"10.1016/j.lungcan.2005.08.013","title":"Twenty-year secular changes in sex specific lung cancer incidence rates in an urban Chinese population","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"Prevent Cancer Foundation","keywords":"Medicine; Poisson regression; Incidence (geometry); Lung cancer; Demography; Population; Cancer registry; Cancer; Cohort; Cohort study; Rate ratio; Cohort effect; Epidemiology; Internal medicine; Environmental health","score_opus":0.0286345065994595,"score_gpt":0.36918787538413966,"score_spread":0.3405533687846802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030607022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993537,0.00006686474,0.000022549179,0.00004019396,0.000004182116,0.000002618757,0.00029659606,0.000003882149,0.00020937991],"genre_scores_gemma":[0.99929225,0.00006561102,0.000024225894,0.000019489125,0.0000054429493,0.0000042728834,0.0003060652,0.0000012342894,0.00028121314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997838,0.00004201063,0.00002608355,0.000047463025,0.000030761497,0.00006982098],"domain_scores_gemma":[0.99925154,0.00009751937,0.00025636883,0.00005084429,0.0001445783,0.00019914699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051269704,0.00022236738,0.00020636049,0.0012095586,0.00044957382,0.00048396573,0.00028727364,0.0003784508,0.0010902513],"category_scores_gemma":[0.0010883918,0.00019546344,0.00044939338,0.0013465668,0.00032850564,0.0005433498,0.0003798862,0.00034995118,0.00026075589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119319164,0.000025508323,0.99775285,0.000006756461,0.000028160786,0.000074920885,0.0002902877,0.000043128035,0.00031511663,0.000015781381,0.0000834328,0.0012448179],"study_design_scores_gemma":[0.0000013868555,0.00003133712,0.9995485,5.4995735e-7,0.000010471055,0.000040428753,0.00020756581,0.00005593771,0.000035209894,0.000004473205,0.000061953964,0.0000021106262],"about_ca_topic_score_codex":0.03015877,"about_ca_topic_score_gemma":0.0355663,"teacher_disagreement_score":0.03015877,"about_ca_system_score_codex":0.0007066187,"about_ca_system_score_gemma":0.0008709233,"threshold_uncertainty_score":0.059966445},"labels":[],"label_agreement":null},{"id":"W2032371685","doi":"10.1016/j.lungcan.2005.06.010","title":"Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline","year":2005,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Cancer Care Ontario","funders":"European Society for Medical Oncology","keywords":"Docetaxel; Taxane; Medicine; Oncology; Vinorelbine; Gemcitabine; Internal medicine; Lung cancer; Cisplatin; Paclitaxel; Guideline; Chemotherapy; Regimen; Cancer; Breast cancer; Pathology","score_opus":0.030239857460425346,"score_gpt":0.4431672683192456,"score_spread":0.41292741085882023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032371685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00076122984,0.994561,0.0005399174,0.0016734651,0.00045926054,0.00032687737,0.00053966156,0.000019987398,0.0011186745],"genre_scores_gemma":[0.00996834,0.98296976,0.0036251605,0.0017179538,0.00015247895,0.00034256943,0.00038239404,0.0000071705513,0.00083420164],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.998386,0.0005047084,0.0006128074,0.0001417126,0.00031350524,0.00004131808],"domain_scores_gemma":[0.9968566,0.0015583072,0.0009978475,0.00004704381,0.00045851935,0.000081761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032617392,0.00072692416,0.0033742848,0.0020186508,0.00025176007,0.0007213201,0.0015683008,0.0011682059,0.0024722773],"category_scores_gemma":[0.0075939763,0.000518843,0.0034652508,0.0021961692,0.0002653722,0.0008065796,0.0005047969,0.0011634605,0.00040553705],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009878594,0.00006296397,0.0013606523,0.46615416,0.009777627,0.00023996356,0.00016615776,0.00089644064,0.0012178251,0.0011015467,0.05967259,0.4583622],"study_design_scores_gemma":[0.004525586,0.0009480635,0.012673276,0.51222277,0.08295919,0.001438137,0.00023636207,0.0010018618,0.0015455687,0.002251654,0.38009486,0.00010263194],"about_ca_topic_score_codex":0.007895039,"about_ca_topic_score_gemma":0.045490574,"teacher_disagreement_score":0.007895039,"about_ca_system_score_codex":0.0018381367,"about_ca_system_score_gemma":0.003921922,"threshold_uncertainty_score":0.017249942},"labels":[],"label_agreement":null},{"id":"W2033412371","doi":"10.1016/j.lungcan.2004.11.003","title":"Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary","year":2005,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Cancer Care Ontario; Hamilton Health Sciences; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Mesothelioma; Extrapleural Pneumonectomy; Randomized controlled trial; Pneumonectomy; Pleural disease; Lung cancer; Clinical trial; Surgery; Pleurectomy; General surgery; Oncology; Internal medicine; Respiratory disease; Lung; Pathology; Peritoneal mesothelioma","score_opus":0.03974358463808642,"score_gpt":0.38401631942893144,"score_spread":0.344272734790845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033412371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00068551034,0.99891436,0.000045578618,0.000095530726,0.000051215226,0.00003467667,0.00006976245,0.0000017557606,0.00010159112],"genre_scores_gemma":[0.010633431,0.9887093,0.00025430354,0.00020256815,0.00004878774,0.000044268858,0.00006527494,0.000001024029,0.000041021183],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99835485,0.00054873334,0.00059203745,0.00016214527,0.0002827904,0.000059431128],"domain_scores_gemma":[0.9945727,0.0037283527,0.0011898916,0.000055801956,0.00035923207,0.00009398749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025041527,0.0008411606,0.0048829583,0.0031126977,0.00031910834,0.0009942458,0.0012181898,0.00096708967,0.0023787005],"category_scores_gemma":[0.009561472,0.00059033785,0.004605227,0.003781949,0.00048525873,0.00087890244,0.00076081126,0.00075225456,0.00018401621],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043671686,0.0000340912,0.0019075024,0.877363,0.018055342,0.00019713311,0.000113838745,0.0002469405,0.0002663431,0.00013253154,0.0025122825,0.09873428],"study_design_scores_gemma":[0.0015190868,0.0010934796,0.021205839,0.6559615,0.2667864,0.0018293024,0.000616614,0.0002932501,0.00051462575,0.00061387685,0.049476415,0.00008960561],"about_ca_topic_score_codex":0.004880364,"about_ca_topic_score_gemma":0.022202456,"teacher_disagreement_score":0.0048829583,"about_ca_system_score_codex":0.001192772,"about_ca_system_score_gemma":0.0033025148,"threshold_uncertainty_score":0.013243377},"labels":[],"label_agreement":null},{"id":"W2034309045","doi":"10.1016/s0169-5002(03)00161-2","title":"Ongoing and future trials of biologic therapies in lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Chemotherapy; Oncology; Clinical trial; Cancer; Intensive care medicine; Targeted therapy; Internal medicine; Lung","score_opus":0.05967837281913717,"score_gpt":0.4635147829541828,"score_spread":0.4038364101350456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034309045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011221024,0.99857664,0.00009359766,0.00039331635,0.00014984747,0.0000099081635,0.000016988488,0.0000052181786,0.0006423451],"genre_scores_gemma":[0.000732788,0.99769115,0.00027916723,0.00070944504,0.00017647403,0.000018509609,0.00003243136,0.0000016738193,0.00035837034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99954337,0.00013894206,0.00008304193,0.00006729753,0.00012716779,0.00004012514],"domain_scores_gemma":[0.9985037,0.0010640941,0.00017917341,0.000028014074,0.00016396606,0.000061040664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022762886,0.0010589618,0.0039177253,0.001751767,0.00035778698,0.0014630515,0.0014266594,0.0017961783,0.00489354],"category_scores_gemma":[0.0021665278,0.00035664937,0.0013494703,0.0023450425,0.00059599895,0.0015744332,0.0004978717,0.0027950185,0.0014754913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059644756,0.00015102909,0.0002223923,0.025009297,0.0003417733,0.00020133455,0.00004426603,0.0004107922,0.0014042167,0.0017819139,0.022327134,0.9475094],"study_design_scores_gemma":[0.001028902,0.0011912865,0.0019786207,0.016430788,0.0017062763,0.0013671994,0.00014022515,0.00021463032,0.0008039907,0.0027602743,0.97234017,0.000037706406],"about_ca_topic_score_codex":0.0016889344,"about_ca_topic_score_gemma":0.0058586,"teacher_disagreement_score":0.00489354,"about_ca_system_score_codex":0.0009682693,"about_ca_system_score_gemma":0.0017267377,"threshold_uncertainty_score":0.016370535},"labels":[],"label_agreement":null},{"id":"W2036437506","doi":"10.1016/j.lungcan.2004.06.004","title":"Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Vindesine; Medicine; Cisplatin; Oncology; Mitomycin C; Chemotherapy; Internal medicine; Induction chemotherapy; Lung cancer; Stage (stratigraphy); Surgery; Vincristine","score_opus":0.01791368138287724,"score_gpt":0.3282780373517002,"score_spread":0.31036435596882295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036437506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835144,0.0063904994,0.0003709946,0.000867688,0.00015326693,0.0012504273,0.0023430716,0.00010607544,0.005003544],"genre_scores_gemma":[0.98078454,0.0057552764,0.0013599932,0.00088296353,0.00013506674,0.0010696283,0.0052490975,0.00003174759,0.004731681],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970514,0.00012217689,0.000011413858,0.00004183992,0.000039068225,0.00008026238],"domain_scores_gemma":[0.9992945,0.00009837623,0.00012790826,0.000049240654,0.00003804457,0.00039185307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011002425,0.0012529304,0.001644224,0.0002762793,0.0004438186,0.000679804,0.001039932,0.00082448527,0.0027900909],"category_scores_gemma":[0.00074662926,0.0002682477,0.0010911023,0.0005683602,0.0007540319,0.00048578077,0.00038462048,0.0017042413,0.00051706715],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75733185,0.011775692,0.012818448,0.0015148375,0.0027953829,0.00020710823,0.00051284325,0.0063468963,0.012810871,0.0007918347,0.01651926,0.17657506],"study_design_scores_gemma":[0.71397954,0.1917429,0.07581075,0.00018350565,0.0019303246,0.00027374167,0.00016983332,0.0022530342,0.0027148686,0.00042749796,0.010460839,0.000053077678],"about_ca_topic_score_codex":0.036553416,"about_ca_topic_score_gemma":0.13102798,"teacher_disagreement_score":0.036553416,"about_ca_system_score_codex":0.003875104,"about_ca_system_score_gemma":0.0035278462,"threshold_uncertainty_score":0.07268131},"labels":[],"label_agreement":null},{"id":"W2037773581","doi":"10.1016/s0169-5002(03)00279-4","title":"Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Regional Cancer Foundation","funders":"","keywords":"MYB; Transcription factor; Ectopic expression; Biology; Promoter; Transgene; Molecular biology; Gene expression; Gene; Genetics","score_opus":0.011591769996007207,"score_gpt":0.25886049443820053,"score_spread":0.24726872444219333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037773581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902964,0.0039515276,0.002430047,0.0002745207,0.00007028804,0.000018424953,0.00046670248,0.00010438497,0.0023876724],"genre_scores_gemma":[0.9945135,0.0006530088,0.0012520921,0.00005901919,0.000019872441,0.000022707078,0.0006616477,0.000020961159,0.00279717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998357,0.000036483925,0.000009387208,0.000028125298,0.00002591061,0.000064324086],"domain_scores_gemma":[0.99982065,0.000055785367,0.000034635977,0.00002706634,0.000012642669,0.000049159764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021706932,0.00041496832,0.00019453562,0.0003480447,0.00019310249,0.00034089573,0.00016480265,0.00022015523,0.001812268],"category_scores_gemma":[0.0001658815,0.00019701007,0.00030172238,0.00017798749,0.0003040371,0.0002103551,0.00028115025,0.00063439994,0.0004091419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032335834,0.00003217785,0.0002276918,0.00003443042,0.0000032638152,0.00005295192,0.000012196224,0.000060675928,0.99768376,0.00021966221,0.000077945624,0.0012719458],"study_design_scores_gemma":[0.00004067417,0.00023677487,0.004436647,0.000010128396,0.0000068140484,0.00013846312,0.000034103887,0.000912161,0.99255145,0.00009758901,0.0015306227,0.0000045582174],"about_ca_topic_score_codex":0.00081454706,"about_ca_topic_score_gemma":0.0016869123,"teacher_disagreement_score":0.001812268,"about_ca_system_score_codex":0.00055132585,"about_ca_system_score_gemma":0.00024419648,"threshold_uncertainty_score":0.0060626864},"labels":[],"label_agreement":null},{"id":"W2037994031","doi":"10.1016/s0169-5002(00)80748-5","title":"Diet, tea drinking and risk of lung cancer among non-smoking women in Canada","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Tea Polyphenols and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Lung cancer; Environmental health; Cancer; Oncology; Gerontology; Internal medicine","score_opus":0.003404514095020909,"score_gpt":0.24201310627956632,"score_spread":0.23860859218454541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037994031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951054,0.0019539015,0.00008038242,0.0009876954,0.000041980576,0.000035598634,0.003962054,0.000015173358,0.0034127252],"genre_scores_gemma":[0.99398214,0.0014280276,0.00012567997,0.00022777157,0.000015532944,0.000011626363,0.0009413467,0.000008068075,0.0032598064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957186,0.00003358462,0.0000335235,0.000062678904,0.000119635115,0.00017870958],"domain_scores_gemma":[0.9987961,0.000077999866,0.00015703287,0.000027408249,0.00044389616,0.0004974961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028582136,0.00026733725,0.00047330357,0.0013161898,0.0027293283,0.0012034785,0.0008767721,0.00077643944,0.003508038],"category_scores_gemma":[0.0011162126,0.00049742917,0.0007685046,0.003893289,0.0005032859,0.00036861285,0.0004927107,0.0010598247,0.0002628972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019055033,0.000069654074,0.99540114,0.000029790235,0.00006614347,0.00012027215,0.00038489656,0.00006204224,0.00021651629,0.00009127407,0.00089968456,0.0024679704],"study_design_scores_gemma":[0.000026259757,0.000031776188,0.9974275,0.000026955397,0.00006553295,0.000062993044,0.0010525673,0.00020203962,0.000052841173,0.000036927977,0.0010040053,0.000010592531],"about_ca_topic_score_codex":0.99497414,"about_ca_topic_score_gemma":0.9969434,"teacher_disagreement_score":0.016788535,"about_ca_system_score_codex":0.016788535,"about_ca_system_score_gemma":0.024057878,"threshold_uncertainty_score":0.1218099},"labels":[],"label_agreement":null},{"id":"W2040566551","doi":"10.1016/s0169-5002(00)80040-9","title":"Clinical dose-response relationships in non-small cell lung cancer: Implications for resistance mechanisms and resistance modulation","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Resistance (ecology); Lung cancer; Modulation (music); Oncology; Internal medicine; Biology","score_opus":0.023279597182410006,"score_gpt":0.32883180567986825,"score_spread":0.30555220849745823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040566551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76576155,0.13693166,0.039622836,0.012021169,0.0007941118,0.0019329748,0.0025057865,0.0013650502,0.03906484],"genre_scores_gemma":[0.9726078,0.01045219,0.0053653615,0.0019678692,0.00032170472,0.0003665409,0.0010390808,0.00019783924,0.007681606],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995466,0.0034940888,0.00017695599,0.00022108828,0.0004521512,0.00018970617],"domain_scores_gemma":[0.988025,0.008165174,0.0015130871,0.00093321153,0.0008198325,0.0005436366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007421875,0.00058855634,0.0016958775,0.0007165963,0.00036489085,0.0016656045,0.0008280357,0.0013282956,0.008923698],"category_scores_gemma":[0.010897634,0.00052939466,0.00075947656,0.0010300777,0.0007587601,0.0011657597,0.0003884901,0.0022379241,0.0026261965],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06276672,0.0074970224,0.07043591,0.0022507587,0.000978233,0.00087190536,0.0010667999,0.014589759,0.37872753,0.008555231,0.011551788,0.44070834],"study_design_scores_gemma":[0.00409703,0.2073198,0.34731212,0.00041168838,0.0016769852,0.0069753868,0.001650929,0.025273763,0.28028303,0.012007925,0.11275162,0.00023975583],"about_ca_topic_score_codex":0.0005594141,"about_ca_topic_score_gemma":0.0011633326,"teacher_disagreement_score":0.008923698,"about_ca_system_score_codex":0.0012080019,"about_ca_system_score_gemma":0.0009954779,"threshold_uncertainty_score":0.03925115},"labels":[],"label_agreement":null},{"id":"W2044028214","doi":"10.1016/s0169-5002(00)80329-3","title":"Outcome results of long term follow up, for population based cohort of patients with stage IIIA NSCLC treated with aggressive combined modality treatment approach in a prospective study","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Stage (stratigraphy); Outcome (game theory); Prospective cohort study; Cohort; Term (time); Internal medicine; Physical therapy; Oncology","score_opus":0.01912592164815841,"score_gpt":0.33551937115371,"score_spread":0.3163934495055516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044028214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999046,0.00014829685,0.000050263883,0.000020548403,0.0000065234435,0.000006939535,0.0004981872,0.0000022091888,0.00022091951],"genre_scores_gemma":[0.9983997,0.000076085445,0.000021567987,0.000018047902,0.0000131835295,0.000011587916,0.0011898646,0.0000020218486,0.00026792553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995821,0.000069641195,0.00004648993,0.00012367131,0.000042472384,0.00013566946],"domain_scores_gemma":[0.9987685,0.00018753536,0.00033415918,0.0001226462,0.00022509908,0.00036189225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069483666,0.00040186165,0.0005552677,0.0008063103,0.0010830546,0.0010240844,0.00037846682,0.00075684057,0.0012656992],"category_scores_gemma":[0.0017890689,0.00023874626,0.0010514806,0.000843811,0.00042686533,0.0008993972,0.0007166714,0.0008340989,0.00040449362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013340801,0.00015979346,0.99650455,0.000008801994,0.000114138595,0.00022775301,0.0001220194,0.000093422146,0.0003558434,0.000014830853,0.00009312727,0.0009715757],"study_design_scores_gemma":[0.000039278868,0.0009588742,0.9976513,0.0000046687205,0.00019229476,0.00041608064,0.00030708782,0.00013335235,0.00009593374,0.000031998123,0.00015748541,0.000011690555],"about_ca_topic_score_codex":0.0065635154,"about_ca_topic_score_gemma":0.0054898914,"teacher_disagreement_score":0.0065635154,"about_ca_system_score_codex":0.0005223465,"about_ca_system_score_gemma":0.0005540195,"threshold_uncertainty_score":0.013050616},"labels":[],"label_agreement":null},{"id":"W2048035888","doi":"10.1016/j.lungcan.2008.09.008","title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia","year":2008,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pemetrexed; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Mesothelioma; Chemotherapy; Surgery; Pathology","score_opus":0.018305678976831656,"score_gpt":0.3451744749100672,"score_spread":0.32686879593323553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048035888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011521293,0.99828196,0.000012242867,0.00018479755,0.00002938082,0.000004119175,0.00006773626,0.0000018418225,0.0002658036],"genre_scores_gemma":[0.0067589246,0.9928797,0.000068280555,0.00011032831,0.000019800971,0.0000047054714,0.00007324114,9.512591e-7,0.00008412231],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990933,0.00015206366,0.00024444528,0.00013659058,0.00031654845,0.000057085355],"domain_scores_gemma":[0.99698836,0.0013600169,0.0006783458,0.000043802702,0.0007992966,0.00013015274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018042506,0.00042832748,0.0021461954,0.0026697475,0.0003223409,0.0012258879,0.0011097235,0.00064227916,0.0012393408],"category_scores_gemma":[0.005147236,0.0002691854,0.001044691,0.0075994506,0.00039164844,0.0004748396,0.0004348713,0.0006463754,0.00013238465],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052799773,0.00007546161,0.017570712,0.10425109,0.002167127,0.00030448585,0.0003493843,0.00059185136,0.00047462079,0.0003437284,0.020365605,0.85297793],"study_design_scores_gemma":[0.00068292476,0.0009262619,0.3238213,0.2325275,0.025565054,0.005455614,0.0019460727,0.00093121664,0.0012531863,0.00071994844,0.4059695,0.00020138145],"about_ca_topic_score_codex":0.14459974,"about_ca_topic_score_gemma":0.36686936,"teacher_disagreement_score":0.85540026,"about_ca_system_score_codex":0.0043853293,"about_ca_system_score_gemma":0.009681023,"threshold_uncertainty_score":0.28751612},"labels":[],"label_agreement":null},{"id":"W2050229398","doi":"10.1016/j.lungcan.2012.09.010","title":"Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Context (archaeology); Stage (stratigraphy); Lung cancer; Internal medicine; Prospective cohort study; Multivariate analysis; Proportional hazards model; T-stage; Cancer; Gastroenterology; Surgery","score_opus":0.08286221255533598,"score_gpt":0.39448108810022103,"score_spread":0.31161887554488504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050229398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97413796,0.012318414,0.001124783,0.0018263874,0.0004383497,0.00025654343,0.006803633,0.000095928575,0.0029979653],"genre_scores_gemma":[0.9908953,0.00089979323,0.0004896107,0.00042935106,0.00023569683,0.00015007985,0.006137409,0.000034424906,0.0007284233],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959054,0.0027297747,0.00025359786,0.00058051845,0.0002649155,0.00026588183],"domain_scores_gemma":[0.9946576,0.0028195265,0.00084640103,0.0009476313,0.000287377,0.00044146433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009121133,0.0014170787,0.0031204193,0.00038387283,0.00038057016,0.0019142048,0.001368358,0.0010793036,0.002489924],"category_scores_gemma":[0.010246106,0.00043354803,0.004544138,0.0010194285,0.00062326476,0.001763401,0.00091377273,0.0022272111,0.00046017804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65240866,0.00058978965,0.22947407,0.0019115746,0.026734397,0.00032568112,0.0001941225,0.004887939,0.004577924,0.000751899,0.012727796,0.06541618],"study_design_scores_gemma":[0.2017696,0.034888983,0.64930993,0.00072405115,0.067861065,0.001116786,0.00043139642,0.0170062,0.0035790717,0.004932482,0.018154558,0.0002258486],"about_ca_topic_score_codex":0.002659096,"about_ca_topic_score_gemma":0.006980597,"teacher_disagreement_score":0.009121133,"about_ca_system_score_codex":0.00067365554,"about_ca_system_score_gemma":0.0011078343,"threshold_uncertainty_score":0.04823774},"labels":[],"label_agreement":null},{"id":"W2050506643","doi":"10.1016/j.lungcan.2003.08.012","title":"Induction therapy for stage III lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Stage (stratigraphy); Induction therapy; Lung cancer; Radiation therapy; Disease; Induction chemotherapy; Surgery; Chemotherapy; Pneumonectomy; Oncology; Internal medicine","score_opus":0.05736270721518764,"score_gpt":0.43144547449529397,"score_spread":0.3740827672801063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050506643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030748537,0.9982753,0.000098980294,0.000098883116,0.00011321101,0.00001504671,0.000040482744,0.0000072113635,0.0010434616],"genre_scores_gemma":[0.0018686783,0.9968458,0.0001966802,0.00023771403,0.00009484412,0.000017991908,0.000059557075,0.000001837877,0.00067695597],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998847,0.00002747955,0.000026774927,0.000022600807,0.000029305495,0.0000090359745],"domain_scores_gemma":[0.9997099,0.00015822254,0.0000799497,0.000008738315,0.000028620809,0.000014550664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039146608,0.000588703,0.0017338424,0.0013331776,0.0001733399,0.00041546943,0.0007333551,0.00045301532,0.00451905],"category_scores_gemma":[0.0007058918,0.0001817448,0.00065836636,0.0016182214,0.00020743207,0.00050180027,0.00031672788,0.0009501469,0.0010332331],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020549225,0.00008641598,0.00023551624,0.03298733,0.00019787514,0.00014331669,0.000029990315,0.00025863538,0.0010485279,0.00034739313,0.016530445,0.947929],"study_design_scores_gemma":[0.00044356185,0.00088711694,0.007294602,0.021748852,0.0020795881,0.0033901818,0.00008323867,0.0001680645,0.0016394849,0.0006233013,0.9616075,0.000034478395],"about_ca_topic_score_codex":0.0012042152,"about_ca_topic_score_gemma":0.0039849603,"teacher_disagreement_score":0.00451905,"about_ca_system_score_codex":0.0005053879,"about_ca_system_score_gemma":0.0007473799,"threshold_uncertainty_score":0.015117705},"labels":[],"label_agreement":null},{"id":"W2052354574","doi":"10.1016/j.lungcan.2013.07.023","title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"University of Chicago","keywords":"Medicine; Radiation therapy; Lung; Primary tumor; Oncology; Lung cancer; Internal medicine; Carcinoma; Metastasis; Radiology; Cancer","score_opus":0.010122525381446625,"score_gpt":0.2650764802135764,"score_spread":0.25495395483212974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052354574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973997,0.0015726585,0.000097241405,0.000103699094,0.0000108534905,0.0000036999652,0.00012114983,0.0000033002584,0.0006876542],"genre_scores_gemma":[0.99937505,0.00030543763,0.00003747441,0.000019704361,0.000020515414,0.0000018975674,0.00016657209,9.805023e-7,0.00007238374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99986744,0.000029515515,0.000014048007,0.000023108034,0.00002770281,0.000038235055],"domain_scores_gemma":[0.9995302,0.00012221378,0.00017362976,0.000017887323,0.0000248187,0.00013136619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002475612,0.00015958473,0.0002448117,0.0002504617,0.00025800912,0.00034025998,0.00021163297,0.00025107784,0.0010713817],"category_scores_gemma":[0.0011383606,0.00007576591,0.00027682114,0.0004131806,0.00017873204,0.00030753657,0.00027451225,0.00025135162,0.00009171474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006839891,0.000065026405,0.9811536,0.000025412062,0.0000633624,0.00048308293,0.000042319545,0.00018301992,0.0010319711,0.00005663078,0.00024653447,0.01596497],"study_design_scores_gemma":[0.000020014424,0.00030861917,0.9972916,0.0000071722307,0.00006072837,0.0012892145,0.00013440233,0.00029377957,0.00015045445,0.00012309926,0.00031669834,0.000004015464],"about_ca_topic_score_codex":0.00077766646,"about_ca_topic_score_gemma":0.0027114,"teacher_disagreement_score":0.0010713817,"about_ca_system_score_codex":0.00027551962,"about_ca_system_score_gemma":0.00032020334,"threshold_uncertainty_score":0.0035841465},"labels":[],"label_agreement":null},{"id":"W2053609037","doi":"10.1016/j.lungcan.2004.01.016","title":"Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of Hong Kong","keywords":"Medicine; Glutathione S-transferase; Lung cancer; Glutathione transferase; Gene; Glutathione; Cancer research; Oncology; Cancer; Transferase; Genetics; Internal medicine; Enzyme; Biology; Biochemistry","score_opus":0.006984964008787215,"score_gpt":0.2764814705197298,"score_spread":0.2694965065109426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053609037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990165,0.0001473928,0.00007006524,0.000050781404,0.0000065933004,0.0000059535573,0.0001251071,0.0000019380736,0.0005757004],"genre_scores_gemma":[0.99908245,0.000098979865,0.000033940232,0.000020453155,0.0000039431875,0.0000051486713,0.00008502673,0.0000015773614,0.0006685612],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977833,0.000053770564,0.0000301284,0.00004815418,0.000032241776,0.000057342168],"domain_scores_gemma":[0.99952173,0.0000908467,0.00009018943,0.000032625343,0.000085924774,0.00017868138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157143,0.0002602018,0.00036844844,0.0006243298,0.0007749308,0.00056495843,0.00026060702,0.0002657801,0.0017186514],"category_scores_gemma":[0.00047360233,0.0003436096,0.0003992483,0.001286771,0.00042389243,0.00021448938,0.00029567903,0.0004406678,0.0002035624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036756683,0.00008030653,0.9935183,0.000019538173,0.000101101316,0.0007192095,0.0005925505,0.00016351484,0.002747691,0.00011993903,0.00018121432,0.0013890985],"study_design_scores_gemma":[0.000016316537,0.000069232185,0.9979929,0.000005435389,0.00005806823,0.00020929669,0.0007260908,0.00030585995,0.00023902091,0.000034126464,0.00033790374,0.0000058791593],"about_ca_topic_score_codex":0.190616,"about_ca_topic_score_gemma":0.11219382,"teacher_disagreement_score":0.190616,"about_ca_system_score_codex":0.0008534119,"about_ca_system_score_gemma":0.0011443268,"threshold_uncertainty_score":0.379013},"labels":[],"label_agreement":null},{"id":"W2054847513","doi":"10.1016/j.lungcan.2005.04.008","title":"cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Fondation de France; Ligue Contre le Cancer","keywords":"Gemcitabine; Medicine; Oncology; Chemotherapy; Internal medicine; Lung cancer; Immunohistochemistry; Univariate analysis; Cancer research; Nucleoside analogue; Nucleoside; Multivariate analysis; Biology","score_opus":0.011942105896832894,"score_gpt":0.3245001958730316,"score_spread":0.3125580899761987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054847513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99880147,0.00043804257,0.000045248053,0.00006629826,0.000014860871,0.000004202604,0.0001098606,0.0000020388702,0.0005179089],"genre_scores_gemma":[0.99932253,0.0001160192,0.000048044087,0.00003361485,0.000014111713,0.000003645548,0.00022261869,0.0000012541209,0.00023827534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99990773,0.000025975542,0.000010812955,0.000017134975,0.0000152328375,0.000023038021],"domain_scores_gemma":[0.99949753,0.00013325278,0.00016753665,0.000019759129,0.000042231146,0.00013973551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019826605,0.00018629449,0.0002801394,0.00020181283,0.00021921536,0.00044348746,0.0001491748,0.00037568188,0.0007884966],"category_scores_gemma":[0.0010707359,0.000105454106,0.00024670424,0.00033070653,0.00016020129,0.0002251384,0.00017888958,0.00042239894,0.00013037398],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001175809,0.00003452268,0.99333453,0.000009393356,0.000045767014,0.00009573487,0.000022017362,0.000108756954,0.0023539953,0.000011666865,0.00015587913,0.0026520346],"study_design_scores_gemma":[0.00002917202,0.00027642294,0.9974516,0.0000049972264,0.000083531864,0.00034082463,0.000080140206,0.0006750426,0.0005662405,0.000032772656,0.0004556277,0.000003525453],"about_ca_topic_score_codex":0.0014000515,"about_ca_topic_score_gemma":0.0029955206,"teacher_disagreement_score":0.0014000515,"about_ca_system_score_codex":0.00032844866,"about_ca_system_score_gemma":0.00018191437,"threshold_uncertainty_score":0.002783835},"labels":[],"label_agreement":null},{"id":"W2054887777","doi":"10.1016/j.lungcan.2014.04.005","title":"Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Platinum; Medicine; Lung cancer; Chemotherapy; Immunohistochemistry; Oncology; Internal medicine; Cancer; Pathology; Biology","score_opus":0.008513368554682004,"score_gpt":0.2763658677077164,"score_spread":0.2678524991530344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054887777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981231,0.00084299274,0.00012789374,0.00007375949,0.0000068848344,0.0000043738096,0.00022439055,0.000015203649,0.0005814148],"genre_scores_gemma":[0.99896264,0.000089480935,0.000052799445,0.000016591692,0.0000035349244,0.0000035569692,0.00014315454,0.0000024856524,0.00072582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998921,0.000020878597,0.000008024138,0.00002970448,0.000021471167,0.000027810727],"domain_scores_gemma":[0.99968505,0.0000703342,0.000101997655,0.000018369727,0.00006669913,0.000057475438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016938103,0.00011846435,0.00026897067,0.00038954034,0.00021730436,0.00042981774,0.00020904487,0.00032830183,0.0021553596],"category_scores_gemma":[0.0006928549,0.00015385934,0.00014238297,0.00039117585,0.00024307589,0.00026700785,0.00015608681,0.00032265976,0.00028855525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009076264,0.00018076957,0.76370585,0.00017425737,0.00018384423,0.0011309945,0.00029851552,0.0003539259,0.20692524,0.00024743358,0.0015472071,0.016175566],"study_design_scores_gemma":[0.00004782766,0.00064263016,0.9668128,0.000011714481,0.00013433825,0.0018784022,0.000416253,0.0017089719,0.026468202,0.00020181625,0.0016601118,0.000017021826],"about_ca_topic_score_codex":0.004944712,"about_ca_topic_score_gemma":0.0046451828,"teacher_disagreement_score":0.004944712,"about_ca_system_score_codex":0.00068106985,"about_ca_system_score_gemma":0.0002144943,"threshold_uncertainty_score":0.009831846},"labels":[],"label_agreement":null},{"id":"W2056180028","doi":"10.1016/j.lungcan.2011.10.020","title":"Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gefitinib; Adenocarcinoma; Erlotinib; Immunohistochemistry; Lung cancer; Epidermal growth factor receptor; Pathology; Adenosquamous carcinoma; Stage (stratigraphy); Oncology; Cancer; Cancer research; Internal medicine; Biology","score_opus":0.027699810195255678,"score_gpt":0.3586723438470089,"score_spread":0.3309725336517532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056180028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985057,0.00035048416,0.00009515765,0.000045203524,0.0000071409086,0.0000068911595,0.000061854276,0.0000045389856,0.00092309195],"genre_scores_gemma":[0.999509,0.00010534429,0.000107058135,0.00001040415,0.000008710877,0.0000047494864,0.000083849656,0.0000011719235,0.00016976066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985313,0.000032171974,0.000023250901,0.00001994394,0.00002843215,0.0000430081],"domain_scores_gemma":[0.9993606,0.00018112118,0.00021758227,0.000030513555,0.00008453215,0.00012564553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003718976,0.0001703556,0.0002321968,0.0008576449,0.00028933433,0.00035855372,0.0002177451,0.00035165861,0.0010899381],"category_scores_gemma":[0.00096779846,0.00013680669,0.00023108679,0.00040502183,0.00040212087,0.0002645981,0.00015085094,0.00017575396,0.00015728697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014259281,0.00006200317,0.9688728,0.00003649441,0.000053738037,0.0034296848,0.000058721114,0.0002012475,0.020239891,0.000044681787,0.00014695637,0.005427955],"study_design_scores_gemma":[0.0000131402285,0.00015366726,0.9920031,0.0000050352173,0.000057133126,0.0054275896,0.00015300832,0.00036528095,0.0014919076,0.00004560657,0.0002792862,0.0000053024783],"about_ca_topic_score_codex":0.0010726005,"about_ca_topic_score_gemma":0.0021505174,"teacher_disagreement_score":0.0010899381,"about_ca_system_score_codex":0.00027047787,"about_ca_system_score_gemma":0.00022121679,"threshold_uncertainty_score":0.003646195},"labels":[],"label_agreement":null},{"id":"W2057149384","doi":"10.1016/s0169-5002(01)00377-4","title":"Angiogenesis inhibitors in the treatment of lung cancer","year":2001,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Carboplatin; Internal medicine; Angiogenesis; Angiogenesis inhibitor; Cancer; Chemotherapy; Cancer research; Cisplatin","score_opus":0.026606143450541214,"score_gpt":0.3623009195765483,"score_spread":0.33569477612600707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057149384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002017024,0.9971378,0.0004043361,0.00042789755,0.0005502399,0.00001131537,0.000021462007,0.000016149901,0.0012291359],"genre_scores_gemma":[0.001222031,0.99584264,0.00060783373,0.00037199853,0.0004208011,0.00002035229,0.000053060357,0.000003876771,0.001457462],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978346,0.000038118764,0.000024680377,0.000037523063,0.000091414084,0.000024840525],"domain_scores_gemma":[0.99956125,0.00021854418,0.00004719179,0.000012722301,0.00010272405,0.000057573423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009953727,0.0013674729,0.002359076,0.0020110807,0.00043835532,0.0009993331,0.0013906183,0.0016374112,0.002672569],"category_scores_gemma":[0.0009305745,0.00035326948,0.0006278806,0.0024520888,0.00067937595,0.0012554026,0.00049772894,0.0036413304,0.0019918762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031051843,0.00023167944,0.00014803844,0.005105189,0.00011380688,0.0003932817,0.00004718219,0.00074625807,0.0029440904,0.0031593658,0.058014546,0.92878604],"study_design_scores_gemma":[0.00025007688,0.00041426672,0.0010567815,0.0013846842,0.00019505041,0.0020850315,0.000041871182,0.00029478877,0.001214031,0.0020338804,0.990999,0.000030721705],"about_ca_topic_score_codex":0.001868142,"about_ca_topic_score_gemma":0.0048602372,"teacher_disagreement_score":0.002672569,"about_ca_system_score_codex":0.00079123967,"about_ca_system_score_gemma":0.0009276337,"threshold_uncertainty_score":0.008940697},"labels":[],"label_agreement":null},{"id":"W2059479059","doi":"10.1016/s0169-5002(00)80204-4","title":"Phase I/II study of biweekly paclitaxel and cisplatin in nonsmall cell lung cancer (NSCLC). Final result with QOL data","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cisplatin; Paclitaxel; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Chemotherapy; A549 cell","score_opus":0.03128569605859117,"score_gpt":0.39326052230896336,"score_spread":0.3619748262503722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059479059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97347903,0.0035980716,0.001946319,0.0016004663,0.00046741645,0.009609715,0.0039025869,0.00034356766,0.005052881],"genre_scores_gemma":[0.9629057,0.004138578,0.0043909973,0.0022585776,0.00028381502,0.009936832,0.0051427153,0.00013042208,0.0108123915],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995346,0.00021120728,0.00001946064,0.0000757986,0.000035484,0.00012349585],"domain_scores_gemma":[0.99915814,0.00008928149,0.000111944995,0.00009364726,0.000050265786,0.00049671694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014331889,0.0015663032,0.0024542278,0.000633538,0.00076298945,0.0011992365,0.0015986976,0.0021234036,0.0065377504],"category_scores_gemma":[0.000860234,0.00093435205,0.0017148481,0.0006354873,0.0010890559,0.0012015051,0.0005754289,0.0042501893,0.001898665],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78659976,0.081590086,0.002807927,0.0007113349,0.0018641144,0.00018432747,0.00026496532,0.002651084,0.028395213,0.00035295435,0.0078322515,0.086745866],"study_design_scores_gemma":[0.74267685,0.24479568,0.0060889204,0.000027495502,0.0004885995,0.00012653878,0.0000587834,0.0005281412,0.0022696343,0.00027318386,0.0026376836,0.000028434528],"about_ca_topic_score_codex":0.0029605068,"about_ca_topic_score_gemma":0.005288538,"teacher_disagreement_score":0.0065377504,"about_ca_system_score_codex":0.0010715878,"about_ca_system_score_gemma":0.0020835348,"threshold_uncertainty_score":0.02187103},"labels":[],"label_agreement":null},{"id":"W2059645245","doi":"10.1016/s0169-5002(02)00167-8","title":"Second line chemotherapy for NSCLC: establishing a gold standard","year":2002,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Oncology; Lung cancer; Internal medicine; Paclitaxel; Ifosfamide; Chemotherapy; Population; Surgery; Etoposide; Cisplatin","score_opus":0.03752359896036843,"score_gpt":0.41298845336235307,"score_spread":0.3754648544019846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059645245","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019750933,0.9980806,0.00019374327,0.0006001163,0.00036151818,0.000008910117,0.000014827771,0.0000068401114,0.0005359422],"genre_scores_gemma":[0.0015587076,0.99579084,0.00080820394,0.0008922669,0.0003339496,0.00001516539,0.00005433738,0.000003246507,0.0005431549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961936,0.00008617222,0.00007750965,0.000077229844,0.00011592667,0.00002378029],"domain_scores_gemma":[0.99931633,0.00032785445,0.00013356077,0.000020605696,0.00015969542,0.00004186775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015066147,0.0009706185,0.0039280048,0.0016404353,0.00030089048,0.0011017334,0.0015766608,0.0017678173,0.0020832443],"category_scores_gemma":[0.0012443466,0.00035087686,0.0007844162,0.0015955855,0.0006431242,0.0015501406,0.0005732387,0.0028415488,0.0012312727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020517889,0.00007917438,0.00031840827,0.013630509,0.00016397085,0.00019666016,0.00003312029,0.00044588733,0.0008509471,0.0016281668,0.023421321,0.95902675],"study_design_scores_gemma":[0.00025794288,0.0005101382,0.003265962,0.010636285,0.0007766785,0.0029767496,0.000101465674,0.00042223817,0.0011800756,0.0019637574,0.977856,0.000052749503],"about_ca_topic_score_codex":0.0016376388,"about_ca_topic_score_gemma":0.0040668626,"teacher_disagreement_score":0.0039280048,"about_ca_system_score_codex":0.0013055408,"about_ca_system_score_gemma":0.0016081027,"threshold_uncertainty_score":0.00947237},"labels":[],"label_agreement":null},{"id":"W2059812828","doi":"10.1016/j.lungcan.2013.07.026","title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Radiosurgery; SABR volatility model; Lung cancer; Radiation therapy; Oncology; Internal medicine; Stage (stratigraphy); Randomized controlled trial; Surgery","score_opus":0.020849039471685926,"score_gpt":0.35157146969722763,"score_spread":0.3307224302255417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059812828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046478742,0.99917334,0.000023150491,0.000097630385,0.00003254872,0.000021069556,0.00012039945,0.0000010444265,0.000066027394],"genre_scores_gemma":[0.007912843,0.99156296,0.00012161911,0.00022149255,0.000040007853,0.000037783426,0.00007454647,8.14354e-7,0.00002782555],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9971826,0.0007374999,0.0012393802,0.0003164512,0.00042632048,0.000097871896],"domain_scores_gemma":[0.988884,0.007957067,0.0023429347,0.000106394895,0.00057754293,0.00013207587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030249374,0.000984829,0.0060641808,0.006666727,0.00048252285,0.0017626918,0.0011572604,0.0015098203,0.003296388],"category_scores_gemma":[0.01793247,0.00081295084,0.005209538,0.008082804,0.00086796697,0.0018525127,0.001253987,0.0010057549,0.00016804902],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021798695,0.000015066136,0.0023764707,0.9436601,0.0091372505,0.00014292866,0.00017144048,0.00007444234,0.00014231063,0.00019165737,0.0016257546,0.042244613],"study_design_scores_gemma":[0.00029468624,0.00023855889,0.016818302,0.81451714,0.13538928,0.0014821974,0.0006377348,0.0001026346,0.00019356412,0.00055828,0.029695539,0.000072066956],"about_ca_topic_score_codex":0.0096909655,"about_ca_topic_score_gemma":0.036151197,"teacher_disagreement_score":0.0096909655,"about_ca_system_score_codex":0.0020660697,"about_ca_system_score_gemma":0.0060033025,"threshold_uncertainty_score":0.019269109},"labels":[],"label_agreement":null},{"id":"W2060209568","doi":"10.1016/s0169-5002(03)00308-8","title":"Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Angiogenesis; Medicine; Endostatin; Angiostatin; Lung cancer; Vascular endothelial growth factor; Pharmacology; Matrix metalloproteinase inhibitor; Matrix metalloproteinase; Cancer research; Sulindac; Immunology; Internal medicine; VEGF receptors","score_opus":0.022801210206394484,"score_gpt":0.35417343992182143,"score_spread":0.33137222971542696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060209568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012353159,0.99795485,0.0003711334,0.0002866315,0.00050588814,0.0000110966885,0.000023106102,0.00001467418,0.000709043],"genre_scores_gemma":[0.0005841336,0.9971155,0.00056944153,0.0003738548,0.00043820325,0.000018916897,0.00005110866,0.0000033580764,0.0008455744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997687,0.000033688215,0.00003467006,0.000038734168,0.000100376186,0.00002389283],"domain_scores_gemma":[0.999519,0.00021569128,0.000057930465,0.000010748319,0.00012205027,0.00007466329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009348076,0.0014274686,0.0028806003,0.0025339902,0.00040137983,0.0012641052,0.0017526813,0.0015882615,0.0028046812],"category_scores_gemma":[0.00088153436,0.0004343735,0.0006888742,0.0031121843,0.0005271716,0.0016181745,0.00063863856,0.0030784034,0.0023699056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028064562,0.00022186122,0.00014716078,0.010750493,0.00014644244,0.00040910172,0.000045700635,0.0005128734,0.0033962303,0.0016669405,0.08061999,0.9018025],"study_design_scores_gemma":[0.00018297332,0.00035269704,0.00070062757,0.0019640808,0.00026640086,0.0023664862,0.000045253626,0.00022267437,0.0011571292,0.0011264627,0.9915781,0.000037141075],"about_ca_topic_score_codex":0.001419858,"about_ca_topic_score_gemma":0.0037058687,"teacher_disagreement_score":0.0028806003,"about_ca_system_score_codex":0.00071437075,"about_ca_system_score_gemma":0.0010726674,"threshold_uncertainty_score":0.009382546},"labels":[],"label_agreement":null},{"id":"W2060696690","doi":"10.1016/j.lungcan.2013.11.020","title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme","keywords":"Medicine; Erlotinib; Internal medicine; Neutropenia; Oncology; Lung cancer; Adverse effect; Surgery; Cancer; Epidermal growth factor receptor; Chemotherapy","score_opus":0.009580312840794003,"score_gpt":0.29764311509174984,"score_spread":0.2880628022509558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060696690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851163,0.0034587246,0.0008155112,0.0011793944,0.0010145669,0.0031281796,0.0015491823,0.00016942636,0.0035688463],"genre_scores_gemma":[0.9844563,0.0020869465,0.0015952449,0.0015154702,0.00050488417,0.003305251,0.001597249,0.00005178495,0.0048869336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994641,0.00027144575,0.000023528855,0.00009973948,0.000030864423,0.00011042713],"domain_scores_gemma":[0.9992111,0.00021488356,0.00014703677,0.0000717123,0.00004874002,0.0003066524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014475563,0.001948596,0.003435514,0.00045171264,0.00046263557,0.0013763609,0.0010312594,0.0015462686,0.008561474],"category_scores_gemma":[0.0017111885,0.0010541029,0.0016770128,0.00043665146,0.0013780015,0.0016301373,0.00049497397,0.003858104,0.0013668134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98123485,0.004568965,0.00037112707,0.00027058803,0.00049325364,0.000024931003,0.00003239276,0.0004947301,0.0017316402,0.00013839448,0.00074705336,0.009892122],"study_design_scores_gemma":[0.96104246,0.036434915,0.0008297262,0.000013983368,0.0002407279,0.000025373209,0.000020259908,0.0004070912,0.00022113576,0.00016876438,0.00058375526,0.0000117858945],"about_ca_topic_score_codex":0.0017812678,"about_ca_topic_score_gemma":0.0053878524,"teacher_disagreement_score":0.008561474,"about_ca_system_score_codex":0.0015389082,"about_ca_system_score_gemma":0.0015551168,"threshold_uncertainty_score":0.028640926},"labels":[],"label_agreement":null},{"id":"W2062547449","doi":"10.1016/j.lungcan.2013.11.010","title":"KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Lung cancer; Carcinogenesis; Oncology; Internal medicine; Cancer research; Genotype; Cancer; Biology; Genetics; Gene","score_opus":0.010244901197998242,"score_gpt":0.32954041298713815,"score_spread":0.3192955117891399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062547449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31413335,0.53623044,0.0022630924,0.09822012,0.0015984534,0.000054193275,0.0004291817,0.000074661584,0.046996493],"genre_scores_gemma":[0.84537286,0.14187032,0.0017998972,0.004989155,0.0019710297,0.000040208175,0.00021579505,0.000018394832,0.0037223513],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995776,0.00012999527,0.00005689177,0.000055297798,0.0001298191,0.000050514525],"domain_scores_gemma":[0.99857223,0.00084781094,0.00025397108,0.0000290008,0.00015018717,0.00014665032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010417044,0.00020625014,0.0005947871,0.00070900656,0.00027066696,0.0010544398,0.0004705698,0.0011554026,0.0026477983],"category_scores_gemma":[0.0031557577,0.00014685343,0.0004613116,0.0007551119,0.0007202643,0.0012749879,0.00038324867,0.0011181392,0.00023174121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038765096,0.00084772595,0.14994578,0.001516483,0.000277263,0.004284849,0.00030379128,0.004092384,0.013913489,0.039264273,0.01727019,0.7644072],"study_design_scores_gemma":[0.00071420695,0.004420568,0.6542982,0.0022544607,0.0009618288,0.034696817,0.003379473,0.008489627,0.008335696,0.062416226,0.21985418,0.00017876353],"about_ca_topic_score_codex":0.0020412684,"about_ca_topic_score_gemma":0.0065417844,"teacher_disagreement_score":0.0026477983,"about_ca_system_score_codex":0.0012625067,"about_ca_system_score_gemma":0.0014580326,"threshold_uncertainty_score":0.009160101},"labels":[],"label_agreement":null},{"id":"W2063481154","doi":"10.1016/j.lungcan.2003.08.026","title":"Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Western University","funders":"","keywords":"Medicine; DLCO; Internal medicine; Pulmonary function testing; Pulmonary toxicity; Toxicity; Diffusing capacity; Etoposide; Vincristine; Cumulative incidence; Gastroenterology; Urology; Surgery; Cyclophosphamide; Lung; Chemotherapy; Cohort","score_opus":0.02322103713015736,"score_gpt":0.3031683424275841,"score_spread":0.27994730529742673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063481154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99968266,0.00012567524,0.000017633247,0.0000156949,0.0000012233551,0.0000017811989,0.000021772428,7.414661e-7,0.0001328489],"genre_scores_gemma":[0.9998447,0.000040228744,0.000014685462,0.000006368913,0.000002962981,0.00000202502,0.000038542807,4.4364356e-7,0.000049895698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99986076,0.00005521091,0.0000129889495,0.000022412009,0.000022415814,0.000026163265],"domain_scores_gemma":[0.9986632,0.00040564558,0.0004829203,0.00011143026,0.000082947845,0.00025387312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035872945,0.00020434435,0.00028666106,0.00031135764,0.00027285767,0.00042335817,0.00024070896,0.0003351884,0.00094128546],"category_scores_gemma":[0.001976138,0.00013241771,0.00031189123,0.00036972214,0.00030734402,0.00026008673,0.00020955535,0.0004121446,0.000089655136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00182082,0.00015817092,0.9933177,0.000010759879,0.00007383715,0.00005305378,0.000060415532,0.00013884783,0.0019295347,0.000019845142,0.000048438043,0.0023686674],"study_design_scores_gemma":[0.000026618376,0.000603467,0.9983032,0.000002469304,0.0000631268,0.00017762152,0.000067358334,0.00026931058,0.00036481407,0.000023619197,0.000095352254,0.0000029892888],"about_ca_topic_score_codex":0.0036615506,"about_ca_topic_score_gemma":0.0031111874,"teacher_disagreement_score":0.0036615506,"about_ca_system_score_codex":0.00033563416,"about_ca_system_score_gemma":0.00032390922,"threshold_uncertainty_score":0.007280469},"labels":[],"label_agreement":null},{"id":"W2068132555","doi":"10.1016/j.lungcan.2009.09.007","title":"The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Medicine; Taxane; Lung cancer; Oncology; Regimen; Internal medicine; Cancer; Disease; Chemotherapy; Bioinformatics; Breast cancer; Biology","score_opus":0.010544525231161473,"score_gpt":0.34552796477521425,"score_spread":0.3349834395440528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068132555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026014887,0.99891996,0.00011797594,0.00022493386,0.00009565744,0.000002623996,0.000019616375,0.000005768243,0.00035341416],"genre_scores_gemma":[0.0028566876,0.9961051,0.00031194204,0.00020175462,0.0001659927,0.0000052674245,0.000048341975,0.000001758715,0.00030322358],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99973196,0.00004923929,0.000041856885,0.00005274782,0.000105442276,0.000018730969],"domain_scores_gemma":[0.9993063,0.00038386564,0.00010516073,0.000013311901,0.00016400493,0.000027296592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009234621,0.00093626004,0.0026876736,0.0017064363,0.00015442212,0.000890755,0.0010121174,0.0010537549,0.00083356985],"category_scores_gemma":[0.0013787668,0.00038699215,0.00074566336,0.0018192623,0.00042463435,0.0007160174,0.00033919117,0.0016778295,0.0007297463],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014379546,0.00005114205,0.0019795755,0.0056693936,0.00029521855,0.00020490031,0.000021767833,0.00058168615,0.0011213514,0.0006095472,0.014171552,0.9751501],"study_design_scores_gemma":[0.00023739591,0.0006308079,0.023488201,0.010777467,0.0028724265,0.0062525817,0.00016429828,0.0021613166,0.00437263,0.004124461,0.94478595,0.00013239196],"about_ca_topic_score_codex":0.0034250943,"about_ca_topic_score_gemma":0.0046898574,"teacher_disagreement_score":0.0034250943,"about_ca_system_score_codex":0.0007242565,"about_ca_system_score_gemma":0.00092260074,"threshold_uncertainty_score":0.0068103075},"labels":[],"label_agreement":null},{"id":"W2068437736","doi":"10.1016/j.lungcan.2012.07.004","title":"An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Allos Therapeutics; European Society for Medical Oncology; Chugai Pharmaceutical; Daiichi-Sankyo; GlaxoSmithKline; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Bevacizumab; Incidence (geometry); Angiogenesis; Brain metastasis; Metastasis; Vascular endothelial growth factor; Cancer; Clinical trial; Lung; Chemotherapy; Pathology; VEGF receptors","score_opus":0.042605661423771216,"score_gpt":0.3554587908685443,"score_spread":0.3128531294447731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068437736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018945662,0.99950683,0.00002604317,0.00005302875,0.000042015854,0.000014532885,0.00006679984,0.0000016805059,0.00009962158],"genre_scores_gemma":[0.0017029673,0.9979578,0.00010604366,0.000109922425,0.000030955704,0.00001157666,0.000043140106,6.4212816e-7,0.00003705704],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99892575,0.00020496758,0.0004884607,0.00011406195,0.00022756319,0.000039225404],"domain_scores_gemma":[0.9971896,0.0017499025,0.00073212944,0.000027771186,0.00025011715,0.00005047956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017477433,0.0010563522,0.0049663694,0.003949154,0.00026455798,0.0012989634,0.001355232,0.0011981884,0.0031758922],"category_scores_gemma":[0.005083152,0.0005422315,0.004525209,0.0047213575,0.0004061077,0.0010828009,0.0006952653,0.0010179359,0.0002760563],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048520725,0.00003914938,0.00065013935,0.78139186,0.0069787335,0.00017066464,0.00007579223,0.00021668553,0.00042550964,0.0002825298,0.005685597,0.2035981],"study_design_scores_gemma":[0.0008560147,0.0009806454,0.012997048,0.6624097,0.12522069,0.0028863866,0.00031404782,0.00025946158,0.000651262,0.00090737955,0.19239308,0.00012420559],"about_ca_topic_score_codex":0.00427726,"about_ca_topic_score_gemma":0.010257201,"teacher_disagreement_score":0.0049663694,"about_ca_system_score_codex":0.001046636,"about_ca_system_score_gemma":0.0024294367,"threshold_uncertainty_score":0.010624409},"labels":[],"label_agreement":null},{"id":"W2068558121","doi":"10.1016/j.lungcan.2006.10.006","title":"Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.009922891560607522,"score_gpt":0.27498225672799337,"score_spread":0.2650593651673858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068558121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770004,0.0003358597,0.00027098213,0.000324227,0.000026066995,0.00001966248,0.00009671551,0.0000034862085,0.0012228335],"genre_scores_gemma":[0.9995499,0.00008579431,0.00012701265,0.00005415863,0.000029800785,0.000010965993,0.0000712316,0.0000013254629,0.00006970047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980514,0.0012240169,0.00013904674,0.00012337975,0.00033047717,0.00013165358],"domain_scores_gemma":[0.97406536,0.018328657,0.0037340892,0.00069023954,0.0020466233,0.0011350358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032822762,0.00018555064,0.00035106004,0.0004502407,0.0003791555,0.00064802234,0.0002953497,0.00069584924,0.0011605788],"category_scores_gemma":[0.03183027,0.0001374111,0.0004160695,0.00041219435,0.0004131782,0.0009122716,0.00039627156,0.00072898244,0.00018805168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033963642,0.0003512462,0.97692525,0.000057422683,0.00006330342,0.00012226899,0.00029036516,0.00035985743,0.00048601328,0.00009659091,0.0002267311,0.017624542],"study_design_scores_gemma":[0.000101107114,0.0044700475,0.99023026,0.00005228686,0.000074134536,0.00039679863,0.00073484983,0.0026180034,0.0004585798,0.0002978524,0.0005521267,0.0000139991425],"about_ca_topic_score_codex":0.0010719345,"about_ca_topic_score_gemma":0.0012368985,"teacher_disagreement_score":0.0032822762,"about_ca_system_score_codex":0.00028135566,"about_ca_system_score_gemma":0.00071036565,"threshold_uncertainty_score":0.017358541},"labels":[],"label_agreement":null},{"id":"W2069169809","doi":"10.1016/s0169-5002(00)80490-0","title":"Outpatient management of malignant pleural effusions using an indwelling cuffed silastic catheter","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Silastic; Malignant pleural effusion; Catheter; Indwelling catheter; Surgery; Pleural effusion; Intensive care medicine","score_opus":0.02770053051704053,"score_gpt":0.31117535780643574,"score_spread":0.2834748272893952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069169809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819904,0.0045236023,0.0025009234,0.00151113,0.00040524776,0.0001393564,0.00013103415,0.00032937832,0.008468875],"genre_scores_gemma":[0.99100316,0.0016873606,0.0027311724,0.0008017782,0.00169049,0.000059606173,0.00019610241,0.000055367695,0.0017749177],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99981517,0.000041089104,0.00002368752,0.000024703955,0.000047355235,0.00004807446],"domain_scores_gemma":[0.999368,0.00011825171,0.0001236374,0.000023789551,0.000036767564,0.0003295347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018829407,0.0007163867,0.000736862,0.0007300618,0.0009917619,0.000561581,0.00047342043,0.00088222465,0.0019710343],"category_scores_gemma":[0.0017645311,0.00029266966,0.00049711607,0.00030029725,0.00022708949,0.0005071735,0.0004015463,0.0012632489,0.00039698635],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008099327,0.008461419,0.33424467,0.0006714443,0.00029696792,0.34221935,0.0011024767,0.0013291725,0.05136741,0.0003816025,0.01457151,0.23725472],"study_design_scores_gemma":[0.0017918685,0.025508076,0.53693324,0.0004221196,0.00044338952,0.3984502,0.0010132025,0.007949567,0.011760024,0.0005665306,0.015063984,0.00009787006],"about_ca_topic_score_codex":0.0003343946,"about_ca_topic_score_gemma":0.0011878297,"teacher_disagreement_score":0.0019710343,"about_ca_system_score_codex":0.00026067783,"about_ca_system_score_gemma":0.00037607335,"threshold_uncertainty_score":0.006593764},"labels":[],"label_agreement":null},{"id":"W2069954767","doi":"10.1016/j.lungcan.2007.06.013","title":"Lung cancer after exposure to disease modifying anti-rheumatic drugs","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Rheumatoid arthritis; Cohort; Cancer; Oncology; Cohort study; Logistic regression; Population; Relative risk; Confidence interval; Environmental health","score_opus":0.009153614697970517,"score_gpt":0.32510730099877794,"score_spread":0.31595368630080745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069954767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986187,0.003404667,0.00012199599,0.0006905782,0.00011320519,0.000060003164,0.0005986119,0.00001996358,0.008803939],"genre_scores_gemma":[0.99548495,0.0007297754,0.0000317594,0.00024051948,0.00015580535,0.000007499926,0.0004781887,0.000003257821,0.0028682419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992101,0.00013180997,0.00005972202,0.00009395897,0.00016793054,0.00033642838],"domain_scores_gemma":[0.9974644,0.0006956702,0.00073931523,0.00017365602,0.00037631165,0.0005505078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006465008,0.00019894511,0.0006973316,0.001134777,0.00094796537,0.0008843008,0.00034159518,0.0012540681,0.0058860723],"category_scores_gemma":[0.002934363,0.00017930573,0.0010161651,0.0011340199,0.00032703948,0.0005312212,0.00048368238,0.0011320065,0.0006479825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028438254,0.0004955843,0.97550243,0.00007807769,0.00020546069,0.007467116,0.0002785469,0.00009221101,0.0010165825,0.00007965493,0.0005493824,0.011391211],"study_design_scores_gemma":[0.000031457086,0.0011703307,0.99281037,0.000016258826,0.00014722107,0.0036180306,0.00032545294,0.00009564248,0.0003169427,0.00008593162,0.0013706608,0.00001170425],"about_ca_topic_score_codex":0.015274405,"about_ca_topic_score_gemma":0.012671271,"teacher_disagreement_score":0.015274405,"about_ca_system_score_codex":0.0006875431,"about_ca_system_score_gemma":0.0007161833,"threshold_uncertainty_score":0.03037101},"labels":[],"label_agreement":null},{"id":"W2069960588","doi":"10.1016/s0169-5002(02)00503-2","title":"Small stage I cancers of the lung: genuineness and curability","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Asymptomatic; Lymph node; Case fatality rate; Cancer; Lung; Mediastinal lymph node; Surgery; Epidemiology; Radiology; Internal medicine; Metastasis","score_opus":0.019882833956268466,"score_gpt":0.3052485709424172,"score_spread":0.28536573698614875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069960588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8418923,0.08283306,0.011115537,0.02924829,0.0008823059,0.00012121027,0.0007183916,0.00008467418,0.03310433],"genre_scores_gemma":[0.99268895,0.003991262,0.00089620485,0.00051187054,0.0008265841,0.00001268847,0.000107235595,0.000010739622,0.0009544605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849415,0.0006783862,0.00012471621,0.00016478624,0.00043770426,0.000100277386],"domain_scores_gemma":[0.98400223,0.010052277,0.002727207,0.0014380914,0.001163204,0.000617054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035929296,0.0002214508,0.0006847787,0.001544449,0.0007785725,0.0015979892,0.00054044666,0.0007337962,0.0020153308],"category_scores_gemma":[0.029553866,0.00014767447,0.00053775846,0.0006864036,0.002302311,0.0023094334,0.0014125595,0.0008716393,0.00015147145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014730642,0.00014684672,0.47804,0.0013309581,0.000342996,0.0015157057,0.004674393,0.0010645903,0.010511036,0.0321451,0.004052355,0.46470296],"study_design_scores_gemma":[0.00010140799,0.0013825152,0.7910629,0.00053296814,0.0009699184,0.011837815,0.0038021745,0.002299036,0.007278423,0.1440073,0.03659819,0.00012737086],"about_ca_topic_score_codex":0.00069685426,"about_ca_topic_score_gemma":0.001499887,"teacher_disagreement_score":0.0035929296,"about_ca_system_score_codex":0.0008332462,"about_ca_system_score_gemma":0.0006304567,"threshold_uncertainty_score":0.019001424},"labels":[],"label_agreement":null},{"id":"W2071340558","doi":"10.1016/j.lungcan.2014.09.013","title":"A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Cohort; Lung cancer; Population; Chemotherapy; Retrospective cohort study; Cohort study; Emergency medicine; Cancer; Surgery; Internal medicine","score_opus":0.014337200830847788,"score_gpt":0.3034205436464504,"score_spread":0.2890833428156026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071340558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924326,0.00011016472,0.000033289536,0.00006184373,0.000004961965,0.000007785019,0.00030583254,0.0000013315599,0.00023141019],"genre_scores_gemma":[0.99943095,0.000073349416,0.000032391916,0.000055946388,0.000011084312,0.000012605326,0.00030613833,0.0000013279431,0.00007628209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849033,0.0006731102,0.00018882747,0.00023214816,0.00019555436,0.00021999875],"domain_scores_gemma":[0.9971553,0.00069963257,0.0011364473,0.00020999038,0.00026699764,0.0005317007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010855886,0.00046417853,0.0005751256,0.0012274062,0.0009480155,0.0013979924,0.00069096347,0.0014508837,0.0014796159],"category_scores_gemma":[0.004498213,0.0006968108,0.0016836774,0.0028613652,0.0006637416,0.0014770117,0.00086484634,0.0016372942,0.00027421955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038249447,0.00026471107,0.9978586,0.000012977586,0.00034326222,0.000102783466,0.00012401577,0.00010743955,0.0000816314,0.000028920493,0.0001204885,0.0005726834],"study_design_scores_gemma":[0.00003545853,0.00032543464,0.9983467,0.0000051303086,0.000110035966,0.00020376466,0.00052524096,0.00028087202,0.0000128142,0.000030626394,0.00011217027,0.0000117926165],"about_ca_topic_score_codex":0.018237993,"about_ca_topic_score_gemma":0.019602953,"teacher_disagreement_score":0.018237993,"about_ca_system_score_codex":0.0014635915,"about_ca_system_score_gemma":0.0007576184,"threshold_uncertainty_score":0.036263704},"labels":[],"label_agreement":null},{"id":"W2073260977","doi":"10.1016/j.lungcan.2015.11.018","title":"Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Lung cancer; Adenocarcinoma; Oncology; Medicine; Lung; Oncogene; Internal medicine; Cancer; Pathology; Cell cycle","score_opus":0.01760095957507451,"score_gpt":0.34243629148413984,"score_spread":0.32483533190906533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073260977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754804,0.0008940627,0.000084877924,0.0000921843,0.000019902498,0.0000047662834,0.00029781304,0.000014091062,0.001044337],"genre_scores_gemma":[0.9992269,0.00016363304,0.00002631536,0.00001551397,0.000015757108,0.0000042824236,0.00023684866,0.0000018561337,0.00030896722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984336,0.000020117866,0.000014676804,0.00003032448,0.000029620092,0.000061814404],"domain_scores_gemma":[0.9993494,0.000112175905,0.0002182771,0.000036267073,0.00008772729,0.0001962117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022774648,0.0002789228,0.00037053935,0.0006719765,0.0005115928,0.0009284127,0.00033505677,0.00057411246,0.002800907],"category_scores_gemma":[0.0011680062,0.00019950434,0.0003085395,0.0006993019,0.0002845109,0.00035667708,0.000455781,0.000548052,0.00054552173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031953616,0.000028699895,0.9939389,0.000014482307,0.000048231697,0.00040375223,0.000033515706,0.00008562912,0.0020588576,0.000027800766,0.00032154637,0.0027189662],"study_design_scores_gemma":[0.0000061264686,0.00006877912,0.9968746,0.0000066397756,0.000060230865,0.0012397515,0.00017233874,0.00032490608,0.0006166949,0.00010324624,0.00052080024,0.000005915324],"about_ca_topic_score_codex":0.0018402227,"about_ca_topic_score_gemma":0.0021962163,"teacher_disagreement_score":0.002800907,"about_ca_system_score_codex":0.00042202263,"about_ca_system_score_gemma":0.00027416935,"threshold_uncertainty_score":0.009369969},"labels":[],"label_agreement":null},{"id":"W2073397984","doi":"10.1016/s0169-5002(00)80192-0","title":"Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based chemotherapy","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Randomized controlled trial","score_opus":0.013373242699183347,"score_gpt":0.33694084528434476,"score_spread":0.32356760258516143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073397984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245795,0.015728675,0.024810052,0.0018462065,0.00093345495,0.01088306,0.015641155,0.0007095425,0.00486847],"genre_scores_gemma":[0.9722801,0.0010976269,0.011199943,0.001116418,0.00032133356,0.003939441,0.007383501,0.00015170967,0.0025098945],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9605676,0.031612866,0.0013787372,0.002924917,0.0017974125,0.001718452],"domain_scores_gemma":[0.9543288,0.033511672,0.004825924,0.003926035,0.001518816,0.0018888924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03267357,0.0028938006,0.007680611,0.0015246093,0.00046647686,0.002388118,0.002104344,0.002429387,0.011015196],"category_scores_gemma":[0.041902393,0.001251926,0.01826207,0.001321773,0.0011678782,0.0021025303,0.0017836586,0.004023663,0.0007038678],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9303404,0.00088884874,0.0045228987,0.00063494203,0.04537218,0.000059446902,0.000033127348,0.002235917,0.0012148757,0.0003120224,0.0010664242,0.013318898],"study_design_scores_gemma":[0.68395454,0.07887946,0.04673481,0.00022625721,0.16648565,0.00016948032,0.000079857884,0.015646052,0.00224819,0.0022137228,0.0032492776,0.00011265108],"about_ca_topic_score_codex":0.002243057,"about_ca_topic_score_gemma":0.0032401138,"teacher_disagreement_score":0.03267357,"about_ca_system_score_codex":0.0023690027,"about_ca_system_score_gemma":0.0028344484,"threshold_uncertainty_score":0.17279643},"labels":[],"label_agreement":null},{"id":"W2075202876","doi":"10.1016/j.lungcan.2014.12.014","title":"Maintenance chemotherapy in advanced NSCLC: A population-based assessment of eligibility","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Maintenance therapy; Chemotherapy; Internal medicine; Population; Performance status; Oncology; Cancer","score_opus":0.01605880244225595,"score_gpt":0.4216548494356635,"score_spread":0.40559604699340757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075202876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802834,0.00030777103,0.00017936312,0.00009215975,0.0000049016653,0.000036478003,0.00064908504,0.0000054471807,0.0006965064],"genre_scores_gemma":[0.9991554,0.000070998365,0.00010762639,0.00005361329,0.000006026395,0.000030192035,0.00046896434,0.0000020046348,0.00010506777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887115,0.00043323316,0.0001422973,0.00023138248,0.00021574687,0.000106150124],"domain_scores_gemma":[0.9979754,0.00053694565,0.0009532128,0.00011530317,0.0002162615,0.00020292535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016334233,0.00018521339,0.00054770475,0.0010174443,0.00043393954,0.0008210208,0.00053357176,0.00086982106,0.0014876364],"category_scores_gemma":[0.005197244,0.00018709876,0.0008500188,0.0013754993,0.00031048703,0.0010982193,0.000810541,0.00067205814,0.00029978863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004791622,0.00007190268,0.9959365,0.000012415963,0.00013751183,0.000035827386,0.00008033886,0.00011801517,0.0001704783,0.000041434407,0.0001967652,0.002719597],"study_design_scores_gemma":[0.000020299127,0.00030183556,0.9983449,0.0000074287636,0.00007502063,0.00017855766,0.00018069275,0.00049904356,0.0000402682,0.00007852884,0.00026715125,0.0000063151865],"about_ca_topic_score_codex":0.0022295148,"about_ca_topic_score_gemma":0.0030174057,"teacher_disagreement_score":0.0022295148,"about_ca_system_score_codex":0.0004109251,"about_ca_system_score_gemma":0.00027885393,"threshold_uncertainty_score":0.008638442},"labels":[],"label_agreement":null},{"id":"W2075402438","doi":"10.1016/j.lungcan.2010.08.002","title":"Effects of Aerobic Training on Oxidative Status in Postsurgical Non-Small Cell Lung Cancer Patients: A Pilot Study","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Antioxidant Activity and Oxidative Stress","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Aerobic exercise; Physical therapy","score_opus":0.013697876784615565,"score_gpt":0.29989237289991466,"score_spread":0.2861944961152991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075402438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996126,0.0000638145,0.000029799925,0.000017911025,0.0000092848895,0.000088241904,0.000040341645,0.0000018701933,0.00013603325],"genre_scores_gemma":[0.99893206,0.0001468364,0.00012345813,0.00006180237,0.000046628815,0.00016361567,0.00014539016,0.0000017406002,0.00037828909],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970454,0.000093896866,0.00001946027,0.000051204337,0.000024844345,0.00010615291],"domain_scores_gemma":[0.9991979,0.00015022811,0.000069673595,0.00007035344,0.000059336835,0.0004525762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070021447,0.00096763205,0.0014272975,0.0004043153,0.0010537836,0.0003905722,0.00036255945,0.000760663,0.00253403],"category_scores_gemma":[0.0006519426,0.00035382158,0.00088024634,0.00052153564,0.0007208315,0.00048645522,0.00043070383,0.0013352736,0.00034663294],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4588294,0.24116737,0.2017764,0.0003985346,0.00094204943,0.0011782161,0.0015947702,0.00048318377,0.049008068,0.00011171163,0.0005366471,0.043973755],"study_design_scores_gemma":[0.015048447,0.5835115,0.39626664,0.000015669539,0.0004833905,0.00025254744,0.00076637615,0.00036553375,0.0027113578,0.00006365323,0.0004828222,0.00003207166],"about_ca_topic_score_codex":0.0023085778,"about_ca_topic_score_gemma":0.0024021696,"teacher_disagreement_score":0.00253403,"about_ca_system_score_codex":0.00032502037,"about_ca_system_score_gemma":0.00073421595,"threshold_uncertainty_score":0.008477151},"labels":[],"label_agreement":null},{"id":"W2080373479","doi":"10.1016/j.lungcan.2013.02.008","title":"The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Carboplatin; Amifostine; Internal medicine; Chemoradiotherapy; Oncology; Hazard ratio; Regimen; Paclitaxel; Radiation therapy; Lung cancer; Urology; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.0061225479966184075,"score_gpt":0.2849646875992788,"score_spread":0.27884213960266035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080373479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898532,0.0034469997,0.00039545252,0.0009431791,0.00094168086,0.0013572922,0.0012237312,0.00008303201,0.0017555237],"genre_scores_gemma":[0.9885506,0.0018502253,0.00069371035,0.0012565516,0.00075336674,0.0013364733,0.0018472911,0.00003051675,0.0036814003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976653,0.0015019573,0.00012755487,0.00032477765,0.00010035155,0.00028002285],"domain_scores_gemma":[0.9974136,0.00094049744,0.0005520774,0.00025247977,0.00013271332,0.0007087632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029046172,0.0021062584,0.004961939,0.00057281024,0.0007769091,0.0020702633,0.0017620308,0.003059803,0.0071923854],"category_scores_gemma":[0.0033941097,0.0010758773,0.0043727704,0.00076182117,0.0019011725,0.0017248654,0.0008175308,0.006485448,0.0014686323],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.994484,0.0010873706,0.0004092442,0.00012590158,0.00081914745,0.000013269107,0.000019085295,0.0001567244,0.00036696272,0.00004430715,0.00025690216,0.0022170937],"study_design_scores_gemma":[0.939103,0.055242825,0.0029238672,0.000030787516,0.001495317,0.00002366586,0.00003207559,0.00035188947,0.00023560325,0.00013289727,0.00040699172,0.000020986814],"about_ca_topic_score_codex":0.0036662123,"about_ca_topic_score_gemma":0.0068116244,"teacher_disagreement_score":0.0071923854,"about_ca_system_score_codex":0.0015328235,"about_ca_system_score_gemma":0.001969532,"threshold_uncertainty_score":0.024060905},"labels":[],"label_agreement":null},{"id":"W2080555188","doi":"10.1016/j.lungcan.2015.02.018","title":"Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Taiwan University Hospital; Ministry of Health, British Columbia; Ministry of Science and Technology, Taiwan; Ministry of Health and Welfare","keywords":"Medicine; Malignant pleural effusion; Pleural effusion; Adenocarcinoma; Metastatic adenocarcinoma; Lung; Oncology; Internal medicine; Pathology; Radiology; Cancer","score_opus":0.033619703688109695,"score_gpt":0.3827414251283273,"score_spread":0.34912172144021764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080555188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945095,0.0019527307,0.00012123075,0.0002967174,0.000025736375,0.000005991821,0.00027439257,0.000009628884,0.0028040835],"genre_scores_gemma":[0.99946886,0.0001674392,0.000046835798,0.000024241686,0.000030194886,0.0000020583573,0.00011020041,0.0000016736942,0.00014859368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963224,0.00007856684,0.00004466821,0.00006362986,0.00008247504,0.000098380384],"domain_scores_gemma":[0.99909294,0.0002705122,0.00030625373,0.000041553798,0.00010306806,0.00018575601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032342447,0.000275769,0.00026152973,0.00069276616,0.00048589078,0.0006957146,0.00035971965,0.0006214627,0.0028273626],"category_scores_gemma":[0.0031245945,0.00018900748,0.00034447596,0.0007372311,0.0004242138,0.00060175505,0.0003763418,0.000486734,0.0003001982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038819227,0.000017119793,0.98790854,0.000019632245,0.000051130348,0.0021621098,0.00006446554,0.00019370162,0.0023356532,0.00010763787,0.00023579702,0.006516127],"study_design_scores_gemma":[0.000014859702,0.0001345924,0.988806,0.00001836329,0.00011828679,0.007986476,0.00035879298,0.0006979034,0.00059503777,0.0003731102,0.00088381907,0.000012670396],"about_ca_topic_score_codex":0.0014027728,"about_ca_topic_score_gemma":0.0032422892,"teacher_disagreement_score":0.0028273626,"about_ca_system_score_codex":0.00040144598,"about_ca_system_score_gemma":0.0002776985,"threshold_uncertainty_score":0.009458542},"labels":[],"label_agreement":null},{"id":"W2083528984","doi":"10.1016/s0169-5002(00)80809-0","title":"An evaluation of screening for lung cancer in Niigata prefecture, Japan. A population-based case control study","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.028015871405128834,"score_gpt":0.4197786026991805,"score_spread":0.39176273129405165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083528984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99918133,0.00026668445,0.00011773365,0.000032884673,0.000008162015,0.00003947523,0.00013332767,0.0000021152846,0.00021820042],"genre_scores_gemma":[0.99923563,0.00012285204,0.0001498483,0.000049699378,0.000013128583,0.000049588354,0.0002476733,0.0000026224432,0.00012905072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958995,0.0015599448,0.00050352444,0.001068072,0.00057285075,0.00039614987],"domain_scores_gemma":[0.9965519,0.00064822397,0.0009109606,0.00051593955,0.0006785753,0.00069441495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030856482,0.0011919866,0.001086068,0.0020062774,0.00234496,0.001335222,0.0014442455,0.0012685142,0.001079358],"category_scores_gemma":[0.0060679843,0.0017610933,0.0011906032,0.00236634,0.0012813971,0.00081070786,0.001150831,0.0008777714,0.00020621101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004578164,0.00021856806,0.99678975,0.000028354474,0.00031108694,0.0002912853,0.0006085294,0.000025389434,0.00042707747,0.000021249565,0.000085414395,0.0007353893],"study_design_scores_gemma":[0.000065325316,0.00028646976,0.9983652,0.000005935496,0.00028709415,0.0002897968,0.000411561,0.00011887148,0.000033008568,0.000009131884,0.00011969576,0.00000789297],"about_ca_topic_score_codex":0.06673113,"about_ca_topic_score_gemma":0.06908925,"teacher_disagreement_score":0.06673113,"about_ca_system_score_codex":0.0017441382,"about_ca_system_score_gemma":0.0011897219,"threshold_uncertainty_score":0.13268542},"labels":[],"label_agreement":null},{"id":"W2083744249","doi":"10.1016/j.lungcan.2005.08.005","title":"A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Willingness to pay; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Marital status; Population; Environmental health","score_opus":0.011568644818447691,"score_gpt":0.33183083068366953,"score_spread":0.3202621858652218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083744249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807703,0.00033151728,0.00011225608,0.00038064067,0.00006647104,0.00019653533,0.00014950137,0.0000032356907,0.00068273494],"genre_scores_gemma":[0.9986436,0.00014823499,0.00008995367,0.00022218651,0.0000841449,0.00016818655,0.00014573404,0.0000013860307,0.000496525],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99755436,0.0016095932,0.00011798759,0.0002328425,0.00014187625,0.0003433427],"domain_scores_gemma":[0.99301344,0.0043385904,0.000699786,0.0003540159,0.00020396695,0.0013901282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00423737,0.0011887669,0.0020231563,0.0005073664,0.0011514226,0.001441463,0.0010364249,0.0029622952,0.006832126],"category_scores_gemma":[0.008208241,0.0008305672,0.0031080656,0.0006796126,0.001325085,0.0019109752,0.0007719039,0.0040171556,0.00056829903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8578787,0.04883636,0.06496383,0.00042928592,0.0023859874,0.00047848004,0.00041018098,0.0016053094,0.0013309739,0.00089365034,0.00074421096,0.020043008],"study_design_scores_gemma":[0.3821078,0.4201061,0.17178276,0.00018557702,0.006138081,0.0005281372,0.002136208,0.010222189,0.00079517334,0.0032658381,0.0025084123,0.00022382109],"about_ca_topic_score_codex":0.0030959698,"about_ca_topic_score_gemma":0.002148104,"teacher_disagreement_score":0.006832126,"about_ca_system_score_codex":0.0017233128,"about_ca_system_score_gemma":0.0017868538,"threshold_uncertainty_score":0.022855699},"labels":[],"label_agreement":null},{"id":"W2084340355","doi":"10.1016/j.lungcan.2013.06.008","title":"An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Erlotinib; Medicine; Rash; Internal medicine; Adverse effect; Bioavailability; Gastroenterology; Tyrosine-kinase inhibitor; Diarrhea; Erlotinib Hydrochloride; Drug; Pharmacology; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.017004457116695577,"score_gpt":0.36295304428943587,"score_spread":0.3459485871727403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084340355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98249716,0.011678227,0.0005023531,0.00076467445,0.000116579635,0.00018732685,0.00033278373,0.000018264807,0.0039027492],"genre_scores_gemma":[0.9955929,0.0022932386,0.0006222294,0.00028256534,0.00007880317,0.00003689406,0.00021473345,0.0000038268145,0.0008747987],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99914753,0.00044403772,0.00006246627,0.00007651222,0.00019222408,0.00007721894],"domain_scores_gemma":[0.99925786,0.00043981973,0.0001346248,0.000022854623,0.00006455312,0.00008028893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010002309,0.0003277177,0.0008275171,0.00028308955,0.00032885847,0.0005558162,0.00032872587,0.0007699211,0.0028251426],"category_scores_gemma":[0.0020352567,0.00013398645,0.0010533951,0.00031282037,0.00021892149,0.00032469825,0.00022302198,0.0005715417,0.00024676352],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32085058,0.009598648,0.123301886,0.002681189,0.0052854335,0.008835478,0.0003954718,0.0032642325,0.12854747,0.0012639681,0.002458754,0.39351684],"study_design_scores_gemma":[0.018880572,0.4526702,0.29781377,0.0004740322,0.020918583,0.015202839,0.0009809808,0.012887586,0.1219214,0.0010276719,0.05709087,0.00013142613],"about_ca_topic_score_codex":0.00085259025,"about_ca_topic_score_gemma":0.002198876,"teacher_disagreement_score":0.0028251426,"about_ca_system_score_codex":0.0005445469,"about_ca_system_score_gemma":0.0006719784,"threshold_uncertainty_score":0.009451032},"labels":[],"label_agreement":null},{"id":"W2085286841","doi":"10.1016/j.lungcan.2013.10.007","title":"A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Chemotherapy; Oncology; Disease; Mutation; Internal medicine; Tyrosine-kinase inhibitor; Population; Cancer research; Cancer; Gene; Genetics; Receptor","score_opus":0.010582962090107244,"score_gpt":0.33281845815150135,"score_spread":0.3222354960613941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085286841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001673767,0.9995208,0.000026832651,0.00007086243,0.000034136363,0.0000045938627,0.00003166173,8.4619745e-7,0.00014279548],"genre_scores_gemma":[0.0014755588,0.9981976,0.00008430206,0.00012617988,0.00003455417,0.0000049179916,0.000031349613,5.6361375e-7,0.000045066445],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99955624,0.000097879834,0.00015779109,0.00007460656,0.00009442573,0.000019153022],"domain_scores_gemma":[0.99853563,0.0010214574,0.00023388116,0.000015624502,0.00016507716,0.000028289567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011800554,0.00047124943,0.0020181446,0.0017650889,0.00012616717,0.00073153165,0.00077542354,0.00058365247,0.0019815038],"category_scores_gemma":[0.0027113575,0.00028401843,0.0016577021,0.0023946601,0.00022286086,0.0006907567,0.0003085848,0.00076735823,0.00023409363],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004554258,0.000054260585,0.001054522,0.1993479,0.0022686375,0.00016699145,0.00007802526,0.00041061113,0.0007341461,0.000688429,0.011960959,0.7827801],"study_design_scores_gemma":[0.00055732,0.0014911628,0.028262364,0.20582645,0.03308826,0.0052185063,0.0003653621,0.00044379005,0.001382342,0.0014869182,0.7217401,0.00013733862],"about_ca_topic_score_codex":0.002328501,"about_ca_topic_score_gemma":0.006408447,"teacher_disagreement_score":0.002328501,"about_ca_system_score_codex":0.0007758755,"about_ca_system_score_gemma":0.0016243289,"threshold_uncertainty_score":0.0066287518},"labels":[],"label_agreement":null},{"id":"W2085851845","doi":"10.1016/j.lungcan.2003.10.009","title":"Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Ottawa","funders":"","keywords":"Vinorelbine; Medicine; Gemcitabine; Cisplatin; Regimen; Etoposide; Lung cancer; Paclitaxel; Chemotherapy; Internal medicine; Oncology; Pharmacology; Cancer; Drug resistance; Biology","score_opus":0.01439211725772029,"score_gpt":0.38193406914075567,"score_spread":0.3675419518830354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085851845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952933,0.00084528094,0.0004800892,0.00022473962,0.00014109375,0.0015153022,0.00041379762,0.00006932831,0.0010170101],"genre_scores_gemma":[0.9880243,0.0013615494,0.0023399827,0.00046983178,0.00020767575,0.0033913439,0.0011499288,0.000042296837,0.0030131121],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994512,0.00024285166,0.000022896333,0.0001093557,0.000037253627,0.00013642466],"domain_scores_gemma":[0.9990553,0.00019524094,0.00012886463,0.00015085167,0.00004739055,0.0004222865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012825736,0.0015764154,0.0035782806,0.000854872,0.0006724115,0.00095290283,0.0014884257,0.0016512249,0.005579883],"category_scores_gemma":[0.001141508,0.0007940438,0.0013686077,0.0007752488,0.0014102658,0.0011513744,0.0005107204,0.00407481,0.0008105252],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74560505,0.12187054,0.0024651915,0.0004706368,0.001060351,0.00008096946,0.0002485454,0.0049377703,0.027458776,0.00040415968,0.0017400323,0.09365791],"study_design_scores_gemma":[0.49986497,0.4905689,0.003669317,0.000020462907,0.00029558435,0.00008352134,0.000057134177,0.0013832619,0.0025593836,0.00023404356,0.0012377481,0.000025640742],"about_ca_topic_score_codex":0.0022256623,"about_ca_topic_score_gemma":0.003476114,"teacher_disagreement_score":0.005579883,"about_ca_system_score_codex":0.0009999031,"about_ca_system_score_gemma":0.0019929023,"threshold_uncertainty_score":0.018666565},"labels":[],"label_agreement":null},{"id":"W2085996111","doi":"10.1016/j.lungcan.2013.06.015","title":"Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Oncology; Mucin; Adjuvant chemotherapy; Lung cancer; Adjuvant; Internal medicine; Chemotherapy; Expression (computer science); Cancer; Pathology; Breast cancer","score_opus":0.005833187482472542,"score_gpt":0.26013805620361263,"score_spread":0.2543048687211401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085996111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985316,0.00021945003,0.00025763898,0.000034314307,0.00002099008,0.00001628976,0.0006313727,0.00001096337,0.00027732644],"genre_scores_gemma":[0.99728787,0.000047304366,0.00015134424,0.000025706384,0.000015238111,0.000014253064,0.0022651388,0.000010926932,0.0001822328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828774,0.0008014859,0.00013754825,0.0003847499,0.00022233198,0.00016609217],"domain_scores_gemma":[0.9938922,0.002195493,0.00083472306,0.0012798054,0.0010711668,0.0007266142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055462155,0.0006017049,0.0006732845,0.00091327174,0.0006053047,0.00094960653,0.00084904616,0.00074880355,0.00122517],"category_scores_gemma":[0.0068937303,0.00028181743,0.00096020283,0.00077862927,0.0005948197,0.00043455843,0.00088468223,0.0007388016,0.00070887856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034422844,0.00019911843,0.9833625,0.000032924094,0.0009256062,0.00006781192,0.00023823607,0.0005210596,0.005013988,0.00003732942,0.00061233615,0.0055468697],"study_design_scores_gemma":[0.00015573009,0.00058498763,0.99346995,0.000012663188,0.00064237317,0.0002598331,0.00016982596,0.0023064446,0.0014086321,0.000050082206,0.00092152925,0.000017933322],"about_ca_topic_score_codex":0.003433774,"about_ca_topic_score_gemma":0.0034698728,"teacher_disagreement_score":0.0055462155,"about_ca_system_score_codex":0.00043998114,"about_ca_system_score_gemma":0.00042159823,"threshold_uncertainty_score":0.029331505},"labels":[],"label_agreement":null},{"id":"W2086962483","doi":"10.1016/s0169-5002(00)80188-9","title":"Phase II trial of alternating 4 chemotherapy regimens in non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine","score_opus":0.01205030497229059,"score_gpt":0.36270405458209004,"score_spread":0.35065374960979945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086962483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992942,0.0018300716,0.0004371228,0.0006012783,0.0003600814,0.0016801835,0.00062972517,0.00012839404,0.0013911612],"genre_scores_gemma":[0.98070437,0.0021222024,0.002746871,0.0011083955,0.00043247678,0.005244988,0.0020927344,0.00007408408,0.005473861],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99919456,0.0003434883,0.000035597317,0.00016965953,0.00003876757,0.00021798389],"domain_scores_gemma":[0.99859995,0.00032792447,0.00017851114,0.0002203341,0.00006274229,0.00061051536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018690429,0.0023235925,0.0058643348,0.0010390308,0.00091368775,0.0013745924,0.0019276224,0.002628358,0.009194702],"category_scores_gemma":[0.0018351113,0.0011177139,0.002461557,0.0008110282,0.0020420018,0.0021693325,0.0008471092,0.0059286016,0.001504339],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.884335,0.042393718,0.0012811479,0.00034859718,0.0008552793,0.000052026146,0.00014607565,0.0031797988,0.006126818,0.0002072132,0.001484954,0.059589352],"study_design_scores_gemma":[0.70457965,0.289609,0.002357172,0.000026880847,0.00022444018,0.000050401544,0.00005166044,0.0010352363,0.0008034979,0.0003029619,0.0009316025,0.000027507393],"about_ca_topic_score_codex":0.0022320035,"about_ca_topic_score_gemma":0.003972149,"teacher_disagreement_score":0.009194702,"about_ca_system_score_codex":0.0015609353,"about_ca_system_score_gemma":0.0020874746,"threshold_uncertainty_score":0.030759335},"labels":[],"label_agreement":null},{"id":"W2090077894","doi":"10.1016/s0169-5002(00)80641-8","title":"Hepatocyte growth factor and its isoforms are predominantly expressed by epithelial cells in normal lung and primary non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Liver physiology and pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Hepatocyte growth factor; Medicine; Lung; Hepatocyte; Lung cancer; Gene isoform; Primary (astronomy); Cancer research; Growth factor; Cell growth; Internal medicine; Oncology; In vitro; Biology; Gene; Biochemistry; Receptor","score_opus":0.006075988665649558,"score_gpt":0.23714168083962772,"score_spread":0.23106569217397815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090077894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924077,0.004103085,0.0008705222,0.00006792719,0.00002633935,0.000012618356,0.0005348914,0.000030193376,0.0019466053],"genre_scores_gemma":[0.9942106,0.0013397466,0.0006156458,0.000033178338,0.000027248561,0.000024058285,0.0012458853,0.000012122881,0.0024914937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997727,0.00002825714,0.000023246772,0.000036455924,0.00006484213,0.00007446235],"domain_scores_gemma":[0.9997644,0.000039444098,0.000033281754,0.000026646689,0.0000692889,0.000066975845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013983487,0.00016446765,0.000360682,0.00063141616,0.00038104173,0.00040767144,0.00014199832,0.00017974962,0.0016110445],"category_scores_gemma":[0.00022744483,0.00021357577,0.00022607627,0.000690247,0.0002567373,0.00032012703,0.00023236225,0.0003284045,0.00044019823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006917571,0.0000144013975,0.007557298,0.00005993251,0.000017375942,0.00021204943,0.000081424834,0.00002017864,0.98861223,0.0000967132,0.00008295696,0.0025536977],"study_design_scores_gemma":[0.00008054472,0.00063346775,0.44447517,0.000018727376,0.0001474657,0.006313027,0.0011387308,0.0008518284,0.5353813,0.00028853983,0.010644114,0.00002703249],"about_ca_topic_score_codex":0.0020209018,"about_ca_topic_score_gemma":0.0020587621,"teacher_disagreement_score":0.0020209018,"about_ca_system_score_codex":0.00028152176,"about_ca_system_score_gemma":0.00027052377,"threshold_uncertainty_score":0.0053895116},"labels":[],"label_agreement":null},{"id":"W2092041185","doi":"10.1016/s0169-5002(01)00289-6","title":"Commentary on “Carboplatin–etoposide association in small cell lung cancer patients older than 70 years: a phase II trial”","year":2002,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Lung cancer; Oncology; Internal medicine; Clinical trial; Chemotherapy; Cisplatin","score_opus":0.020139594596299222,"score_gpt":0.34367419092856416,"score_spread":0.32353459633226495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092041185","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007916107,0.0015902744,0.0000687757,0.9678639,0.02714328,0.00004863648,0.00034468703,0.000026691976,0.002122211],"genre_scores_gemma":[0.0023994981,0.00057715515,0.00013292175,0.9698601,0.023613362,0.0001284461,0.000099263976,0.000018196488,0.0031710716],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99153465,0.0041318326,0.0010109629,0.0008941888,0.0013367614,0.0010916429],"domain_scores_gemma":[0.97411704,0.017795049,0.0018566116,0.0005227363,0.0022512397,0.0034573323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011404225,0.0011063726,0.003547867,0.0008245949,0.0041373144,0.0032305922,0.0032255277,0.06738254,0.008369563],"category_scores_gemma":[0.03917702,0.0013558135,0.002641825,0.0014467831,0.002231818,0.0025619783,0.0017152262,0.04039774,0.005321392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000815209,0.000042250475,0.00043947963,0.00015292941,0.00006540969,0.000389176,0.000080062324,0.00006022536,0.00014214501,0.000714826,0.99071246,0.006385902],"study_design_scores_gemma":[0.003616888,0.00066422904,0.0033900745,0.0011711752,0.0005692281,0.0007389303,0.00029708643,0.00051212474,0.0006244859,0.0045398683,0.9837533,0.00012262168],"about_ca_topic_score_codex":0.006630125,"about_ca_topic_score_gemma":0.015121898,"teacher_disagreement_score":0.06738254,"about_ca_system_score_codex":0.005040866,"about_ca_system_score_gemma":0.007664224,"threshold_uncertainty_score":0.060312033},"labels":[],"label_agreement":null},{"id":"W2092373171","doi":"10.1016/s0169-5002(02)00025-9","title":"Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells","year":2002,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute; Jewish General Hospital","funders":"National Cancer Institute; National Research Council Canada","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Cadherin; Catenin; Heparin-binding EGF-like growth factor; Cancer research; Cell culture; Biology; A549 cell; ErbB; Cell biology; Receptor; Cell; Signal transduction; Wnt signaling pathway; Biochemistry","score_opus":0.018491766832027388,"score_gpt":0.2745728072245829,"score_spread":0.25608104039255547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092373171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540186,0.0017228967,0.0007134112,0.00007246032,0.000013926546,0.000019897288,0.0003664832,0.000031538893,0.0016574467],"genre_scores_gemma":[0.99624443,0.00069038797,0.00036530697,0.000026394899,0.000003924153,0.00002302417,0.0005057334,0.0000064445867,0.0021343434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998592,0.000032531512,0.000013005565,0.000018385372,0.00003055039,0.000046297406],"domain_scores_gemma":[0.9999453,0.000015691285,0.0000058690107,0.000010285778,0.000012406556,0.000010504844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012869333,0.00011919395,0.00024010085,0.00026611023,0.00024135082,0.00045566083,0.00012358805,0.00017139314,0.0014832732],"category_scores_gemma":[0.00014025297,0.00014486251,0.00018230331,0.0003273436,0.00017414404,0.00017987409,0.0001287137,0.00027427915,0.00037093202],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002406883,0.0000348221,0.00064494356,0.00002658059,0.000007168992,0.000113788774,0.000051125222,0.00005073142,0.997488,0.000152882,0.0000732759,0.0011159716],"study_design_scores_gemma":[0.000029358107,0.00019113717,0.029505687,0.000003755788,0.000026112737,0.00034627243,0.00016566234,0.0011430299,0.96527773,0.00006114345,0.0032435174,0.0000065574295],"about_ca_topic_score_codex":0.0051561855,"about_ca_topic_score_gemma":0.0048796344,"teacher_disagreement_score":0.0051561855,"about_ca_system_score_codex":0.0003936758,"about_ca_system_score_gemma":0.00022310855,"threshold_uncertainty_score":0.0102523565},"labels":[],"label_agreement":null},{"id":"W2093235552","doi":"10.1016/j.lungcan.2015.03.002","title":"The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Yonsei University","keywords":"Medicine; Carboplatin; Internal medicine; Hazard ratio; Etoposide; Oncology; Fibroblast growth factor receptor 1; Chemotherapy; Lung cancer; Cisplatin; Cancer; Confidence interval; Fibroblast growth factor; Receptor","score_opus":0.028932526743423267,"score_gpt":0.36817816782713864,"score_spread":0.33924564108371535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093235552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992291,0.00020356973,0.000031295513,0.000033200802,0.0000037766538,0.0000025381817,0.00011618172,0.0000016784951,0.00037870323],"genre_scores_gemma":[0.9996872,0.00007898346,0.00001696078,0.000014877184,0.0000048537313,0.0000020730674,0.000109189335,9.789396e-7,0.00008481094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999671,0.000051955998,0.000053219963,0.000076559605,0.000043927517,0.0001032568],"domain_scores_gemma":[0.9991301,0.00015579234,0.00038404603,0.000046987036,0.00009750761,0.00018566675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035612666,0.00025309072,0.0002339863,0.0008759258,0.00042351134,0.00059076224,0.00036955986,0.0004086235,0.0017265643],"category_scores_gemma":[0.0013692615,0.00025623254,0.0004185307,0.0010569426,0.00036514923,0.00061172445,0.00045301617,0.00042817622,0.00022787681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007961528,0.000010468701,0.9984415,0.0000047783747,0.000019958032,0.00019483463,0.000038201688,0.000026151529,0.00036982782,0.000010918164,0.000028523906,0.0007751022],"study_design_scores_gemma":[0.000003373068,0.000038853683,0.9984989,0.0000026610992,0.000037339505,0.0007715546,0.00031300084,0.000100682155,0.0000784331,0.000027892962,0.00012235997,0.0000048337015],"about_ca_topic_score_codex":0.0036380375,"about_ca_topic_score_gemma":0.004375582,"teacher_disagreement_score":0.0036380375,"about_ca_system_score_codex":0.00035779105,"about_ca_system_score_gemma":0.00034660404,"threshold_uncertainty_score":0.0072336793},"labels":[],"label_agreement":null},{"id":"W2094897257","doi":"10.1016/j.lungcan.2007.09.027","title":"Current state and future directions of pleural mesothelioma imaging","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Mesothelioma; Medicine; Context (archaeology); Medical physics; Modalities; Radiology; Presentation (obstetrics); Pathology","score_opus":0.00611489564978099,"score_gpt":0.3067610939387378,"score_spread":0.3006461982889568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094897257","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009346844,0.9158695,0.01998853,0.03742434,0.0016439842,0.00017575796,0.0002713349,0.0006350448,0.014644562],"genre_scores_gemma":[0.15157917,0.7206236,0.07685432,0.021011898,0.020328106,0.00084551546,0.001281786,0.00022860408,0.007247024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969458,0.0011985439,0.0006327572,0.00043364856,0.00047283433,0.0003164168],"domain_scores_gemma":[0.972232,0.019778172,0.0010007389,0.0007521224,0.005060852,0.0011760405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023368917,0.0011915943,0.0028086877,0.004737241,0.00152567,0.006810198,0.004964534,0.0077183037,0.011667457],"category_scores_gemma":[0.014721087,0.0011761435,0.0016125945,0.0023082471,0.004971023,0.013131396,0.0014669928,0.004405763,0.0028850343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017258102,0.0010073708,0.027359417,0.010521068,0.00045398463,0.0015940462,0.0008123885,0.002303658,0.01083446,0.02081134,0.039360434,0.883216],"study_design_scores_gemma":[0.0011296989,0.004966951,0.029720066,0.014291054,0.0029727975,0.03176425,0.006365641,0.022519318,0.01141344,0.07617197,0.7979722,0.0007125751],"about_ca_topic_score_codex":0.0060168137,"about_ca_topic_score_gemma":0.010577024,"teacher_disagreement_score":0.023368917,"about_ca_system_score_codex":0.0029847145,"about_ca_system_score_gemma":0.0065400302,"threshold_uncertainty_score":0.123588085},"labels":[],"label_agreement":null},{"id":"W2097042869","doi":"10.1016/j.lungcan.2004.02.002","title":"Response to ‘is “no treatment” better than radiotherapy and chemotherapy? by L. Debevec’","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine; Carcinoma","score_opus":0.006875953594191144,"score_gpt":0.3305384188192248,"score_spread":0.32366246522503367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097042869","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075915694,0.124910966,0.0003920536,0.83196795,0.03830729,0.000012328863,0.000071851005,0.000030551004,0.003547805],"genre_scores_gemma":[0.029950822,0.21138453,0.0018271517,0.5886521,0.14821607,0.00009691938,0.0002010169,0.00018448193,0.019486904],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966624,0.0017577426,0.00033195183,0.0006287495,0.00046994543,0.0001493467],"domain_scores_gemma":[0.9889465,0.008332983,0.00044536867,0.00018843374,0.0015704122,0.0005162735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070583457,0.0007963815,0.0014782597,0.000946856,0.0008020083,0.0022528598,0.0011945423,0.0033824055,0.0038973154],"category_scores_gemma":[0.022931786,0.00041520078,0.0007390878,0.00081524794,0.0030712017,0.0027685766,0.0010099476,0.012177464,0.001966189],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022586633,0.000020484142,0.0005765065,0.00049861206,0.00006819112,0.0001781387,0.00023616946,0.00012730004,0.0001199089,0.0041874456,0.9295839,0.06417748],"study_design_scores_gemma":[0.00013681904,0.00012907867,0.0032887638,0.0020192862,0.00008306475,0.001999566,0.0005614062,0.00042551,0.00029452718,0.01911498,0.9718649,0.00008202501],"about_ca_topic_score_codex":0.0048151766,"about_ca_topic_score_gemma":0.0068598334,"teacher_disagreement_score":0.0070583457,"about_ca_system_score_codex":0.0022233645,"about_ca_system_score_gemma":0.0015295327,"threshold_uncertainty_score":0.0373286},"labels":[],"label_agreement":null},{"id":"W2097463411","doi":"10.1016/j.lungcan.2012.05.111","title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Medicine; Pemetrexed; Bevacizumab; Clinical endpoint; Internal medicine; Mesothelioma; Neutropenia; Progression-free survival; Oncology; Vascular endothelial growth factor; Gastroenterology; Cisplatin; Phases of clinical research; Survival rate; Chemotherapy; Surgery; Pathology; Clinical trial; VEGF receptors","score_opus":0.006440750221946768,"score_gpt":0.2942190817725004,"score_spread":0.2877783315505536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097463411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959603,0.0016788549,0.00027676034,0.00034088173,0.000099029916,0.00079216115,0.00030700967,0.000028355476,0.0005167379],"genre_scores_gemma":[0.99476236,0.0012500952,0.0008872656,0.00045475585,0.00014963429,0.00091012125,0.0008060537,0.000018750085,0.000760997],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992229,0.00041895322,0.000043173746,0.0001461863,0.00005616068,0.00011276769],"domain_scores_gemma":[0.9989095,0.000203856,0.00019295674,0.000112206115,0.00007367336,0.00050780835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002194116,0.0013273167,0.002860877,0.0004525779,0.0005452943,0.001171846,0.00093021325,0.0010628069,0.0022127514],"category_scores_gemma":[0.0015548341,0.0008573405,0.0018329525,0.0005593587,0.0011116819,0.0015095234,0.0004907397,0.0035512452,0.0004989844],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88415456,0.03243285,0.009328959,0.0004386637,0.00210787,0.00012192432,0.00025715065,0.0016703305,0.016744511,0.00016177908,0.0016194572,0.050961994],"study_design_scores_gemma":[0.727581,0.2540012,0.013735372,0.000021488819,0.00091841654,0.00013515867,0.00007997789,0.00075590773,0.0011769771,0.0001241153,0.0014429938,0.000027434206],"about_ca_topic_score_codex":0.0014361057,"about_ca_topic_score_gemma":0.0029148976,"teacher_disagreement_score":0.002860877,"about_ca_system_score_codex":0.0012333062,"about_ca_system_score_gemma":0.0016502677,"threshold_uncertainty_score":0.011603773},"labels":[],"label_agreement":null},{"id":"W2103524216","doi":"10.1016/j.lungcan.2013.05.014","title":"The role of epigenetics in malignant pleural mesothelioma","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds Spéciaux de Recherche; Belgian Federal Science Policy Office; Stichting Tegen Kanker; European Commission; Direction Générale des Infrastructures, des Transports et de la Mer; Gouvernement Wallon; Fonds De La Recherche Scientifique - FNRS; Institut National Du Cancer; Institut national de la recherche scientifique; Cement Association of Canada","keywords":"Medicine; Mesothelioma; Epigenetics; Oncology; Internal medicine; Cancer research; Pathology; Genetics; Biology","score_opus":0.01629315142229983,"score_gpt":0.3366757089558819,"score_spread":0.3203825575335821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103524216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000720189,0.9989248,0.00012996887,0.00029102946,0.0001970684,0.0000014515343,0.000009760436,0.000003447833,0.0003705061],"genre_scores_gemma":[0.0007250211,0.9981086,0.00014781898,0.00020794867,0.0004025238,0.0000026068556,0.00001892175,9.379911e-7,0.00038550593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998155,0.000029688697,0.000025042506,0.000034682304,0.0000749067,0.000020210822],"domain_scores_gemma":[0.9996891,0.00013894086,0.000047547,0.000011537703,0.00007952676,0.000033453976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006999229,0.00070343993,0.0012626823,0.0015351204,0.00023154552,0.00091684685,0.000978434,0.0012096305,0.0015040403],"category_scores_gemma":[0.0008121677,0.00027550518,0.00036092554,0.0018789198,0.0006902717,0.0011068212,0.0008287245,0.0017608989,0.00096428755],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007802644,0.000034903605,0.0003142514,0.0073404238,0.00009894566,0.00040148277,0.00003800381,0.00046896073,0.0032489197,0.0032250248,0.035214078,0.94953704],"study_design_scores_gemma":[0.000021774917,0.00005627005,0.0013433439,0.0014996671,0.00014164067,0.002010417,0.000051284966,0.00017982168,0.0011198388,0.0028018951,0.9907504,0.000023766077],"about_ca_topic_score_codex":0.0012949711,"about_ca_topic_score_gemma":0.0025306756,"teacher_disagreement_score":0.0015351204,"about_ca_system_score_codex":0.0007141012,"about_ca_system_score_gemma":0.0009472119,"threshold_uncertainty_score":0.005181253},"labels":[],"label_agreement":null},{"id":"W2104258423","doi":"10.1016/j.lungcan.2012.10.007","title":"Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Society for Medical Oncology","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Cancer; Overall survival; Progression-free survival","score_opus":0.055567186221244326,"score_gpt":0.4467526399012807,"score_spread":0.3911854536800364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104258423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034847797,0.99918073,0.00006575278,0.00008844005,0.00003837089,0.0000096997655,0.00002875681,0.0000037313491,0.0002360172],"genre_scores_gemma":[0.0045095887,0.9946116,0.00025265227,0.00026504562,0.00007469641,0.000024770825,0.00007178936,0.0000024996923,0.00018735368],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996474,0.000108750406,0.000072638955,0.00004951945,0.00009144157,0.000030271329],"domain_scores_gemma":[0.9993461,0.0004148064,0.00014484677,0.00000980093,0.00006104988,0.0000234026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001427625,0.0007911029,0.0034774144,0.0009728233,0.00013005303,0.00072434655,0.0010701448,0.00076899753,0.0019494727],"category_scores_gemma":[0.001650776,0.000282477,0.001826641,0.0013783533,0.00027338156,0.0007197583,0.00034594347,0.001591917,0.0003379538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001468884,0.0001065534,0.00043676293,0.050949994,0.0014220981,0.00009056024,0.000038939037,0.0009792937,0.0010240289,0.0008486268,0.01299642,0.9296379],"study_design_scores_gemma":[0.005340278,0.005174272,0.016441891,0.058480233,0.022112789,0.0030986578,0.00022736573,0.001774073,0.0025407367,0.005140507,0.8795039,0.00016534126],"about_ca_topic_score_codex":0.0011014568,"about_ca_topic_score_gemma":0.0035737169,"teacher_disagreement_score":0.0034774144,"about_ca_system_score_codex":0.0007461463,"about_ca_system_score_gemma":0.0008225235,"threshold_uncertainty_score":0.0075500607},"labels":[],"label_agreement":null},{"id":"W2104507554","doi":"10.1016/s0169-5002(99)00122-1","title":"RARβ2 specificity in mediating RA inhibition of growth of lung cancer-derived cells","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Medical Research Council","keywords":"Retinoic acid; Retinoid; Transfection; Cancer research; Cell culture; Gene isoform; In vivo; In vitro; Receptor; Retinoic acid receptor beta; Retinoic acid receptor; Tretinoin; Growth inhibition; Cell growth; Medicine; Retinoid X receptor gamma; Lung cancer; Epidermoid carcinoma; Biology; Internal medicine; Cancer; Biochemistry; Gene","score_opus":0.005271635240152299,"score_gpt":0.2538674442420975,"score_spread":0.2485958090019452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104507554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970812,0.007904674,0.0052798386,0.00021355,0.00007525198,0.00008380837,0.0011552433,0.00026865114,0.014206983],"genre_scores_gemma":[0.98852706,0.002200041,0.0012630224,0.00007339554,0.000019085115,0.000046178866,0.00066936977,0.00004937963,0.007152484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965334,0.000087930806,0.00003468971,0.00004570508,0.000054278404,0.0001241417],"domain_scores_gemma":[0.9998222,0.000052186344,0.000012992711,0.000050910014,0.000032281587,0.000029456449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044957933,0.0005960964,0.0005548476,0.0005335751,0.00029191698,0.00065929815,0.00039657028,0.00028262276,0.0021151137],"category_scores_gemma":[0.00022530976,0.00026742238,0.00037912498,0.00035067037,0.000321496,0.00025947942,0.00023722668,0.00061334326,0.0012251841],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002270308,0.000024706238,0.00017922588,0.000029544548,0.000006480354,0.00007223943,0.000023136543,0.00007551534,0.9981306,0.00023639256,0.000042859876,0.0009522715],"study_design_scores_gemma":[0.000013945138,0.00017236106,0.001823953,0.0000037963232,0.0000128088905,0.00025154723,0.00003062445,0.00022498544,0.9953496,0.00003504069,0.0020786044,0.0000027300948],"about_ca_topic_score_codex":0.0029091476,"about_ca_topic_score_gemma":0.0033282514,"teacher_disagreement_score":0.0029091476,"about_ca_system_score_codex":0.0004391663,"about_ca_system_score_gemma":0.00043452712,"threshold_uncertainty_score":0.007075727},"labels":[],"label_agreement":null},{"id":"W2104963800","doi":"10.1016/s0169-5002(00)00116-1","title":"Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Autocrine signalling; Epidermal growth factor receptor; TGF alpha; Cancer research; Epidermal growth factor; Adenocarcinoma; Transforming growth factor; Signal transduction; Medicine; Biology; Receptor; Internal medicine; Cancer; Cell biology","score_opus":0.013661247539169781,"score_gpt":0.3215154356152042,"score_spread":0.3078541880760344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104963800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99690706,0.0010178831,0.00031550386,0.00008333044,0.000020944824,0.000007712955,0.000096349315,0.000033802185,0.0015173503],"genre_scores_gemma":[0.99896085,0.00021416412,0.00015639173,0.000012818819,0.000010295388,0.000003312559,0.00013466801,0.000007079069,0.00050054275],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99961334,0.00007741919,0.000044910965,0.00004675817,0.0001411249,0.000076473756],"domain_scores_gemma":[0.9987197,0.00039279464,0.00027270277,0.00020447902,0.00015919088,0.00025118128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003270454,0.00022725215,0.00046750248,0.000992036,0.0003440941,0.0007665166,0.00032282315,0.0003681396,0.0018014789],"category_scores_gemma":[0.0012444818,0.00032608863,0.0004384617,0.00036626623,0.00045668776,0.00033798782,0.00030605923,0.0005720739,0.00063773646],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003365593,0.00017400787,0.10192138,0.00004443504,0.00008772928,0.0037357085,0.00005018041,0.00013753492,0.883426,0.0004085432,0.00019497346,0.006453966],"study_design_scores_gemma":[0.00008686788,0.00095169764,0.7083964,0.000015075724,0.0002296237,0.037410975,0.0003145695,0.0027938809,0.24638638,0.00059095916,0.0028009426,0.000022692719],"about_ca_topic_score_codex":0.00087277626,"about_ca_topic_score_gemma":0.0009127703,"teacher_disagreement_score":0.0018014789,"about_ca_system_score_codex":0.0003378061,"about_ca_system_score_gemma":0.000329625,"threshold_uncertainty_score":0.006026566},"labels":[],"label_agreement":null},{"id":"W2105518844","doi":"10.1016/j.lungcan.2010.05.022","title":"A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Bayer Canada; Eli Lilly and Company","keywords":"Medicine; Sorafenib; Carboplatin; Pemetrexed; Internal medicine; Etoposide; Oncology; Refractory (planetary science); Lung cancer; Cisplatin; Urology; Chemotherapy; Hepatocellular carcinoma","score_opus":0.01762870376819342,"score_gpt":0.3877932423721357,"score_spread":0.3701645386039423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105518844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909637,0.0025945546,0.00038813718,0.0012202814,0.00035409944,0.0016042261,0.00093151594,0.00009371826,0.0018497964],"genre_scores_gemma":[0.9877643,0.0025447686,0.00133155,0.001022169,0.0003082452,0.0018388467,0.0021491367,0.00004407732,0.0029968263],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993957,0.00030545943,0.000028363827,0.000107631335,0.000031022988,0.0001318665],"domain_scores_gemma":[0.9989147,0.00020099997,0.00013244615,0.00008034797,0.00004812048,0.0006234015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018003337,0.002138079,0.0031559633,0.0005935831,0.0006809151,0.0012956292,0.0010897664,0.0015543854,0.0058626174],"category_scores_gemma":[0.0014109967,0.0008230331,0.002674775,0.0005727286,0.0014984338,0.0015536043,0.0005388568,0.004889515,0.001192952],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9286229,0.021547105,0.0013972488,0.0005313532,0.001304585,0.00013845111,0.00017460564,0.0015873308,0.009244852,0.00022679652,0.0027789783,0.032445814],"study_design_scores_gemma":[0.852589,0.14270398,0.0020560073,0.00001781151,0.0003425875,0.000084226136,0.000045934805,0.00037856447,0.0007412364,0.00011043804,0.0009152278,0.000014912562],"about_ca_topic_score_codex":0.0018954842,"about_ca_topic_score_gemma":0.0044959784,"teacher_disagreement_score":0.0058626174,"about_ca_system_score_codex":0.0013009158,"about_ca_system_score_gemma":0.002084454,"threshold_uncertainty_score":0.019612432},"labels":[],"label_agreement":null},{"id":"W2106925270","doi":"10.1016/j.lungcan.2010.08.001","title":"Analysis of Wait Times and Costs During the Peri-Diagnostic Period for Non-Small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Quartile; Lung cancer; Health care; Emergency medicine; Cancer registry; Population; Cohort; Demographics; Cancer; Confidence interval; Internal medicine; Demography","score_opus":0.005472328541034408,"score_gpt":0.2805572885981869,"score_spread":0.2750849600571525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106925270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968733,0.0009684341,0.00039285375,0.00023077682,0.000016957001,0.000013348232,0.0008952017,0.000011344996,0.00059771276],"genre_scores_gemma":[0.9991227,0.00010042122,0.00011387497,0.000014270193,0.0000085456,0.000007681749,0.00040655702,0.0000038600924,0.00022205559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898034,0.00032181083,0.000081661376,0.000107331216,0.00011887883,0.00038990058],"domain_scores_gemma":[0.990339,0.006013957,0.0018877601,0.00018989052,0.00048577055,0.0010836329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015563722,0.00040561537,0.0005623054,0.0011864422,0.00041748886,0.0010046958,0.0007940011,0.0007013368,0.0040176897],"category_scores_gemma":[0.0115426555,0.00036047024,0.0016151166,0.0016053154,0.00031273504,0.00095790613,0.00047058234,0.0010214798,0.0002470234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008843839,0.0005081602,0.93413085,0.00015471785,0.0009183954,0.0005416811,0.00021145951,0.0374346,0.0006242084,0.0019012798,0.0013403283,0.013390443],"study_design_scores_gemma":[0.00014634804,0.0015827031,0.93157405,0.000040201678,0.00069737626,0.0008651305,0.0011699708,0.061353248,0.00044239903,0.0012991354,0.0007810289,0.000048533377],"about_ca_topic_score_codex":0.020161793,"about_ca_topic_score_gemma":0.020637607,"teacher_disagreement_score":0.020161793,"about_ca_system_score_codex":0.0026748294,"about_ca_system_score_gemma":0.0020853083,"threshold_uncertainty_score":0.040088892},"labels":[],"label_agreement":null},{"id":"W2111088515","doi":"10.1016/j.lungcan.2004.02.009","title":"15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Surgical resection; Single Center; Vena cava; Superior vena cava; Resection; Center (category theory); Surgery; Radiology; Oncology","score_opus":0.01292059429815852,"score_gpt":0.2944366569894449,"score_spread":0.2815160626912864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111088515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761,0.000726915,0.0003970078,0.00007273966,0.000024723724,0.000017677576,0.000070571856,0.00001672438,0.001063657],"genre_scores_gemma":[0.99732023,0.00053779804,0.0003061036,0.00011379025,0.000039716302,0.000013263049,0.00032925452,0.000012455502,0.0013273844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958616,0.000068137764,0.000051616167,0.00009640724,0.00004723435,0.00015047636],"domain_scores_gemma":[0.9991704,0.00010709947,0.00013200183,0.000046291996,0.000048897862,0.0004952985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058764237,0.0005847265,0.00046879234,0.0005143118,0.0011959756,0.00067467615,0.00045450046,0.0005603558,0.0027790188],"category_scores_gemma":[0.0010564362,0.00025953757,0.00094493234,0.00049890595,0.00047894855,0.0005355319,0.0007662942,0.0005187943,0.0008042258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013087431,0.005965001,0.8791437,0.000112455,0.00051996775,0.016868714,0.0024222492,0.002799651,0.008166142,0.00026734907,0.0013642471,0.08106178],"study_design_scores_gemma":[0.00026710032,0.023886636,0.8992574,0.00007119465,0.00033663106,0.05895009,0.0026505254,0.0022487994,0.004732954,0.00051761215,0.006957625,0.00012337566],"about_ca_topic_score_codex":0.0028654647,"about_ca_topic_score_gemma":0.00632183,"teacher_disagreement_score":0.0028654647,"about_ca_system_score_codex":0.0007287786,"about_ca_system_score_gemma":0.00081089174,"threshold_uncertainty_score":0.009296715},"labels":[],"label_agreement":null},{"id":"W2113086549","doi":"10.1016/j.lungcan.2007.03.024","title":"General practitioner assessment of stage and performance status in lung cancer patients at a population level: Implications for prognosis and radiotherapy needs analyses","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of British Columbia","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Population; Oncology; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.09381405147741641,"score_gpt":0.4650619677710754,"score_spread":0.371247916293659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113086549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946641,0.00075196003,0.00028599545,0.00073377497,0.000014817712,0.00002372527,0.00039741577,0.000008352295,0.0031198075],"genre_scores_gemma":[0.9987219,0.0002824245,0.00033210433,0.00012455777,0.00001345197,0.000009833584,0.00014495314,0.0000024759295,0.00036829902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99912053,0.00051311374,0.00007184832,0.00006432302,0.00014225492,0.00008800195],"domain_scores_gemma":[0.9979499,0.0008813736,0.0004247821,0.000086316766,0.00038964162,0.00026799107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013488226,0.00013093563,0.000416033,0.00077438715,0.00035830308,0.0004899307,0.00025962642,0.00045812526,0.0020115986],"category_scores_gemma":[0.00877567,0.0001619542,0.0003348789,0.0010763131,0.00018783701,0.0005642806,0.0005137087,0.00038351346,0.0002297011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007040055,0.000036120095,0.99385107,0.00001986519,0.000019126974,0.00005388663,0.0002538933,0.00006500625,0.000112462214,0.0000252226,0.00021669269,0.0052762316],"study_design_scores_gemma":[0.000005941707,0.000118344666,0.9984515,0.000012017536,0.00002392839,0.00011573735,0.0006447802,0.00029951296,0.00003206923,0.000066382934,0.00022660424,0.0000032873454],"about_ca_topic_score_codex":0.01953274,"about_ca_topic_score_gemma":0.044267442,"teacher_disagreement_score":0.01953274,"about_ca_system_score_codex":0.00048631174,"about_ca_system_score_gemma":0.00060246006,"threshold_uncertainty_score":0.03883809},"labels":[],"label_agreement":null},{"id":"W2114472079","doi":"10.1016/j.lungcan.2009.08.020","title":"Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Zoledronic acid; Lung cancer; Internal medicine; Placebo; Quality of life (healthcare); Oncology; Incidence (geometry); Cancer; Pathology","score_opus":0.026639713843766392,"score_gpt":0.35221910547645463,"score_spread":0.32557939163268823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114472079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027321573,0.9992269,0.000026045911,0.00018522314,0.000050056507,0.0000014137187,0.000013545316,0.000001470621,0.00022206224],"genre_scores_gemma":[0.002208683,0.9973362,0.00008924567,0.00014708862,0.00008965069,0.000002340984,0.00002230663,5.519912e-7,0.00010387143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980813,0.00003106697,0.000040173065,0.000026502026,0.00008104594,0.000013088299],"domain_scores_gemma":[0.9994825,0.00027008963,0.000119862634,0.0000062049526,0.000099814686,0.000021403097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042071595,0.00047325826,0.002094188,0.0013020203,0.00012716981,0.00055128196,0.00053391623,0.0006817228,0.001546742],"category_scores_gemma":[0.0008897315,0.00022168466,0.0006370042,0.0016511063,0.0002548725,0.0004167918,0.00031950715,0.00092859985,0.00042175537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015271857,0.00006047984,0.002510374,0.021330535,0.00039868098,0.0003159526,0.00003717859,0.0002413069,0.00067657226,0.00060041505,0.015220531,0.9584551],"study_design_scores_gemma":[0.0003602739,0.00078091153,0.088084474,0.050280623,0.0047221817,0.014179209,0.00063358154,0.00062279793,0.0012362144,0.0025775353,0.83639246,0.0001298153],"about_ca_topic_score_codex":0.004225773,"about_ca_topic_score_gemma":0.011671005,"teacher_disagreement_score":0.004225773,"about_ca_system_score_codex":0.00049928296,"about_ca_system_score_gemma":0.0012116433,"threshold_uncertainty_score":0.008402348},"labels":[],"label_agreement":null},{"id":"W2116664839","doi":"10.1016/j.lungcan.2006.02.006","title":"Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Toronto East General Hospital; University of Toronto; Northeast Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Vincristine; Internal medicine; Cyclophosphamide; Gastroenterology; Chemotherapy; Oncology; Surgery","score_opus":0.009898937503427602,"score_gpt":0.31056079973476003,"score_spread":0.3006618622313324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116664839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351525,0.0016225643,0.0005580677,0.00036527964,0.00020633281,0.0018373624,0.0005664026,0.00009744595,0.001231403],"genre_scores_gemma":[0.99144745,0.001731979,0.0010459912,0.00034850018,0.00021251077,0.0017356994,0.0010346351,0.000036181667,0.0024071017],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994466,0.00025909406,0.000020602998,0.000111745176,0.000038167098,0.00012378716],"domain_scores_gemma":[0.9991708,0.00014226642,0.000115543604,0.00009372224,0.00003984981,0.00043786052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015240975,0.0017863469,0.0033368357,0.00069308444,0.0005738113,0.001352369,0.0014985722,0.0017186424,0.0037235336],"category_scores_gemma":[0.000903761,0.00093249744,0.0013009376,0.0006845017,0.0014227403,0.0012828301,0.00043288455,0.0039684703,0.0010319513],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7594244,0.11096323,0.0029608372,0.00062530435,0.0011878883,0.00025304075,0.00040457956,0.002954288,0.058842372,0.00041336974,0.0022747396,0.059696045],"study_design_scores_gemma":[0.53744674,0.44830963,0.0046747774,0.000018704202,0.00037880597,0.00015724199,0.00007969928,0.0010625224,0.005992958,0.000080640064,0.0017682111,0.000030062723],"about_ca_topic_score_codex":0.0021434105,"about_ca_topic_score_gemma":0.0040737092,"teacher_disagreement_score":0.0037235336,"about_ca_system_score_codex":0.0012431802,"about_ca_system_score_gemma":0.002137658,"threshold_uncertainty_score":0.012456477},"labels":[],"label_agreement":null},{"id":"W2116720928","doi":"10.1016/j.lungcan.2013.07.025","title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; Canadian Institutes of Health Research; Canary Foundation; U.S. Department of Defense","keywords":"Lung cancer; Medicine; Disease; Cancer; Adenocarcinoma; Oncology; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.037756950148784545,"score_gpt":0.39314686098660384,"score_spread":0.3553899108378193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116720928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014459954,0.9984932,0.00010538828,0.0002804924,0.00013370949,0.000004117054,0.00003262987,0.0000055514615,0.000800282],"genre_scores_gemma":[0.0009534516,0.9978962,0.00020388747,0.00028826928,0.00013414412,0.0000044076073,0.000047253074,0.0000010452884,0.0004713374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984264,0.000023004293,0.000031969503,0.00003367934,0.000052486885,0.000016214508],"domain_scores_gemma":[0.9997297,0.0001419109,0.000052302286,0.0000063108664,0.000053750413,0.000016011405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042192728,0.0007374475,0.0012311754,0.0016495641,0.00016029159,0.0007336253,0.00059053535,0.0007875339,0.0027194305],"category_scores_gemma":[0.0008563906,0.00027015212,0.0005115277,0.0015548015,0.00033474388,0.00075611245,0.0004929465,0.001218346,0.0007649522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008270411,0.000035863122,0.00038922424,0.013228866,0.0001375667,0.0001879932,0.000029462972,0.0003935964,0.0014670996,0.0013578758,0.020914145,0.9617756],"study_design_scores_gemma":[0.000050109615,0.00010847496,0.002302687,0.007571856,0.00071558397,0.0021791852,0.000086278655,0.00018572334,0.0008520552,0.0021607382,0.9837541,0.000033153112],"about_ca_topic_score_codex":0.001384293,"about_ca_topic_score_gemma":0.0035028693,"teacher_disagreement_score":0.0027194305,"about_ca_system_score_codex":0.0005474023,"about_ca_system_score_gemma":0.0010498451,"threshold_uncertainty_score":0.009097397},"labels":[],"label_agreement":null},{"id":"W2119768199","doi":"10.1016/j.lungcan.2014.09.017","title":"Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: A retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; National Institute on Aging","keywords":"Medicine; Carboplatin; Hazard ratio; Bevacizumab; Internal medicine; Proportional hazards model; Cohort; Retrospective cohort study; Paclitaxel; Oncology; Lung cancer; Surgery; Cancer; Chemotherapy; Confidence interval","score_opus":0.00681406673692153,"score_gpt":0.33009641403799533,"score_spread":0.3232823473010738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119768199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99938655,0.00012441585,0.000029004581,0.00001641745,0.000004002588,0.0000041703056,0.000326793,0.0000011966736,0.00010741593],"genre_scores_gemma":[0.9992311,0.00007567989,0.000030508989,0.00001579203,0.000007831987,0.000005792872,0.0005687007,0.0000014728644,0.00006310177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992255,0.00014710469,0.000114671486,0.00025016026,0.00010091255,0.0001616054],"domain_scores_gemma":[0.9984238,0.00027286026,0.00074564945,0.00014801846,0.0001302093,0.00027939517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006272959,0.00031649845,0.00049973675,0.0008459521,0.0005212367,0.00068198924,0.0004910661,0.0006571227,0.0013718957],"category_scores_gemma":[0.0019473435,0.00042068405,0.0012177739,0.0011689439,0.00033428465,0.00070681,0.00052749726,0.00060669816,0.00018141152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010429651,0.000048776386,0.99762386,0.000006334847,0.00023019941,0.00007337868,0.00004370836,0.000063024134,0.00023592985,0.000019944217,0.000057177418,0.0005546229],"study_design_scores_gemma":[0.000044511402,0.0003190151,0.99861896,0.000003426454,0.00010061852,0.00027787412,0.00021250073,0.00021459654,0.0000705167,0.000021256305,0.00011054081,0.0000062319873],"about_ca_topic_score_codex":0.009107967,"about_ca_topic_score_gemma":0.008777685,"teacher_disagreement_score":0.009107967,"about_ca_system_score_codex":0.00082309946,"about_ca_system_score_gemma":0.00051703217,"threshold_uncertainty_score":0.018109918},"labels":[],"label_agreement":null},{"id":"W2120616064","doi":"10.1016/j.lungcan.2003.07.004","title":"Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Radiation therapy; Population; Lung cancer; Chemotherapy; Cancer; Disease; Internal medicine; Surgery","score_opus":0.015905256602102007,"score_gpt":0.3731261203917312,"score_spread":0.3572208637896292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120616064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894629,0.0014877348,0.00008259138,0.00239929,0.00004328492,0.000035998706,0.0031867484,0.000012570899,0.003288915],"genre_scores_gemma":[0.9963491,0.00060512585,0.00006791354,0.00028674127,0.0000086870405,0.000030592586,0.0013650222,0.000004893591,0.0012819582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951656,0.0017389833,0.00033387248,0.00035586074,0.0010666903,0.0013390272],"domain_scores_gemma":[0.9887404,0.0023486298,0.0013953834,0.00070250354,0.0047829184,0.0020301556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041174935,0.0003190442,0.0008253759,0.0012750159,0.0014031283,0.0015601276,0.0020079126,0.0010483919,0.001979309],"category_scores_gemma":[0.018470423,0.00035511146,0.0008715733,0.004288251,0.0009538184,0.0008197321,0.0018092608,0.0016011557,0.00018868642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009925767,0.00026056773,0.9779571,0.00009950774,0.00037666058,0.00017360435,0.0008906875,0.001091684,0.00016758744,0.00062178285,0.00426697,0.013101245],"study_design_scores_gemma":[0.000059807062,0.00009216828,0.99692386,0.000051541178,0.0001381744,0.000028113758,0.0010792966,0.0003911317,0.00006834116,0.00010939348,0.0010389367,0.000019156985],"about_ca_topic_score_codex":0.98505396,"about_ca_topic_score_gemma":0.99043685,"teacher_disagreement_score":0.02942243,"about_ca_system_score_codex":0.02942243,"about_ca_system_score_gemma":0.035912197,"threshold_uncertainty_score":0.2134757},"labels":[],"label_agreement":null},{"id":"W2122221221","doi":"10.1016/j.lungcan.2014.06.008","title":"Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Cisplatin; Mesothelioma; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Progression-free survival; Phases of clinical research; Performance status; Population; Randomized controlled trial; Gastroenterology; Urology; Pathology","score_opus":0.008115870399044054,"score_gpt":0.2984022568962651,"score_spread":0.29028638649722105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122221221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860805,0.0037023004,0.0007463694,0.0013200417,0.0007569768,0.0031434293,0.0013478159,0.00015214212,0.0027503679],"genre_scores_gemma":[0.98682934,0.0022339677,0.0012317332,0.0012639908,0.00034114555,0.0028252283,0.0015003622,0.000041915006,0.0037322969],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950707,0.00024140491,0.00002344495,0.00011148221,0.00002705522,0.00008947567],"domain_scores_gemma":[0.99931335,0.00016606868,0.0001088017,0.00007805761,0.000034456545,0.00029933557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013517927,0.0017744116,0.003289094,0.00047881567,0.00049855676,0.0013818154,0.0013425037,0.0015432877,0.009322331],"category_scores_gemma":[0.0014324302,0.0009493885,0.0017470778,0.0005189523,0.0016045895,0.0015550161,0.000596312,0.0044527277,0.001531889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9688516,0.007260509,0.0006003588,0.0005058622,0.0008392242,0.000045844277,0.000053196323,0.000716293,0.003708077,0.0001643205,0.0010838403,0.016170818],"study_design_scores_gemma":[0.9484663,0.048772153,0.0011287185,0.00001869968,0.00035740447,0.000024916802,0.00001979164,0.00027044213,0.0002863112,0.00011581782,0.00052940537,0.0000100670295],"about_ca_topic_score_codex":0.0018808104,"about_ca_topic_score_gemma":0.0036747376,"teacher_disagreement_score":0.009322331,"about_ca_system_score_codex":0.0013308605,"about_ca_system_score_gemma":0.0015002248,"threshold_uncertainty_score":0.031186342},"labels":[],"label_agreement":null},{"id":"W2122397603","doi":"10.1007/978-1-60761-524-8_10","title":"Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"book-chapter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Erlotinib; Gefitinib; Cetuximab; Medicine; Epidermal growth factor receptor; Docetaxel; Lung cancer; Oncology; Bevacizumab; Erlotinib Hydrochloride; Internal medicine; Chemotherapy; Clinical trial; EGFR inhibitors; Monoclonal antibody; Tyrosine kinase; Pharmacology; Cancer research; Cancer; Immunology; Receptor; Antibody","score_opus":0.014440951987985687,"score_gpt":0.30870348784135115,"score_spread":0.2942625358533655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122397603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012028748,0.7863968,0.002096816,0.0063026617,0.004917757,0.00005992366,0.0001752174,0.00017069084,0.19867733],"genre_scores_gemma":[0.006927427,0.6208647,0.0041285045,0.005904584,0.0030433945,0.00006667514,0.00033015703,0.00005890085,0.35867557],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992037,0.000012375369,0.000004190454,0.000008151927,0.000049061106,0.000005854576],"domain_scores_gemma":[0.9999465,0.000023608218,0.0000053564495,0.0000020237167,0.000012604386,0.000009864259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018968413,0.0005599436,0.00034923095,0.000660874,0.00016498032,0.0005595733,0.00036372337,0.00053383684,0.010470444],"category_scores_gemma":[0.00018793822,0.0001145714,0.00018008277,0.0007037923,0.00017321615,0.00075055065,0.00034648756,0.0014283715,0.010134223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005293193,0.0000857662,0.00008769457,0.00070786686,0.0000091876,0.00015962063,0.00008031244,0.00038379998,0.0018044573,0.007948867,0.40410027,0.5845793],"study_design_scores_gemma":[0.000008945244,0.000027497983,0.00025152543,0.00018707155,0.0000040530717,0.00049448153,0.000011677307,0.00008090127,0.00017695606,0.001828068,0.99692565,0.0000033529125],"about_ca_topic_score_codex":0.0006228452,"about_ca_topic_score_gemma":0.0029238253,"teacher_disagreement_score":0.010470444,"about_ca_system_score_codex":0.0004360839,"about_ca_system_score_gemma":0.00042561893,"threshold_uncertainty_score":0.035027146},"labels":[],"label_agreement":null},{"id":"W2126013413","doi":"10.1016/j.lungcan.2004.03.007","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Progressive disease; Performance status; Gastroenterology; Surgery","score_opus":0.02758055674964294,"score_gpt":0.3685417805657494,"score_spread":0.34096122381610644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126013413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022406,0.0039428356,0.00033143698,0.0008407765,0.00035581083,0.0017112236,0.0007414415,0.00008669351,0.0017656472],"genre_scores_gemma":[0.98180056,0.0053641866,0.0014780515,0.001151206,0.00028775784,0.002306205,0.0018882621,0.000043976423,0.005679776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99947697,0.00025455418,0.0000217972,0.00009367428,0.000032014672,0.00012095353],"domain_scores_gemma":[0.9992161,0.00016544238,0.00011584587,0.000058195434,0.000031123935,0.0004133096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014990796,0.0020790712,0.0031833972,0.00046187258,0.00057489245,0.0012819683,0.0010788317,0.0019971528,0.004275106],"category_scores_gemma":[0.0012640246,0.00087225705,0.001991718,0.00056470244,0.0014409944,0.0012698935,0.00047107582,0.005271606,0.0010657569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91885203,0.023533534,0.0016178889,0.0006374995,0.0011716478,0.00010389419,0.0001709815,0.0020601237,0.004448295,0.00028826875,0.0028113972,0.044304565],"study_design_scores_gemma":[0.8596247,0.13435368,0.002835782,0.00004395543,0.00038171755,0.00008614965,0.000043535863,0.0005380226,0.0005064098,0.00018852523,0.00137298,0.000024457044],"about_ca_topic_score_codex":0.0016188156,"about_ca_topic_score_gemma":0.0053189415,"teacher_disagreement_score":0.004275106,"about_ca_system_score_codex":0.0012218772,"about_ca_system_score_gemma":0.0018725564,"threshold_uncertainty_score":0.014301658},"labels":[],"label_agreement":null},{"id":"W2126270742","doi":"10.1016/j.lungcan.2009.11.018","title":"Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Erlotinib; Gefitinib; Oncology; Cetuximab; Bevacizumab; Internal medicine; Lung cancer; Adenocarcinoma; Clinical trial; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Colorectal cancer","score_opus":0.04081135753217011,"score_gpt":0.44960652796712375,"score_spread":0.4087951704349536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126270742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010941663,0.9984224,0.000061921004,0.00075008674,0.00024691725,0.0000056335934,0.000023366814,0.0000036445158,0.00037670718],"genre_scores_gemma":[0.0009016364,0.99758005,0.00019279572,0.00074779894,0.00023567303,0.00000793634,0.00005879965,0.000001665195,0.00027366672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963486,0.0000761254,0.00007198258,0.0000533113,0.00013477159,0.000028893503],"domain_scores_gemma":[0.9989675,0.00052840076,0.00017728333,0.000014984675,0.0002632822,0.00004842323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019251875,0.00076759985,0.0022469405,0.0013564677,0.00021462032,0.0009493442,0.0009659597,0.0012761002,0.0022794507],"category_scores_gemma":[0.0015379237,0.0003367816,0.001027109,0.0017925194,0.0003018884,0.0011293149,0.00047632126,0.001979954,0.0008593562],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021884326,0.00006560803,0.00024468527,0.025618514,0.00022695262,0.0001429825,0.00003602561,0.0004874095,0.0009292301,0.00071869214,0.05090847,0.9204026],"study_design_scores_gemma":[0.00022443409,0.0003737054,0.0034237162,0.0140946545,0.0013083768,0.001232613,0.00008057127,0.00029529395,0.0008533392,0.00082113605,0.97725666,0.00003548446],"about_ca_topic_score_codex":0.0020168456,"about_ca_topic_score_gemma":0.0065086926,"teacher_disagreement_score":0.0022794507,"about_ca_system_score_codex":0.0009759138,"about_ca_system_score_gemma":0.0014550041,"threshold_uncertainty_score":0.010181487},"labels":[],"label_agreement":null},{"id":"W2127759166","doi":"10.1016/j.lungcan.2005.03.037","title":"Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Survivin; Lung cancer; Medicine; Apoptosis; Cancer research; Inhibitor of apoptosis; Cell; Programmed cell death; Cancer; Oncology; Internal medicine; Biology; Genetics","score_opus":0.005188085557054171,"score_gpt":0.22435495131988595,"score_spread":0.2191668657628318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127759166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936706,0.00032235443,0.00006854812,0.00001306319,0.0000026100329,0.0000013099823,0.00007019739,0.00000425697,0.00015064051],"genre_scores_gemma":[0.99925417,0.00009002669,0.000052056763,0.000012201938,0.0000031119885,0.0000025517888,0.00019977143,0.000002504627,0.00038360775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988127,0.000023184795,0.0000150131345,0.000024650943,0.000023706849,0.000032104745],"domain_scores_gemma":[0.99962676,0.000066496454,0.00013464947,0.000030382454,0.000054200766,0.00008744804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017510944,0.000121347446,0.00024212248,0.00050794444,0.00018046868,0.00044174955,0.00015439121,0.00024574198,0.0011817884],"category_scores_gemma":[0.0004241141,0.0001490916,0.00015951293,0.00034252225,0.0001981789,0.00017023027,0.0002163515,0.00032545632,0.00023694728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001848177,0.00006872051,0.80138654,0.000026906897,0.000117224736,0.00048360947,0.000085801905,0.000093793475,0.19076203,0.000076910495,0.00014146531,0.0049088737],"study_design_scores_gemma":[0.000010023726,0.00011356934,0.9904553,0.000002166332,0.000045565474,0.0013560297,0.00008783544,0.00018334872,0.0074144714,0.00005118205,0.00027684696,0.0000036178378],"about_ca_topic_score_codex":0.0006341155,"about_ca_topic_score_gemma":0.0008061808,"teacher_disagreement_score":0.0011817884,"about_ca_system_score_codex":0.00017286504,"about_ca_system_score_gemma":0.000106864434,"threshold_uncertainty_score":0.003953457},"labels":[],"label_agreement":null},{"id":"W2132037522","doi":"10.1016/j.lungcan.2004.11.029","title":"Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"GlaxoSmithKline","keywords":"Vinorelbine; Gemcitabine; Medicine; Internal medicine; Lung cancer; Performance status; Population; Chemotherapy; Progressive disease; Oncology; Phases of clinical research; Antimetabolite; Gastroenterology; Surgery","score_opus":0.011925274054068338,"score_gpt":0.3126804444621362,"score_spread":0.3007551704080679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132037522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283034,0.0028645913,0.00035395502,0.0005583764,0.0003545831,0.001056252,0.00062918075,0.00008163403,0.0012709704],"genre_scores_gemma":[0.9873378,0.0034180817,0.0015425475,0.0009752743,0.00030408893,0.0015821676,0.0017224263,0.00003389335,0.0030836097],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99956423,0.00018568739,0.000022642807,0.00010171666,0.00002811951,0.00009753407],"domain_scores_gemma":[0.9992003,0.00014326032,0.00013617388,0.00006733257,0.00003178046,0.00042118755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001680824,0.0020805905,0.0035890345,0.0004902883,0.00046250393,0.001145593,0.0011075775,0.001381001,0.004191377],"category_scores_gemma":[0.0011692607,0.0007274734,0.0019747016,0.00057553995,0.001057495,0.0013518237,0.00051578606,0.004070503,0.00094900007],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91989875,0.01687204,0.002319599,0.000620666,0.0017026161,0.000062949715,0.00014687465,0.0024213067,0.0053687333,0.0002227774,0.002420839,0.047942825],"study_design_scores_gemma":[0.8536946,0.13837649,0.004434105,0.0000391119,0.00043494775,0.00007082426,0.000045547436,0.0010546953,0.0006599964,0.00022172564,0.0009429358,0.000025071513],"about_ca_topic_score_codex":0.0017358838,"about_ca_topic_score_gemma":0.0046874094,"teacher_disagreement_score":0.004191377,"about_ca_system_score_codex":0.0011078381,"about_ca_system_score_gemma":0.0013787767,"threshold_uncertainty_score":0.014021516},"labels":[],"label_agreement":null},{"id":"W2132247116","doi":"10.1016/j.lungcan.2003.09.002","title":"Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Cancer Care Ontario","keywords":"Medicine; Regimen; Etoposide; Guideline; Vincristine; Oncology; Randomized controlled trial; Chemotherapy; Internal medicine; Anthracycline; Chemotherapy regimen; Intensive care medicine; Cyclophosphamide; Cancer; Breast cancer; Pathology","score_opus":0.06482960285760901,"score_gpt":0.47039443093817324,"score_spread":0.4055648280805642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132247116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069851073,0.9037665,0.0087760305,0.052572187,0.0130812675,0.0016467081,0.002580355,0.00033537418,0.016543062],"genre_scores_gemma":[0.004332901,0.87898636,0.062922835,0.032683577,0.00277369,0.0025286633,0.003639159,0.00005508828,0.012077725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971424,0.00090558256,0.00092983455,0.00018691282,0.00073399453,0.000101261794],"domain_scores_gemma":[0.9930773,0.0029153565,0.0011069066,0.00013342389,0.0024268054,0.00034028545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049070353,0.001719279,0.003775826,0.004517043,0.00076189626,0.001266252,0.0056479387,0.0060242643,0.006523884],"category_scores_gemma":[0.007853667,0.0007830861,0.0032951743,0.0041150423,0.0009400338,0.0018292546,0.0010544821,0.0053139166,0.004808128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018907206,0.00020029195,0.00045753588,0.033579834,0.00036662034,0.0006254323,0.00012818011,0.00068597344,0.000855066,0.0027538082,0.47873122,0.48142698],"study_design_scores_gemma":[0.00058239227,0.00019817075,0.0041549783,0.08492488,0.0014256262,0.0020546908,0.00019508127,0.0007231358,0.00048690898,0.0057602325,0.8994144,0.00007955809],"about_ca_topic_score_codex":0.0155925825,"about_ca_topic_score_gemma":0.032363806,"teacher_disagreement_score":0.0155925825,"about_ca_system_score_codex":0.0027750663,"about_ca_system_score_gemma":0.008670566,"threshold_uncertainty_score":0.031003654},"labels":[],"label_agreement":null},{"id":"W2136509120","doi":"10.1016/j.lungcan.2015.05.018","title":"Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Toronto General Hospital; University Health Network","funders":"Ministry of Health, British Columbia; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Histopathology; Endobronchial ultrasound; Lung cancer; Pathology; Lymph; Cancer; Radiology; Internal medicine","score_opus":0.02311757728303318,"score_gpt":0.2882637951881348,"score_spread":0.2651462179051016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136509120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90509266,0.0051024077,0.055567212,0.0007291189,0.00091954245,0.0021849289,0.019831445,0.0007951214,0.009777512],"genre_scores_gemma":[0.93067527,0.0031802403,0.0319072,0.0004199945,0.00008707585,0.0015263637,0.021333603,0.00013521963,0.01073501],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992198,0.00012803417,0.00011987708,0.00017535445,0.00025293336,0.000104130544],"domain_scores_gemma":[0.9994849,0.00012910434,0.00006350724,0.00015136003,0.00008083883,0.00009033605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011854024,0.000516706,0.00065924507,0.0005868138,0.00037229026,0.00065952,0.0006135558,0.000996387,0.0062628593],"category_scores_gemma":[0.0005083389,0.00039050632,0.0005464978,0.00057356275,0.00030577133,0.0004574474,0.00027748782,0.0019913625,0.0026952608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013340103,0.0009646771,0.0024680593,0.00030817263,0.0000892494,0.00083428423,0.00021454356,0.0007740022,0.98318845,0.0017966818,0.0026654343,0.005362421],"study_design_scores_gemma":[0.0007266565,0.0058256895,0.019526634,0.00007687765,0.00039553546,0.009669844,0.0003631997,0.013950707,0.89603174,0.0009927283,0.052380227,0.000060100287],"about_ca_topic_score_codex":0.0010883461,"about_ca_topic_score_gemma":0.0018203702,"teacher_disagreement_score":0.0062628593,"about_ca_system_score_codex":0.0003273383,"about_ca_system_score_gemma":0.00041771398,"threshold_uncertainty_score":0.02095139},"labels":[],"label_agreement":null},{"id":"W2138158777","doi":"10.1016/s0169-5002(02)00384-7","title":"Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers","year":2002,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Loss of heterozygosity; Lung cancer; Carcinogenesis; Adenocarcinoma; Medicine; Pathogenesis; Lung; Allele; Pathology; Internal medicine; Gastroenterology; Oncology; Cancer; Biology; Genetics; Gene","score_opus":0.010056139901448954,"score_gpt":0.27317194805641315,"score_spread":0.2631158081549642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138158777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984925,0.00027769402,0.00030048515,0.000020142179,0.0000035482599,0.000004963668,0.00021666821,0.000012384337,0.0006715551],"genre_scores_gemma":[0.9980894,0.00013825059,0.00016188972,0.00001804133,0.000005111607,0.000007983985,0.00043045264,0.000010530703,0.0011384501],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997347,0.000060253165,0.000031360178,0.00005097046,0.00006243418,0.000060226394],"domain_scores_gemma":[0.99921966,0.0002631704,0.00016693275,0.00007713244,0.00013893575,0.00013422816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036070985,0.00015994241,0.00029434304,0.0014184747,0.0003164375,0.0005417647,0.00032599387,0.00025377914,0.0031399378],"category_scores_gemma":[0.001106018,0.00022466494,0.00031065554,0.00042024377,0.00031901774,0.0002457661,0.00045728893,0.000258741,0.00048512046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031823576,0.000060588718,0.47319058,0.00005814736,0.00019364143,0.00068252266,0.0004201265,0.000102134356,0.51229113,0.0002670037,0.00010963981,0.009442115],"study_design_scores_gemma":[0.000015179772,0.00019846656,0.98178494,0.000004359471,0.000055516088,0.0021170976,0.00030973897,0.00021486628,0.01468243,0.0001242768,0.00048582267,0.000007353182],"about_ca_topic_score_codex":0.0010551779,"about_ca_topic_score_gemma":0.0013430709,"teacher_disagreement_score":0.0031399378,"about_ca_system_score_codex":0.00010351972,"about_ca_system_score_gemma":0.000090054,"threshold_uncertainty_score":0.010504127},"labels":[],"label_agreement":null},{"id":"W2139248900","doi":"10.1016/j.lungcan.2013.07.017","title":"Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Chest radiograph; Lung cancer; Radiology; Biopsy; Cancer screening; Cancer; Lung; Lung cancer screening; Colorectal cancer; Radiography; Internal medicine","score_opus":0.018258253489458205,"score_gpt":0.3354660521680322,"score_spread":0.317207798678574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139248900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810885,0.009994326,0.00019536052,0.002478194,0.00040520506,0.00021630646,0.00059161586,0.000032272183,0.004998171],"genre_scores_gemma":[0.9971482,0.001015391,0.00011880676,0.00069275,0.00021267356,0.000055514836,0.00049149396,0.000001954426,0.00026333256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930334,0.00039165735,0.00004183946,0.00008236436,0.000060508402,0.00012031111],"domain_scores_gemma":[0.99837273,0.0007400432,0.00034913086,0.00007148968,0.00009948654,0.00036721962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001089235,0.0005254356,0.0011706299,0.00035481973,0.00049507775,0.00093291816,0.00048446198,0.0013539812,0.0014378676],"category_scores_gemma":[0.0047477023,0.00021504905,0.0010823044,0.00043663668,0.00042469022,0.00046056812,0.00023381838,0.0012411576,0.00018819411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35993767,0.0036288938,0.52678436,0.0014078016,0.0029107512,0.0020309982,0.0002158903,0.0011600512,0.004763013,0.001118637,0.00977356,0.0862684],"study_design_scores_gemma":[0.05658727,0.050440423,0.85780686,0.0008631394,0.011576107,0.003083925,0.0006262429,0.0047175256,0.0030851208,0.0025711376,0.008513861,0.00012842337],"about_ca_topic_score_codex":0.0027749557,"about_ca_topic_score_gemma":0.0050365506,"teacher_disagreement_score":0.0027749557,"about_ca_system_score_codex":0.00071000523,"about_ca_system_score_gemma":0.0010358607,"threshold_uncertainty_score":0.005760491},"labels":[],"label_agreement":null},{"id":"W2142559775","doi":"10.1016/j.lungcan.2011.10.009","title":"Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Proportional hazards model; Oncology; Prospective cohort study; Performance status; Cancer; Physical therapy; Confidence interval","score_opus":0.021640138703919252,"score_gpt":0.24715349456760763,"score_spread":0.22551335586368837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142559775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896324,0.00024396148,0.000033837616,0.000095285,0.000010811418,0.000002379828,0.00018484784,0.0000029609928,0.00046259095],"genre_scores_gemma":[0.99960726,0.00005384418,0.000015171263,0.000016726088,0.000015667338,0.0000022757904,0.00019475617,9.698219e-7,0.0000934101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997552,0.000056394278,0.0000292865,0.000040039024,0.000038864746,0.000080179954],"domain_scores_gemma":[0.9984664,0.0004305442,0.00044462417,0.000060043956,0.00011401102,0.00048439918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032871333,0.00032336373,0.00041368112,0.0007672515,0.00054261845,0.00068489875,0.00044229478,0.0007847276,0.0016875386],"category_scores_gemma":[0.002840317,0.00017378807,0.00051895354,0.0011415983,0.0004858294,0.00061996625,0.0005211773,0.0008536136,0.00024422279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091521244,0.000019531728,0.9991033,0.0000025567379,0.000020776572,0.00005521735,0.000019025094,0.000037903705,0.000085542204,0.000008450745,0.000035206063,0.0005209099],"study_design_scores_gemma":[0.00000346539,0.000056082332,0.99944884,0.0000014578701,0.00001568351,0.00014682204,0.00007701957,0.00016168626,0.000019045347,0.000024367153,0.00004329175,0.000002250555],"about_ca_topic_score_codex":0.0039524552,"about_ca_topic_score_gemma":0.0062160557,"teacher_disagreement_score":0.0039524552,"about_ca_system_score_codex":0.00031942705,"about_ca_system_score_gemma":0.00038571598,"threshold_uncertainty_score":0.007858872},"labels":[],"label_agreement":null},{"id":"W2146428449","doi":"10.1016/j.lungcan.2003.09.020","title":"Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario","funders":"Lake Champlain Sea Grant, University of Vermont; Cancer Care Ontario","keywords":"Medicine; Radiation therapy; Guideline; Lung cancer; Meta-analysis; Randomized controlled trial; Stage (stratigraphy); Surgery; Cancer; Clinical trial; Oncology; Internal medicine; Pathology","score_opus":0.04559062140614087,"score_gpt":0.4188323485450281,"score_spread":0.37324172713888726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146428449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014548058,0.9945802,0.00042604157,0.0011468729,0.00043025785,0.0005320743,0.0007122719,0.000017742865,0.000699646],"genre_scores_gemma":[0.022991683,0.9704897,0.0032377983,0.0014683611,0.00017338934,0.0007322053,0.0004405739,0.00000802617,0.00045835553],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968804,0.0010510167,0.0013222585,0.00022820251,0.00044388662,0.00007418775],"domain_scores_gemma":[0.9927055,0.003734844,0.002329863,0.00013020747,0.0009548325,0.00014461944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045420155,0.00071101723,0.0043551396,0.002724928,0.00025360234,0.0007175588,0.0013255936,0.0010222509,0.0017710162],"category_scores_gemma":[0.014340846,0.00060862384,0.004344046,0.003141608,0.00041153905,0.0008381751,0.00065440626,0.00093274534,0.00021898265],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005723456,0.00004061535,0.0027362444,0.70108813,0.01045057,0.00020002217,0.00026294112,0.00043571336,0.00073244236,0.00037227117,0.024432966,0.2586757],"study_design_scores_gemma":[0.0030876899,0.0008099768,0.025741212,0.72194755,0.11851584,0.001303969,0.0003744246,0.00044419797,0.00094471674,0.00088387844,0.12585384,0.00009281151],"about_ca_topic_score_codex":0.0117358705,"about_ca_topic_score_gemma":0.052666314,"teacher_disagreement_score":0.0117358705,"about_ca_system_score_codex":0.002465356,"about_ca_system_score_gemma":0.006037916,"threshold_uncertainty_score":0.024020731},"labels":[],"label_agreement":null},{"id":"W2146508678","doi":"10.1016/j.lungcan.2004.04.002","title":"Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Microarray; Medicine; Lung cancer; Microarray analysis techniques; Oncology; Univariate analysis; Gene; Internal medicine; Significance analysis of microarrays; Log-rank test; Multivariate analysis; Cancer research; Survival analysis; Pathology; Gene expression; Biology; Genetics","score_opus":0.010127123842548554,"score_gpt":0.27535194305599037,"score_spread":0.2652248192134418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146508678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99606895,0.00045624818,0.001960135,0.000120813515,0.000027133325,0.000024486235,0.0006040296,0.000028860477,0.0007091905],"genre_scores_gemma":[0.9960162,0.00016247833,0.0020488177,0.000066945475,0.000021090838,0.000038898197,0.0012049369,0.0000069248927,0.00043366334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944645,0.00016096781,0.00003734501,0.000108432076,0.00014158835,0.00010527372],"domain_scores_gemma":[0.9988261,0.0006199374,0.00010837831,0.00013954459,0.00023249412,0.00007348512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011125538,0.0002542657,0.00044904742,0.0007455535,0.00036624758,0.00061849965,0.00021591359,0.00044169903,0.0011327999],"category_scores_gemma":[0.0018669793,0.00011982596,0.00022515235,0.00075703673,0.00026837306,0.000268586,0.00020181516,0.00040772252,0.000422695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023888208,0.00036701676,0.33539283,0.00009375556,0.00019661168,0.00018985692,0.00011157527,0.0009827163,0.635615,0.00024193925,0.00063105475,0.023788836],"study_design_scores_gemma":[0.00011007421,0.0020743746,0.75424474,0.0000186178,0.00045424257,0.0009709417,0.0003554937,0.010047943,0.22743765,0.0005897919,0.0036693697,0.000026823058],"about_ca_topic_score_codex":0.00081746833,"about_ca_topic_score_gemma":0.0015930199,"teacher_disagreement_score":0.0011327999,"about_ca_system_score_codex":0.0002700548,"about_ca_system_score_gemma":0.0003568284,"threshold_uncertainty_score":0.005883813},"labels":[],"label_agreement":null},{"id":"W2152671064","doi":"10.1016/j.lungcan.2010.03.012","title":"The function of IGF-IR in NNK-mediated lung tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Carcinogenesis; Transgene; Genetically modified mouse; Cancer research; Lung cancer; Biology; Endocrinology; Medicine; Cancer; Pathology; Internal medicine; Gene; Biochemistry","score_opus":0.006085799970421772,"score_gpt":0.265390230194649,"score_spread":0.2593044302242273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152671064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9035362,0.055864543,0.004392892,0.00249656,0.00055037107,0.000038264177,0.00070520764,0.00020075285,0.032215204],"genre_scores_gemma":[0.99012077,0.0039937347,0.0007141865,0.00010896459,0.000073102085,0.000012677617,0.00015409409,0.0000090938365,0.0048134043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999206,0.000017748383,0.000004964907,0.000010567384,0.00001900876,0.000027161543],"domain_scores_gemma":[0.9998747,0.000027477912,0.000013005344,0.00001578336,0.000019362795,0.000049711532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026895682,0.00039138083,0.00018632256,0.0003893883,0.0003191327,0.00067931693,0.0002645368,0.00027772336,0.0013228209],"category_scores_gemma":[0.00024122267,0.000096511176,0.00021521603,0.000110189874,0.0005220546,0.00036503418,0.00023229094,0.00071700173,0.00026787302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003954083,0.00019137809,0.01511764,0.00032862648,0.000052782936,0.001679854,0.00012531625,0.0010682369,0.90278286,0.006600548,0.0015875647,0.066511214],"study_design_scores_gemma":[0.00028135083,0.0018088025,0.2338957,0.00014968088,0.00014479965,0.0042890613,0.001033005,0.0058647916,0.7054725,0.006190952,0.040770944,0.00009845346],"about_ca_topic_score_codex":0.0039388197,"about_ca_topic_score_gemma":0.0037973784,"teacher_disagreement_score":0.0039388197,"about_ca_system_score_codex":0.0010146633,"about_ca_system_score_gemma":0.00042090492,"threshold_uncertainty_score":0.007831812},"labels":[],"label_agreement":null},{"id":"W2154916497","doi":"10.1016/s0169-5002(03)00144-2","title":"Angiogenesis inhibitors under study for the treatment of lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Angiogenesis; Endostatin; Vascular endothelial growth factor; Matrix metalloproteinase inhibitor; Thalidomide; Pharmacology; Matrix metalloproteinase; Lung cancer; Clinical trial; Cancer research; Internal medicine; Immunology; Oncology; Multiple myeloma; VEGF receptors","score_opus":0.039632083794956356,"score_gpt":0.3885463755680744,"score_spread":0.34891429177311806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154916497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025826212,0.9967668,0.0005165641,0.0004735883,0.0004880776,0.000014979095,0.000030384621,0.000020235078,0.0014311409],"genre_scores_gemma":[0.0015860192,0.995271,0.00078466197,0.0005121366,0.0003230788,0.000025218129,0.00008303333,0.0000056627296,0.0014091154],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997321,0.00004076191,0.00003258904,0.00005550333,0.00010201899,0.00003709189],"domain_scores_gemma":[0.9994117,0.00023886815,0.00009013685,0.000018902867,0.00014491499,0.00009543183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001121138,0.0015684927,0.0028872972,0.0023479136,0.0005358362,0.00125129,0.0015983947,0.0018617008,0.0029399656],"category_scores_gemma":[0.0008935567,0.00047828973,0.00081191777,0.0031799492,0.000958621,0.0016349147,0.0006134196,0.0044858027,0.0023336445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039723757,0.00026192627,0.0002240453,0.0071742684,0.00016474926,0.00051321374,0.00006969559,0.00072133425,0.0063541313,0.0044580894,0.05158268,0.92807865],"study_design_scores_gemma":[0.00025250015,0.000431339,0.0011387067,0.001324415,0.00025859996,0.002539208,0.000051713138,0.00022605687,0.0025797603,0.0022245194,0.9889352,0.000038012255],"about_ca_topic_score_codex":0.00192491,"about_ca_topic_score_gemma":0.004821597,"teacher_disagreement_score":0.0029399656,"about_ca_system_score_codex":0.001044354,"about_ca_system_score_gemma":0.0013117146,"threshold_uncertainty_score":0.009835184},"labels":[],"label_agreement":null},{"id":"W2155240409","doi":"10.1016/j.lungcan.2005.07.003","title":"Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norges Forskningsråd; Cancer Research Society; Kreftforeningen; Cancer Research Institute","keywords":"Lung cancer; Interleukin 1 receptor antagonist; Medicine; Odds ratio; Carcinogenesis; Allele; Immunology; Internal medicine; Receptor antagonist; Oncology; Cancer research; Cancer; Gene; Genetics; Receptor; Biology; Antagonist","score_opus":0.0045534807937737155,"score_gpt":0.25280510815699875,"score_spread":0.24825162736322504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155240409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996863,0.001233666,0.00072218536,0.00032557198,0.000023329161,0.0000057502534,0.00014776127,0.000011917666,0.000666802],"genre_scores_gemma":[0.9991296,0.00017826958,0.00024077971,0.000056801233,0.00003935895,0.0000055680634,0.00006014375,0.000004211336,0.00028527578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956864,0.0002420383,0.000027184862,0.00007161151,0.000043519158,0.0000469844],"domain_scores_gemma":[0.9984327,0.0009572925,0.00026877943,0.00008954518,0.00006680363,0.0001849062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050157454,0.0004890656,0.0005281533,0.00072092016,0.00030141877,0.0004438662,0.0003486556,0.00086093595,0.0031692823],"category_scores_gemma":[0.0017035502,0.0002935838,0.0005150155,0.0007214995,0.00034504096,0.00020625426,0.0001877047,0.00060335506,0.00022101794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006904237,0.00027322207,0.93304205,0.000053547086,0.0011899705,0.0034286284,0.00016875849,0.0004906328,0.04736217,0.0004631885,0.0002957412,0.006327825],"study_design_scores_gemma":[0.00024894008,0.0008191057,0.98756534,0.000014003514,0.0009615245,0.004186051,0.0001014384,0.0021007718,0.0030580668,0.00047494168,0.0004464759,0.000023375576],"about_ca_topic_score_codex":0.00093516795,"about_ca_topic_score_gemma":0.0007174262,"teacher_disagreement_score":0.0031692823,"about_ca_system_score_codex":0.000107647254,"about_ca_system_score_gemma":0.00020340699,"threshold_uncertainty_score":0.010602236},"labels":[],"label_agreement":null},{"id":"W2158708198","doi":"10.1016/j.lungcan.2011.05.010","title":"Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Hounsfield scale; Chemoradiotherapy; Lung cancer; Nuclear medicine; Radiological weapon; Radiation therapy; Radiology; Lung; Radiation treatment planning; Pneumonitis; Asymptomatic; Surgery; Computed tomography; Internal medicine","score_opus":0.01981456385210116,"score_gpt":0.31745330301067526,"score_spread":0.2976387391585741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158708198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974952,0.001119334,0.0001972215,0.00004682197,0.00002107877,0.000016142443,0.0002529374,0.000021376272,0.00082992617],"genre_scores_gemma":[0.9993274,0.000103708255,0.000045411594,0.00001360019,0.000014006905,0.0000067138726,0.00015037488,0.000004281866,0.00033449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999663,0.00009360999,0.00003206078,0.000048405396,0.00008341534,0.00007953416],"domain_scores_gemma":[0.99578047,0.0021013778,0.0010380198,0.00023333727,0.00040933635,0.00043752076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000597482,0.00021170785,0.00061529444,0.00060483505,0.00020631899,0.00037905233,0.00031656423,0.00054270483,0.0015836625],"category_scores_gemma":[0.005963431,0.00017627559,0.0005655621,0.0006802055,0.00028585378,0.0004133963,0.00023697439,0.00071857433,0.00026404342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076548114,0.0016337704,0.8378814,0.00017989118,0.00075765233,0.0012719055,0.00046462184,0.003293511,0.036207095,0.00019562307,0.0006876587,0.04087875],"study_design_scores_gemma":[0.000055423086,0.0023925062,0.99257374,0.000004450213,0.00015081369,0.0004056907,0.00006340474,0.0007354879,0.0031437834,0.00004654464,0.0004131229,0.000015076444],"about_ca_topic_score_codex":0.0045894654,"about_ca_topic_score_gemma":0.0048634163,"teacher_disagreement_score":0.0045894654,"about_ca_system_score_codex":0.00053834927,"about_ca_system_score_gemma":0.0003233369,"threshold_uncertainty_score":0.009125531},"labels":[],"label_agreement":null},{"id":"W2159023504","doi":"10.1016/j.lungcan.2014.03.008","title":"A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Lung cancer; Hazard ratio; Internal medicine; Proportional hazards model; Stage (stratigraphy); Cancer; Biology; Confidence interval","score_opus":0.01713595473144952,"score_gpt":0.3254411212676625,"score_spread":0.308305166536213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159023504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978594,0.0004992995,0.00037320235,0.00016879609,0.000026138252,0.000012817722,0.0004957237,0.000022561202,0.0005419131],"genre_scores_gemma":[0.99918896,0.000058320416,0.00016982644,0.00004134886,0.000009782151,0.0000034799727,0.00020537795,0.0000049531477,0.00031786543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998124,0.000043052678,0.00002707559,0.000052871528,0.000036638725,0.000028027285],"domain_scores_gemma":[0.9995522,0.000109249995,0.00020862812,0.000019152143,0.000026479784,0.00008427634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018479902,0.0004011803,0.0002498023,0.0005311863,0.0002979357,0.00034360206,0.00035222247,0.00080770254,0.004132624],"category_scores_gemma":[0.000985957,0.000119834534,0.00040555312,0.0005945023,0.00028200046,0.00016167294,0.000280075,0.0005429931,0.00045168723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054139206,0.00021928825,0.7569538,0.00027439304,0.0006915099,0.01932259,0.00038033372,0.0014139308,0.17829545,0.00094595883,0.0019082325,0.034180593],"study_design_scores_gemma":[0.0002509244,0.00082172925,0.9509469,0.00011109045,0.0005487492,0.02734485,0.0002638681,0.003143167,0.012002908,0.0013430561,0.0031708127,0.000051860497],"about_ca_topic_score_codex":0.0022846458,"about_ca_topic_score_gemma":0.0027650846,"teacher_disagreement_score":0.004132624,"about_ca_system_score_codex":0.00021800767,"about_ca_system_score_gemma":0.00016999636,"threshold_uncertainty_score":0.013824999},"labels":[],"label_agreement":null},{"id":"W2163703503","doi":"10.1016/j.lungcan.2014.08.012","title":"Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Lung Association; American Society of Clinical Oncology; Uniting Against Lung Cancer; American Cancer Society","keywords":"Medicine; Carcinoid tumors; Etoposide; Octreotide; Internal medicine; Regimen; Chemotherapy; Gastroenterology; Progressive disease; Chemotherapy regimen; Neuroendocrine tumors; Surgery; Oncology; Somatostatin","score_opus":0.01264226874378579,"score_gpt":0.3416283456782169,"score_spread":0.32898607693443116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163703503","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8024468,0.14810297,0.0038055428,0.0056753443,0.0008038149,0.0003782671,0.00053408864,0.00014852527,0.0381046],"genre_scores_gemma":[0.96080667,0.02997977,0.0017883606,0.0006729911,0.0003170938,0.00012117387,0.0002790072,0.00004223533,0.005992692],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99990976,0.00003290306,0.000010840503,0.000012298552,0.000014773118,0.000019377847],"domain_scores_gemma":[0.9997931,0.00010411809,0.000031376912,0.000024800902,0.000012335078,0.000034412158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021347885,0.00014852404,0.0004556131,0.0004178406,0.00023665601,0.00019058134,0.00021576027,0.0002358071,0.0027250878],"category_scores_gemma":[0.00058423047,0.000092322836,0.00029562434,0.00041026104,0.00022798264,0.0002696385,0.00023232572,0.00057172397,0.00029206873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016536806,0.00085039507,0.019190423,0.0017019941,0.0003535549,0.0031988048,0.0002953142,0.005333223,0.051265057,0.0027494107,0.008891586,0.8896334],"study_design_scores_gemma":[0.014093524,0.061984405,0.39057443,0.0014194356,0.0019164793,0.02900144,0.00039488616,0.008143919,0.074949525,0.0058807265,0.41151425,0.00012701642],"about_ca_topic_score_codex":0.0010617665,"about_ca_topic_score_gemma":0.0045324382,"teacher_disagreement_score":0.0027250878,"about_ca_system_score_codex":0.00056067953,"about_ca_system_score_gemma":0.00029722703,"threshold_uncertainty_score":0.009116352},"labels":[],"label_agreement":null},{"id":"W2166913932","doi":"10.1016/j.lungcan.2011.05.026","title":"Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs","keywords":"Medicine; Physical therapy; Lung cancer; Quality of life (healthcare); Physical strength; Internal medicine","score_opus":0.03817123558172534,"score_gpt":0.32995214051964655,"score_spread":0.2917809049379212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166913932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987004,0.0001377121,0.00015576916,0.000041719217,0.00001264762,0.0001400826,0.00005936875,0.000004669513,0.00074764347],"genre_scores_gemma":[0.99895847,0.00013470442,0.0002899972,0.000021708656,0.000028437391,0.000103992876,0.00014483933,0.0000030226054,0.0003148839],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992223,0.00044493488,0.000051327886,0.000072988034,0.00009735604,0.000111114336],"domain_scores_gemma":[0.9984971,0.0009520431,0.00009695862,0.00012527923,0.00014655567,0.00018200629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002594421,0.00040962684,0.00041010702,0.00034273983,0.00033176475,0.00032802214,0.00041741246,0.00041513646,0.0019467134],"category_scores_gemma":[0.004076157,0.00017531878,0.0006301449,0.00023832984,0.00044627793,0.00047792424,0.00037384036,0.0005808859,0.00036043453],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24307904,0.068347454,0.3437498,0.00075529766,0.00053298176,0.0008057814,0.0014642698,0.003145188,0.09099485,0.0003850092,0.0006134147,0.24612692],"study_design_scores_gemma":[0.0040913336,0.50450164,0.4733658,0.000057683836,0.0004500125,0.0003889449,0.00072174496,0.002131648,0.013037158,0.00011983151,0.0011062386,0.000028026232],"about_ca_topic_score_codex":0.0016160941,"about_ca_topic_score_gemma":0.0013440191,"teacher_disagreement_score":0.002594421,"about_ca_system_score_codex":0.00016332339,"about_ca_system_score_gemma":0.0005897425,"threshold_uncertainty_score":0.01372081},"labels":[],"label_agreement":null},{"id":"W2168227366","doi":"10.1016/j.lungcan.2005.02.008","title":"A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Medicine; Topotecan; Neutropenia; Etoposide; Internal medicine; Gastroenterology; Regimen; Surgery; Febrile neutropenia; Lung cancer; Chemotherapy","score_opus":0.00883246383519371,"score_gpt":0.30646718245021914,"score_spread":0.29763471861502544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168227366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99152035,0.0012930756,0.00064711925,0.00046531152,0.00036259237,0.0033356557,0.0007872974,0.000069557536,0.0015189252],"genre_scores_gemma":[0.9884105,0.0015915678,0.0013755107,0.0008093393,0.0005738738,0.0033909066,0.0013989299,0.00004182216,0.002407545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980134,0.0013155908,0.00008751439,0.00024114602,0.000104959996,0.00023735758],"domain_scores_gemma":[0.9967002,0.0010690619,0.00052851584,0.00041427507,0.00014137622,0.0011465084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003093641,0.0028678172,0.00513934,0.0007923164,0.0008012177,0.0015788677,0.0018189567,0.0023521283,0.006301742],"category_scores_gemma":[0.0035983985,0.0015723521,0.0023768828,0.001032,0.0032619347,0.0021341017,0.0007368835,0.0061447425,0.001169034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98154473,0.010598524,0.0003849993,0.00012233251,0.00037950967,0.00003237593,0.000037649686,0.0002913892,0.0020352928,0.0000670105,0.00024028392,0.0042660167],"study_design_scores_gemma":[0.90421367,0.09415873,0.0007079832,0.0000058728833,0.00020710428,0.000018323686,0.000013171589,0.00013519553,0.0002724199,0.000053681862,0.00020490198,0.000009031349],"about_ca_topic_score_codex":0.0028800676,"about_ca_topic_score_gemma":0.0039210985,"teacher_disagreement_score":0.006301742,"about_ca_system_score_codex":0.0019235518,"about_ca_system_score_gemma":0.0028986628,"threshold_uncertainty_score":0.021081388},"labels":[],"label_agreement":null},{"id":"W2169810666","doi":"10.1016/j.lungcan.2013.04.018","title":"A genome-wide association study for malignant mesothelioma risk","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Canada Research Chairs; Ontario Institute for Cancer Research; University of Toronto; Women's College Hospital","funders":"National Medical Research Council; National Health and Medical Research Council; Cancer Australia; Ontario Institute for Cancer Research","keywords":"Asbestos; Mesothelioma; Single-nucleotide polymorphism; Genotyping; Medicine; Genome-wide association study; Genetic association; Genetics; Case-control study; Genotype; Oncology; Pathology; Gene; Biology","score_opus":0.007849009480797028,"score_gpt":0.2772130378574949,"score_spread":0.2693640283766979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169810666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974534,0.0006313033,0.00036037288,0.00024115463,0.000031821135,0.0000071975082,0.0007192856,0.000017793764,0.00053762656],"genre_scores_gemma":[0.99909115,0.00011309896,0.00020140584,0.00003587611,0.000017093213,0.000004276863,0.00022672153,0.0000064891387,0.00030382964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998931,0.00036477638,0.00008832684,0.00036936425,0.00010728549,0.00013922689],"domain_scores_gemma":[0.9985892,0.00049988483,0.00026490891,0.00028454504,0.00014415971,0.00021733242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010919439,0.0005019957,0.00040237376,0.0009679331,0.0010462811,0.0008229017,0.0005825929,0.00089581317,0.0025510022],"category_scores_gemma":[0.002165322,0.00048444787,0.0016410743,0.0013679236,0.00036937583,0.00031230898,0.0007243938,0.0009821067,0.00024952402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032641033,0.00019185305,0.96814954,0.000056163364,0.0030988816,0.00093702786,0.0002850759,0.0001796813,0.019069957,0.00020137882,0.00061453134,0.00395175],"study_design_scores_gemma":[0.00009273359,0.00018967946,0.99606174,0.000007094968,0.0013080258,0.0005199084,0.00014071658,0.00029139555,0.0006299795,0.00011199512,0.0006374426,0.000009384742],"about_ca_topic_score_codex":0.008202397,"about_ca_topic_score_gemma":0.010632142,"teacher_disagreement_score":0.008202397,"about_ca_system_score_codex":0.00030517255,"about_ca_system_score_gemma":0.00043560006,"threshold_uncertainty_score":0.01630932},"labels":[],"label_agreement":null},{"id":"W2170603432","doi":"10.1016/j.lungcan.2010.07.015","title":"Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Comorbidity; Stage (stratigraphy); Internal medicine; Proportional hazards model; Lung cancer; Radiation therapy; Retrospective cohort study; Cancer; Performance status; Oncology; Surgery","score_opus":0.010356648751411126,"score_gpt":0.29477256964678145,"score_spread":0.2844159208953703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170603432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997656,0.0010207021,0.000045978533,0.00029114445,0.000010708996,0.0000040963337,0.0004082263,0.0000024609112,0.0005606719],"genre_scores_gemma":[0.9994023,0.00021763865,0.000029570794,0.000018299826,0.000015092888,0.000002326999,0.00024750992,9.3508856e-7,0.00006620465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994531,0.0001657993,0.00009063953,0.00006895544,0.0000921841,0.00012921133],"domain_scores_gemma":[0.9980039,0.00045551386,0.0008295212,0.00006601222,0.00016830755,0.0004767811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005716188,0.0002280457,0.0005142662,0.001047885,0.00067241915,0.001013419,0.00042760067,0.00073171844,0.0020690104],"category_scores_gemma":[0.0042845486,0.00023695969,0.00069646526,0.0032870315,0.00026825894,0.0009432876,0.00078015256,0.0006905237,0.00017638116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037879974,0.000012067479,0.999278,0.0000032481812,0.000027067339,0.000030292713,0.000018936655,0.000023603105,0.000019272818,0.000011186861,0.000042951524,0.0004954026],"study_design_scores_gemma":[0.0000022349843,0.0000254011,0.99937844,0.0000033248714,0.000020253474,0.00014196674,0.00017619168,0.00015757912,0.0000071316736,0.000038285154,0.000046559024,0.000002576856],"about_ca_topic_score_codex":0.0178844,"about_ca_topic_score_gemma":0.031481426,"teacher_disagreement_score":0.0178844,"about_ca_system_score_codex":0.00085113314,"about_ca_system_score_gemma":0.00092240557,"threshold_uncertainty_score":0.035560608},"labels":[],"label_agreement":null},{"id":"W2258384277","doi":"10.1016/j.lungcan.2016.02.002","title":"Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Lung cancer; Cancer; General surgery; Internal medicine","score_opus":0.012496099743748972,"score_gpt":0.2878871232613033,"score_spread":0.2753910235175543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258384277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754706,0.0059575196,0.00013937992,0.0059560887,0.00008402042,0.00009917006,0.002216623,0.000012244962,0.010064285],"genre_scores_gemma":[0.9919402,0.0040563717,0.00025700076,0.0018975358,0.00004527594,0.000023010118,0.00078518206,0.0000059050817,0.0009896609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998181,0.00017287246,0.00013405386,0.00016592749,0.00078276824,0.00056335586],"domain_scores_gemma":[0.99466765,0.00041484655,0.0020969135,0.0000540248,0.0012653656,0.0015012551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007027344,0.00020347236,0.00023815241,0.0012651737,0.0026393398,0.00111465,0.0011644457,0.00071357127,0.003043603],"category_scores_gemma":[0.0044605555,0.0002820389,0.00043810823,0.002666957,0.00071046175,0.00041663207,0.0009554028,0.0008028494,0.000214998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047758745,0.00006187476,0.9886486,0.00007712933,0.000037124875,0.00015477522,0.0014119161,0.000059911054,0.00023794238,0.000118107906,0.0026970622,0.006447917],"study_design_scores_gemma":[0.000005862367,0.00003969524,0.99210817,0.000088785375,0.000014312284,0.00029540225,0.0043912693,0.00007904269,0.000025386786,0.000026115877,0.002912878,0.000013085732],"about_ca_topic_score_codex":0.89387316,"about_ca_topic_score_gemma":0.95499194,"teacher_disagreement_score":0.106126845,"about_ca_system_score_codex":0.013486307,"about_ca_system_score_gemma":0.023446329,"threshold_uncertainty_score":0.21350366},"labels":[],"label_agreement":null},{"id":"W2260636514","doi":"10.1016/j.lungcan.2016.01.021","title":"Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Physical Activity and Health","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Canadian Cancer Society Research Institute; Alberta Innovates - Health Solutions; World Health Organization; Alberta Cancer Foundation; Cancer Research Institute","keywords":"Medicine; Relative risk; Lung cancer; Meta-analysis; Confidence interval; Confounding; Internal medicine; Population; Lower risk; Cancer; Oncology; Demography; Environmental health","score_opus":0.07407870955170781,"score_gpt":0.44193483318317395,"score_spread":0.36785612363146614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260636514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033395528,0.9955746,0.00026862317,0.000090361704,0.00009260138,0.0001591377,0.0003324096,0.000017954526,0.00012471603],"genre_scores_gemma":[0.09972819,0.8962458,0.0018248665,0.0008116499,0.00016032772,0.0004405056,0.00040437136,0.000022174307,0.00036210628],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9960867,0.0013171316,0.0013865576,0.0005248089,0.00046907662,0.00021580838],"domain_scores_gemma":[0.99390453,0.0036691527,0.0015578654,0.00022607259,0.0005069765,0.00013545345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006456081,0.0031372628,0.017144235,0.005651756,0.0006405303,0.0028502578,0.0020641368,0.002567504,0.0049156486],"category_scores_gemma":[0.014734523,0.0022155673,0.028974304,0.0065503456,0.00076406077,0.0019792186,0.0021704002,0.0019958084,0.00041603798],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001548708,0.000053815293,0.0031985985,0.5074013,0.47250617,0.0001819699,0.00011879985,0.000319727,0.00033878125,0.00007378526,0.00067247474,0.013585824],"study_design_scores_gemma":[0.0006259613,0.00016582035,0.0032101632,0.022012405,0.9717096,0.00013262872,0.000058752692,0.00008345259,0.00007808836,0.000088121975,0.0018054525,0.000029470699],"about_ca_topic_score_codex":0.008492298,"about_ca_topic_score_gemma":0.03190317,"teacher_disagreement_score":0.017144235,"about_ca_system_score_codex":0.0021240383,"about_ca_system_score_gemma":0.0036977704,"threshold_uncertainty_score":0.03414339},"labels":[],"label_agreement":null},{"id":"W2266584353","doi":"10.1016/j.lungcan.2016.01.022","title":"Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Stage (stratigraphy); Lung cancer; Proportional hazards model; Oncology; Head and neck cancer; Cancer; Cancer registry","score_opus":0.020771305269990752,"score_gpt":0.3339487697123087,"score_spread":0.3131774644423179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266584353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969144,0.005670504,0.000057817488,0.00048872153,0.00005642749,0.000018114151,0.0010358925,0.0000017329662,0.0029793102],"genre_scores_gemma":[0.99516875,0.0017979448,0.000025132253,0.00013893566,0.000027760723,0.000016507272,0.0007396096,0.0000035636995,0.0020817844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990361,0.00034253986,0.0001028708,0.00015173567,0.00012385818,0.00024292959],"domain_scores_gemma":[0.99883145,0.00029113074,0.0004274283,0.0000479677,0.00013206947,0.00026999996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008814164,0.00018150358,0.00042414345,0.00047306274,0.00037549945,0.0010278921,0.0006427208,0.0007244183,0.0020078039],"category_scores_gemma":[0.0041254885,0.0002210148,0.0012133404,0.0010677095,0.00025935797,0.0006059726,0.0005261791,0.00072424987,0.00019283514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012438281,0.00025398555,0.9874843,0.00018834183,0.00056079554,0.0004464554,0.00080159865,0.00038395578,0.00026320957,0.00018482812,0.0011253479,0.0070632403],"study_design_scores_gemma":[0.00006843968,0.0002442095,0.99519074,0.00009315202,0.00027416865,0.00020703804,0.001333946,0.00022929745,0.00009660336,0.00006618097,0.002185411,0.000010847924],"about_ca_topic_score_codex":0.2612674,"about_ca_topic_score_gemma":0.3811956,"teacher_disagreement_score":0.2612674,"about_ca_system_score_codex":0.0027370434,"about_ca_system_score_gemma":0.0024502794,"threshold_uncertainty_score":0.51949334},"labels":[],"label_agreement":null},{"id":"W2273853937","doi":"10.1016/j.lungcan.2016.02.013","title":"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Cetuximab; In vivo; Monoclonal antibody; A549 cell; Epidermal growth factor receptor; Chemistry; Cancer research; Apoptosis; Pharmacology; Receptor; Medicine; Biology; Antibody; Immunology; Biochemistry","score_opus":0.0188192176814274,"score_gpt":0.35069398863298906,"score_spread":0.33187477095156165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273853937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738521,0.005863914,0.006965457,0.0008432685,0.00033584624,0.00022882411,0.002293853,0.000584889,0.009031822],"genre_scores_gemma":[0.9715334,0.004262375,0.004344166,0.00020872527,0.000054121272,0.00020962654,0.003759641,0.000077664714,0.015550337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997662,0.000035647412,0.0000129872515,0.000032358996,0.00006996725,0.00008288367],"domain_scores_gemma":[0.9999485,0.000007991499,0.000008472464,0.000007874486,0.000011626543,0.000015431397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037454488,0.00067172776,0.000571261,0.00043296404,0.000231718,0.00042359086,0.0005940364,0.0005503073,0.002816352],"category_scores_gemma":[0.00010756526,0.00022444718,0.00058572326,0.0002803617,0.00018500071,0.00044233905,0.00015610168,0.0013990906,0.00068040384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015881691,0.0009136393,0.00032771644,0.000152053,0.00007354571,0.00012051301,0.000030574025,0.00053889916,0.9830436,0.0004738816,0.002086725,0.010650675],"study_design_scores_gemma":[0.0003827589,0.0024450114,0.0019384195,0.000009096008,0.00009509813,0.0003427314,0.00003179573,0.0022534102,0.9810594,0.00009285666,0.011339146,0.000010347459],"about_ca_topic_score_codex":0.0012352654,"about_ca_topic_score_gemma":0.0032321434,"teacher_disagreement_score":0.002816352,"about_ca_system_score_codex":0.0005635977,"about_ca_system_score_gemma":0.0004538242,"threshold_uncertainty_score":0.009421647},"labels":[],"label_agreement":null},{"id":"W2325642881","doi":"10.1016/j.lungcan.2016.04.004","title":"EGFR mutation status on brain metastases from non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Incidence (geometry); Clinical endpoint; Brain metastasis; Cumulative incidence; Epidermal growth factor receptor; Multivariate analysis; Population; Cancer; Metastasis; Cohort; Clinical trial","score_opus":0.011819419277273258,"score_gpt":0.3313313429954913,"score_spread":0.319511923718218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325642881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964715,0.00086960074,0.00003125627,0.00007661012,0.000013756556,0.0000044503176,0.00054017274,0.0000031572833,0.0019895046],"genre_scores_gemma":[0.998591,0.00025735714,0.000012543753,0.000026569664,0.000017937791,0.000002228003,0.00045426065,0.000002047274,0.0006360879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997999,0.000042680334,0.00001841817,0.00003062593,0.00004197238,0.000066413275],"domain_scores_gemma":[0.9995314,0.0001541438,0.00011968276,0.000021308704,0.000073099094,0.000100509635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026528494,0.00020871367,0.0003372139,0.00046988687,0.00018826661,0.00033758202,0.00025464853,0.00045585138,0.0037703684],"category_scores_gemma":[0.0013901495,0.00008650872,0.0006398113,0.0004964624,0.00018658461,0.00055508164,0.00024197892,0.00039765905,0.00034446464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077460455,0.0001577604,0.9579144,0.00010745138,0.00041814725,0.0013759483,0.0001136983,0.0004671358,0.0040920265,0.00013051757,0.00088049937,0.026596183],"study_design_scores_gemma":[0.000017902179,0.00040322202,0.9977088,0.000013213099,0.00013353555,0.00053919747,0.00009328269,0.00020050438,0.00028218646,0.000080128244,0.00052145764,0.0000066376556],"about_ca_topic_score_codex":0.007762188,"about_ca_topic_score_gemma":0.016199877,"teacher_disagreement_score":0.007762188,"about_ca_system_score_codex":0.0004224467,"about_ca_system_score_gemma":0.0002532061,"threshold_uncertainty_score":0.015434027},"labels":[],"label_agreement":null},{"id":"W2337624919","doi":"10.1016/j.lungcan.2016.04.007","title":"Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Systemic therapy; Intensive care medicine; Cancer; Palliative care; Oncology; Internal medicine; Nursing","score_opus":0.14783931423759905,"score_gpt":0.4464103802403956,"score_spread":0.29857106600279654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337624919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023542934,0.9993704,0.000013906866,0.00019107953,0.000060173166,0.0000026409866,0.000017962546,6.702975e-7,0.000107699656],"genre_scores_gemma":[0.0024322618,0.99700963,0.000094567775,0.00032286812,0.00006221289,0.000006394386,0.000025207913,4.3087152e-7,0.0000463511],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996043,0.000119476514,0.00008756282,0.00005936992,0.000092955626,0.00003634867],"domain_scores_gemma":[0.9987471,0.000816901,0.00025905055,0.000011647122,0.000111054826,0.00005420748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010271912,0.00059198984,0.0018119548,0.0020682388,0.00023872327,0.00086425524,0.000580311,0.0008452483,0.0022464925],"category_scores_gemma":[0.0031198333,0.00020911565,0.0014959031,0.003315825,0.00031549434,0.0010973347,0.0008095781,0.0010389645,0.00014213026],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025691302,0.0000856333,0.0035868273,0.13574542,0.0023860142,0.00009989612,0.00025602468,0.0002129774,0.00029802657,0.0016164584,0.01842015,0.8370357],"study_design_scores_gemma":[0.00038407574,0.00046700114,0.030297626,0.35856453,0.01824148,0.0016167557,0.001561085,0.0002909171,0.00035321087,0.004001246,0.58411765,0.00010448773],"about_ca_topic_score_codex":0.0040053213,"about_ca_topic_score_gemma":0.014775965,"teacher_disagreement_score":0.0040053213,"about_ca_system_score_codex":0.001017867,"about_ca_system_score_gemma":0.0024200007,"threshold_uncertainty_score":0.007964015},"labels":[],"label_agreement":null},{"id":"W2345787467","doi":"10.1016/j.lungcan.2016.04.020","title":"Erratum to “The function of IGF-IR in NNK-mediated lung tumorigenesis” [Lung Cancer 71 (1) (2011) 11–18]","year":2016,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Lung cancer; Carcinogenesis; Magnification; Lung; Medicine; Cancer research; Cancer; Pathology; Epidermal growth factor receptor; Internal medicine; Physics","score_opus":0.007828705652879176,"score_gpt":0.2700077450826435,"score_spread":0.26217903942976434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345787467","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014235883,0.0025678198,0.00027165964,0.043488733,0.9473137,0.000026660922,0.0006207674,0.00013749275,0.005430802],"genre_scores_gemma":[0.0058268304,0.024247967,0.0027612718,0.15063323,0.41960186,0.00017601695,0.0037167887,0.00065021834,0.3923859],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99767023,0.00025020217,0.0006210631,0.00025465805,0.0009856238,0.00021827826],"domain_scores_gemma":[0.9908229,0.0017600269,0.00079229655,0.0005645707,0.005394063,0.0006660302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00243458,0.0020332858,0.0020927875,0.0034465624,0.002859532,0.0031904548,0.002777127,0.006667637,0.032997128],"category_scores_gemma":[0.018293355,0.0012694842,0.0022502632,0.0016672878,0.0017615168,0.0019810428,0.0014237352,0.008460523,0.032599248],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050326627,0.00001330006,0.00008414937,0.00009901998,0.000011785358,0.00021670214,0.0000082405095,0.00003336624,0.00008678363,0.00034305136,0.9930674,0.0059857615],"study_design_scores_gemma":[0.00004259993,0.000036934347,0.0012658058,0.00029936616,0.00005087242,0.00040444985,0.000038481172,0.00013051863,0.00045971436,0.00065241766,0.99658304,0.00003586265],"about_ca_topic_score_codex":0.020279655,"about_ca_topic_score_gemma":0.028941462,"teacher_disagreement_score":0.032997128,"about_ca_system_score_codex":0.0036869035,"about_ca_system_score_gemma":0.005990015,"threshold_uncertainty_score":0.11038637},"labels":[],"label_agreement":null},{"id":"W2470680043","doi":"10.1016/j.lungcan.2016.06.018","title":"Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish Rehabilitation Hospital; University of Ottawa; Jewish General Hospital; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre","funders":"Jewish General Hospital","keywords":"Medicine; Quality of life (healthcare); Chemotherapy; Oncology; Lung cancer; Performance status; Cancer; Internal medicine; Physical therapy; Intensive care medicine","score_opus":0.013960056677810416,"score_gpt":0.295440526174325,"score_spread":0.28148046949651456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470680043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983127,0.00010899762,0.00008565134,0.00002172307,0.0000028867712,0.000023623363,0.0012632002,0.0000021257883,0.00017913828],"genre_scores_gemma":[0.9974962,0.00004256827,0.00010657053,0.000019500385,0.000006375702,0.000047086927,0.0021669874,0.0000026541077,0.0001120247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976146,0.001213831,0.00024572565,0.00025072272,0.0003730044,0.0003021771],"domain_scores_gemma":[0.99542916,0.0020755108,0.0013127382,0.00031714048,0.00039492382,0.00047052428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027028222,0.00041655247,0.0009757492,0.0017559212,0.0005033766,0.0009553304,0.00047924055,0.00038846993,0.0017402016],"category_scores_gemma":[0.006438474,0.00024632583,0.0022660152,0.002248459,0.0005558109,0.0009156818,0.001283822,0.0008305962,0.0002582343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011129669,0.0001932556,0.9963176,0.00003586048,0.0004635695,0.00004180896,0.00012303382,0.00014863757,0.00016266784,0.000028460054,0.00012803063,0.0012440999],"study_design_scores_gemma":[0.00004634658,0.00063801656,0.9979284,0.000010171366,0.00014350581,0.00009630905,0.00037502908,0.00046705964,0.00007692484,0.00003445657,0.00017575274,0.000008005996],"about_ca_topic_score_codex":0.0041101067,"about_ca_topic_score_gemma":0.005965543,"teacher_disagreement_score":0.0041101067,"about_ca_system_score_codex":0.00067522225,"about_ca_system_score_gemma":0.0007756559,"threshold_uncertainty_score":0.014294028},"labels":[],"label_agreement":null},{"id":"W2471534305","doi":"10.1016/j.lungcan.2016.06.026","title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Nivolumab; Adverse effect; Lung cancer; Immune system; Cancer; Combination therapy; Toxicity; Oncology; Internal medicine; Immunology; Immunotherapy","score_opus":0.008072019970002274,"score_gpt":0.251468389813785,"score_spread":0.2433963698437827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471534305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597413,0.0065648733,0.0019687398,0.00999464,0.00063649623,0.00027858248,0.0005859139,0.0002975603,0.019931896],"genre_scores_gemma":[0.9954932,0.0008896707,0.00044513622,0.001739263,0.00045484738,0.000012208712,0.00012122308,0.000021725893,0.00082275126],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99960095,0.00005419363,0.000056132547,0.000089581416,0.00007350139,0.00012563512],"domain_scores_gemma":[0.9989543,0.00034285564,0.0001618825,0.000049957973,0.000086263506,0.00040480334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000281379,0.0013325429,0.0010250679,0.0013008367,0.0016370261,0.0012090298,0.0010611063,0.00403091,0.0015959417],"category_scores_gemma":[0.0017662814,0.00066975696,0.0013782555,0.0008638255,0.0009596185,0.00090417103,0.0007163563,0.0034640916,0.00050860964],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002083274,0.000044407734,0.009912945,0.000038038175,0.000027065329,0.9865536,0.00006129196,0.00012950759,0.0010519718,0.00008605397,0.00050027715,0.0013864838],"study_design_scores_gemma":[0.00005621127,0.00033930605,0.021741686,0.00003317309,0.00009649167,0.9739875,0.00014539326,0.0010511668,0.001027681,0.00023605283,0.0012622419,0.000023156033],"about_ca_topic_score_codex":0.003538594,"about_ca_topic_score_gemma":0.0049380884,"teacher_disagreement_score":0.00403091,"about_ca_system_score_codex":0.001728143,"about_ca_system_score_gemma":0.00080418284,"threshold_uncertainty_score":0.0125386715},"labels":[],"label_agreement":null},{"id":"W2479045143","doi":"10.1016/j.lungcan.2016.07.016","title":"Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; Manitoba Health; Winnipeg Regional Health Authority; University of Manitoba; McMaster University; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Radiation therapy; Lung cancer; Randomized controlled trial; Meta-analysis; Oncology; Stage (stratigraphy); Blinding; Hazard ratio; Clinical trial; MEDLINE; Subgroup analysis; Confidence interval","score_opus":0.027030630380851833,"score_gpt":0.3465600761323956,"score_spread":0.31952944575154374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479045143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009032225,0.9895201,0.00032320773,0.0001230259,0.00016757901,0.00015099431,0.0004386889,0.000020653762,0.00022354108],"genre_scores_gemma":[0.34288812,0.6513635,0.0019137816,0.0016932058,0.00031740873,0.00045233546,0.0006824144,0.000039458235,0.0006497977],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9963486,0.001536345,0.0010657547,0.000533746,0.00032105643,0.00019450895],"domain_scores_gemma":[0.9949986,0.003163611,0.0012256554,0.0001883907,0.0003063303,0.00011747225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049320003,0.002500506,0.014039093,0.0028405439,0.00048551665,0.0019367213,0.0018170531,0.0021645678,0.0043496904],"category_scores_gemma":[0.012264683,0.0014909201,0.0324901,0.0036829486,0.00062196754,0.001548214,0.0014893664,0.0020710889,0.00035684867],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041741016,0.000043959248,0.0044127028,0.24655963,0.7334348,0.00012130409,0.00010471836,0.00038808034,0.00029841886,0.00008131073,0.00054401957,0.009836921],"study_design_scores_gemma":[0.0010241847,0.00022942519,0.002714816,0.0074367695,0.9872502,0.0000645633,0.000042326705,0.00007969857,0.000055762448,0.00008351542,0.0009994986,0.000019274901],"about_ca_topic_score_codex":0.00806447,"about_ca_topic_score_gemma":0.033037342,"teacher_disagreement_score":0.014039093,"about_ca_system_score_codex":0.002212864,"about_ca_system_score_gemma":0.0020221246,"threshold_uncertainty_score":0.026083231},"labels":[],"label_agreement":null},{"id":"W2520203377","doi":"10.1016/j.lungcan.2016.09.009","title":"High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Liver physiology and pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Centre National de la Recherche Scientifique; Association pour la Recherche sur le Cancer","keywords":"Medicine; Receptor tyrosine kinase; Phosphorylation; Carcinogenesis; Cancer research; Biomarker; Lung cancer; Receptor; Proteases; Immunohistochemistry; Tumor progression; Kinase; Cancer; Pathology; Internal medicine; Biology; Cell biology; Enzyme","score_opus":0.01484584182013317,"score_gpt":0.24558744532706114,"score_spread":0.23074160350692796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520203377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99907446,0.00015265403,0.00010524829,0.000026542959,0.0000052703294,0.0000026298035,0.000096993856,0.000008533852,0.00052772055],"genre_scores_gemma":[0.99930096,0.000046205456,0.000069273294,0.000007022351,0.0000058903975,0.0000025410748,0.00021242231,0.0000021334133,0.00035353663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998902,0.000019196988,0.0000136738045,0.000017202838,0.000025667205,0.000034042427],"domain_scores_gemma":[0.9993474,0.00012838995,0.00021155454,0.000048045145,0.000052391093,0.00021219546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522667,0.00021729132,0.00021646396,0.0006139176,0.00023508248,0.00044343123,0.00017649119,0.00027665967,0.0032464664],"category_scores_gemma":[0.0005873252,0.00017500945,0.000173091,0.00041092353,0.00033330926,0.0002762564,0.00022508774,0.0003736086,0.00044650026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025482604,0.00014410907,0.6731885,0.00004441533,0.00009085578,0.0013936268,0.00008970561,0.00009882619,0.31680015,0.00010641726,0.00022571716,0.005269306],"study_design_scores_gemma":[0.000014244118,0.00033591123,0.9790238,0.0000023133773,0.000027449058,0.0033181766,0.0001275887,0.00039618064,0.01638687,0.00009287003,0.00026952114,0.000005057837],"about_ca_topic_score_codex":0.000632452,"about_ca_topic_score_gemma":0.0010233934,"teacher_disagreement_score":0.0032464664,"about_ca_system_score_codex":0.00013592794,"about_ca_system_score_gemma":0.0001286959,"threshold_uncertainty_score":0.010860503},"labels":[],"label_agreement":null},{"id":"W2526187706","doi":"10.1016/j.lungcan.2016.09.013","title":"Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Canadian Partnership Against Cancer; Public Health Ontario; University of Toronto; Statistics Canada; Cancer Care Ontario; McMaster University","funders":"Economic and Social Research Council; Medical Research Council; Health Canada","keywords":"Medicine; Smoking cessation; Lung cancer screening; Lung cancer; Oncology; Environmental health; Pathology","score_opus":0.015248205644547421,"score_gpt":0.3161021554672888,"score_spread":0.3008539498227414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526187706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94451725,0.028037764,0.00027960414,0.008790633,0.00022583769,0.00038641784,0.008429022,0.00004839299,0.009285068],"genre_scores_gemma":[0.9908023,0.004862122,0.00032795826,0.00061130064,0.00006718093,0.000038944054,0.0024277177,0.0000055787737,0.0008568387],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99735993,0.00038177107,0.00016828883,0.0002498597,0.0010043213,0.00083590334],"domain_scores_gemma":[0.99574476,0.000499605,0.00082043547,0.00008016017,0.0009334727,0.001921576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014763591,0.00048194063,0.0009647967,0.0011006995,0.0011860185,0.0023319798,0.0015815842,0.0012808692,0.0026210893],"category_scores_gemma":[0.0081362985,0.0003017805,0.002278384,0.0043050195,0.00070358516,0.00095866126,0.0013267839,0.0019933376,0.000121201745],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045115226,0.0022239627,0.86726844,0.0010124479,0.0025329853,0.00027761215,0.0002712609,0.006123865,0.00025815217,0.00094522064,0.009416708,0.105157726],"study_design_scores_gemma":[0.00060311524,0.0005784986,0.9902955,0.00037230382,0.0013979333,0.0001341762,0.0005799176,0.003839085,0.00007114487,0.0002921026,0.0017938457,0.000042534917],"about_ca_topic_score_codex":0.98439884,"about_ca_topic_score_gemma":0.98930573,"teacher_disagreement_score":0.94632185,"about_ca_system_score_codex":0.053678166,"about_ca_system_score_gemma":0.086535186,"threshold_uncertainty_score":0.3894642},"labels":[],"label_agreement":null},{"id":"W2544627141","doi":"10.1016/j.lungcan.2016.10.011","title":"Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Boehringer Ingelheim (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Nintedanib; Internal medicine; Lung cancer; Hazard ratio; Placebo; Clinical endpoint; Oncology; Bevacizumab; Gastroenterology; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Lung; Idiopathic pulmonary fibrosis; Pathology","score_opus":0.02024304551739279,"score_gpt":0.34881623179503624,"score_spread":0.3285731862776434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544627141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856448,0.0059689004,0.0006621329,0.0008883238,0.0009863222,0.0027881064,0.00092789036,0.00017569542,0.001957926],"genre_scores_gemma":[0.9847527,0.0038431,0.0013332859,0.000965977,0.00045132102,0.0029244558,0.0009415237,0.00002944284,0.0047581685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99959654,0.00019272887,0.00002358484,0.000087924294,0.000025987054,0.00007320069],"domain_scores_gemma":[0.9994906,0.00014072884,0.00009097721,0.000037945567,0.000028583605,0.00021106047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013783553,0.001915684,0.0035976358,0.0004071273,0.00043522567,0.00095306535,0.0011069477,0.0016217383,0.0060520954],"category_scores_gemma":[0.0011880011,0.0007784134,0.0016922269,0.00036299904,0.0012495136,0.0013626128,0.00040509927,0.0031433303,0.0011759318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9833356,0.0041508744,0.00021767411,0.00047544466,0.0005703877,0.000022334403,0.00003369164,0.00027119886,0.0018297678,0.00007320166,0.00044481427,0.008574977],"study_design_scores_gemma":[0.9596024,0.038782585,0.00056916015,0.000015801616,0.00022708878,0.0000152109105,0.00001504035,0.00026271006,0.00019332951,0.00007081158,0.00023754915,0.000008295241],"about_ca_topic_score_codex":0.0010582252,"about_ca_topic_score_gemma":0.002404376,"teacher_disagreement_score":0.0060520954,"about_ca_system_score_codex":0.00070375716,"about_ca_system_score_gemma":0.0009842316,"threshold_uncertainty_score":0.020246327},"labels":[],"label_agreement":null},{"id":"W2562390400","doi":"10.1016/j.lungcan.2016.12.019","title":"An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Neutropenia; Internal medicine; Vomiting; Constipation; Phases of clinical research; Adverse effect; Lung cancer; Polo-like kinase; Gastroenterology; Oncology; Cancer; Surgery; Clinical trial; Chemotherapy; Cell cycle","score_opus":0.02410631831682526,"score_gpt":0.36205355458020266,"score_spread":0.3379472362633774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562390400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987588,0.003540557,0.00083472126,0.00056144735,0.00029817136,0.0030660082,0.0016379646,0.00018490978,0.002288224],"genre_scores_gemma":[0.9846126,0.002920758,0.0022731978,0.0011279398,0.00030712454,0.002891789,0.002739659,0.0000531422,0.003073676],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993729,0.00030330525,0.000029294992,0.00011904378,0.00005001314,0.00012547678],"domain_scores_gemma":[0.9990607,0.00017854769,0.00013004917,0.00009097296,0.00005516915,0.00048457243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002103534,0.0021781474,0.0032147265,0.00064579694,0.00071609864,0.0015270204,0.0014535727,0.0017878915,0.004968484],"category_scores_gemma":[0.00108749,0.0011302184,0.0021312363,0.0006297661,0.0015093475,0.0015395597,0.00045276317,0.0058312877,0.0015597756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8709274,0.052141327,0.002192318,0.000749293,0.0009659275,0.00014042432,0.00022509531,0.0012864948,0.018526899,0.00019176732,0.0021734552,0.050479583],"study_design_scores_gemma":[0.6508949,0.34041476,0.0043718056,0.000028661296,0.00044610747,0.00014310503,0.00007659824,0.0008241117,0.001437329,0.00012427573,0.001206329,0.00003208254],"about_ca_topic_score_codex":0.0019785874,"about_ca_topic_score_gemma":0.005596123,"teacher_disagreement_score":0.004968484,"about_ca_system_score_codex":0.0011381188,"about_ca_system_score_gemma":0.0023242293,"threshold_uncertainty_score":0.016621292},"labels":[],"label_agreement":null},{"id":"W2565864153","doi":"10.1016/j.lungcan.2016.12.004","title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre; Northeast Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Mesothelioma; Internal medicine; Oncology; Pathology","score_opus":0.03524471519742882,"score_gpt":0.4049771911149531,"score_spread":0.3697324759175243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565864153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859159,0.0045604543,0.00020718812,0.0016791291,0.00021275216,0.0015391585,0.0018414272,0.00004386965,0.0040001543],"genre_scores_gemma":[0.9810378,0.0045519006,0.0008613981,0.0015091503,0.00016931906,0.0011422145,0.0044927,0.000028155971,0.0062072882],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975663,0.000072915165,0.000008704405,0.00003973261,0.000032933647,0.00008910192],"domain_scores_gemma":[0.99945766,0.000052379135,0.00007348042,0.00003547257,0.000041379037,0.00033969127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008915667,0.0010569511,0.0013340057,0.00029307205,0.0007213259,0.0009568338,0.000915257,0.0010951431,0.0028148817],"category_scores_gemma":[0.0007179521,0.0003140892,0.0012916778,0.00041185005,0.0008200051,0.00043252573,0.00036724593,0.0017550472,0.0004584523],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6213034,0.022696601,0.030227713,0.0018771382,0.0032339818,0.0006408737,0.0008704214,0.0035822017,0.03984353,0.000868663,0.035077702,0.23977768],"study_design_scores_gemma":[0.69271475,0.1672384,0.10791075,0.00014226952,0.0014576954,0.00062573643,0.00036841427,0.0020866813,0.0027294913,0.00069278036,0.023963323,0.00006978654],"about_ca_topic_score_codex":0.0352827,"about_ca_topic_score_gemma":0.15358368,"teacher_disagreement_score":0.0352827,"about_ca_system_score_codex":0.003305742,"about_ca_system_score_gemma":0.0036567042,"threshold_uncertainty_score":0.07015467},"labels":[],"label_agreement":null},{"id":"W2566738039","doi":"10.1016/j.lungcan.2016.12.014","title":"Oligometastatic non-small cell lung cancer: Where do we go next?","year":2016,"lang":"de","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Disease; Cancer","score_opus":0.008859829446741413,"score_gpt":0.3254124924975059,"score_spread":0.3165526630507645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566738039","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003146735,0.03141367,0.00010420103,0.05855744,0.90897477,0.000012008511,0.00004611751,0.000028217131,0.0008321519],"genre_scores_gemma":[0.000311095,0.018797943,0.00009441863,0.027108643,0.949736,0.000016197442,0.000025407317,0.000015058793,0.0038952653],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955935,0.0009508751,0.00080289255,0.00047548697,0.0018310603,0.00034618648],"domain_scores_gemma":[0.9820837,0.008397106,0.0017991468,0.00035076909,0.00463347,0.002735813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00761613,0.0032669103,0.0047496133,0.002962874,0.002353759,0.0071118297,0.002908221,0.016679877,0.008768616],"category_scores_gemma":[0.020820422,0.0015516883,0.0029969409,0.0014604081,0.0023970662,0.0058498443,0.001905927,0.026972972,0.008286397],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004925026,0.0000133450785,0.000043170807,0.0004960679,0.000038976475,0.00013272688,0.000011045999,0.00002558552,0.000052805273,0.00027742123,0.9883482,0.010511433],"study_design_scores_gemma":[0.00014662517,0.000062244304,0.0003442793,0.0013140745,0.00016785876,0.0006958953,0.000054381024,0.00013870533,0.000102513266,0.0011352635,0.99580413,0.000034033797],"about_ca_topic_score_codex":0.0014690721,"about_ca_topic_score_gemma":0.004900922,"teacher_disagreement_score":0.016679877,"about_ca_system_score_codex":0.003639037,"about_ca_system_score_gemma":0.0037884994,"threshold_uncertainty_score":0.040278435},"labels":[],"label_agreement":null},{"id":"W2609723037","doi":"10.1016/j.lungcan.2017.04.016","title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","year":2017,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Exon; Epidermal growth factor receptor; Point mutation; Lung cancer; Medicine; Cancer research; Mutation; Tyrosine kinase; Gefitinib; Gene; Genetics; Biology; Cancer; Oncology; Internal medicine; Receptor","score_opus":0.040083472598513976,"score_gpt":0.4348004016307965,"score_spread":0.3947169290322825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609723037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009805817,0.99896526,0.0000513636,0.00017537334,0.000104125276,0.0000025768277,0.00002174351,0.000003879071,0.00057759037],"genre_scores_gemma":[0.0009704042,0.9981304,0.00011247039,0.00031150205,0.00014740144,0.000003155622,0.00003437443,0.0000010988158,0.00028916114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977964,0.000031582946,0.0000567103,0.00004477379,0.0000673959,0.000019922381],"domain_scores_gemma":[0.999546,0.00025498556,0.00010034368,0.000008286063,0.000065895285,0.000024527273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044938934,0.0006167799,0.0014828313,0.0020409916,0.0001791685,0.0009661365,0.0006804703,0.0008941985,0.0033541417],"category_scores_gemma":[0.0011110054,0.00029520076,0.0007229049,0.0016808873,0.00030783817,0.0011099238,0.00058458577,0.0013927534,0.00083252083],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008288739,0.00003240996,0.00043418046,0.03314052,0.00023445768,0.00023059173,0.00004180176,0.00030023992,0.00074025744,0.0012010839,0.025019757,0.9385417],"study_design_scores_gemma":[0.00006912962,0.0001345862,0.002700116,0.021088159,0.0012236024,0.0037318303,0.00009702371,0.00019496497,0.00045058512,0.0017569612,0.96851224,0.000040831543],"about_ca_topic_score_codex":0.0010673964,"about_ca_topic_score_gemma":0.0035020607,"teacher_disagreement_score":0.0033541417,"about_ca_system_score_codex":0.00048539703,"about_ca_system_score_gemma":0.0009819294,"threshold_uncertainty_score":0.011220694},"labels":[],"label_agreement":null},{"id":"W2611025812","doi":"10.1016/j.lungcan.2017.04.021","title":"Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine","score_opus":0.03873701686102035,"score_gpt":0.3714446377825013,"score_spread":0.332707620921481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611025812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616843,0.0016908676,0.0011527163,0.00009588081,0.000058646714,0.000046826404,0.0004047511,0.000007059308,0.00037475687],"genre_scores_gemma":[0.9989473,0.00017725624,0.00021506895,0.000055512148,0.00003929874,0.000024808367,0.0003163691,0.0000048110046,0.00021963815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952311,0.0025753502,0.00047843895,0.0009217,0.0002999081,0.0004933899],"domain_scores_gemma":[0.9937736,0.00300358,0.0015878235,0.00094366964,0.00020021698,0.0004910601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004072069,0.00041915235,0.0012478562,0.0006175172,0.00043369867,0.00088125764,0.0009157922,0.0009478276,0.0032134906],"category_scores_gemma":[0.0094729075,0.00049564603,0.0034981556,0.0012391455,0.000497023,0.0009446393,0.0007217368,0.0011240259,0.000264353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090639666,0.0006084751,0.8602946,0.0003544857,0.02026433,0.00035682024,0.00028588527,0.0024075413,0.0023874072,0.00070036587,0.0012255671,0.020474868],"study_design_scores_gemma":[0.006767629,0.014355587,0.94271946,0.000089235626,0.015464613,0.0008381709,0.0008672037,0.01256128,0.0010539419,0.0025833538,0.0026095517,0.00008991785],"about_ca_topic_score_codex":0.002601163,"about_ca_topic_score_gemma":0.0026071253,"teacher_disagreement_score":0.004072069,"about_ca_system_score_codex":0.0004582124,"about_ca_system_score_gemma":0.0006482849,"threshold_uncertainty_score":0.021535397},"labels":[],"label_agreement":null},{"id":"W2612399534","doi":"10.1016/j.lungcan.2017.05.010","title":"Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Afatinib; Erlotinib; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Population; Gastroenterology; Adenocarcinoma; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.01816073625509867,"score_gpt":0.3500462134743749,"score_spread":0.33188547721927625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612399534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941403,0.0029446033,0.00024156051,0.0003411595,0.00008930131,0.00011683265,0.0011239994,0.0000748695,0.0009271758],"genre_scores_gemma":[0.9959615,0.0006768868,0.000440466,0.00033578466,0.000051715786,0.000075204276,0.0018276896,0.00001171183,0.00061902805],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99924195,0.00030721247,0.000042518226,0.00018715319,0.00013699564,0.00008421227],"domain_scores_gemma":[0.9988716,0.00033868686,0.00032145408,0.00006412976,0.00013291214,0.00027117052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018492857,0.00093766564,0.0018809187,0.0003242695,0.00027019205,0.0011586165,0.00081036915,0.0012952023,0.0013482948],"category_scores_gemma":[0.0018609388,0.00037135484,0.001528024,0.00042686777,0.0004332179,0.0009735771,0.00026509605,0.0016413463,0.00046388063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4526243,0.0035564508,0.37662804,0.00081071455,0.00563344,0.000464208,0.00019494406,0.0032787882,0.028427618,0.0004314905,0.0056576007,0.12229243],"study_design_scores_gemma":[0.14322063,0.18750016,0.6208565,0.00017036688,0.006285761,0.003187541,0.00029928077,0.012171523,0.015547284,0.00090791954,0.009646659,0.00020632723],"about_ca_topic_score_codex":0.0008866763,"about_ca_topic_score_gemma":0.0021760522,"teacher_disagreement_score":0.0018809187,"about_ca_system_score_codex":0.0008933009,"about_ca_system_score_gemma":0.00084916677,"threshold_uncertainty_score":0.009780049},"labels":[],"label_agreement":null},{"id":"W2613700593","doi":"10.1016/j.lungcan.2017.05.004","title":"Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Contraindication; Stage (stratigraphy); Lung cancer; Cancer; Logistic regression; Pneumonectomy; Medicaid; Surgical oncology; Surgery; General surgery; Internal medicine; Health care; Pathology","score_opus":0.07380272844780107,"score_gpt":0.41596516259941896,"score_spread":0.3421624341516179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613700593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899545,0.006285908,0.00006336607,0.0011297227,0.00002193357,0.000009028033,0.0010441932,0.0000034143436,0.0014880161],"genre_scores_gemma":[0.9956527,0.0031769066,0.00007105435,0.00014409085,0.000046865633,0.000009109662,0.00063953496,0.000003849578,0.0002559332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981804,0.00053373154,0.00042520332,0.00025460878,0.00034944064,0.00025668376],"domain_scores_gemma":[0.9860525,0.0031239584,0.0071504335,0.0003010043,0.001959738,0.001412343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016675275,0.0000919056,0.00027370392,0.0018709672,0.0003404886,0.00094611425,0.00044547694,0.00053154206,0.0018154512],"category_scores_gemma":[0.012732858,0.00019217691,0.0005358048,0.0039347005,0.00034302927,0.0014183755,0.0005440439,0.0007351979,0.00021926427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010336006,0.000041560557,0.99413496,0.00004810853,0.00005322012,0.0000236872,0.00025066783,0.000030109739,0.00006134684,0.000061874925,0.00026697092,0.0049241083],"study_design_scores_gemma":[0.0000040346654,0.000056874058,0.9978855,0.000052088737,0.000021592497,0.000090613605,0.0011760407,0.000096207885,0.00003355496,0.000026394819,0.00055304205,0.000003995959],"about_ca_topic_score_codex":0.035226293,"about_ca_topic_score_gemma":0.048927,"teacher_disagreement_score":0.035226293,"about_ca_system_score_codex":0.0010057732,"about_ca_system_score_gemma":0.001562597,"threshold_uncertainty_score":0.07004249},"labels":[],"label_agreement":null},{"id":"W2655216406","doi":"10.1016/j.lungcan.2017.06.014","title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Lung cancer; T790M; Internal medicine; Missense mutation; Oncology; Epidermal growth factor receptor; Sanger sequencing; Mutation; Cancer; Gefitinib; Gene; Biology","score_opus":0.004125159358973921,"score_gpt":0.2923107701616074,"score_spread":0.2881856108026335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2655216406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976943,0.0010108154,0.000075721335,0.00016974409,0.00005080695,0.0000042478755,0.00019051942,0.0000070376286,0.0007967248],"genre_scores_gemma":[0.9993648,0.00015164612,0.00003180871,0.000026817515,0.000050368133,0.000002090191,0.00018827326,0.0000016797064,0.00018251901],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996754,0.000079394114,0.000034009543,0.00006698929,0.00004798351,0.000096254334],"domain_scores_gemma":[0.99870527,0.00039457498,0.00035479877,0.00007393699,0.00010068798,0.00037075975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048044536,0.00045730872,0.00044226527,0.00058572163,0.0004509277,0.0007126786,0.00049742515,0.00085498486,0.002253144],"category_scores_gemma":[0.0027012548,0.00020392821,0.0007370857,0.00076649396,0.00041398648,0.0006623808,0.0004445467,0.0009063541,0.0003613075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007246284,0.00004654357,0.9954934,0.000008979986,0.000079554215,0.00024320405,0.000020989097,0.00010495179,0.00048140125,0.000021429947,0.00012708726,0.0026477878],"study_design_scores_gemma":[0.000019488249,0.00023099639,0.9974241,0.0000070141305,0.00018476785,0.00074422295,0.00013773404,0.0006790912,0.00020454123,0.00009373452,0.00026528153,0.000009104832],"about_ca_topic_score_codex":0.0018070774,"about_ca_topic_score_gemma":0.0035658418,"teacher_disagreement_score":0.002253144,"about_ca_system_score_codex":0.00032172966,"about_ca_system_score_gemma":0.0003433111,"threshold_uncertainty_score":0.007537544},"labels":[],"label_agreement":null},{"id":"W2735375447","doi":"10.1016/j.lungcan.2017.07.012","title":"Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Niilo Helanderin Säätiö; Institute of Cancer Research","keywords":"Nivolumab; Medicine; Lung cancer; Adenocarcinoma; Oncology; Cancer research; Mutant; Cell; Internal medicine; Cancer; Immunotherapy; Gene; Biology","score_opus":0.017948375462460104,"score_gpt":0.3245573099012019,"score_spread":0.3066089344387418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735375447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98943067,0.0013476256,0.00039070495,0.0022967847,0.00015277261,0.000046036006,0.00023951904,0.000046831665,0.0060491245],"genre_scores_gemma":[0.9983627,0.0002241751,0.00012943053,0.0005670234,0.00006238507,0.000003696974,0.000100830795,0.000008221486,0.0005415333],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99980026,0.000021580827,0.00003196135,0.000052209594,0.000032388252,0.00006160418],"domain_scores_gemma":[0.9994561,0.00017721481,0.000059292768,0.00003086041,0.000065778615,0.00021075571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016975905,0.00042539486,0.00060085894,0.00053599174,0.00079228316,0.0005923415,0.00054429733,0.0017285732,0.001199172],"category_scores_gemma":[0.0011486126,0.00020565768,0.0007805311,0.00033316726,0.00041683865,0.00035419568,0.00024679623,0.001299446,0.00041208588],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012471988,0.00021007289,0.1128041,0.000079325415,0.00007402591,0.8628219,0.00029181255,0.00034317453,0.01144327,0.00022227787,0.0010096454,0.009453253],"study_design_scores_gemma":[0.000089996145,0.0018411796,0.16102491,0.000039864695,0.00020083354,0.82566065,0.0005646451,0.0020339605,0.004979356,0.00031576332,0.0032089574,0.000040001185],"about_ca_topic_score_codex":0.0038697808,"about_ca_topic_score_gemma":0.0049008294,"teacher_disagreement_score":0.0038697808,"about_ca_system_score_codex":0.00080010574,"about_ca_system_score_gemma":0.00042727895,"threshold_uncertainty_score":0.007694483},"labels":[],"label_agreement":null},{"id":"W2738954122","doi":"10.1016/j.lungcan.2017.07.017","title":"Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; Alberta Health Services; University of Alberta; University of Saskatchewan; Foothills Medical Centre; BC Cancer Agency; Brock University; University of Calgary","funders":"Alberta Cancer Foundation; Arnie Charbonneau Cancer Institute, University of Calgary","keywords":"Medicine; Lung cancer; Term (time); Tobacco use; Environmental health; Cancer; Oncology; Internal medicine","score_opus":0.04444944837980226,"score_gpt":0.36314412029608634,"score_spread":0.3186946719162841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738954122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99925417,0.00015993576,0.000012498259,0.00009280697,0.000008426812,0.000004524688,0.00007578203,0.0000013420437,0.00039049462],"genre_scores_gemma":[0.99927455,0.00007287285,0.000014908531,0.000056761604,0.00001256827,0.0000038629996,0.00014372476,0.0000011831904,0.00041940584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968517,0.000075679694,0.00003181229,0.000035851874,0.000051033207,0.00012054316],"domain_scores_gemma":[0.9977679,0.00041052824,0.00071446586,0.00008421211,0.00012428651,0.0008985937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006443009,0.0002393772,0.0004290569,0.00067064096,0.00073851616,0.0011613629,0.00040902512,0.0012715396,0.0025043087],"category_scores_gemma":[0.0027815148,0.0003805324,0.0008745802,0.0005504429,0.00037601957,0.0008754185,0.0006628875,0.0015214983,0.00041814684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016164877,0.000281485,0.99859613,0.0000032947742,0.000028672312,0.00003627487,0.000081435115,0.00001232098,0.000079672056,0.000011153095,0.00003687919,0.0006709785],"study_design_scores_gemma":[0.0000057807156,0.00011077877,0.9993905,0.000004154971,0.00001920834,0.000041184732,0.00024632018,0.00008883812,0.000014465281,0.00001749373,0.00005841758,0.000002877913],"about_ca_topic_score_codex":0.009335834,"about_ca_topic_score_gemma":0.01335978,"teacher_disagreement_score":0.009335834,"about_ca_system_score_codex":0.00039197953,"about_ca_system_score_gemma":0.00046484207,"threshold_uncertainty_score":0.018563032},"labels":[],"label_agreement":null},{"id":"W2740458257","doi":"10.1016/j.lungcan.2017.07.033","title":"Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative care; Radiation therapy; Lung cancer; Physical therapy; Performance status; Cancer; Internal medicine","score_opus":0.029245556888266605,"score_gpt":0.38288724949363295,"score_spread":0.3536416926053664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740458257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993462,0.0001031224,0.000029117815,0.00002791759,0.0000045368056,0.000009010476,0.00022777103,0.0000013615585,0.00025105043],"genre_scores_gemma":[0.99951196,0.0000440006,0.000031343865,0.000033281474,0.000007715055,0.00000801335,0.00028721508,0.0000011953305,0.00007512731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914956,0.00032535673,0.00009818388,0.00013370326,0.00011644269,0.00017675543],"domain_scores_gemma":[0.9975032,0.0004846552,0.0010456828,0.0000988352,0.00019942726,0.0006681184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007065833,0.0002950955,0.0005222131,0.00086406217,0.000740693,0.001222483,0.00046469894,0.0006656614,0.0019268446],"category_scores_gemma":[0.002715626,0.00033219325,0.000823959,0.0015802108,0.00048920943,0.00075236027,0.00077263836,0.00094769,0.00023397204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001829957,0.00008677432,0.99914193,0.0000055323035,0.0000579333,0.00005968259,0.00005468703,0.000020032558,0.00006543077,0.0000070713904,0.00004215244,0.000275794],"study_design_scores_gemma":[0.000016499065,0.00028915546,0.99898034,0.0000033463732,0.000034566197,0.0001197437,0.0003623415,0.00010767077,0.00001634789,0.000008796438,0.00005626959,0.0000048116412],"about_ca_topic_score_codex":0.0077168103,"about_ca_topic_score_gemma":0.010229075,"teacher_disagreement_score":0.0077168103,"about_ca_system_score_codex":0.0005836984,"about_ca_system_score_gemma":0.00055243337,"threshold_uncertainty_score":0.015343785},"labels":[],"label_agreement":null},{"id":"W2744441485","doi":"10.1016/j.lungcan.2017.07.038","title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; Docetaxel; Refractory (planetary science); Population; Placebo; Lung cancer; Clinical endpoint; Surgery; Randomized controlled trial; Oncology; Cancer; Pathology","score_opus":0.02050992220569165,"score_gpt":0.37174037695729134,"score_spread":0.3512304547515997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744441485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945791,0.0029698545,0.00015666438,0.0002963103,0.00015226238,0.00048475395,0.00039270162,0.00003730674,0.00093109196],"genre_scores_gemma":[0.99528223,0.0012494008,0.00041734698,0.00048140332,0.00021528949,0.00051984563,0.0006837897,0.000015662905,0.0011350013],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99922323,0.0003935671,0.000035521865,0.00012790352,0.000057314755,0.00016252979],"domain_scores_gemma":[0.99911326,0.00020621826,0.00024251593,0.000070707596,0.000035589634,0.00033175194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001697122,0.0014500177,0.0027746574,0.00036409823,0.0004804293,0.0012500498,0.00087276543,0.0011758768,0.0026418956],"category_scores_gemma":[0.0012044482,0.0006255315,0.0029538542,0.00032450544,0.0011143946,0.0010034647,0.0004166051,0.0037831208,0.00052554376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.948132,0.009455872,0.004018898,0.00039104006,0.0018262686,0.00007493733,0.00010162128,0.00069522305,0.0032981297,0.00011021243,0.0010799979,0.03081579],"study_design_scores_gemma":[0.8154802,0.16608052,0.014186624,0.000038828664,0.001622707,0.00010872274,0.000063792155,0.00060714973,0.00063724513,0.00017143419,0.00096815254,0.000034648543],"about_ca_topic_score_codex":0.0015275097,"about_ca_topic_score_gemma":0.0045498656,"teacher_disagreement_score":0.0027746574,"about_ca_system_score_codex":0.0013585453,"about_ca_system_score_gemma":0.0011336575,"threshold_uncertainty_score":0.009856939},"labels":[],"label_agreement":null},{"id":"W2747540574","doi":"10.1016/j.lungcan.2017.08.007","title":"Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Cancer Research Society","funders":"Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail","keywords":"Asbestos; Medicine; Lung cancer; Logistic regression; Occupational exposure; Tobacco smoke; Cancer; Environmental health; Pathology; Internal medicine; Oncology","score_opus":0.024921894114561433,"score_gpt":0.37046707656793265,"score_spread":0.34554518245337124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747540574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983808,0.00037244387,0.00021826611,0.00003495359,0.000011026951,0.000010766029,0.0007270896,0.000009110073,0.00023557895],"genre_scores_gemma":[0.9988165,0.00007455568,0.00012029012,0.000021084963,0.00002272116,0.000015349953,0.0008032694,0.00001145469,0.00011481327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966709,0.0015266624,0.00032263686,0.0008545631,0.00034776877,0.00027746722],"domain_scores_gemma":[0.9932682,0.0022776257,0.0015121571,0.0017845249,0.00046897118,0.00068839244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002275639,0.0010631466,0.0013148949,0.0017818079,0.001121951,0.0016701061,0.0016060637,0.0013947788,0.002354796],"category_scores_gemma":[0.007234715,0.001122824,0.0018983544,0.0019150914,0.00087990006,0.0009341977,0.001243625,0.0012184457,0.00034156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018116821,0.00014695492,0.9929066,0.00003314604,0.0014173081,0.00073267537,0.00016562908,0.00010342962,0.0012881125,0.000065639935,0.0003531918,0.0009756627],"study_design_scores_gemma":[0.00011667549,0.00033645122,0.9961443,0.000009638836,0.00072553696,0.001346868,0.0002612897,0.00043423977,0.00020781829,0.00007057182,0.00032640633,0.000020224543],"about_ca_topic_score_codex":0.008422557,"about_ca_topic_score_gemma":0.008967439,"teacher_disagreement_score":0.008422557,"about_ca_system_score_codex":0.000443906,"about_ca_system_score_gemma":0.0005447278,"threshold_uncertainty_score":0.016747057},"labels":[],"label_agreement":null},{"id":"W2748332094","doi":"10.1016/j.lungcan.2017.08.012","title":"Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Medicine; Guideline; Stage (stratigraphy); Retrospective cohort study; Cancer; Lung cancer; Internal medicine; Surgery","score_opus":0.09635859508647926,"score_gpt":0.3858657086977959,"score_spread":0.28950711361131665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748332094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950653,0.001192071,0.00017757979,0.0019050385,0.000036081925,0.000008238997,0.0005364291,0.0000073358237,0.001071946],"genre_scores_gemma":[0.9991703,0.00014935386,0.00004617955,0.00008317426,0.000030964624,0.0000026185182,0.00034723995,0.0000020964596,0.00016801724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575126,0.0022510833,0.0005503485,0.00034183354,0.00051782216,0.00058771396],"domain_scores_gemma":[0.9494731,0.020693637,0.022452975,0.0022396536,0.0020417918,0.003098874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006755931,0.00019155125,0.000521932,0.0009324303,0.00034292744,0.0013515237,0.00063437934,0.0015609463,0.0023696045],"category_scores_gemma":[0.04424355,0.00025684453,0.0012592665,0.0017537161,0.00046017845,0.0010681623,0.0009146581,0.001855868,0.00022702907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033644878,0.00017881821,0.9936905,0.0000166426,0.0002498535,0.000056537938,0.000060874416,0.00069266773,0.00001923377,0.00009515956,0.0002446256,0.0043585678],"study_design_scores_gemma":[0.000016653503,0.00017689186,0.9972951,0.000016149783,0.00010688754,0.000061948376,0.00016186088,0.0017162968,0.000030014126,0.00026304528,0.00014895319,0.000006238981],"about_ca_topic_score_codex":0.014045291,"about_ca_topic_score_gemma":0.012360042,"teacher_disagreement_score":0.014045291,"about_ca_system_score_codex":0.0009264974,"about_ca_system_score_gemma":0.0012377488,"threshold_uncertainty_score":0.03572923},"labels":[],"label_agreement":null},{"id":"W2752034854","doi":"10.1016/j.lungcan.2017.09.002","title":"Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Toronto General Hospital","funders":"","keywords":"Medicine; Lung cancer; Folate receptor; In vivo; Lymph node; Cancer; Cancer research; Photodynamic therapy; Pathology; Lung; Cancer cell; Internal medicine; Biology; Chemistry","score_opus":0.017785663424110452,"score_gpt":0.37541122422792067,"score_spread":0.3576255608038102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752034854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95369416,0.031410005,0.0054383553,0.0006106794,0.00012533487,0.00014987952,0.00009752763,0.00010652809,0.008367677],"genre_scores_gemma":[0.9868889,0.0057039144,0.0019729165,0.0001463204,0.00001831266,0.000029754387,0.0000813901,0.000012047246,0.005146275],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989045,0.000026289425,0.000004386977,0.000027282089,0.000020962516,0.000030568128],"domain_scores_gemma":[0.99995506,0.000015784359,0.000010105034,0.000004820913,0.000008800815,0.0000053382137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038769175,0.0002825767,0.00023467577,0.0002465453,0.00023517504,0.00027068038,0.00026921643,0.0005093213,0.0013883746],"category_scores_gemma":[0.00024129145,0.00014146637,0.00029380558,0.00012868276,0.00020297109,0.00045231436,0.00017314416,0.00031794922,0.00022715899],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008350089,0.00037905553,0.0002330868,0.00029291114,0.000043288157,0.00013450091,0.00012756132,0.0007571544,0.9738148,0.00071924867,0.00062276097,0.022040704],"study_design_scores_gemma":[0.00009990505,0.0028454142,0.0016738952,0.000023592134,0.00013313949,0.00042372014,0.000069464775,0.0018957411,0.98162687,0.00013993704,0.011055324,0.000012916493],"about_ca_topic_score_codex":0.0030409317,"about_ca_topic_score_gemma":0.0033079975,"teacher_disagreement_score":0.0030409317,"about_ca_system_score_codex":0.0007899462,"about_ca_system_score_gemma":0.00035139002,"threshold_uncertainty_score":0.006046474},"labels":[],"label_agreement":null},{"id":"W2754952150","doi":"10.1016/j.lungcan.2017.08.022","title":"An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Adenocarcinoma; Population; Lung cancer; Metastasis; Stage (stratigraphy); Oncology; Bone metastasis; Cancer; Environmental health","score_opus":0.015829704587617663,"score_gpt":0.37095163349537746,"score_spread":0.3551219289077598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754952150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882386,0.0017601879,0.00035963845,0.0002584358,0.00006096814,0.000040543106,0.0071346513,0.0000087693825,0.002138093],"genre_scores_gemma":[0.99179924,0.00080650306,0.0003840319,0.00013766576,0.00003575468,0.000043319564,0.005809032,0.000011056317,0.00097344693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957234,0.00009916468,0.00006483914,0.0000997208,0.00006554711,0.00009846366],"domain_scores_gemma":[0.9991978,0.00011556028,0.00020912994,0.00006545977,0.00017981954,0.00023221185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006643457,0.00027874307,0.00036388708,0.0019609604,0.0006958313,0.00085892394,0.00039445076,0.0004315087,0.001878456],"category_scores_gemma":[0.0014109953,0.00024897128,0.000671267,0.0029757512,0.00015190363,0.00031014177,0.00083630905,0.0006691339,0.00036375094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100823054,0.000029413492,0.9964265,0.00002456277,0.00007736028,0.00013204255,0.000105313666,0.000028271494,0.00019239746,0.00009788502,0.00047591364,0.0023093862],"study_design_scores_gemma":[0.0000073765723,0.000052202806,0.9973411,0.000023770574,0.000058086232,0.00031636993,0.00038046445,0.00007257366,0.000072752315,0.000038725706,0.0016312655,0.000005228718],"about_ca_topic_score_codex":0.017285153,"about_ca_topic_score_gemma":0.011915633,"teacher_disagreement_score":0.017285153,"about_ca_system_score_codex":0.00046089073,"about_ca_system_score_gemma":0.00090465747,"threshold_uncertainty_score":0.03436911},"labels":[],"label_agreement":null},{"id":"W2765592067","doi":"10.1016/j.lungcan.2017.10.011","title":"GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine; Crizotinib; Adenocarcinoma; Internal medicine; Lung; Oncology; Lung cancer; Cancer","score_opus":0.030852924415628154,"score_gpt":0.42492225879756107,"score_spread":0.3940693343819329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765592067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761415,0.014399446,0.0003148701,0.0019890289,0.00013250716,0.00003725977,0.0003235563,0.000037476588,0.006624294],"genre_scores_gemma":[0.99604565,0.0018336816,0.00020148495,0.00029496205,0.000038359536,0.000009647123,0.0003422139,0.0000062011736,0.0012277148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997776,0.000048809346,0.000022957915,0.000024168372,0.000064148575,0.000062336185],"domain_scores_gemma":[0.9997645,0.0000547246,0.000048514623,0.000018529829,0.000053735886,0.00005993145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044434227,0.00019218096,0.00025195337,0.0003107663,0.00021188881,0.0005799214,0.00016559876,0.0005352433,0.0011646531],"category_scores_gemma":[0.0005195851,0.000088241555,0.00029743707,0.0003704394,0.00023903417,0.00031355247,0.000179678,0.0005539992,0.00023864886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017073018,0.0010700687,0.16254793,0.00060683646,0.0004639143,0.017549848,0.00034846755,0.0064156624,0.51824784,0.00450076,0.011185951,0.25998977],"study_design_scores_gemma":[0.0018430797,0.015111984,0.4830954,0.0002155025,0.0013131198,0.06441698,0.0012535948,0.012231398,0.27968016,0.003467438,0.13725893,0.00011238324],"about_ca_topic_score_codex":0.0013023708,"about_ca_topic_score_gemma":0.004203461,"teacher_disagreement_score":0.0013023708,"about_ca_system_score_codex":0.0009463784,"about_ca_system_score_gemma":0.00050007674,"threshold_uncertainty_score":0.006866455},"labels":[],"label_agreement":null},{"id":"W2789558317","doi":"10.1016/j.lungcan.2018.03.005","title":"Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; University of the Fraser Valley; Lakeridge Health; Juravinski Cancer Centre; Cancer Care Ontario; BC Cancer Agency; Hôpital Notre-Dame; Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Hazard ratio; Docetaxel; Chemotherapy; Oncology; Lung cancer; Progression-free survival; Taxane; KRAS; Randomized controlled trial; Cancer; Confidence interval; Gastroenterology; Breast cancer; Colorectal cancer","score_opus":0.02215609923453452,"score_gpt":0.35197683959996273,"score_spread":0.3298207403654282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789558317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702562,0.009544183,0.00052155607,0.0032046097,0.000958417,0.003159859,0.004116211,0.00022292181,0.008016022],"genre_scores_gemma":[0.97995317,0.0044362317,0.0010270019,0.002384299,0.00044384197,0.0016878841,0.004053316,0.000034609657,0.005979659],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99938726,0.00028980424,0.000024738216,0.00009901394,0.000056881105,0.0001423206],"domain_scores_gemma":[0.99940145,0.00011829493,0.000105883264,0.00004289313,0.000043288423,0.00028816002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012561932,0.0013572068,0.0024251172,0.00028709378,0.00065971236,0.0010056482,0.0009976099,0.0014635462,0.0085296035],"category_scores_gemma":[0.0016819936,0.00045350505,0.0020142128,0.0006154698,0.0010895374,0.0005448283,0.00038369704,0.0033935742,0.00082254387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9712387,0.0024015047,0.0014054633,0.0004997755,0.0013810641,0.000050455998,0.000035768153,0.00035843943,0.0011793033,0.00021040544,0.0043065185,0.016932627],"study_design_scores_gemma":[0.9703986,0.02154047,0.0045515243,0.000038532547,0.0010475777,0.000034035515,0.000026005453,0.0002800373,0.00016382198,0.00014053576,0.0017604781,0.00001836241],"about_ca_topic_score_codex":0.034574907,"about_ca_topic_score_gemma":0.103278145,"teacher_disagreement_score":0.034574907,"about_ca_system_score_codex":0.0029337744,"about_ca_system_score_gemma":0.0048896195,"threshold_uncertainty_score":0.06874728},"labels":[],"label_agreement":null},{"id":"W2789688210","doi":"10.1016/j.lungcan.2018.03.009","title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"CDKN2A; Mesothelioma; BAP1; Medicine; Pleural effusion; Pathology; Exome sequencing; Mutation; Somatic cell; Cancer research; Malignant pleural effusion; Pleural disease; Cancer; Gene; Biology; Lung; Respiratory disease; Internal medicine; Genetics","score_opus":0.01181235053123601,"score_gpt":0.280764804200338,"score_spread":0.268952453669102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789688210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598324,0.00093087036,0.00045716623,0.00013352814,0.000030502737,0.000012022885,0.0007488057,0.000054124896,0.0016497953],"genre_scores_gemma":[0.99850595,0.00020721075,0.0003327045,0.000040919545,0.000017702125,0.000006481195,0.00042662493,0.00001300988,0.00044945595],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99973327,0.000023139155,0.000042100906,0.000058322366,0.000084147345,0.000059081758],"domain_scores_gemma":[0.99970144,0.0000915894,0.000068346075,0.000031906635,0.00005644774,0.000050303093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000143693,0.00047526186,0.00025187194,0.0012899725,0.00048932555,0.0008987834,0.00035743188,0.0008225921,0.0031572492],"category_scores_gemma":[0.0011340983,0.00021390205,0.00032821763,0.0006070302,0.00034133295,0.00028257372,0.00044722293,0.00027983508,0.0008175284],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010997858,0.00009916283,0.4007384,0.00015228702,0.0001509455,0.02771518,0.00096634374,0.00035068847,0.5396643,0.0003322602,0.0015581205,0.027172549],"study_design_scores_gemma":[0.00006177265,0.0002845045,0.7729422,0.000054909728,0.0003264468,0.09085713,0.0011550726,0.001755037,0.123202294,0.0007352374,0.008594132,0.000031191434],"about_ca_topic_score_codex":0.00078513345,"about_ca_topic_score_gemma":0.00075539586,"teacher_disagreement_score":0.0031572492,"about_ca_system_score_codex":0.00018866158,"about_ca_system_score_gemma":0.000114093884,"threshold_uncertainty_score":0.010562062},"labels":[],"label_agreement":null},{"id":"W2789788927","doi":"10.1016/j.lungcan.2018.03.010","title":"Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Athabasca University","funders":"National Medical Research Council; Alberta Innovates - Health Solutions; National Health and Medical Research Council; Canada Research Chairs; Athabasca University","keywords":"Medicine; Percentile; Lung cancer; Quality of life (healthcare); Physical therapy; Quantile regression; Internal medicine","score_opus":0.02950641604610083,"score_gpt":0.3615634614051252,"score_spread":0.33205704535902436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789788927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97123116,0.00057956565,0.02512429,0.00032688532,0.000041515093,0.00007896858,0.0018667821,0.00011578838,0.0006350549],"genre_scores_gemma":[0.9955029,0.00009121543,0.002355109,0.000041237752,0.000019954039,0.000075362084,0.001014529,0.000032042328,0.00086776726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970091,0.0017963293,0.00011904241,0.0005653899,0.00019213963,0.0003179348],"domain_scores_gemma":[0.9930449,0.0045781243,0.0006017396,0.0011686157,0.00040836429,0.00019814023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074071847,0.00046622482,0.00095312257,0.00073124893,0.00042080344,0.000878635,0.0019127777,0.000769076,0.0039782003],"category_scores_gemma":[0.014926985,0.0004804133,0.0023380339,0.0011166135,0.0005785371,0.00071136525,0.0013150622,0.0020825625,0.00049735524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076476426,0.00030422356,0.96516186,0.00006610693,0.0019598317,0.00011200365,0.00040887613,0.011162296,0.0005552819,0.0015527086,0.0008487075,0.01710325],"study_design_scores_gemma":[0.000056953555,0.00040978804,0.9006968,0.000033099972,0.0006795373,0.00015714706,0.0005098353,0.09415647,0.00027155533,0.0018687267,0.00112601,0.000034140976],"about_ca_topic_score_codex":0.025343606,"about_ca_topic_score_gemma":0.009328026,"teacher_disagreement_score":0.025343606,"about_ca_system_score_codex":0.000502614,"about_ca_system_score_gemma":0.00063789455,"threshold_uncertainty_score":0.05039215},"labels":[],"label_agreement":null},{"id":"W2793051369","doi":"10.1016/j.lungcan.2018.02.011","title":"Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Lung cancer; Adverse effect; Oncology; Internal medicine; Overall survival; Intensive care medicine; Lung","score_opus":0.007534355708445017,"score_gpt":0.3166972310667556,"score_spread":0.3091628753583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793051369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99061453,0.004653624,0.00014039845,0.00075389637,0.00006649325,0.000013962755,0.0006807266,0.0000050699937,0.0030712541],"genre_scores_gemma":[0.9979158,0.0009411802,0.00008534843,0.00023880924,0.000078616686,0.0000052126074,0.0004362124,0.0000016857845,0.00029721425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996871,0.00009967063,0.000044486533,0.000025723099,0.000062055864,0.00008103466],"domain_scores_gemma":[0.9984829,0.0002981709,0.000728767,0.00003204728,0.00015071794,0.00030739245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038023273,0.00017213507,0.00037962515,0.00021558776,0.00026749022,0.0006688945,0.00013780736,0.0002977412,0.0017064966],"category_scores_gemma":[0.0024938153,0.00007384681,0.001005572,0.00039754418,0.00011362159,0.00036111395,0.00037644638,0.00060054153,0.00012641212],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010681195,0.000089847934,0.97680295,0.00008715797,0.0005709969,0.0003442662,0.000039315008,0.00041939347,0.00024343928,0.00009171689,0.0010670129,0.019175729],"study_design_scores_gemma":[0.000026833237,0.0002892208,0.99715084,0.000035070876,0.0002661032,0.0005623619,0.0001190473,0.00046404192,0.000058948477,0.00023533138,0.0007854964,0.00000678224],"about_ca_topic_score_codex":0.0017894744,"about_ca_topic_score_gemma":0.005516194,"teacher_disagreement_score":0.0017894744,"about_ca_system_score_codex":0.00051312335,"about_ca_system_score_gemma":0.00042306306,"threshold_uncertainty_score":0.0057088733},"labels":[],"label_agreement":null},{"id":"W2794945244","doi":"10.1016/j.lungcan.2018.03.025","title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Oncology; Docetaxel; Internal medicine; Bevacizumab; Ramucirumab; Lung cancer; Nintedanib; Refractory (planetary science); Chemotherapy; Lung; Idiopathic pulmonary fibrosis","score_opus":0.018027658250240105,"score_gpt":0.3736487933526319,"score_spread":0.3556211351023918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794945244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016522394,0.99909484,0.000046390574,0.00015976527,0.000072867246,0.0000036614258,0.000015517335,0.000002704776,0.00043899292],"genre_scores_gemma":[0.0020486698,0.99704057,0.00012886639,0.0002769591,0.000105635656,0.0000063214966,0.000039429517,0.0000010913793,0.0003525466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989986,0.00002263469,0.00001730078,0.000017649445,0.000031272622,0.00001126897],"domain_scores_gemma":[0.9998097,0.00011385235,0.000038468417,0.0000032533048,0.000023902083,0.000010754388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000290372,0.00036950473,0.001016954,0.00080737047,0.00014267082,0.00056778954,0.00050492375,0.0005214061,0.00276985],"category_scores_gemma":[0.0005839042,0.00013652405,0.000569448,0.00059330737,0.00015653424,0.0005223216,0.0002902267,0.0012557721,0.00051269267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011227549,0.00006380551,0.00024766385,0.019688593,0.0002526377,0.0001407101,0.000029368359,0.0002893595,0.00094931235,0.0012362087,0.019233309,0.9577568],"study_design_scores_gemma":[0.000217592,0.00033258428,0.0029428361,0.017539723,0.0012032024,0.0033085004,0.000075828124,0.00031784692,0.00088819314,0.002088871,0.97104496,0.000039858664],"about_ca_topic_score_codex":0.0006833242,"about_ca_topic_score_gemma":0.0025303361,"teacher_disagreement_score":0.00276985,"about_ca_system_score_codex":0.00028565,"about_ca_system_score_gemma":0.0005047635,"threshold_uncertainty_score":0.0092660785},"labels":[],"label_agreement":null},{"id":"W2800404669","doi":"10.1016/j.lungcan.2018.04.018","title":"The eighth TNM classification for lung cancer—What is next?","year":2018,"lang":"en","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.020716744633585277,"score_gpt":0.37177032357607254,"score_spread":0.35105357894248723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800404669","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010432936,0.007699771,0.00007355802,0.024766505,0.96702117,0.000006293554,0.000026793012,0.000023096887,0.00037229483],"genre_scores_gemma":[0.00015266324,0.0076430263,0.00009803929,0.017868808,0.97194844,0.000014585766,0.000034062603,0.000018879507,0.0022215436],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99125576,0.0019299305,0.0018070502,0.00081275,0.003623185,0.0005713614],"domain_scores_gemma":[0.95473814,0.016582917,0.0033705088,0.0009948644,0.019348849,0.004964761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012428577,0.0037973498,0.006306641,0.0054994854,0.0027942704,0.009380818,0.0048452783,0.019095069,0.009651758],"category_scores_gemma":[0.04143633,0.0017534816,0.0045494945,0.0021598244,0.003270462,0.007145109,0.002514453,0.03344106,0.011691847],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032784967,0.000011903737,0.00004652299,0.0002796221,0.000024525436,0.00006455925,0.000007998363,0.00002508117,0.00003102432,0.00023823167,0.9909604,0.008277264],"study_design_scores_gemma":[0.00012225717,0.00005039724,0.00048549895,0.0015296416,0.00016091751,0.00037738107,0.00006846643,0.0002343447,0.000094767114,0.00136935,0.9954619,0.000045124772],"about_ca_topic_score_codex":0.003489551,"about_ca_topic_score_gemma":0.00692642,"teacher_disagreement_score":0.019095069,"about_ca_system_score_codex":0.004497265,"about_ca_system_score_gemma":0.0058073453,"threshold_uncertainty_score":0.06572938},"labels":[],"label_agreement":null},{"id":"W2801122736","doi":"10.1016/j.lungcan.2018.04.010","title":"Building the case for comprehensive hospital-based tobacco addiction services: Applying the Ottawa Model to the City of Manchester","year":2018,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Abstinence; Smoking cessation; Scopus; Intervention (counseling); Intensive care; Family medicine; Addiction; MEDLINE; Psychiatry","score_opus":0.03987965582644165,"score_gpt":0.33592257070484494,"score_spread":0.2960429148784033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801122736","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17061587,0.0021779053,0.0025781973,0.7617836,0.0014476038,0.00029691515,0.000091421854,0.00004532993,0.06096323],"genre_scores_gemma":[0.8726172,0.003049591,0.0075826356,0.08799246,0.00053223636,0.00032739027,0.000040707208,0.0000700757,0.027787752],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929703,0.0030419983,0.00027306168,0.0004141031,0.0005524284,0.002748075],"domain_scores_gemma":[0.98847175,0.0034586254,0.0006219607,0.00033024582,0.0011801929,0.005937213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042865835,0.0006389862,0.00048945035,0.0008990973,0.023517631,0.010432988,0.0036310307,0.0154368235,0.013541039],"category_scores_gemma":[0.012149299,0.0011719296,0.0012063915,0.0009432458,0.008304913,0.0063140774,0.011616667,0.017860988,0.0007619689],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029861464,0.00076853606,0.07299216,0.00096330035,0.00019648316,0.18346623,0.2126357,0.005128509,0.002097205,0.30024683,0.18177795,0.039428513],"study_design_scores_gemma":[0.0001650396,0.0005083646,0.03181697,0.002876461,0.00027990696,0.028245622,0.49248788,0.0069772694,0.00085549644,0.058593795,0.37660995,0.0005832449],"about_ca_topic_score_codex":0.51027805,"about_ca_topic_score_gemma":0.8163096,"teacher_disagreement_score":0.51027805,"about_ca_system_score_codex":0.044680443,"about_ca_system_score_gemma":0.057497554,"threshold_uncertainty_score":0.985212},"labels":[],"label_agreement":null},{"id":"W2808151162","doi":"10.1016/j.lungcan.2018.06.011","title":"The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Radiology; Lung cancer; Biopsy; Malignancy; Retrospective cohort study; Positron emission tomography; Lymph node; Nuclear medicine; Surgery; Oncology; Internal medicine","score_opus":0.010758052397543252,"score_gpt":0.302814488675023,"score_spread":0.29205643627747974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808151162","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46081385,0.49394578,0.008893177,0.010494022,0.0018322763,0.00017464545,0.00018051507,0.00020741856,0.023458319],"genre_scores_gemma":[0.9358358,0.051695917,0.0074371314,0.0023359316,0.0011176456,0.000035192974,0.00011960869,0.00005379425,0.0013690788],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906045,0.00045075838,0.000088658155,0.00008506273,0.00024761714,0.000067485395],"domain_scores_gemma":[0.9957623,0.0021234283,0.00049247773,0.0001902653,0.0011177885,0.00031375373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003147017,0.0003583073,0.00052433665,0.0005991648,0.0003224085,0.0015986192,0.0005662868,0.0008333709,0.0013256214],"category_scores_gemma":[0.007461011,0.0001715776,0.0004358588,0.00038882412,0.0007409503,0.001137228,0.00024978802,0.00078187964,0.00035740124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036103218,0.0003779645,0.17475979,0.0008561937,0.00030894575,0.0013147148,0.00031755396,0.0017799349,0.010359195,0.0011397522,0.004008774,0.80116683],"study_design_scores_gemma":[0.0011041274,0.009822045,0.78052634,0.0029922796,0.0027929614,0.020914156,0.0022544225,0.034907475,0.020564662,0.0036562663,0.120222665,0.00024252472],"about_ca_topic_score_codex":0.0066886456,"about_ca_topic_score_gemma":0.017255524,"teacher_disagreement_score":0.0066886456,"about_ca_system_score_codex":0.001022733,"about_ca_system_score_gemma":0.0020489867,"threshold_uncertainty_score":0.016643226},"labels":[],"label_agreement":null},{"id":"W2808971718","doi":"10.1016/j.lungcan.2018.06.023","title":"The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Internal medicine; Oncology; Univariate analysis; Adenocarcinoma; Stage (stratigraphy); Somatic cell; Mutation; Cancer; Multivariate analysis; Gene; Genetics; Biology; Colorectal cancer","score_opus":0.008431921663189132,"score_gpt":0.3190394140510542,"score_spread":0.31060749238786506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808971718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980877,0.0010226796,0.00012553684,0.000087199645,0.00001917112,0.0000021443634,0.00013727775,0.0000056365625,0.00051258295],"genre_scores_gemma":[0.99958557,0.000111747824,0.00003436589,0.000011558478,0.000015686464,7.303845e-7,0.00010751696,0.0000016954699,0.00013106175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996425,0.00010109918,0.00004861109,0.00006682311,0.000059306087,0.00008157807],"domain_scores_gemma":[0.9984016,0.00068097,0.00041952872,0.00010140659,0.000103502854,0.00029301303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006507399,0.00023393902,0.0002984756,0.00043537817,0.00023650216,0.00053797814,0.00027035386,0.00041745006,0.0015637],"category_scores_gemma":[0.0032869237,0.0001383154,0.00055560144,0.00035084592,0.00036179935,0.0005771817,0.0003797075,0.00039987944,0.00018239043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002572189,0.000049723832,0.9744076,0.00003349468,0.00023737349,0.00058631256,0.000053918535,0.0008128298,0.004589006,0.0000777789,0.00014450871,0.016435295],"study_design_scores_gemma":[0.000019083085,0.00030305213,0.99593675,0.000009857064,0.0002250587,0.0008766533,0.00012623264,0.0011042253,0.0008465743,0.00022167558,0.00032239,0.000008487755],"about_ca_topic_score_codex":0.0010468813,"about_ca_topic_score_gemma":0.0035868867,"teacher_disagreement_score":0.0015637,"about_ca_system_score_codex":0.00029492646,"about_ca_system_score_gemma":0.00020495101,"threshold_uncertainty_score":0.0052310824},"labels":[],"label_agreement":null},{"id":"W2810920486","doi":"10.1016/j.lungcan.2018.06.029","title":"Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cohort; Proportional hazards model; Oncology; Internal medicine; Hazard ratio; AJCC staging system; Lung cancer; Stage (stratigraphy); Cancer; Primary tumor; Metastasis; Staging system; Confidence interval","score_opus":0.012809949895531265,"score_gpt":0.3324448465430033,"score_spread":0.3196348966474721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810920486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978605,0.00020773824,0.000076426055,0.00005066917,0.00002784922,0.00000837415,0.0009877447,0.0000051409625,0.0007755733],"genre_scores_gemma":[0.9976546,0.000102734426,0.000035694495,0.000027602013,0.000016478332,0.000008686121,0.0017759529,0.0000054758657,0.000372752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993724,0.00011113347,0.00005190067,0.00019768237,0.00010075283,0.00016602624],"domain_scores_gemma":[0.9984133,0.0003456457,0.0004892649,0.000121876205,0.00032875556,0.00030111222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008522852,0.00033786587,0.0005748823,0.0010541802,0.0004746726,0.0010892318,0.00064003846,0.00059686386,0.0024256941],"category_scores_gemma":[0.0029257678,0.00033802888,0.0009282115,0.0011405466,0.0003107059,0.0009005042,0.0008674138,0.00081911834,0.00049538695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000784411,0.000039462957,0.9970282,0.00001057729,0.0001654912,0.00005588789,0.000109376444,0.00007092191,0.00037484177,0.00002830211,0.0002622696,0.0010703288],"study_design_scores_gemma":[0.000010938994,0.00009448885,0.9989974,0.0000037309494,0.000048642865,0.000055065364,0.0004066972,0.00016011928,0.000025470941,0.000018764571,0.0001748559,0.000003881338],"about_ca_topic_score_codex":0.016052177,"about_ca_topic_score_gemma":0.023704728,"teacher_disagreement_score":0.016052177,"about_ca_system_score_codex":0.00054352975,"about_ca_system_score_gemma":0.00052517717,"threshold_uncertainty_score":0.031917512},"labels":[],"label_agreement":null},{"id":"W2885572675","doi":"10.1016/j.lungcan.2018.08.005","title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; William Osler Health System; University of Calgary; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Systemic therapy; Multivariate analysis; Oncology; Internal medicine; Lung cancer; Radiation therapy; Radiosurgery; Univariate analysis; Cancer; Incidence (geometry)","score_opus":0.04174369330707757,"score_gpt":0.3573469884208799,"score_spread":0.31560329511380236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885572675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65548563,0.17295991,0.0063303406,0.11371062,0.0050168894,0.0002367065,0.00037158985,0.0003709193,0.045517378],"genre_scores_gemma":[0.9556471,0.027164692,0.0043223426,0.006655134,0.0025748708,0.000071376286,0.0002213568,0.00003327705,0.0033098354],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99977833,0.000048376092,0.000030209132,0.000039889404,0.000046290173,0.000057041314],"domain_scores_gemma":[0.99872607,0.00043106033,0.00036982176,0.00003467148,0.00013627525,0.00030207357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057896215,0.00021042651,0.0005877533,0.0003046778,0.00035960446,0.00080861273,0.00041005266,0.0011069503,0.0056352518],"category_scores_gemma":[0.00312623,0.00012508535,0.00043297227,0.00027553827,0.0003163304,0.0014566795,0.00029122148,0.0015110753,0.0005943785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050540823,0.0016147841,0.054907087,0.0009429922,0.00019129805,0.00156175,0.00023807652,0.0012827286,0.006763455,0.0024406046,0.023153655,0.90184957],"study_design_scores_gemma":[0.0039165807,0.025104178,0.633814,0.0042040283,0.0021675017,0.019656587,0.0031954467,0.0100370515,0.014758674,0.021048767,0.2617559,0.00034122262],"about_ca_topic_score_codex":0.0020252417,"about_ca_topic_score_gemma":0.011835418,"teacher_disagreement_score":0.0056352518,"about_ca_system_score_codex":0.000724582,"about_ca_system_score_gemma":0.0016123204,"threshold_uncertainty_score":0.018851817},"labels":[],"label_agreement":null},{"id":"W2885834865","doi":"10.1016/j.lungcan.2018.07.041","title":"Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; Japan Society for the Promotion of Science; World Health Organization","keywords":"Mesothelioma; Medicine; Pathology; BAP1; CDKN2A; Biopsy; Immunohistochemistry; Mesothelial Cell; Cancer; Internal medicine","score_opus":0.013346659137844462,"score_gpt":0.2951272475276357,"score_spread":0.28178058838979125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885834865","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016825143,0.03020717,0.003139888,0.5745411,0.36404404,0.0006449289,0.0012692108,0.00014761083,0.009180999],"genre_scores_gemma":[0.08983817,0.024585435,0.0096007185,0.15043469,0.68647385,0.0008871007,0.0032538027,0.00026834646,0.03465797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616075,0.0007383768,0.00059196807,0.0005781228,0.0012780578,0.00065271545],"domain_scores_gemma":[0.9857933,0.001734986,0.0012618758,0.00049158774,0.0056624673,0.005055802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0158969,0.0014653892,0.0015472803,0.0018918513,0.002412578,0.004595911,0.0023809762,0.010123414,0.0032517617],"category_scores_gemma":[0.009143186,0.0006141725,0.001867853,0.0009606878,0.0015167674,0.0022882768,0.0026895914,0.0083516305,0.0016572484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006512511,0.0002638683,0.008642461,0.0004903452,0.000093289775,0.001336048,0.0002925096,0.00023585674,0.0045909006,0.000775875,0.92318285,0.05944476],"study_design_scores_gemma":[0.00021527566,0.0004072964,0.035501424,0.0007605374,0.00026244696,0.0025603082,0.0011906177,0.0009139235,0.0035418079,0.0023108365,0.9522122,0.00012340391],"about_ca_topic_score_codex":0.0027280583,"about_ca_topic_score_gemma":0.009073121,"teacher_disagreement_score":0.0158969,"about_ca_system_score_codex":0.0025100198,"about_ca_system_score_gemma":0.0055376696,"threshold_uncertainty_score":0.084071875},"labels":[],"label_agreement":null},{"id":"W2888952267","doi":"10.1016/j.lungcan.2018.08.024","title":"Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Alberta Cancer Foundation; University of Calgary; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Innovative Research Group Project of the National Natural Science Foundation of China","keywords":"Osimertinib; Medicine; Lung cancer; Afatinib; Cost effectiveness; Oncology; Quality-adjusted life year; Confidence interval; Internal medicine; Adenocarcinoma; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.005681807896931517,"score_gpt":0.30050355462623246,"score_spread":0.29482174672930095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888952267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570673,0.0068044867,0.00034923395,0.009107059,0.00008602443,0.00024840486,0.012531383,0.000026418402,0.01377973],"genre_scores_gemma":[0.99104357,0.002545555,0.00021992544,0.000715826,0.000040098057,0.00002943796,0.0022993672,0.000011047155,0.0030953202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982445,0.00021558028,0.000075730946,0.0000901388,0.0006050828,0.00076896074],"domain_scores_gemma":[0.99690753,0.00047113633,0.00043730723,0.000033482265,0.0010070405,0.001143498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097650196,0.00030699171,0.0005773561,0.0013311577,0.0010503178,0.0020282017,0.0010786611,0.00059075403,0.0026093754],"category_scores_gemma":[0.0046400838,0.00027069717,0.0010350405,0.0027403398,0.0006647865,0.00034078362,0.00064026116,0.0009697764,0.00008898024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012071396,0.0010613132,0.7723145,0.0012143948,0.0015123581,0.0022652901,0.00063579425,0.0459024,0.002272734,0.019271642,0.04386271,0.09761552],"study_design_scores_gemma":[0.0009789385,0.0010836377,0.93484634,0.00027344594,0.0008976483,0.0006493303,0.0020973666,0.03374063,0.00070835964,0.0012787469,0.023352448,0.00009324492],"about_ca_topic_score_codex":0.9880966,"about_ca_topic_score_gemma":0.99277604,"teacher_disagreement_score":0.099989705,"about_ca_system_score_codex":0.099989705,"about_ca_system_score_gemma":0.0913937,"threshold_uncertainty_score":0.7254795},"labels":[],"label_agreement":null},{"id":"W2898895536","doi":"10.1016/j.lungcan.2018.10.020","title":"Ultrasonographic characteristics of lymph nodes as predictors of malignancy during endobronchial ultrasound (EBUS): A systematic review","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Impact","funders":"","keywords":"Medicine; Endobronchial ultrasound; Malignancy; Radiology; Lymph; Ultrasound; Bronchoscopy; Pathology","score_opus":0.013493070367048821,"score_gpt":0.32200076768064045,"score_spread":0.3085076973135916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898895536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016750526,0.99778795,0.000055696328,0.00006237134,0.000042153806,0.000057129913,0.0002176768,0.0000025745617,0.00009944448],"genre_scores_gemma":[0.026087802,0.972741,0.00039426767,0.0003370413,0.000063970576,0.00010877591,0.00018251697,0.0000025786558,0.00008203979],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99817634,0.00046492624,0.00069680804,0.00025283438,0.0003123249,0.00009670153],"domain_scores_gemma":[0.99155176,0.006423854,0.0013951849,0.00010469197,0.00042728885,0.00009732694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023365016,0.0010790727,0.004999667,0.003809717,0.00037966494,0.0016592906,0.0013008479,0.0018399154,0.0034201497],"category_scores_gemma":[0.015584955,0.00089451513,0.008493809,0.0050029275,0.00057182205,0.0014366474,0.0010095206,0.0011642749,0.00025505578],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000613979,0.000050085844,0.0077472194,0.90387934,0.038727764,0.00014764226,0.00018429886,0.00016277011,0.00023537791,0.00013440814,0.0015370423,0.046580046],"study_design_scores_gemma":[0.0007571385,0.00039618343,0.030374674,0.45701706,0.49499592,0.0007498363,0.00043054222,0.00019035846,0.0002659547,0.00032682455,0.01439175,0.000103740196],"about_ca_topic_score_codex":0.010436918,"about_ca_topic_score_gemma":0.032735396,"teacher_disagreement_score":0.010436918,"about_ca_system_score_codex":0.0011083881,"about_ca_system_score_gemma":0.0038910483,"threshold_uncertainty_score":0.02075237},"labels":[],"label_agreement":null},{"id":"W2899436946","doi":"10.1016/j.lungcan.2018.10.028","title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Tolerability; Adverse effect; Internal medicine; Incidence (geometry); Medical record; Observational study; Oncology; Surgery; Epidermal growth factor receptor; Cancer; Gefitinib","score_opus":0.008844275390835923,"score_gpt":0.37523411298275683,"score_spread":0.3663898375919209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899436946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978453,0.0010639698,0.00014827932,0.00010558016,0.000011101694,0.000055103825,0.00038627646,0.000011769857,0.00037271655],"genre_scores_gemma":[0.99871945,0.0002689174,0.0001726139,0.00014413784,0.000020388963,0.000040116312,0.000560865,0.000004418713,0.000069176094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99746644,0.0016905087,0.00018696465,0.00031575465,0.000212379,0.0001279656],"domain_scores_gemma":[0.99632025,0.0009757087,0.0018108044,0.00039516913,0.00018179367,0.0003162861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045640445,0.0004176276,0.0006569915,0.00018703063,0.00015034474,0.00090899447,0.00034846805,0.0005173847,0.0010277241],"category_scores_gemma":[0.0039180457,0.00017234265,0.0014904306,0.0004513343,0.00052580057,0.0006072642,0.00043174424,0.00085918873,0.00018415012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3328979,0.008360688,0.52992177,0.0012030014,0.010042939,0.00024975845,0.0004904493,0.004191438,0.0056320988,0.00021819385,0.0028424335,0.103949316],"study_design_scores_gemma":[0.07937917,0.12828106,0.78123224,0.00008438662,0.0032907415,0.00052635866,0.00022732299,0.0021144252,0.001462703,0.00018787327,0.0031322234,0.00008139006],"about_ca_topic_score_codex":0.0010063545,"about_ca_topic_score_gemma":0.0015417432,"teacher_disagreement_score":0.0045640445,"about_ca_system_score_codex":0.0008182747,"about_ca_system_score_gemma":0.00057983934,"threshold_uncertainty_score":0.024137259},"labels":[],"label_agreement":null},{"id":"W2900911329","doi":"10.1016/j.lungcan.2018.11.016","title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Osimertinib; Gefitinib; Lung cancer; Oncology; Adenocarcinoma; Internal medicine; Cancer research; Histology; Cancer; Epidermal growth factor receptor","score_opus":0.016816815831995433,"score_gpt":0.3249436643751616,"score_spread":0.30812684854316613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900911329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025845878,0.97222906,0.0001830104,0.00008298025,0.000082459206,0.000027254287,0.0010312921,0.000004249345,0.0005138034],"genre_scores_gemma":[0.21362223,0.78124624,0.00050985685,0.0005460157,0.0002713778,0.000072979696,0.0032742324,0.000011448991,0.00044558596],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99926513,0.00015120617,0.0002351539,0.00016884069,0.00011990127,0.00005976719],"domain_scores_gemma":[0.99907565,0.00046303452,0.0002592932,0.000052622276,0.000112628346,0.000036667385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00121298,0.00059129373,0.0029430029,0.0015071895,0.000143808,0.00071243854,0.00049100386,0.0005355309,0.0014568932],"category_scores_gemma":[0.002529708,0.0002549255,0.0053013745,0.002113859,0.00015767783,0.0005047967,0.00046175483,0.0005584174,0.00017846281],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010233523,0.0001502971,0.19253355,0.12252857,0.21302505,0.0017291941,0.00030481422,0.0011951146,0.0017072028,0.00053546124,0.010347068,0.44571018],"study_design_scores_gemma":[0.0011231496,0.0019128609,0.4323673,0.0271434,0.47677836,0.0071826237,0.00080500316,0.00044893884,0.00083224947,0.0009888147,0.05021303,0.00020441407],"about_ca_topic_score_codex":0.0018917054,"about_ca_topic_score_gemma":0.0044959867,"teacher_disagreement_score":0.0029430029,"about_ca_system_score_codex":0.0004059869,"about_ca_system_score_gemma":0.00068934966,"threshold_uncertainty_score":0.00641495},"labels":[],"label_agreement":null},{"id":"W2901525385","doi":"10.1016/j.lungcan.2018.11.024","title":"Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; ALK inhibitor; Internal medicine; Concomitant; Oncology; Cancer; Tyrosine-kinase inhibitor; Receptor","score_opus":0.008287191718323293,"score_gpt":0.3050793065326908,"score_spread":0.29679211481436746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901525385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761446,0.0152852675,0.0008475598,0.00062960136,0.00004569633,0.000027389036,0.00014603607,0.00004475094,0.0068290555],"genre_scores_gemma":[0.9967134,0.0019479342,0.00020639066,0.00006917858,0.000028866594,0.000008599988,0.000097205455,0.000004500143,0.0009239319],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997404,0.00004797062,0.000027273703,0.000041477597,0.000080996026,0.000061748295],"domain_scores_gemma":[0.999694,0.00006705977,0.00012128177,0.00003396036,0.00004621838,0.000037419577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003439216,0.00018296925,0.0003143031,0.00049904815,0.00023229602,0.001006308,0.0003049303,0.0004242314,0.0027800035],"category_scores_gemma":[0.0007005328,0.00014629675,0.00035122776,0.00036812364,0.00026091255,0.00066184753,0.00030325603,0.0004822782,0.0003536518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040291767,0.00069294946,0.16569589,0.0006500194,0.0004908792,0.00972658,0.00034716187,0.0021889596,0.5100101,0.012328111,0.0034517862,0.2903884],"study_design_scores_gemma":[0.0006867285,0.006880606,0.63326067,0.00018354572,0.0011853118,0.067478865,0.0010841315,0.008459163,0.20708154,0.0116782505,0.061933044,0.000088212626],"about_ca_topic_score_codex":0.00035180687,"about_ca_topic_score_gemma":0.00067557977,"teacher_disagreement_score":0.0027800035,"about_ca_system_score_codex":0.0006897338,"about_ca_system_score_gemma":0.00030188207,"threshold_uncertainty_score":0.0092999935},"labels":[],"label_agreement":null},{"id":"W2901988630","doi":"10.1016/j.lungcan.2018.11.032","title":"Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Mesothelioma; Medicine; Peritoneal mesothelioma; Grading (engineering); Interest group; Oncology; Pathology; BAP1; Internal medicine","score_opus":0.051219217279755695,"score_gpt":0.33936100552375503,"score_spread":0.28814178824399933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901988630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036336332,0.9993319,0.000040463303,0.00028526006,0.00017489177,0.00000319712,0.000017631584,0.0000017333953,0.00010852226],"genre_scores_gemma":[0.0002794099,0.99904794,0.0001023236,0.0002533263,0.00019351278,0.0000033761492,0.000028929268,5.219315e-7,0.00009073214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995864,0.000083946885,0.000094946285,0.00006860568,0.00013039398,0.000035707893],"domain_scores_gemma":[0.9985668,0.0007982939,0.00018773187,0.000024506799,0.00034911186,0.00007352246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016463413,0.00096311094,0.0020140593,0.0037975246,0.0002803117,0.0015621865,0.0010270699,0.0013694103,0.002363369],"category_scores_gemma":[0.0021218592,0.00038650548,0.001195249,0.0031100253,0.00048429225,0.0019480601,0.00122279,0.0020051713,0.0007360448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001958391,0.000097586315,0.0008558882,0.06243958,0.00046104667,0.0003593129,0.00012175197,0.00041861105,0.0018903633,0.0026899888,0.059273366,0.8711967],"study_design_scores_gemma":[0.000057981233,0.00015148442,0.0026861809,0.022898529,0.0010409198,0.0013899626,0.00016307938,0.00018102305,0.0006109496,0.0020076341,0.968762,0.00005028785],"about_ca_topic_score_codex":0.0014605278,"about_ca_topic_score_gemma":0.0033422892,"teacher_disagreement_score":0.0037975246,"about_ca_system_score_codex":0.00083680847,"about_ca_system_score_gemma":0.0021038915,"threshold_uncertainty_score":0.008706808},"labels":[],"label_agreement":null},{"id":"W2903232319","doi":"10.1016/j.lungcan.2018.11.034","title":"Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mesothelioma; Medicine; Interest group; Therapeutic modalities; Cancer research; Basic research; Basic science; Internal medicine; Pathology; Biology; Library science; Political science; Neuroscience; Computer science","score_opus":0.150914233341361,"score_gpt":0.46003951698894857,"score_spread":0.30912528364758757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903232319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047779497,0.9991303,0.000037219546,0.0003139338,0.00028400176,0.000004305255,0.000029385606,0.0000025461395,0.00015057364],"genre_scores_gemma":[0.00035346893,0.9987857,0.00010536186,0.00032957294,0.0002672827,0.0000043201694,0.000045155306,9.778208e-7,0.00010831792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992841,0.00012318403,0.00017442436,0.00010144958,0.0002567207,0.00006016504],"domain_scores_gemma":[0.9977271,0.0011662935,0.0003126718,0.0000417973,0.000597382,0.00015468874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024267281,0.0010348058,0.0022918666,0.0048411256,0.00036804416,0.0019089372,0.00094453845,0.0016343015,0.0037808209],"category_scores_gemma":[0.00286521,0.00041693047,0.0011856237,0.0044350997,0.0005499484,0.0024077422,0.0016567586,0.0019479255,0.0010663555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019673682,0.000090813846,0.00062463584,0.09868879,0.0002716281,0.00021962612,0.00015578399,0.00024835285,0.002174674,0.0020747324,0.06432373,0.8309305],"study_design_scores_gemma":[0.000041207404,0.00014102591,0.0020819998,0.02347883,0.0006904562,0.0008273287,0.0001581082,0.00009320088,0.0006236027,0.0010498838,0.97077143,0.000042936703],"about_ca_topic_score_codex":0.001562101,"about_ca_topic_score_gemma":0.003876582,"teacher_disagreement_score":0.0048411256,"about_ca_system_score_codex":0.00091576297,"about_ca_system_score_gemma":0.0030667114,"threshold_uncertainty_score":0.012833893},"labels":[],"label_agreement":null},{"id":"W2916205918","doi":"10.1016/j.lungcan.2019.02.024","title":"Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; University of Northern British Columbia; University of British Columbia","funders":"","keywords":"Medicine; Palliative care; Lung cancer; Quality of life (healthcare); Radiation therapy; Population; Performance status; Univariate analysis; Internal medicine; Cancer; Oncology; Surgery; Multivariate analysis; Nursing","score_opus":0.011899394943807547,"score_gpt":0.35208368562929454,"score_spread":0.340184290685487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916205918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996463,0.0014392585,0.00029315782,0.000085818494,0.000012669062,0.000019179419,0.0011942744,0.0000060274674,0.00048653813],"genre_scores_gemma":[0.9983236,0.0004946315,0.00009234708,0.00006538317,0.00001768435,0.000019941539,0.00084276893,0.0000058432593,0.00013781029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984372,0.000437235,0.0001856102,0.0005033753,0.00020827737,0.00022830117],"domain_scores_gemma":[0.99830675,0.000388156,0.0007157927,0.00019417587,0.00019719623,0.0001978631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010415566,0.00052438764,0.0008948654,0.0011609436,0.0005555771,0.0011872216,0.00073250616,0.0012486754,0.0022064606],"category_scores_gemma":[0.002795477,0.0007676482,0.0038076146,0.002749346,0.00040954386,0.0011253688,0.0011592348,0.0014066376,0.00032319175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056617794,0.00009672892,0.99500954,0.00007361942,0.0018320458,0.00013809858,0.00013620153,0.00017833266,0.00016092509,0.00004625948,0.00024272816,0.0015194786],"study_design_scores_gemma":[0.00004130475,0.0002161314,0.9973475,0.00002436153,0.0008261722,0.00029996457,0.00053264573,0.00035674626,0.000019555875,0.000053581793,0.00026698314,0.000015021777],"about_ca_topic_score_codex":0.010987171,"about_ca_topic_score_gemma":0.0140347695,"teacher_disagreement_score":0.010987171,"about_ca_system_score_codex":0.0006059778,"about_ca_system_score_gemma":0.0005316485,"threshold_uncertainty_score":0.021846414},"labels":[],"label_agreement":null},{"id":"W2916233810","doi":"10.1016/j.lungcan.2019.02.015","title":"A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Immunohistochemistry; Concordance; Lung cancer; Crizotinib; Fluorescence in situ hybridization; Internal medicine; Adenocarcinoma; Carcinoma; Oncology; Fish <Actinopterygii>; Pathology; Cancer; Biology; Gene","score_opus":0.04933984428612437,"score_gpt":0.4332631489433579,"score_spread":0.3839233046572335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916233810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824144,0.013328833,0.0006955994,0.0002824348,0.00006967696,0.00020741021,0.00018550757,0.0000071108184,0.0028088975],"genre_scores_gemma":[0.9960614,0.0022373258,0.0003857992,0.00022375734,0.00016175548,0.00007390544,0.0001754214,0.0000056280596,0.0006750858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967884,0.0020590494,0.00025680635,0.00029273302,0.00046140098,0.00014166055],"domain_scores_gemma":[0.99264985,0.004874495,0.00079986395,0.00055667444,0.00069172925,0.00042736388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006245351,0.00042744543,0.000974261,0.00084898475,0.00043433663,0.00093168387,0.00038478273,0.00069673377,0.0020445348],"category_scores_gemma":[0.0064022285,0.00020733557,0.00069789874,0.0006578436,0.0010447741,0.00089893374,0.00049858174,0.0007309953,0.00036536562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20314066,0.015477664,0.33543402,0.001973176,0.003023539,0.0012467894,0.0012146325,0.0012453076,0.12883013,0.0029024933,0.0012159428,0.30429557],"study_design_scores_gemma":[0.010061721,0.48343897,0.4133383,0.0002689442,0.0045167515,0.0042159837,0.0010810723,0.0018759259,0.05831431,0.0013853398,0.021395922,0.00010672116],"about_ca_topic_score_codex":0.00029274586,"about_ca_topic_score_gemma":0.00026855813,"teacher_disagreement_score":0.006245351,"about_ca_system_score_codex":0.00067066937,"about_ca_system_score_gemma":0.0007382551,"threshold_uncertainty_score":0.03302896},"labels":[],"label_agreement":null},{"id":"W2917122354","doi":"10.1016/j.lungcan.2018.11.033","title":"Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Center for Research Resources; National Cancer Institute; Cancer Research UK; National Institutes of Health; University of Glasgow; Perelman School of Medicine, University of Pennsylvania; University of Pennsylvania","keywords":"Mesothelioma; Medicine; Magnetic resonance imaging; Interest group; Radiology; Medical physics; Pathology","score_opus":0.05369259205617618,"score_gpt":0.3733222517528264,"score_spread":0.31962965969665025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917122354","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029840327,0.9995627,0.000021725806,0.0001720697,0.00012392829,0.0000027736169,0.000010979223,0.0000010947862,0.000074961354],"genre_scores_gemma":[0.00032102416,0.9989361,0.00008760031,0.00029183764,0.00027893722,0.000004185163,0.000021542071,7.042784e-7,0.000058069872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99917334,0.00015355431,0.00024841647,0.00012557585,0.00024116832,0.00005787421],"domain_scores_gemma":[0.9965282,0.0019259454,0.0005301176,0.00005016691,0.0007973794,0.00016828965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023889951,0.0012449601,0.0030120441,0.007193461,0.00035798282,0.0020235905,0.0013535112,0.0020319663,0.0025491538],"category_scores_gemma":[0.004113067,0.0006292942,0.0015990866,0.0056302682,0.00080452196,0.00311994,0.0016000995,0.0023662467,0.00076027383],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020374217,0.000086307715,0.0012522222,0.1023708,0.0005847407,0.00046627797,0.0001964479,0.0004143991,0.0013801988,0.0016631085,0.0575482,0.8338335],"study_design_scores_gemma":[0.00010112365,0.0002131791,0.0056406334,0.072740145,0.00199186,0.0045546894,0.0003550074,0.00025976636,0.0005339864,0.0013540967,0.91215116,0.00010433924],"about_ca_topic_score_codex":0.0023555367,"about_ca_topic_score_gemma":0.0052968073,"teacher_disagreement_score":0.007193461,"about_ca_system_score_codex":0.0010782459,"about_ca_system_score_gemma":0.002597095,"threshold_uncertainty_score":0.012634397},"labels":[],"label_agreement":null},{"id":"W2923788634","doi":"10.1016/j.lungcan.2019.03.019","title":"The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"T790M; Medicine; Osimertinib; KRAS; Lung cancer; Internal medicine; Oncology; Allele; Mutation; Gene; Cancer; Genetics; Biology","score_opus":0.008538635240453023,"score_gpt":0.3203514058084362,"score_spread":0.3118127705679832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923788634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963952,0.0009433903,0.00028561396,0.00009698408,0.000015483229,0.0000063321095,0.00026002148,0.0000133098165,0.0019836838],"genre_scores_gemma":[0.999358,0.0000771635,0.00005801301,0.000015226453,0.000011066825,0.0000019187019,0.000104240244,0.0000024986289,0.00037180306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961627,0.000079046804,0.000057316473,0.00008012891,0.000093241135,0.00007403098],"domain_scores_gemma":[0.9977125,0.0007428233,0.0009397087,0.00016551591,0.00018645977,0.0002529324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057868025,0.0001886105,0.00023628604,0.00076851377,0.00019652488,0.0007119665,0.00027257294,0.0005488126,0.0048299967],"category_scores_gemma":[0.0036840441,0.00016684341,0.00035593877,0.0005097847,0.0002748037,0.000589149,0.00020615969,0.00057787605,0.00036031049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082996406,0.000056147383,0.98797417,0.000015043347,0.00012707632,0.00022722392,0.000033931596,0.0001478566,0.0037157817,0.00013062442,0.00008518598,0.006656965],"study_design_scores_gemma":[0.000011141478,0.00035932322,0.99478287,0.000009943023,0.00010369863,0.0017779547,0.0000981416,0.00072121224,0.0012618088,0.00020469139,0.0006620911,0.0000070569076],"about_ca_topic_score_codex":0.00086103193,"about_ca_topic_score_gemma":0.0007724517,"teacher_disagreement_score":0.0048299967,"about_ca_system_score_codex":0.00020911885,"about_ca_system_score_gemma":0.00017095737,"threshold_uncertainty_score":0.016157985},"labels":[],"label_agreement":null},{"id":"W2925781938","doi":"10.1016/j.lungcan.2019.02.021","title":"Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"MSD K.K.; Chugai Pharmaceutical; Novartis Pharmaceuticals Canada; Kyowa Hakko Kirin; Eli Lilly Japan; Boehringer Ingelheim","keywords":"Osimertinib; Medicine; T790M; Lung cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Erlotinib; Gefitinib","score_opus":0.013287339905226491,"score_gpt":0.33521453676778146,"score_spread":0.32192719686255494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925781938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798314,0.006904923,0.0009236543,0.0011920201,0.00048801885,0.00024011191,0.0004209518,0.000118942815,0.009879966],"genre_scores_gemma":[0.9940935,0.0010907807,0.00041640867,0.00044580604,0.00007636347,0.00005692815,0.00046158503,0.000019750805,0.0033390268],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998548,0.000021769141,0.000012840878,0.000024772457,0.00002779821,0.00005794982],"domain_scores_gemma":[0.9998646,0.000028345756,0.000021197116,0.000023765851,0.000015197314,0.000046779285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032110023,0.00022918962,0.0007119868,0.0002662714,0.00030207672,0.0004932995,0.00024687554,0.00043511012,0.002165666],"category_scores_gemma":[0.0005221218,0.00008929355,0.00061049545,0.00019629604,0.00019771839,0.00034497585,0.00014309386,0.0012330425,0.0005442986],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056884993,0.006671152,0.02390548,0.00069463736,0.0011904789,0.012885898,0.00039203523,0.004539508,0.12687996,0.0021382282,0.01651863,0.747299],"study_design_scores_gemma":[0.029401245,0.14296871,0.29285046,0.00046314282,0.0023809138,0.062326506,0.0008484816,0.024839427,0.18309,0.005043926,0.2555139,0.0002732833],"about_ca_topic_score_codex":0.00087744655,"about_ca_topic_score_gemma":0.0029289813,"teacher_disagreement_score":0.002165666,"about_ca_system_score_codex":0.00073815766,"about_ca_system_score_gemma":0.0003706789,"threshold_uncertainty_score":0.007244885},"labels":[],"label_agreement":null},{"id":"W2932878974","doi":"10.1016/j.lungcan.2019.03.023","title":"The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group","year":2019,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Mesothelioma; Radiation therapy; Interest group; Radiation treatment planning; Adjuvant; Medical physics; Pneumonectomy; Oncology; Surgery; Lung cancer; Pathology","score_opus":0.03697254372315475,"score_gpt":0.3332652654075072,"score_spread":0.2962927216843525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2932878974","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019666462,0.99915147,0.000015920617,0.00035209826,0.000347213,0.0000016827562,0.000011515991,0.0000012743569,0.00009917474],"genre_scores_gemma":[0.00020793792,0.99850345,0.000056665358,0.00062017463,0.00049149455,0.000002743307,0.00001894164,7.443912e-7,0.000097956596],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995216,0.000099756064,0.00009882347,0.00008485611,0.00015206415,0.000042965843],"domain_scores_gemma":[0.99803644,0.001125896,0.00025121204,0.000029944542,0.00043995545,0.00011656236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022917183,0.0008645605,0.0027779897,0.002452791,0.00024103138,0.001876851,0.0011534832,0.0019618399,0.0027474863],"category_scores_gemma":[0.0024640453,0.0003278705,0.0014515014,0.002724055,0.00051304343,0.0019321819,0.0011936966,0.0027639633,0.00095142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027990478,0.000096204974,0.00038318476,0.053190544,0.0004391999,0.00018163482,0.00006936347,0.00042618095,0.0009395794,0.0020409417,0.08991924,0.85203403],"study_design_scores_gemma":[0.00011148389,0.00022257272,0.0019286143,0.01973459,0.001027849,0.0005503671,0.00008809897,0.00015995897,0.00019967888,0.0011509458,0.9747912,0.000034601537],"about_ca_topic_score_codex":0.0020161958,"about_ca_topic_score_gemma":0.0057855295,"teacher_disagreement_score":0.0027779897,"about_ca_system_score_codex":0.0009629196,"about_ca_system_score_gemma":0.0023660823,"threshold_uncertainty_score":0.012119949},"labels":[],"label_agreement":null},{"id":"W2936115947","doi":"10.1016/j.lungcan.2019.04.014","title":"Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Discontinuation; Internal medicine; Oncology; Lung cancer; Retrospective cohort study; Progression-free survival; Epidermal growth factor receptor; Chemotherapy; Cancer; Erlotinib","score_opus":0.007479056460664642,"score_gpt":0.29370941121208277,"score_spread":0.2862303547514181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936115947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993424,0.00028809436,0.000060665447,0.000027311766,0.00000226928,0.000004738272,0.00006185689,0.0000016028106,0.00021104084],"genre_scores_gemma":[0.99970835,0.000059712038,0.000057842783,0.00001733902,0.0000032422283,0.0000040664477,0.00009338544,6.5835064e-7,0.00005541168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996222,0.000088732544,0.000057262994,0.00008895504,0.00007840722,0.000064338754],"domain_scores_gemma":[0.99893504,0.00026713157,0.0005667804,0.000036297075,0.00005875981,0.00013599655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044725704,0.0001150167,0.00027267926,0.00019933225,0.00028113497,0.00032510125,0.00019786472,0.00033302212,0.0007523187],"category_scores_gemma":[0.0016583668,0.00009049674,0.00032987646,0.000366349,0.00015626641,0.00023360622,0.0001425532,0.0003238481,0.000126375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001010123,0.00006679873,0.98424995,0.000029382629,0.000037639526,0.0004486415,0.00011368083,0.00025292297,0.0013404659,0.000017836634,0.00010098397,0.012331609],"study_design_scores_gemma":[0.0000667609,0.0012641597,0.992451,0.00001501223,0.00006162614,0.003030627,0.00012917216,0.00062146096,0.001499496,0.0000672305,0.00078657817,0.0000068500135],"about_ca_topic_score_codex":0.0016093495,"about_ca_topic_score_gemma":0.0034108367,"teacher_disagreement_score":0.0016093495,"about_ca_system_score_codex":0.00054848864,"about_ca_system_score_gemma":0.0005515285,"threshold_uncertainty_score":0.003979504},"labels":[],"label_agreement":null},{"id":"W2937704370","doi":"10.1016/j.lungcan.2019.04.006","title":"First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Afatinib; Medicine; Term (time); Oncology; Internal medicine; Gefitinib; Cancer; Astronomy","score_opus":0.03130357438398415,"score_gpt":0.4238187698056362,"score_spread":0.39251519542165203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937704370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988112,0.008323736,0.00026359045,0.00044682442,0.000043072087,0.0006423726,0.0013335,0.000024470453,0.00081041653],"genre_scores_gemma":[0.9911697,0.0018269253,0.0006448371,0.0005056573,0.00009773022,0.0011268243,0.0039056072,0.0000125404995,0.0007102736],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99665916,0.0024934278,0.00021159842,0.00024093664,0.00018698872,0.00020786782],"domain_scores_gemma":[0.996815,0.0012274405,0.00083900895,0.00027563286,0.00019530614,0.00064752763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006844115,0.00057365134,0.0017706705,0.00031789404,0.00028540092,0.0009986431,0.0007263055,0.00092237047,0.002402677],"category_scores_gemma":[0.0034643272,0.0002428475,0.0034046539,0.00045524712,0.0005030783,0.0009945655,0.0006092811,0.0014651016,0.00038091643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8955234,0.0024311966,0.043794923,0.0016507489,0.008285984,0.00020561894,0.00018228403,0.0010206682,0.004741657,0.0002905929,0.0019898077,0.039883215],"study_design_scores_gemma":[0.6389566,0.1658199,0.16830514,0.0003914408,0.012858767,0.0011995767,0.00037989632,0.0032783954,0.0020696928,0.0010739428,0.0055232355,0.00014332797],"about_ca_topic_score_codex":0.0003979683,"about_ca_topic_score_gemma":0.0014650521,"teacher_disagreement_score":0.006844115,"about_ca_system_score_codex":0.00054784183,"about_ca_system_score_gemma":0.00082588656,"threshold_uncertainty_score":0.036195576},"labels":[],"label_agreement":null},{"id":"W2937841409","doi":"10.1016/j.lungcan.2019.04.009","title":"The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Immunohistochemistry; Biopsy; Pathology; Pembrolizumab; Metastasis; Serous fluid; Lung cancer; Oncology; Lung; Carcinoma; Serous membrane; Internal medicine; Radiology; Cancer; Immunotherapy","score_opus":0.006195992376352095,"score_gpt":0.270509923954496,"score_spread":0.2643139315781439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937841409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997498,0.0008565481,0.00012922782,0.00008029427,0.000016130656,0.0000067953897,0.00008016595,0.000009670444,0.001323173],"genre_scores_gemma":[0.99939036,0.0000985923,0.000040934858,0.000021102791,0.0000041245194,0.0000030969716,0.00004915257,0.0000036542367,0.00038902153],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99983895,0.0000443482,0.000008413543,0.000022509861,0.00004517754,0.000040492407],"domain_scores_gemma":[0.9997522,0.00008710933,0.000042572326,0.000021345877,0.000030235578,0.000066509994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020852809,0.00013821704,0.00034342977,0.0001793013,0.00018239375,0.00043140916,0.0001374014,0.00022356598,0.00212495],"category_scores_gemma":[0.0007301592,0.00012560828,0.00022305558,0.00018014752,0.00021453787,0.00027542532,0.00016814888,0.00035407412,0.00032312673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008646944,0.0006467358,0.20881219,0.0002756907,0.00016451509,0.0012064911,0.0003137953,0.0015795217,0.7281742,0.00035322213,0.0014290545,0.048397664],"study_design_scores_gemma":[0.00022238318,0.004777062,0.8942591,0.00003531805,0.00024397939,0.0025225272,0.0006508987,0.0054420843,0.08562319,0.00063112273,0.0055684648,0.000023912844],"about_ca_topic_score_codex":0.0013834231,"about_ca_topic_score_gemma":0.0024363885,"teacher_disagreement_score":0.00212495,"about_ca_system_score_codex":0.00037812605,"about_ca_system_score_gemma":0.00024004499,"threshold_uncertainty_score":0.0071086287},"labels":[],"label_agreement":null},{"id":"W2943711511","doi":"10.1016/j.lungcan.2019.04.027","title":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; Juravinski Cancer Centre; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Hôpital Notre-Dame; Hamilton Health Sciences; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Pemetrexed; Selumetinib; Chemotherapy; Internal medicine; Hazard ratio; Tolerability; Carboplatin; Oncology; Lung cancer; Surgery; Adverse effect; Gastroenterology; KRAS; Cancer; Cisplatin; Confidence interval; Colorectal cancer","score_opus":0.016899006242002086,"score_gpt":0.3665936275924145,"score_spread":0.3496946213504124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943711511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711836,0.0073128236,0.0001687486,0.0007851794,0.0003157829,0.0007094259,0.001231859,0.000049000242,0.0023087435],"genre_scores_gemma":[0.98862374,0.0045613656,0.00050820404,0.0010629302,0.00026933098,0.0009421244,0.0019111545,0.000011290537,0.0021098037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996536,0.00018291402,0.00002028364,0.00004654338,0.000038187303,0.000058625083],"domain_scores_gemma":[0.9996346,0.000089178684,0.00008201279,0.000019884188,0.000022708024,0.00015158339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009101368,0.0008360553,0.0015471994,0.00025982302,0.00024412572,0.00064513535,0.00055283814,0.00082125404,0.003494137],"category_scores_gemma":[0.00095653173,0.0003717728,0.0013178857,0.000343104,0.0005277638,0.00080365,0.00031572694,0.0016822377,0.00041773586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92714185,0.0063598487,0.0052285013,0.0005134953,0.0023274696,0.0000629879,0.000057360652,0.0007163026,0.0038059982,0.00014842041,0.0033390615,0.0502986],"study_design_scores_gemma":[0.8586406,0.11483638,0.020112976,0.00007873326,0.0017539023,0.00008284061,0.000065612614,0.00076699886,0.0009359905,0.00017460425,0.0025252327,0.000026163887],"about_ca_topic_score_codex":0.0016953473,"about_ca_topic_score_gemma":0.005263231,"teacher_disagreement_score":0.003494137,"about_ca_system_score_codex":0.00075514935,"about_ca_system_score_gemma":0.0009615843,"threshold_uncertainty_score":0.011689067},"labels":[],"label_agreement":null},{"id":"W2946397648","doi":"10.1016/j.lungcan.2019.05.005","title":"Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"BC Cancer Foundation","keywords":"Medicine; Pembrolizumab; Clinical Practice; Oncology; Lung cancer; Internal medicine; Intensive care medicine; Cancer; Family medicine; Immunotherapy","score_opus":0.012976930031351913,"score_gpt":0.3767882010690081,"score_spread":0.3638112710376562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946397648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59881383,0.36100584,0.0032603669,0.016426273,0.0004325189,0.000109170134,0.00028932712,0.00009947375,0.019563163],"genre_scores_gemma":[0.96759206,0.02761329,0.0018808749,0.0016448803,0.00035915614,0.00004073587,0.00010746023,0.000007768923,0.0007537665],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99926966,0.00035245204,0.000070832735,0.000089688816,0.00016835394,0.00004899548],"domain_scores_gemma":[0.99825317,0.0008686684,0.0004400147,0.00007116783,0.00023867775,0.00012815963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001718819,0.00016986414,0.00040924526,0.00023748128,0.000253981,0.000822821,0.00015529791,0.00047563977,0.000867814],"category_scores_gemma":[0.005350392,0.00006689318,0.00019647392,0.0003404894,0.00028797647,0.0007403003,0.00021517437,0.0008011414,0.00023771866],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036884209,0.00033476632,0.037742943,0.0010596056,0.00026954053,0.00027090329,0.00020867409,0.00039362346,0.0068514287,0.0010279443,0.0051501156,0.943002],"study_design_scores_gemma":[0.0029709365,0.017427525,0.7203301,0.004951752,0.0018358423,0.010822254,0.001807263,0.0069691413,0.022503542,0.010232965,0.20001179,0.00013700589],"about_ca_topic_score_codex":0.00045630804,"about_ca_topic_score_gemma":0.0008304533,"teacher_disagreement_score":0.001718819,"about_ca_system_score_codex":0.0006015819,"about_ca_system_score_gemma":0.00045198723,"threshold_uncertainty_score":0.009090066},"labels":[],"label_agreement":null},{"id":"W2946988148","doi":"10.1016/j.lungcan.2019.05.027","title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; McMaster University; Vancouver Hospital and Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Merck Canada; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Oncology; Lung cancer; Pneumonitis; Internal medicine; Chemoradiotherapy; Context (archaeology); Clinical trial; Adverse effect; Cancer; Nivolumab; Immunotherapy; Lung","score_opus":0.019804051459983922,"score_gpt":0.3242405323665668,"score_spread":0.3044364809065829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946988148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006827567,0.9993919,0.00003226539,0.00011446079,0.00008855758,0.0000029720543,0.000011732885,0.0000024026,0.00028744777],"genre_scores_gemma":[0.00081542466,0.99841166,0.0000736254,0.0002557801,0.00012350106,0.0000064078927,0.000025037936,7.407926e-7,0.00028787408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998648,0.000027020516,0.000029631097,0.00002427494,0.000039223876,0.000014950792],"domain_scores_gemma":[0.9997013,0.00015254092,0.000078211626,0.000006630772,0.00004469128,0.000016617632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005534149,0.00066055637,0.0017500594,0.0013808366,0.00013384472,0.00066896144,0.0006497004,0.0007023973,0.0029270535],"category_scores_gemma":[0.00085571676,0.00024580758,0.00069373834,0.0016454919,0.00023043707,0.00071095384,0.0004725674,0.0013910129,0.0009132809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018536641,0.000049529786,0.00019607971,0.02492254,0.00025423744,0.0000666296,0.0000254799,0.0003597118,0.00063011027,0.0007589741,0.023895938,0.9486554],"study_design_scores_gemma":[0.0002494605,0.0005380639,0.0030402234,0.01795522,0.0018424945,0.0011772666,0.000059656664,0.0003072419,0.0006175984,0.0013899286,0.9727886,0.000034233773],"about_ca_topic_score_codex":0.0010092527,"about_ca_topic_score_gemma":0.002938726,"teacher_disagreement_score":0.0029270535,"about_ca_system_score_codex":0.0004986267,"about_ca_system_score_gemma":0.0008397312,"threshold_uncertainty_score":0.00979203},"labels":[],"label_agreement":null},{"id":"W2949244813","doi":"10.1016/j.lungcan.2019.06.012","title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Lung cancer; Oncology; Expression (computer science); Cancer; Ligand (biochemistry); Pathology; Cancer research; Internal medicine; Receptor","score_opus":0.017161885430112406,"score_gpt":0.34280352524772334,"score_spread":0.32564163981761096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949244813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961365,0.00030555026,0.00013058573,0.00006372634,0.000007973967,0.000010357976,0.002979857,0.000009120453,0.0003563282],"genre_scores_gemma":[0.9973787,0.00010024908,0.00008401693,0.000051894935,0.000014247174,0.00001964573,0.002242046,0.0000067603078,0.00010240927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919957,0.0002685683,0.00006506529,0.00028433828,0.00007624466,0.00010622737],"domain_scores_gemma":[0.99849176,0.00023505709,0.0007095173,0.0001921899,0.00015841074,0.00021303205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010589578,0.00047305733,0.0005197634,0.0008293556,0.00032756058,0.0011322174,0.0005882899,0.00078140775,0.0008266561],"category_scores_gemma":[0.0017113872,0.00035997713,0.00063823053,0.001532695,0.0005605569,0.0012049577,0.0009756911,0.0006442386,0.0002466365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019230448,0.000016728118,0.9986118,0.000014593558,0.000108130436,0.0000290902,0.00006235727,0.000045795525,0.00016147336,0.00002148359,0.00022481086,0.00051142834],"study_design_scores_gemma":[0.000014546539,0.00007941796,0.9988405,0.000005559768,0.00006915433,0.00016908182,0.0003188215,0.00018024398,0.00004018635,0.000027156122,0.00024818766,0.0000071984227],"about_ca_topic_score_codex":0.003737957,"about_ca_topic_score_gemma":0.0050601712,"teacher_disagreement_score":0.003737957,"about_ca_system_score_codex":0.00046841113,"about_ca_system_score_gemma":0.00024969538,"threshold_uncertainty_score":0.007432401},"labels":[],"label_agreement":null},{"id":"W2950153856","doi":"10.1016/j.lungcan.2019.06.003","title":"Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Logistic regression; Population; Regimen; Cancer; Multivariate analysis; Mortality rate","score_opus":0.01801350174991846,"score_gpt":0.3217315413157189,"score_spread":0.30371803956580046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950153856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99915886,0.00015716844,0.00005462697,0.000035396213,0.000008631191,0.0000064044257,0.00033440712,0.0000026508098,0.00024196468],"genre_scores_gemma":[0.99912935,0.00010648767,0.000034748027,0.000031484393,0.000016089027,0.000009493903,0.00045558892,0.00000196046,0.00021478526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955195,0.00009624868,0.000044129913,0.0001339846,0.000061029503,0.00011265733],"domain_scores_gemma":[0.9990798,0.00012267579,0.00034899253,0.00007191936,0.00009734169,0.0002792803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005037234,0.00046770505,0.0006653988,0.0008300807,0.000654531,0.0010241113,0.00046536073,0.0011859236,0.0012929351],"category_scores_gemma":[0.0011454036,0.0005200543,0.0012949549,0.0015584239,0.00038824318,0.0010128736,0.0006631194,0.0013784097,0.00031370856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022880638,0.00009233194,0.99883896,0.0000058310075,0.00009571484,0.000078824756,0.000048321694,0.000027602568,0.00017779195,0.00000723039,0.000056298446,0.00034223413],"study_design_scores_gemma":[0.0000070680667,0.00015604282,0.9993611,0.0000019749075,0.00003771676,0.00010702463,0.00017109388,0.000075453776,0.000016065984,0.000008372591,0.000053830456,0.0000042256743],"about_ca_topic_score_codex":0.0068994784,"about_ca_topic_score_gemma":0.0071285153,"teacher_disagreement_score":0.0068994784,"about_ca_system_score_codex":0.00040882357,"about_ca_system_score_gemma":0.00041246045,"threshold_uncertainty_score":0.013718605},"labels":[],"label_agreement":null},{"id":"W2962768820","doi":"10.1016/j.lungcan.2019.07.021","title":"The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"AstraZeneca","keywords":"Medicine; Erlotinib; Afatinib; Adverse effect; Internal medicine; Gefitinib; Lung cancer; Population; Epidermal growth factor receptor; Rate ratio; Cancer; Oncology; Confidence interval","score_opus":0.011533414860820022,"score_gpt":0.2730662465461996,"score_spread":0.26153283168537955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962768820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953441,0.00182297,0.00008461532,0.00013928719,0.000016506876,0.000010434851,0.001833202,0.0000043581645,0.00074460066],"genre_scores_gemma":[0.9986135,0.00038412542,0.00003484826,0.000041992596,0.00001653064,0.0000071103636,0.00076160335,0.0000010877434,0.0001392797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956566,0.00010277212,0.00007953772,0.00007036391,0.00009835544,0.00008329966],"domain_scores_gemma":[0.9985958,0.00028527647,0.0007809434,0.000039892675,0.00011147088,0.000186763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030735604,0.00014644468,0.00035672128,0.0004533186,0.00021769488,0.0005830025,0.00020138093,0.00030368453,0.0013229569],"category_scores_gemma":[0.0018512999,0.00012700028,0.0012966173,0.0008123186,0.00011609744,0.00036091884,0.00029007814,0.0007242623,0.00008322426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006630194,0.000050295515,0.9953701,0.00004149778,0.00037818606,0.00009081115,0.000016961605,0.00032399187,0.00018263081,0.00004618903,0.000248232,0.0025880337],"study_design_scores_gemma":[0.000011772745,0.0001273675,0.998511,0.000008665798,0.00009839467,0.0002180686,0.00007353603,0.0006253681,0.000050533195,0.00004052928,0.00022930546,0.0000054889347],"about_ca_topic_score_codex":0.0064004757,"about_ca_topic_score_gemma":0.007591874,"teacher_disagreement_score":0.0064004757,"about_ca_system_score_codex":0.00079687685,"about_ca_system_score_gemma":0.00049034995,"threshold_uncertainty_score":0.012726426},"labels":[],"label_agreement":null},{"id":"W2965354595","doi":"10.1016/j.lungcan.2019.07.033","title":"PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Law Foundation of British Columbia","keywords":"Medicine; Cytology; Concordance; Lung cancer; Histology; Lung; Lymph; Pathology; Radiology; Internal medicine","score_opus":0.017871589380297107,"score_gpt":0.2916921288345026,"score_spread":0.2738205394542055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965354595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711039,0.0067542675,0.00173911,0.0009785886,0.000163161,0.00012386951,0.00054612214,0.00011346879,0.018477604],"genre_scores_gemma":[0.99710363,0.0007820121,0.0008465181,0.00022971738,0.00004415658,0.0000149209845,0.00017561752,0.000006109513,0.00079733017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999579,0.000065908025,0.000061812614,0.000059270827,0.00014829646,0.00008564507],"domain_scores_gemma":[0.99944407,0.0001953022,0.00004234439,0.00004081964,0.00016932828,0.000108163185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006230462,0.00039809107,0.00033433532,0.0014240694,0.0005983211,0.00065045286,0.0004382438,0.0006872212,0.0023036113],"category_scores_gemma":[0.002090402,0.00016469708,0.00027595734,0.00043421082,0.00054431596,0.0004966077,0.00038885546,0.0004448417,0.00050622027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018406169,0.00016007823,0.77279407,0.00042007345,0.000155232,0.03750282,0.00066646264,0.0006273828,0.10050143,0.00043030572,0.0042526796,0.080648966],"study_design_scores_gemma":[0.00008315688,0.0009695553,0.7704168,0.00047227778,0.0004024701,0.098072186,0.0026398501,0.010185132,0.092715144,0.0011502148,0.022837749,0.000055444423],"about_ca_topic_score_codex":0.0035006478,"about_ca_topic_score_gemma":0.0060495,"teacher_disagreement_score":0.0035006478,"about_ca_system_score_codex":0.000639366,"about_ca_system_score_gemma":0.00050066435,"threshold_uncertainty_score":0.0077062845},"labels":[],"label_agreement":null},{"id":"W2969365775","doi":"10.1016/j.lungcan.2019.08.016","title":"Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]","year":2019,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Nivolumab; Atezolizumab; Medicine; Pembrolizumab; ROS1; Lung cancer; Durvalumab; Oncology; Internal medicine; Cancer; Cancer research; Immunotherapy; Adenocarcinoma","score_opus":0.009040041164799914,"score_gpt":0.28580558810533935,"score_spread":0.27676554694053945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969365775","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015674802,0.0014701794,0.00024186303,0.08834772,0.9039686,0.000023467299,0.0008606914,0.00016421225,0.004766535],"genre_scores_gemma":[0.005534213,0.011405535,0.0022092678,0.3118274,0.45063266,0.00018607067,0.0042264177,0.00074479607,0.21323372],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978223,0.00028634045,0.00048376783,0.00023867712,0.00093329564,0.00023566821],"domain_scores_gemma":[0.987104,0.002968741,0.0008423341,0.0005044735,0.00771389,0.0008665993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029198201,0.0016417548,0.0017546912,0.0029664936,0.0025690102,0.0030129978,0.0020910786,0.006834495,0.02960702],"category_scores_gemma":[0.022410499,0.0010615,0.001683353,0.0015868245,0.0012501784,0.0013354911,0.0010965995,0.008839874,0.030796288],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026681118,0.0000067337082,0.000059778973,0.00003856467,0.000004767652,0.00009390822,0.000003934988,0.000014140414,0.00002048377,0.00010982114,0.99643,0.003191342],"study_design_scores_gemma":[0.00007094002,0.000045820536,0.001244219,0.00031279854,0.00005483718,0.00034730724,0.000039965613,0.00015638354,0.00019236475,0.00047784043,0.9970289,0.000028702541],"about_ca_topic_score_codex":0.022592597,"about_ca_topic_score_gemma":0.03309988,"teacher_disagreement_score":0.02960702,"about_ca_system_score_codex":0.0032152706,"about_ca_system_score_gemma":0.0051971083,"threshold_uncertainty_score":0.099045396},"labels":[],"label_agreement":null},{"id":"W2981392910","doi":"10.1016/j.lungcan.2019.10.019","title":"Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Mount Sinai Hospital; McMaster University; Alberta Cancer Foundation; William Osler Health System; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Lung cancer; Health care; Delphi method; Oncology; Internal medicine; Statistics","score_opus":0.017134282541400463,"score_gpt":0.31103216051956356,"score_spread":0.2938978779781631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981392910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7286524,0.0020507101,0.2153142,0.002762547,0.00076837593,0.00074751733,0.016016658,0.0031733953,0.030514212],"genre_scores_gemma":[0.92343223,0.0005751017,0.060018145,0.0003303448,0.00007289353,0.0003934436,0.00737251,0.0002301224,0.0075751836],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995951,0.00017421013,0.000019834086,0.00008482773,0.00007196654,0.000054126685],"domain_scores_gemma":[0.9982712,0.00095721387,0.0001016889,0.00012473641,0.0004535943,0.00009146054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001419203,0.00064451713,0.00066101924,0.00041037492,0.00027092206,0.0007155103,0.0015207712,0.0006717344,0.0045170984],"category_scores_gemma":[0.0047615,0.00022772151,0.00094506016,0.00033386232,0.00026112085,0.00046044195,0.00062074466,0.0010058968,0.0005698237],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048598804,0.00029758443,0.012011493,0.000217657,0.00023132333,0.00012037403,0.00003530586,0.9479044,0.00075610535,0.003314753,0.00535132,0.029273707],"study_design_scores_gemma":[0.000056765406,0.000117149924,0.0016532552,0.000019411898,0.000074349286,0.00003671788,0.00001614303,0.99478686,0.00046749625,0.001199844,0.001563481,0.000008521899],"about_ca_topic_score_codex":0.044361185,"about_ca_topic_score_gemma":0.03154557,"teacher_disagreement_score":0.044361185,"about_ca_system_score_codex":0.0011532618,"about_ca_system_score_gemma":0.0022073162,"threshold_uncertainty_score":0.08820593},"labels":[],"label_agreement":null},{"id":"W2990345401","doi":"10.1183/13993003.congress-2019.pa3076","title":"Central tumor location and presence of occult lymph node metastasis in cT1N0M0 NSCLC","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"","keywords":"Medicine; Occult; Hilum (anatomy); Radiology; Lymph node; Lung cancer; Mediastinal lymph node; Metastasis; Lung; Incidence (geometry); Lymph; Cancer; Oncology; Internal medicine; Pathology","score_opus":0.009000430885864961,"score_gpt":0.2942786289980203,"score_spread":0.2852781981121554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990345401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99933165,0.0002767565,0.00005466409,0.000016185171,0.0000041235653,0.0000060123652,0.00014473737,0.0000024010765,0.0001632879],"genre_scores_gemma":[0.99954283,0.0000724269,0.00011228582,0.000008023362,0.000010403024,0.0000058039705,0.00019383662,0.000001100549,0.00005340995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996407,0.00009937947,0.000067596244,0.0000693057,0.00007580867,0.000047209676],"domain_scores_gemma":[0.99698526,0.0006444845,0.001600314,0.00013010431,0.00021925483,0.00042054374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077143504,0.00024045158,0.00025926353,0.0014917082,0.00026107056,0.0005386077,0.00035517104,0.00045091112,0.0020216655],"category_scores_gemma":[0.0032098542,0.00019907717,0.00024796044,0.0009268152,0.0003180626,0.00041067568,0.0005559148,0.0002874369,0.00030577483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021790325,0.000013913162,0.9984421,0.000011008284,0.000013154665,0.00008466638,0.000015024589,0.000031596326,0.00020412356,0.0000047534386,0.00004019799,0.0009216394],"study_design_scores_gemma":[0.0000088661445,0.00008848048,0.99868184,0.000008701568,0.000016597678,0.0007025655,0.000069941176,0.00018192141,0.000130254,0.000012726452,0.000095606636,0.0000025389845],"about_ca_topic_score_codex":0.0015480496,"about_ca_topic_score_gemma":0.0028533468,"teacher_disagreement_score":0.0020216655,"about_ca_system_score_codex":0.00030170483,"about_ca_system_score_gemma":0.00033674133,"threshold_uncertainty_score":0.00676316},"labels":[],"label_agreement":null},{"id":"W2994716574","doi":"10.1016/j.lungcan.2019.12.005","title":"Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Allergan Foundation; Sanofi; AstraZeneca; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine; Cohort; Microsatellite instability; Clinical trial; Lung cancer; Targeted therapy; Cancer; Gene; Genetics","score_opus":0.027241171574302885,"score_gpt":0.3084478449207322,"score_spread":0.2812066733464293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994716574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8659861,0.047871236,0.037612896,0.0149809,0.0010483274,0.00016236912,0.0099017145,0.0009743931,0.021462066],"genre_scores_gemma":[0.9668646,0.0078115403,0.016559474,0.0029475638,0.0003102091,0.000045777837,0.0027657705,0.00012198881,0.0025729993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99951756,0.00008407394,0.00004446487,0.0001117964,0.00018401512,0.000058171925],"domain_scores_gemma":[0.9992518,0.00041177307,0.0000957522,0.000050012324,0.00014162935,0.000049019374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008375236,0.00041563518,0.00055874937,0.00087534805,0.00029785762,0.0013528676,0.00041317547,0.0010240102,0.0019556326],"category_scores_gemma":[0.0027089925,0.00023145435,0.0004206488,0.0004966981,0.00026877047,0.0005182047,0.00035152456,0.0008265159,0.00055060844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014132644,0.0002110773,0.18885271,0.00077303546,0.0005671944,0.003799071,0.00026914678,0.012431023,0.18638906,0.008078895,0.021428203,0.57578737],"study_design_scores_gemma":[0.00042302423,0.0011045517,0.2690152,0.0014290896,0.002428991,0.017115928,0.0013153492,0.13298497,0.27078474,0.063356556,0.23984839,0.00019326538],"about_ca_topic_score_codex":0.0016602268,"about_ca_topic_score_gemma":0.0035969864,"teacher_disagreement_score":0.0019556326,"about_ca_system_score_codex":0.00068441394,"about_ca_system_score_gemma":0.0005348124,"threshold_uncertainty_score":0.006542206},"labels":[],"label_agreement":null},{"id":"W2995735677","doi":"10.1016/j.lungcan.2019.12.007","title":"Survival disparities following surgery among patients with different histological types of non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Dalhousie University","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Adenocarcinoma; Proportional hazards model; Pneumonectomy; Stage (stratigraphy); Carcinoma; Lymph node; Survival analysis; Cohort; Cancer; Surgery","score_opus":0.009230554469763548,"score_gpt":0.25354110793386525,"score_spread":0.24431055346410172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995735677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970547,0.0005871401,0.000052627638,0.00034875906,0.000029394894,0.000005981066,0.0008379882,0.0000020726782,0.001081332],"genre_scores_gemma":[0.9990459,0.0001440218,0.000016427153,0.000072120696,0.000020968713,0.0000027745157,0.000514326,0.0000012105365,0.00018224512],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994118,0.00006390777,0.000055982735,0.000116095085,0.00006287312,0.00028934353],"domain_scores_gemma":[0.9990176,0.00016180401,0.0003902529,0.000049050665,0.00009928674,0.00028200718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032985825,0.00014264633,0.00030773866,0.0006454342,0.00052648736,0.0005476635,0.0003576463,0.0005500761,0.0034233255],"category_scores_gemma":[0.002250712,0.00015812214,0.0008067341,0.0012335001,0.00027435028,0.0005970243,0.0007362029,0.0008254031,0.00018837111],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011923834,0.00003330781,0.9977685,0.000011446383,0.0000819345,0.00004255874,0.000064688815,0.000057152392,0.000117909985,0.00011733935,0.00020778645,0.0013780362],"study_design_scores_gemma":[0.0000055935343,0.00003647429,0.99896836,0.000008076796,0.000032330332,0.00006216745,0.00037800116,0.00013407812,0.00002518977,0.00013131164,0.00021439236,0.0000040445707],"about_ca_topic_score_codex":0.019087724,"about_ca_topic_score_gemma":0.04136017,"teacher_disagreement_score":0.019087724,"about_ca_system_score_codex":0.0006667709,"about_ca_system_score_gemma":0.00081517873,"threshold_uncertainty_score":0.037953258},"labels":[],"label_agreement":null},{"id":"W3006944857","doi":"10.1016/j.lungcan.2020.02.004","title":"RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neurofibromatosis and Schwannoma Cases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Ezrin; Medicine; Chemotaxis; Gene isoform; Cancer research; Scaffold protein; Lung; Adenocarcinoma; Scaffold; Cell; Cell migration; Cell biology; Internal medicine; Signal transduction; Receptor; Biology; Cancer; Biochemistry; Gene; Biomedical engineering; Cytoskeleton","score_opus":0.016727888700035574,"score_gpt":0.25387894200942385,"score_spread":0.23715105330938827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006944857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988739,0.00021715609,0.00010090532,0.000021442043,0.0000045765423,0.0000022505799,0.000010428483,0.0000060201132,0.00076337066],"genre_scores_gemma":[0.99955255,0.000061261104,0.00006810501,0.0000061452006,0.00000619913,0.0000015633726,0.000018940396,9.527694e-7,0.00028421663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998202,0.00002925736,0.000016993203,0.000028210256,0.00004074918,0.00006461575],"domain_scores_gemma":[0.9998784,0.00002519558,0.00003313204,0.000012936035,0.0000159542,0.00003428596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013769191,0.00024551456,0.00014754244,0.0005140388,0.00043093303,0.0002499214,0.00021809686,0.0004122305,0.0015969906],"category_scores_gemma":[0.00036523992,0.00014407566,0.00020730749,0.00030173332,0.00029949582,0.00018221104,0.00024857823,0.00015482801,0.00025617002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009643755,0.00010553012,0.22395332,0.00011009171,0.000071892166,0.08025186,0.00047290468,0.00024027491,0.686017,0.0006473841,0.0003640865,0.006801319],"study_design_scores_gemma":[0.00003696518,0.0004384788,0.7236279,0.000011738264,0.00021686888,0.15658318,0.0012501957,0.0034780838,0.11000466,0.0003939419,0.003931967,0.00002600525],"about_ca_topic_score_codex":0.0010828814,"about_ca_topic_score_gemma":0.0015841026,"teacher_disagreement_score":0.0015969906,"about_ca_system_score_codex":0.00025164368,"about_ca_system_score_gemma":0.0001331036,"threshold_uncertainty_score":0.0053424835},"labels":[],"label_agreement":null},{"id":"W3007268864","doi":"10.1016/j.lungcan.2020.02.014","title":"Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Manitoba; Sunnybrook Health Science Centre; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Comorbidity; Disease; Cancer; Population; Cohort; Internal medicine; Retrospective cohort study; Pediatrics; Physical therapy","score_opus":0.018736776937923444,"score_gpt":0.30309725357507694,"score_spread":0.28436047663715347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007268864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631304,0.0002616996,0.000051169904,0.000062109684,0.0000063221446,0.000010527362,0.002865886,0.000006618579,0.00042259382],"genre_scores_gemma":[0.9981913,0.0000735857,0.000022800572,0.000015684345,0.0000040882883,0.0000062677964,0.0015932949,0.0000022670295,0.0000908262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988373,0.00023253578,0.00013442707,0.00021434951,0.00020707461,0.00037435698],"domain_scores_gemma":[0.99598,0.0005246256,0.0020844464,0.0002690197,0.00050065975,0.00064117264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010445407,0.00035104298,0.000532633,0.0016385231,0.00070088677,0.0011284627,0.0009039131,0.00056322286,0.0013690203],"category_scores_gemma":[0.0044720042,0.00033301456,0.0015244393,0.0033489892,0.0006472597,0.0007340788,0.0015815414,0.0009191227,0.00022236779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007059203,0.000009263015,0.99922836,0.000008544769,0.00007922582,0.000023441631,0.0000619376,0.000030668707,0.000027791895,0.0000056313866,0.00008926469,0.00036537423],"study_design_scores_gemma":[0.0000024487865,0.00002626998,0.9994978,0.0000036942758,0.000022330345,0.000049142945,0.00027574727,0.000044372784,0.000008738078,0.0000064074957,0.000060294173,0.0000028429865],"about_ca_topic_score_codex":0.15708624,"about_ca_topic_score_gemma":0.20898917,"teacher_disagreement_score":0.15708624,"about_ca_system_score_codex":0.0016750596,"about_ca_system_score_gemma":0.0022822502,"threshold_uncertainty_score":0.31234384},"labels":[],"label_agreement":null},{"id":"W3008374819","doi":"10.1016/j.lungcan.2020.02.016","title":"A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Cancer Care South East; McMaster University; Queen's University; Centre Hospitalier de l’Université de Montréal; University of Calgary; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Internal medicine; Carboplatin; Durvalumab; Tremelimumab; Chemotherapy; Gemcitabine; Pemetrexed; Pneumonitis; Lung cancer; Oxaliplatin; Gastroenterology; Oncology; Surgery; Cancer; Cisplatin; Pembrolizumab; Immunotherapy; Ipilimumab; Colorectal cancer; Lung","score_opus":0.05066850904979687,"score_gpt":0.39482714856463014,"score_spread":0.3441586395148333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008374819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769557,0.0053256145,0.00069744565,0.001356431,0.0004271089,0.0036972854,0.0061257766,0.00019390207,0.0052208253],"genre_scores_gemma":[0.9681322,0.0061120177,0.0026461554,0.0016991148,0.0003627901,0.0035012027,0.008047512,0.00010484288,0.009394185],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999416,0.00025612628,0.000019107703,0.00008961371,0.00006125268,0.00015794177],"domain_scores_gemma":[0.9992124,0.00010017768,0.00010932269,0.00007111743,0.000037381298,0.000469589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019417347,0.0020153383,0.0029611797,0.00054531824,0.0006977082,0.0015087719,0.0014111035,0.0015055449,0.0062887752],"category_scores_gemma":[0.0011589018,0.0007355823,0.002264501,0.0007459611,0.0014269304,0.0009797319,0.0004257596,0.0041497224,0.0014743634],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89098066,0.027372312,0.002098056,0.0009347847,0.002229396,0.00010755387,0.0002330993,0.001911942,0.013206599,0.0004865962,0.0070031737,0.053435832],"study_design_scores_gemma":[0.8410654,0.14545546,0.0060000895,0.000036387177,0.0009141164,0.0001456984,0.0000628246,0.00059760106,0.0012396955,0.00024040307,0.0042031193,0.00003927374],"about_ca_topic_score_codex":0.013068368,"about_ca_topic_score_gemma":0.03872715,"teacher_disagreement_score":0.013068368,"about_ca_system_score_codex":0.0027679182,"about_ca_system_score_gemma":0.004437545,"threshold_uncertainty_score":0.025984645},"labels":[],"label_agreement":null},{"id":"W3012479383","doi":"10.1016/j.lungcan.2020.03.014","title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Chemotherapy; Epidermal growth factor receptor; Brain metastasis; Metastasis; Medical record; Exon; Cancer; Gene","score_opus":0.014483637179825948,"score_gpt":0.34744462399859594,"score_spread":0.33296098681877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012479383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99942696,0.000084951556,0.000022829734,0.000026672622,0.000001936678,0.0000028953866,0.00027194608,0.0000015220745,0.0001603691],"genre_scores_gemma":[0.99941456,0.000043595646,0.000010632984,0.000015909145,0.0000038767985,0.0000032531857,0.0004507838,0.000001081636,0.00005627011],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994036,0.00009348802,0.00008471123,0.00018111189,0.00007161491,0.00016548006],"domain_scores_gemma":[0.9991155,0.00014282801,0.0003237137,0.00010654715,0.000108612236,0.00020277973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057343516,0.00036966047,0.00053539587,0.0012313684,0.0009056502,0.00083861005,0.00061155594,0.00054649316,0.0013263329],"category_scores_gemma":[0.0012303337,0.0003258643,0.0007416992,0.0026062042,0.00058324204,0.00066712755,0.00082444446,0.00045946377,0.0001891122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099493875,0.00001928786,0.9988054,0.0000056552444,0.0000830206,0.00013873016,0.00011600628,0.000038724946,0.0002182998,0.00002071382,0.00006130569,0.00039346574],"study_design_scores_gemma":[0.0000058516544,0.000021954978,0.9991203,0.0000016705819,0.000056060042,0.00017742884,0.0003252709,0.00014034197,0.00003572056,0.000026075837,0.00008436631,0.0000049349096],"about_ca_topic_score_codex":0.025946394,"about_ca_topic_score_gemma":0.027311401,"teacher_disagreement_score":0.025946394,"about_ca_system_score_codex":0.00096364,"about_ca_system_score_gemma":0.0007077155,"threshold_uncertainty_score":0.05159068},"labels":[],"label_agreement":null},{"id":"W3014650073","doi":"10.1016/j.lungcan.2020.03.021","title":"Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Health Canada","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.025668098241412522,"score_gpt":0.33683787634941825,"score_spread":0.3111697781080057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014650073","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017101456,0.0009004162,0.0022367118,0.94663113,0.034961414,0.00009602204,0.001324686,0.00025209307,0.011887337],"genre_scores_gemma":[0.04127518,0.0016922033,0.008018102,0.8432111,0.031638384,0.00059310865,0.00097435585,0.00053977006,0.07205785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965249,0.0017713367,0.00020330459,0.0003553735,0.0009291998,0.00021591813],"domain_scores_gemma":[0.97490704,0.017247256,0.0005604068,0.0009304583,0.004707674,0.0016472245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067530284,0.00049074437,0.0007942806,0.00043741986,0.0012199375,0.0018927148,0.0012510248,0.008285676,0.017583324],"category_scores_gemma":[0.047174077,0.0002790752,0.00084690575,0.00031882586,0.0009499033,0.0015349749,0.0008359238,0.012717899,0.010827552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021205771,0.000039051454,0.0006883912,0.00003525314,0.000018636045,0.00018475694,0.000031492524,0.00039347884,0.00010691494,0.003016753,0.9814222,0.013850951],"study_design_scores_gemma":[0.0005818363,0.00024104315,0.001583376,0.000263197,0.00008086341,0.00066550594,0.00025920995,0.008455659,0.0010826557,0.017990274,0.96872264,0.00007375164],"about_ca_topic_score_codex":0.005596874,"about_ca_topic_score_gemma":0.008294433,"teacher_disagreement_score":0.017583324,"about_ca_system_score_codex":0.0027801874,"about_ca_system_score_gemma":0.0028757176,"threshold_uncertainty_score":0.058822036},"labels":[],"label_agreement":null},{"id":"W3017107411","doi":"10.1016/j.lungcan.2020.04.011","title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Hazard ratio; Oncology; Anaplastic lymphoma kinase; Cochrane Library; Lung cancer; ALK inhibitor; Randomized controlled trial; Subgroup analysis; Confidence interval","score_opus":0.032884582674672175,"score_gpt":0.37616885597003563,"score_spread":0.3432842732953635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017107411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004760952,0.99370486,0.00033204455,0.000120638324,0.0001243335,0.000110464345,0.0005937941,0.000020712056,0.00023212057],"genre_scores_gemma":[0.16598056,0.82946986,0.0012842221,0.0012477045,0.00022779581,0.00036023377,0.0008851512,0.00003045907,0.0005140549],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9969227,0.0011828697,0.0009495656,0.0004615591,0.000318736,0.00016462953],"domain_scores_gemma":[0.9949463,0.003447172,0.0010313486,0.0001740615,0.00030297283,0.000098171105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049964376,0.0021753751,0.01418237,0.0024996842,0.00035996202,0.002167495,0.0017363748,0.0019699521,0.00493292],"category_scores_gemma":[0.011745238,0.0012497796,0.028211443,0.0038050143,0.00058345194,0.0015369377,0.0012816717,0.002071716,0.00046107065],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034525373,0.000033042415,0.0031665228,0.38859224,0.5882365,0.0001170811,0.0000762746,0.00052627514,0.0003765054,0.00013523767,0.0009353932,0.014352425],"study_design_scores_gemma":[0.0010095354,0.00018127404,0.0030297341,0.012580057,0.98106694,0.00006719464,0.00003934495,0.000097082506,0.00007918279,0.00015300498,0.0016717045,0.000024996392],"about_ca_topic_score_codex":0.005722865,"about_ca_topic_score_gemma":0.017745689,"teacher_disagreement_score":0.01418237,"about_ca_system_score_codex":0.0015948055,"about_ca_system_score_gemma":0.0018758749,"threshold_uncertainty_score":0.02642399},"labels":[],"label_agreement":null},{"id":"W3019468486","doi":"10.1016/j.lungcan.2020.04.021","title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; MSD Life Science Foundation, Public Interest Incorporated Foundation; Ono Pharmaceutical; Nippon Kayaku; AstraZeneca; Astellas Pharma US; Taiho Pharmaceutical; Novartis; Chugai Pharmaceutical; Pfizer","keywords":"Medicine; Ramucirumab; Docetaxel; Internal medicine; Oncology; Chemotherapy","score_opus":0.01685621219898133,"score_gpt":0.3003720634411888,"score_spread":0.28351585124220746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019468486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223703,0.0048025455,0.00014164287,0.00023417303,0.00014712132,0.000078663026,0.00016757615,0.000058218444,0.002132966],"genre_scores_gemma":[0.9978648,0.000716208,0.0002919222,0.0001463883,0.000049214304,0.000032056014,0.00022040824,0.0000042899965,0.00067474705],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997565,0.000064782114,0.00002106877,0.000048062975,0.0000357698,0.00007378908],"domain_scores_gemma":[0.99975747,0.0000702555,0.00004475047,0.000021438775,0.000022062706,0.0000841201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050065934,0.00026883555,0.0010094566,0.0002116007,0.00020780621,0.0005365985,0.00023810066,0.00024160866,0.0015424642],"category_scores_gemma":[0.000859506,0.00015923407,0.00069000927,0.00015898011,0.00016162777,0.0003510495,0.00014373823,0.0010045092,0.00032811126],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.171502,0.010438916,0.09490045,0.001076186,0.0020497367,0.0009770725,0.0003263087,0.0043184813,0.060502045,0.0005099581,0.00793229,0.6454666],"study_design_scores_gemma":[0.035132445,0.2758903,0.55846804,0.00039039267,0.0057924185,0.0061287764,0.00044144312,0.015428319,0.050640568,0.00084158033,0.050618805,0.00022688597],"about_ca_topic_score_codex":0.0006841994,"about_ca_topic_score_gemma":0.0028726878,"teacher_disagreement_score":0.0015424642,"about_ca_system_score_codex":0.00050982815,"about_ca_system_score_gemma":0.000546433,"threshold_uncertainty_score":0.0051600933},"labels":[],"label_agreement":null},{"id":"W3020949563","doi":"10.1016/j.lungcan.2020.03.028","title":"High risk, same reward?","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Lung cancer; Organ transplantation; Lung transplantation; Malignancy; Transplantation; Cancer; Solid organ; Single Center; Surgery; Stage (stratigraphy); Oncology; Internal medicine","score_opus":0.010168717155205134,"score_gpt":0.27272546762376226,"score_spread":0.26255675046855714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020949563","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040690246,0.0005282708,0.00004902417,0.9841761,0.007845621,0.000011940842,0.000046029843,0.000015126803,0.0069210175],"genre_scores_gemma":[0.0023892631,0.00033260311,0.00011418806,0.9718912,0.011359708,0.000029690427,0.000022945718,0.000013616038,0.013846686],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99615955,0.0011241367,0.0002978626,0.00037364243,0.00096039334,0.0010844421],"domain_scores_gemma":[0.99209106,0.0029212222,0.00031803813,0.0002009786,0.0010746622,0.0033939863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040818155,0.00076781283,0.0013234112,0.0008708498,0.009125223,0.006340637,0.0018508063,0.094167605,0.017217327],"category_scores_gemma":[0.020575933,0.00078538974,0.0011825952,0.00064944563,0.0038843362,0.005585201,0.002893319,0.04990829,0.009202055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006763394,0.00007555877,0.0014638575,0.000031068277,0.000017025879,0.0013323007,0.00016536842,0.00005866536,0.00021509524,0.008246041,0.9806085,0.007718811],"study_design_scores_gemma":[0.0001736918,0.00011138167,0.002647508,0.00035149773,0.000029838775,0.0015643574,0.0014287722,0.00057193934,0.00015281948,0.02011098,0.9727501,0.00010705955],"about_ca_topic_score_codex":0.026438938,"about_ca_topic_score_gemma":0.06623958,"teacher_disagreement_score":0.094167605,"about_ca_system_score_codex":0.0057548583,"about_ca_system_score_gemma":0.012490805,"threshold_uncertainty_score":0.057597756},"labels":[],"label_agreement":null},{"id":"W3025802953","doi":"10.1016/j.lungcan.2020.03.022","title":"EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Institute for Cancer Research; Canadian Cancer Society","keywords":"Medicine; Oncology; Cancer research; Lung; Internal medicine; EGFR inhibitors; Epidermal growth factor receptor; Cancer","score_opus":0.0160674318140488,"score_gpt":0.3089211713185431,"score_spread":0.2928537395044943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025802953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903611,0.0016490226,0.003975663,0.00014461607,0.00008396158,0.000054373497,0.0012420896,0.0001281599,0.002361009],"genre_scores_gemma":[0.9932634,0.00067908433,0.0015763304,0.00005737328,0.000011248188,0.00003649654,0.001809142,0.000046026307,0.0025208336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968934,0.000053678887,0.000029686194,0.00005851401,0.000086813256,0.00008203449],"domain_scores_gemma":[0.99959546,0.00013692483,0.00006266926,0.00006660175,0.000047961836,0.0000904721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037133077,0.00044647048,0.00072229624,0.00042858516,0.00020134616,0.0006178766,0.00025188876,0.00040190606,0.0017592014],"category_scores_gemma":[0.00027866176,0.00021323454,0.00045206735,0.0002722745,0.00020180804,0.0005673728,0.00030785459,0.0016512296,0.00042542935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013129422,0.0007164803,0.0035564082,0.00007834428,0.000087900895,0.0001681471,0.00014046069,0.0006748877,0.98582274,0.00042633677,0.0006564693,0.006358903],"study_design_scores_gemma":[0.00008590367,0.005971986,0.04124773,0.000024218418,0.00011817953,0.0016462846,0.00026225654,0.007129436,0.9392822,0.00026906273,0.0039407555,0.000022017372],"about_ca_topic_score_codex":0.0010197127,"about_ca_topic_score_gemma":0.0010977387,"teacher_disagreement_score":0.0017592014,"about_ca_system_score_codex":0.00022423007,"about_ca_system_score_gemma":0.00014665473,"threshold_uncertainty_score":0.005885124},"labels":[],"label_agreement":null},{"id":"W3026323309","doi":"10.1016/j.lungcan.2020.05.013","title":"Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Canada Research Chairs; BC Cancer Agency; University of Toronto","funders":"Bristol-Myers Squibb Canada; Roche; AbbVie; Merck; Bayer; AstraZeneca; Novartis; Princess Margaret Cancer Foundation; Pfizer","keywords":"Medicine; CINAHL; Meta-analysis; MEDLINE; Lung cancer; Psychological intervention; Lung cancer screening; Relative risk; Cochrane Library; Internal medicine; Physical therapy; Confidence interval; Psychiatry","score_opus":0.13721857430288784,"score_gpt":0.4262249540346403,"score_spread":0.28900637973175247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026323309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013304863,0.98479813,0.00051774137,0.00017313454,0.00017546999,0.00016946858,0.0006168886,0.000028217275,0.00021610036],"genre_scores_gemma":[0.44535655,0.54772925,0.0030106278,0.0014924903,0.00029957702,0.0006797524,0.0008825841,0.000042913307,0.0005062805],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9925292,0.0032613492,0.0021887291,0.0010253242,0.0006610058,0.00033429352],"domain_scores_gemma":[0.9849829,0.010946251,0.0024612455,0.0005918751,0.00078415807,0.00023361067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009181665,0.0020464864,0.012562966,0.0024678127,0.0006256388,0.0027231316,0.001918768,0.0025684652,0.0038990946],"category_scores_gemma":[0.02701003,0.0018700092,0.037744712,0.00432522,0.00073053536,0.0018626899,0.0020311263,0.003029079,0.00032837945],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027381864,0.000049614147,0.01710718,0.18962777,0.77801794,0.0001165702,0.00013980689,0.00028379378,0.00014449719,0.000087360175,0.00057236827,0.011114876],"study_design_scores_gemma":[0.000600702,0.00014196265,0.0074870517,0.008701481,0.9819795,0.000056279976,0.00006174435,0.00012305743,0.000049214403,0.00009200891,0.0006862336,0.000020744961],"about_ca_topic_score_codex":0.012118691,"about_ca_topic_score_gemma":0.03292457,"teacher_disagreement_score":0.012562966,"about_ca_system_score_codex":0.0017039266,"about_ca_system_score_gemma":0.0032170652,"threshold_uncertainty_score":0.048557878},"labels":[],"label_agreement":null},{"id":"W3027882342","doi":"10.1016/j.lungcan.2020.05.018","title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canadian Cancer Society; Princess Margaret Cancer Foundation","keywords":"Alectinib; Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Medicine; Cancer research; Lung cancer; Exome sequencing; Adenocarcinoma; Oncology; Mutation; Internal medicine; Cancer; Biology; Gene","score_opus":0.01857981633021402,"score_gpt":0.31091791521905204,"score_spread":0.29233809888883805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027882342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803491,0.012880079,0.0003257254,0.00067560485,0.000033315908,0.000020471498,0.00013881919,0.000032535238,0.0055444287],"genre_scores_gemma":[0.9974989,0.0015072696,0.00018312791,0.00007164679,0.000017061075,0.0000044975263,0.00007780376,0.0000025027157,0.0006372878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997507,0.00005735305,0.000017558277,0.00003303745,0.0000747363,0.00006665364],"domain_scores_gemma":[0.9997948,0.000041800078,0.000078824974,0.000013359687,0.000031300366,0.000039992028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041360737,0.0002822019,0.000386332,0.0006922316,0.00021138995,0.0011501077,0.00027363322,0.000572656,0.0016945992],"category_scores_gemma":[0.00066957285,0.00016162962,0.0005246036,0.00043177078,0.00023269105,0.0005761291,0.00027332868,0.0005145175,0.00019990744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015510233,0.001223467,0.51256305,0.0007136505,0.00083927263,0.010144295,0.00042132536,0.004350991,0.15183549,0.0115096355,0.005654803,0.28523383],"study_design_scores_gemma":[0.0008146459,0.003788159,0.8428901,0.00028026244,0.0017434823,0.045677308,0.0012520199,0.02269074,0.04585522,0.006520972,0.028379805,0.00010741297],"about_ca_topic_score_codex":0.0011487779,"about_ca_topic_score_gemma":0.0023643272,"teacher_disagreement_score":0.0016945992,"about_ca_system_score_codex":0.0007254615,"about_ca_system_score_gemma":0.000659946,"threshold_uncertainty_score":0.005668938},"labels":[],"label_agreement":null},{"id":"W3034428807","doi":"10.1016/j.lungcan.2020.06.005","title":"ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adenocarcinoma; Internal medicine; Neuroendocrine carcinoma; Oncology; Lung; Lung cancer; Mutation; Carcinoma; Small Cell Lung Carcinoma; Large cell; Transformation (genetics); Cancer research; Pathology; Small-cell carcinoma; Cancer; Gene; Genetics; Biology","score_opus":0.033944475025264716,"score_gpt":0.3577773740189569,"score_spread":0.32383289899369216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034428807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98176265,0.0016131934,0.0035707774,0.00081327,0.00026747966,0.00053598324,0.00055025343,0.00014673964,0.010739726],"genre_scores_gemma":[0.99587965,0.00048250446,0.0014217013,0.00024519913,0.00028954132,0.00008550357,0.00025826268,0.000040815266,0.0012967088],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9985084,0.00014078496,0.00018218372,0.00042562306,0.00022690001,0.00051610643],"domain_scores_gemma":[0.99683374,0.0009803693,0.00041881815,0.00048892596,0.00024050681,0.0010377313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074923143,0.002316619,0.0010965869,0.003205849,0.0023351004,0.0023727166,0.0026248791,0.005646442,0.003246368],"category_scores_gemma":[0.006052179,0.0019355319,0.0016817445,0.0014757661,0.0033964314,0.0016914828,0.002671866,0.0029315825,0.0015638996],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000191205,0.00022070532,0.0179168,0.0000463079,0.000019204446,0.9752043,0.00055858947,0.00010671797,0.0033042352,0.00031595587,0.00019937656,0.0019166571],"study_design_scores_gemma":[0.000043217467,0.0002238097,0.027138926,0.000009415642,0.00002922785,0.96901715,0.0003667693,0.00037956136,0.0017289312,0.0002463022,0.0007901283,0.00002650383],"about_ca_topic_score_codex":0.0035038798,"about_ca_topic_score_gemma":0.0029209324,"teacher_disagreement_score":0.005646442,"about_ca_system_score_codex":0.001751602,"about_ca_system_score_gemma":0.0007395906,"threshold_uncertainty_score":0.012708843},"labels":[],"label_agreement":null},{"id":"W3036335108","doi":"10.1016/j.lungcan.2020.06.002","title":"Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Ottawa; Princess Margaret Cancer Centre; BC Cancer Agency; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Bristol-Myers Squibb Canada","keywords":"Concordance; Medicine; Cytology; Lung cancer; Biopsy; Immunohistochemistry; Pathology; Staining; PD-L1; Cancer; Internal medicine; Immunotherapy","score_opus":0.01781178098782026,"score_gpt":0.3258548896462878,"score_spread":0.3080431086584675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036335108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98398054,0.004764255,0.005374936,0.00017397453,0.00006625564,0.00015629653,0.0010597194,0.00016411445,0.0042599062],"genre_scores_gemma":[0.99082536,0.000970912,0.005524711,0.00013816368,0.000023448536,0.00008032131,0.0013281599,0.000019404863,0.0010895102],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994068,0.00006719983,0.000075279044,0.00012871242,0.00023294744,0.00008910141],"domain_scores_gemma":[0.9995202,0.000084107436,0.00006372948,0.000052448948,0.00021117786,0.00006838767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007986789,0.00028121192,0.0003017632,0.0016968079,0.0005568877,0.00064909755,0.00030535678,0.00046832714,0.0012644713],"category_scores_gemma":[0.0008265001,0.00028208192,0.00025467575,0.00063943694,0.0003150306,0.00037926828,0.0006427409,0.00035451693,0.00046386424],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007914871,0.000102364764,0.19483307,0.00041313254,0.00014043579,0.001967773,0.00036549493,0.00020135673,0.7694955,0.00015332254,0.000876765,0.03065939],"study_design_scores_gemma":[0.000049106024,0.0005614219,0.69130844,0.00009454833,0.00034594766,0.013463857,0.0013992495,0.0026933493,0.2753882,0.00030395194,0.014358108,0.00003390861],"about_ca_topic_score_codex":0.0008925794,"about_ca_topic_score_gemma":0.0026813236,"teacher_disagreement_score":0.0016968079,"about_ca_system_score_codex":0.0003262525,"about_ca_system_score_gemma":0.00048521016,"threshold_uncertainty_score":0.0042301416},"labels":[],"label_agreement":null},{"id":"W3037298679","doi":"10.1016/j.lungcan.2020.06.028","title":"Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; York University; University of Toronto","funders":"Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Medicine; Patient-reported outcome; Quality of life (healthcare); Lung cancer; Physical therapy; Receiver operating characteristic; Distress; Rating scale; Scale (ratio); Visual analogue scale; Multivariate analysis; Clinical psychology; Nursing; Internal medicine; Psychology","score_opus":0.03209781318424323,"score_gpt":0.3849937800934827,"score_spread":0.35289596690923947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037298679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972556,0.00055877323,0.0009417256,0.00011339886,0.000041364325,0.00019845525,0.00019462549,0.000006747745,0.0006892441],"genre_scores_gemma":[0.9978967,0.00019038588,0.0010975747,0.00014276386,0.000034765082,0.00023825644,0.00021601647,0.000010718845,0.00017286508],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9044093,0.07360691,0.0076154564,0.003882155,0.009217568,0.0012686104],"domain_scores_gemma":[0.8103483,0.15114348,0.02125144,0.007481962,0.008457146,0.0013177071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052306425,0.0006312049,0.0014930918,0.0011281676,0.00074440695,0.0027596832,0.0014929425,0.0018252939,0.0009893252],"category_scores_gemma":[0.14436367,0.00091249717,0.0033397104,0.001176069,0.0013239924,0.0025895874,0.0016724388,0.0017032858,0.00023910323],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044881618,0.001805028,0.9709171,0.00042933668,0.0028926646,0.000052791158,0.004527029,0.0003724472,0.00039663946,0.0002696598,0.00026892583,0.013580299],"study_design_scores_gemma":[0.0006157649,0.0066717537,0.982382,0.00017499727,0.0010345557,0.00024299092,0.003039947,0.0045065726,0.00038755848,0.00028937153,0.0005502011,0.00010431373],"about_ca_topic_score_codex":0.002665428,"about_ca_topic_score_gemma":0.003602523,"teacher_disagreement_score":0.052306425,"about_ca_system_score_codex":0.0010977215,"about_ca_system_score_gemma":0.00079446007,"threshold_uncertainty_score":0.27662617},"labels":[],"label_agreement":null},{"id":"W3037872250","doi":"10.1016/j.lungcan.2020.06.031","title":"Radiological-pathological correlation of subsolid pulmonary nodules: A single centre retrospective evaluation of the 2011 IASLC adenocarcinoma classification system","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pathological; Adenocarcinoma; Radiological weapon; Radiology; Retrospective cohort study; Correlation; Pathology; Internal medicine; Cancer","score_opus":0.054103775629033776,"score_gpt":0.3014180484604574,"score_spread":0.2473142728314236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037872250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99897754,0.00022865816,0.00010249561,0.000013381664,0.0000036428091,0.000015005059,0.00031186218,0.0000029872058,0.00034444855],"genre_scores_gemma":[0.99947935,0.00004992268,0.00008395262,0.000009756993,0.0000036284503,0.0000063017274,0.00031956378,0.0000023964483,0.00004513727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806195,0.00045322182,0.0003139554,0.00044097716,0.0004788771,0.0002509304],"domain_scores_gemma":[0.9961552,0.00059623877,0.0015305829,0.0003362982,0.0009579568,0.00042366737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015568659,0.00026899658,0.0005337908,0.0022559715,0.00054732745,0.0009878408,0.0005845351,0.000509764,0.00092434726],"category_scores_gemma":[0.0052029,0.00045956825,0.00051150576,0.001993349,0.00060990365,0.00082160113,0.0009372338,0.00037088495,0.00033934953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051975418,0.000006631101,0.99916184,0.000006497655,0.000012879131,0.00006108895,0.0000405731,0.000014092109,0.00021802,0.0000066548896,0.000021787106,0.00039795923],"study_design_scores_gemma":[0.0000016670803,0.000053460215,0.9989772,0.000003408116,0.0000149875195,0.00052808423,0.00019802431,0.00006401786,0.00006561374,0.0000056997637,0.000084688494,0.000003134576],"about_ca_topic_score_codex":0.006651369,"about_ca_topic_score_gemma":0.009915209,"teacher_disagreement_score":0.006651369,"about_ca_system_score_codex":0.00062892033,"about_ca_system_score_gemma":0.0006637122,"threshold_uncertainty_score":0.013225317},"labels":[],"label_agreement":null},{"id":"W3039432873","doi":"10.1016/j.lungcan.2020.06.032","title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Ignyta; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; MacroGenics; Juno Therapeutics; Pfizer; Incyte; Kite Pharma; Spectrum Pharmaceuticals; Yuhan; Merck KGaA; Regeneron Pharmaceuticals; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Oncology; Cohort; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.033566138407838154,"score_gpt":0.387555711866924,"score_spread":0.3539895734590858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039432873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8919322,0.04134216,0.0064342297,0.008390921,0.0008941604,0.0019449461,0.020390715,0.0006487254,0.02802198],"genre_scores_gemma":[0.9047844,0.012643375,0.009645607,0.0124894045,0.00089496456,0.0022878405,0.0483542,0.00021504337,0.008685142],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992367,0.000281773,0.00005045143,0.000065589426,0.00028573273,0.00007968895],"domain_scores_gemma":[0.9977099,0.0004719823,0.0006131667,0.00017373884,0.00054660573,0.0004845966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00483392,0.00043240777,0.0011342888,0.00023942077,0.00021372468,0.0012602108,0.0009538415,0.0007510977,0.002069041],"category_scores_gemma":[0.0023544086,0.00017861176,0.0010196053,0.00030339716,0.00021304189,0.0005753093,0.00043322388,0.0017226253,0.0005947755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12837774,0.0055943374,0.056014378,0.0021450368,0.0037273893,0.0004904177,0.00028204542,0.0035701792,0.04572155,0.0016442555,0.11055475,0.64187807],"study_design_scores_gemma":[0.16493824,0.1492174,0.27493718,0.0008736551,0.006700837,0.0031024301,0.00020327924,0.010175924,0.017935826,0.0018938776,0.36985892,0.00016242113],"about_ca_topic_score_codex":0.0011865777,"about_ca_topic_score_gemma":0.0034846973,"teacher_disagreement_score":0.00483392,"about_ca_system_score_codex":0.0009538634,"about_ca_system_score_gemma":0.0011032195,"threshold_uncertainty_score":0.025564551},"labels":[],"label_agreement":null},{"id":"W3043250176","doi":"10.1016/j.lungcan.2020.07.014","title":"Mechanisms of osimertinib resistance and emerging treatment options","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Osimertinib; Medicine; Acquired resistance; Cancer research; Epidermal growth factor receptor; Internal medicine; Receptor; Cancer","score_opus":0.03198790611506145,"score_gpt":0.4082846209134547,"score_spread":0.3762967147983932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043250176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009297775,0.99845195,0.00007579048,0.00042139884,0.00013686149,0.0000033193853,0.000025797872,0.000006314713,0.00078557385],"genre_scores_gemma":[0.00061987026,0.99821484,0.00013453305,0.00035898204,0.00017945618,0.0000053158637,0.000039439565,0.000001096158,0.00044645643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998388,0.000029594095,0.000024172201,0.00002947186,0.000055187276,0.000022726594],"domain_scores_gemma":[0.9997036,0.00016028993,0.00005335225,0.000005533914,0.000054204884,0.00002292344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006277502,0.0007294863,0.0014329262,0.0014169661,0.00017073142,0.0011777321,0.0007791507,0.0010350961,0.0046578418],"category_scores_gemma":[0.0009151236,0.00022670721,0.0006038613,0.0013194587,0.00035993132,0.0011417724,0.0005498336,0.0018048286,0.0013264997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014775974,0.00004685383,0.00019626353,0.014913722,0.0001222412,0.0001244473,0.000029259707,0.0005009743,0.0009174336,0.0036399956,0.032443207,0.9469178],"study_design_scores_gemma":[0.000083607294,0.0001623339,0.0010384422,0.007724661,0.00040785686,0.00094917364,0.00006166821,0.00027139005,0.00034612927,0.003407169,0.985523,0.000024695773],"about_ca_topic_score_codex":0.001141427,"about_ca_topic_score_gemma":0.0032339105,"teacher_disagreement_score":0.0046578418,"about_ca_system_score_codex":0.0007150706,"about_ca_system_score_gemma":0.0011058911,"threshold_uncertainty_score":0.015582025},"labels":[],"label_agreement":null},{"id":"W3045441518","doi":"10.1016/j.lungcan.2020.07.020","title":"Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cancer registry; Retrospective cohort study; Cancer; Oncology; Population; Neutropenia; Univariate analysis; Incidence (geometry); Chemotherapy; Surgery; Multivariate analysis","score_opus":0.011311917309429615,"score_gpt":0.3030001983973754,"score_spread":0.2916882810879458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045441518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99892837,0.00014762934,0.00009211742,0.000009523919,0.0000034318593,0.0000063577627,0.00044330658,0.0000028378654,0.0003664384],"genre_scores_gemma":[0.9992756,0.00006954491,0.000036751368,0.000014432919,0.0000071459717,0.0000055969413,0.00050453923,0.0000018771254,0.00008450627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921393,0.00017476577,0.00013542031,0.0001994257,0.000122623,0.00015379167],"domain_scores_gemma":[0.9982785,0.00026318745,0.0006960315,0.00021008981,0.00021126377,0.00034096226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075579766,0.00027934433,0.00035041873,0.0011356961,0.0007323114,0.0008235478,0.00038331663,0.00046055362,0.0015420686],"category_scores_gemma":[0.0016726985,0.00043417353,0.00054432114,0.001515064,0.0004521904,0.0006099016,0.00070422236,0.00051040726,0.00030830986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012883416,0.000025148418,0.99918586,0.000005358913,0.000038264672,0.00008091899,0.000044427692,0.000020647065,0.0001123028,0.000013894105,0.000039353436,0.00030497182],"study_design_scores_gemma":[0.000008205507,0.000196386,0.9982522,0.000003737771,0.000035574565,0.000707671,0.00037079764,0.00009317092,0.00008643815,0.00001888677,0.00022189155,0.000004971312],"about_ca_topic_score_codex":0.0062456704,"about_ca_topic_score_gemma":0.0046459744,"teacher_disagreement_score":0.0062456704,"about_ca_system_score_codex":0.00050050183,"about_ca_system_score_gemma":0.00051510095,"threshold_uncertainty_score":0.012418628},"labels":[],"label_agreement":null},{"id":"W3046772302","doi":"10.1016/j.lungcan.2020.07.013","title":"PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; Cystic Fibrosis Canada; University of Toronto","funders":"University Health Network","keywords":"Medicine; Adenocarcinoma; Immunohistochemistry; Pathology; PD-L1; clone (Java method); Flow cytometry; Lung cancer; Carcinoma; Antibody; Antigen; Concordance; Cancer; Immunotherapy; Internal medicine; Immunology; Biology","score_opus":0.026740633659572962,"score_gpt":0.3051447161582569,"score_spread":0.2784040824986839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046772302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754701,0.0030759107,0.016233595,0.00012758441,0.00004367904,0.000120023076,0.0006732068,0.00017832889,0.004077513],"genre_scores_gemma":[0.9827004,0.0010624018,0.013082287,0.00014681481,0.000035949502,0.00023146583,0.00065228407,0.000020921338,0.0020673596],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9996879,0.00006451096,0.0000303904,0.000080284655,0.0000818732,0.000055048433],"domain_scores_gemma":[0.9999019,0.000024681844,0.00001861272,0.000011766399,0.000027251455,0.000015738606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003961535,0.00019502074,0.00014469617,0.0006914628,0.00027045852,0.0005115153,0.00016797917,0.00032011635,0.0013969969],"category_scores_gemma":[0.0003413378,0.00012467167,0.0001061871,0.00036272145,0.00016603705,0.00031003953,0.00027628432,0.00042581698,0.00033542415],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029749068,0.00005818358,0.009027025,0.00011247729,0.000016979102,0.00007330711,0.00019274067,0.00018612674,0.9752685,0.00044620535,0.0001995061,0.014121538],"study_design_scores_gemma":[0.00004424765,0.0003958291,0.050903853,0.000032329175,0.00007072691,0.00089240854,0.00025690164,0.013552313,0.9219744,0.0005854629,0.011276137,0.000015272442],"about_ca_topic_score_codex":0.00019680915,"about_ca_topic_score_gemma":0.00030824283,"teacher_disagreement_score":0.0013969969,"about_ca_system_score_codex":0.00019659215,"about_ca_system_score_gemma":0.00014535482,"threshold_uncertainty_score":0.004673362},"labels":[],"label_agreement":null},{"id":"W3083196805","doi":"10.1016/j.lungcan.2020.09.002","title":"Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"BAP1; Mesothelioma; Peritoneal mesothelioma; Germline mutation; Exome sequencing; Cancer research; Copy number analysis; Somatic cell; Germline; Fluorescence in situ hybridization; Exome; Biology; Pathology; Copy-number variation; Mutation; Medicine; Genetics; Gene; Chromosome; Genome","score_opus":0.022117794658010108,"score_gpt":0.2903933627755822,"score_spread":0.2682755681175721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083196805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993786,0.00048582003,0.0007142127,0.00034067966,0.000028447197,0.000011066796,0.002277919,0.000077586556,0.0022783135],"genre_scores_gemma":[0.99576426,0.0003069086,0.00060176774,0.00011658482,0.000012267553,0.000007223024,0.001207115,0.000017286367,0.0019665898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998068,0.000009587278,0.000015103865,0.00006952126,0.000065427004,0.00003351287],"domain_scores_gemma":[0.99978036,0.000084625666,0.000046385896,0.000027562239,0.00002718445,0.00003390058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013888012,0.0003499977,0.00017413872,0.0007942924,0.0004450487,0.00066497596,0.0002634148,0.0009490566,0.00414348],"category_scores_gemma":[0.0006037991,0.00019080698,0.0003607446,0.00045514342,0.00024505082,0.00020009222,0.00041414,0.0004178994,0.0006907287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008019956,0.00008911843,0.120419435,0.00018341141,0.00025033197,0.017345488,0.0006000357,0.00092546147,0.8242927,0.00044700308,0.0017363784,0.032908496],"study_design_scores_gemma":[0.00006412885,0.0003429617,0.7741779,0.00007110449,0.00043172756,0.05853909,0.0011147952,0.0029666428,0.14353152,0.0014571974,0.01726814,0.00003486043],"about_ca_topic_score_codex":0.001273212,"about_ca_topic_score_gemma":0.0027765885,"teacher_disagreement_score":0.00414348,"about_ca_system_score_codex":0.00025888387,"about_ca_system_score_gemma":0.00014364232,"threshold_uncertainty_score":0.013861299},"labels":[],"label_agreement":null},{"id":"W3093890556","doi":"10.1016/j.lungcan.2020.10.008","title":"Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Associazione Italiana per la Ricerca sul Cancro; MedImmune; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; Seattle Genetics; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Novartis; Ipsen; British Mycological Society; Daiichi-Sankyo; United Therapeutics Corporation; MSD Life Science Foundation, Public Interest Incorporated Foundation; Bayer; Celgene; AstraZeneca; Roche; Astellas Pharma US; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Clinical endpoint; Chemotherapy; Immunotherapy; Retrospective cohort study; Confidence interval; Gemcitabine; Hazard ratio; Cancer; Clinical trial","score_opus":0.007440933025061391,"score_gpt":0.3071473753137865,"score_spread":0.2997064422887251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093890556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728155,0.001255483,0.00010935802,0.00006772551,0.00001009073,0.00003220945,0.0007737108,0.0000027746678,0.00046714453],"genre_scores_gemma":[0.9974694,0.00039381883,0.00010201599,0.00012705676,0.000039682487,0.000027396078,0.0016469023,0.000005880123,0.0001878793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986953,0.00043717268,0.00012529739,0.00040270452,0.00013327463,0.00020636646],"domain_scores_gemma":[0.9968978,0.0005106294,0.001614463,0.0004272527,0.0002325322,0.00031727058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015165176,0.00043532567,0.0007697689,0.00057126314,0.0005257662,0.0009812228,0.00063068717,0.00090393756,0.001324864],"category_scores_gemma":[0.0035261416,0.00057701033,0.0010577937,0.0013693861,0.00052171387,0.0011256175,0.0008090933,0.0007011002,0.0002633676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041606245,0.00015722123,0.9914705,0.000042985255,0.0005289624,0.00013634864,0.000115808325,0.00010672671,0.00069999526,0.000085847816,0.00036569138,0.0021292379],"study_design_scores_gemma":[0.00029217583,0.00067355,0.99715096,0.000017175827,0.00036719264,0.00024601092,0.00019031872,0.00011889516,0.000105530635,0.000035378354,0.00079049164,0.000012377539],"about_ca_topic_score_codex":0.0056526028,"about_ca_topic_score_gemma":0.007874095,"teacher_disagreement_score":0.0056526028,"about_ca_system_score_codex":0.0008179149,"about_ca_system_score_gemma":0.00057826197,"threshold_uncertainty_score":0.011239409},"labels":[],"label_agreement":null},{"id":"W3096141323","doi":"10.1183/13993003.congress-2020.2925","title":"Performance and safety of endoscopic procedures in superior vena cava syndrome","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Airway Management and Intubation Techniques","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Superior vena cava syndrome; Surgery; Pneumothorax; Superior vena cava; Malignancy; Bronchoscopy; Airway; Radiology; Airway obstruction; Fistula; Internal medicine","score_opus":0.01011679245102978,"score_gpt":0.2730615732906085,"score_spread":0.26294478083957873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096141323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971808,0.0014132998,0.00039288343,0.0001435814,0.000016829252,0.000006128725,0.00005592588,0.000012871811,0.0007775837],"genre_scores_gemma":[0.999398,0.0002263195,0.00018513844,0.00003319245,0.000033589764,0.0000027196932,0.00007557914,0.0000032472485,0.000042286585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990922,0.00029756944,0.00012837627,0.0001117241,0.00026216297,0.00010798043],"domain_scores_gemma":[0.99213964,0.003148744,0.0028737364,0.00028201926,0.00067338976,0.0008823476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012687994,0.00017737724,0.00019845461,0.0006706336,0.00025218865,0.0004464164,0.0002078167,0.00061377743,0.0012264012],"category_scores_gemma":[0.013509774,0.000090975045,0.000285929,0.00046718103,0.00039153104,0.00046208594,0.0002836369,0.0004062928,0.0002723763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003084788,0.000042289554,0.9754723,0.000038861403,0.000030464847,0.0016274629,0.00006170382,0.00023247767,0.0007977049,0.000025450447,0.00023906762,0.021123642],"study_design_scores_gemma":[0.00001107261,0.0006611913,0.9861687,0.000046544046,0.000027621125,0.010744539,0.00015932985,0.0009507313,0.00083741976,0.000043514305,0.0003403633,0.00000908316],"about_ca_topic_score_codex":0.0009552731,"about_ca_topic_score_gemma":0.0008955188,"teacher_disagreement_score":0.0012687994,"about_ca_system_score_codex":0.0003187754,"about_ca_system_score_gemma":0.0003929834,"threshold_uncertainty_score":0.0067101717},"labels":[],"label_agreement":null},{"id":"W3096173347","doi":"10.1016/j.lungcan.2020.10.023","title":"Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Immunotherapy; Logistic regression; Odds ratio; Cancer; Cohort; PD-L1","score_opus":0.008505465539782077,"score_gpt":0.2914343701218268,"score_spread":0.2829289045820447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096173347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763227,0.0007303661,0.00004649279,0.000121187564,0.0000187363,0.000004913107,0.00023648082,0.000005534617,0.0012039773],"genre_scores_gemma":[0.99902153,0.00011271165,0.000018422565,0.00006770891,0.000019139801,0.000003994119,0.00019392537,0.0000014550001,0.0005610301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997639,0.000052104384,0.000020844605,0.000053722528,0.000034399996,0.00007500921],"domain_scores_gemma":[0.9994554,0.00017814801,0.00019407547,0.000023293976,0.00004449362,0.000104683684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003228493,0.00013100445,0.00023613671,0.00032069153,0.00026929937,0.00067038403,0.00020378691,0.00055240706,0.002476029],"category_scores_gemma":[0.0012493118,0.00013767407,0.000349204,0.0004334187,0.00018151413,0.0004540505,0.00026386877,0.00064966135,0.0003891293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011109607,0.000104173174,0.9929295,0.000017897484,0.00007880085,0.00011450016,0.000051049265,0.00009953963,0.0006479994,0.00003632613,0.00021250577,0.004596858],"study_design_scores_gemma":[0.00002762668,0.00045016425,0.99642855,0.000014927884,0.000101406855,0.00047807858,0.00024590065,0.00070629525,0.00030462892,0.0001406216,0.0010940034,0.000007857189],"about_ca_topic_score_codex":0.0010056831,"about_ca_topic_score_gemma":0.0015385359,"teacher_disagreement_score":0.002476029,"about_ca_system_score_codex":0.00027044254,"about_ca_system_score_gemma":0.00019559206,"threshold_uncertainty_score":0.008283138},"labels":[],"label_agreement":null},{"id":"W3097246853","doi":"10.1016/j.lungcan.2020.10.015","title":"Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; British Microcirculation Society; Boehringer Ingelheim; Roche","keywords":"Medicine; Series (stratigraphy); Morphology (biology); Pathology; Neuroendocrine differentiation; Internal medicine; Biology; Zoology; Cancer; Paleontology","score_opus":0.014150203855641454,"score_gpt":0.3237106748629496,"score_spread":0.3095604710073081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097246853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012655715,0.9969531,0.00022250469,0.00027916484,0.0001536468,0.000005452304,0.000031325853,0.000009429832,0.0010797642],"genre_scores_gemma":[0.006282108,0.9921732,0.00043532593,0.00029499986,0.00034251405,0.0000043784235,0.00004785716,0.000001959615,0.000417685],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998066,0.000028368559,0.00005407065,0.000039734332,0.00005265445,0.00001848865],"domain_scores_gemma":[0.99965894,0.00017578657,0.0000759054,0.0000111275585,0.00004404738,0.00003410691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000266608,0.0008218286,0.001107693,0.0042776843,0.00035747397,0.001063526,0.00059741904,0.0008756004,0.0017691433],"category_scores_gemma":[0.0007246441,0.00022248147,0.00046225314,0.0036703933,0.00050795363,0.0013434746,0.00061263226,0.00081173907,0.00072321226],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010294526,0.00008340275,0.004728744,0.02659247,0.00027315982,0.05772853,0.0004109858,0.0006760409,0.0058655436,0.0015340495,0.02481586,0.8771884],"study_design_scores_gemma":[0.000021932861,0.00012829348,0.012525765,0.012283897,0.0008269355,0.36099872,0.0009452654,0.00034462006,0.0012965675,0.0018333984,0.60869515,0.000099510165],"about_ca_topic_score_codex":0.0009903399,"about_ca_topic_score_gemma":0.0024341124,"teacher_disagreement_score":0.0042776843,"about_ca_system_score_codex":0.00037199896,"about_ca_system_score_gemma":0.0008162226,"threshold_uncertainty_score":0.005918443},"labels":[],"label_agreement":null},{"id":"W3107615104","doi":"10.1016/j.lungcan.2020.11.029","title":"The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Norges Idrettshøgskole","keywords":"Medicine; Underweight; Body mass index; Overweight; Internal medicine; Lung cancer; Hazard ratio; Obesity; Obesity paradox; Demography; Oncology; Proportional hazards model; Confidence interval","score_opus":0.014965659577513226,"score_gpt":0.3041517916218181,"score_spread":0.2891861320443049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107615104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766435,0.018176053,0.00068877294,0.00007487513,0.00007210896,0.00003158814,0.0035837006,0.000036042737,0.00069336995],"genre_scores_gemma":[0.99489117,0.0017239846,0.00016609063,0.000055624423,0.00006849958,0.00002885625,0.002791999,0.000014286283,0.00025939188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980768,0.00072888203,0.0002820718,0.00048883545,0.00023192371,0.00019148555],"domain_scores_gemma":[0.9976804,0.000864432,0.0005701903,0.00042029392,0.00026722232,0.00019740716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029297057,0.0009559628,0.002477119,0.0020625785,0.00039254103,0.0010356703,0.0005757139,0.0007139028,0.0009041335],"category_scores_gemma":[0.0033179244,0.0007363429,0.006330931,0.0023474332,0.0002670015,0.00066304964,0.00086504006,0.000515968,0.00017241367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056921933,0.000043521795,0.95390195,0.00024941214,0.03316743,0.00012306403,0.00006247946,0.00029987682,0.00080753025,0.00001911792,0.00043723837,0.005196262],"study_design_scores_gemma":[0.00016534612,0.00039760463,0.9769836,0.000027578983,0.021091728,0.00016312346,0.00011711084,0.00042632123,0.00013955563,0.00003497506,0.0004315844,0.000021467371],"about_ca_topic_score_codex":0.0075008124,"about_ca_topic_score_gemma":0.015010412,"teacher_disagreement_score":0.0075008124,"about_ca_system_score_codex":0.00039108208,"about_ca_system_score_gemma":0.0004087495,"threshold_uncertainty_score":0.015493929},"labels":[],"label_agreement":null},{"id":"W3108642522","doi":"10.1016/j.lungcan.2020.11.015","title":"A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Saskatchewan Cancer Agency; Mount Sinai Hospital; McMaster University; Alberta Cancer Foundation; William Osler Health System; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.024112624666970464,"score_gpt":0.3370667255501405,"score_spread":0.31295410088317005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108642522","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020925436,0.00040812406,0.00013633228,0.9787225,0.019764934,0.000014909599,0.0002030402,0.000025513875,0.0005153386],"genre_scores_gemma":[0.0010943677,0.0002503691,0.00021104798,0.9849996,0.011165082,0.00005021978,0.000054440683,0.000023662924,0.0021511526],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940394,0.002165029,0.0008186782,0.00092621025,0.00135064,0.0007000489],"domain_scores_gemma":[0.9714137,0.020244466,0.0014412551,0.00070030143,0.0040284307,0.0021718598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010577413,0.0010338732,0.0018465021,0.0007793208,0.003576528,0.0039019715,0.0026302976,0.04980978,0.007142738],"category_scores_gemma":[0.05731901,0.0011564333,0.0022737992,0.00084146165,0.002343332,0.0035464496,0.002182134,0.05719683,0.0067799576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081941595,0.000021987184,0.00040409568,0.000040582916,0.000023638304,0.00017436767,0.00006161644,0.00007473357,0.000065555774,0.0012190175,0.9951331,0.0026994362],"study_design_scores_gemma":[0.00047881858,0.00015985228,0.0022304922,0.0004999656,0.00014743595,0.00058624527,0.00048625545,0.0011613918,0.00059127616,0.010643636,0.9828268,0.00018772653],"about_ca_topic_score_codex":0.01266814,"about_ca_topic_score_gemma":0.01784048,"teacher_disagreement_score":0.04980978,"about_ca_system_score_codex":0.0052052108,"about_ca_system_score_gemma":0.007336219,"threshold_uncertainty_score":0.055939376},"labels":[],"label_agreement":null},{"id":"W3116093824","doi":"10.1016/j.lungcan.2020.12.026","title":"Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; AstraZeneca France; Pfizer; British Microcirculation Society; Boehringer Ingelheim; AbbVie; Roche","keywords":"Medicine; Lung cancer; Incidence (geometry); Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Medical record; Oncology; Retrospective cohort study; Disease; Progressive disease","score_opus":0.010774719639024865,"score_gpt":0.25192111033758624,"score_spread":0.24114639069856136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116093824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735177,0.0014898994,0.00023584999,0.00007678836,0.000006194448,0.000028644337,0.00037055713,0.0000040486607,0.00043632064],"genre_scores_gemma":[0.9989605,0.00027198123,0.00016775736,0.00001940281,0.000010529004,0.000017265547,0.00052996253,0.0000010872864,0.000021568663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986154,0.00040132395,0.0003937835,0.00017524137,0.0002996036,0.00011465088],"domain_scores_gemma":[0.99511933,0.00096527144,0.0030986578,0.00020055045,0.00040314626,0.00021305527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020900278,0.00016032966,0.0002613298,0.0011870221,0.00034143662,0.0005186002,0.00044774907,0.0002382912,0.00039441691],"category_scores_gemma":[0.0053437296,0.000100074496,0.0003181084,0.0012818597,0.00035163653,0.00047595525,0.0005582828,0.0003424826,0.00008250518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003800219,0.00000458294,0.99831176,0.000013296319,0.000009518113,0.00006743373,0.000042150525,0.000031783857,0.000042242962,0.000012427713,0.00004571035,0.0013811686],"study_design_scores_gemma":[0.0000053843855,0.00005989667,0.9970835,0.00003279235,0.000031659554,0.0014751339,0.00032498813,0.0003966231,0.00016948929,0.000059495935,0.00035693953,0.000004099527],"about_ca_topic_score_codex":0.0009406902,"about_ca_topic_score_gemma":0.001649151,"teacher_disagreement_score":0.0020900278,"about_ca_system_score_codex":0.00039602912,"about_ca_system_score_gemma":0.0005635475,"threshold_uncertainty_score":0.011053205},"labels":[],"label_agreement":null},{"id":"W3118230868","doi":"10.1016/j.lungcan.2020.12.029","title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Roche; Merck; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb Canada; Boehringer Ingelheim","keywords":"SABR volatility model; Medicine; Radiation therapy; Clinical endpoint; Lung cancer; Oncology; Internal medicine; Randomized controlled trial","score_opus":0.020383404452767706,"score_gpt":0.3443107984212012,"score_spread":0.3239273939684335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118230868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99911016,0.00049394433,0.000049204536,0.000029812456,0.000013199847,0.000060299077,0.00010353947,0.0000056569593,0.00013420629],"genre_scores_gemma":[0.9983589,0.00048399126,0.00015221004,0.00009542572,0.00005108195,0.00007795547,0.00044229647,0.0000065603494,0.00033159662],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999534,0.00021521948,0.000023830336,0.00010092484,0.00005558884,0.00007036361],"domain_scores_gemma":[0.9987453,0.0003341106,0.00043494056,0.00010992349,0.000057508434,0.00031816153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016735841,0.0011878234,0.0010881025,0.00032103047,0.00039461022,0.0009011325,0.0005909334,0.0008003527,0.0014305054],"category_scores_gemma":[0.0011975819,0.00049913116,0.0011590414,0.0005475362,0.0009972816,0.00064467406,0.0003398194,0.0013858053,0.00028333743],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5942692,0.02610714,0.28167397,0.0005713011,0.0042552613,0.0002907748,0.00033412102,0.0014164294,0.034525186,0.00013658787,0.0010923232,0.055327658],"study_design_scores_gemma":[0.06465953,0.28388172,0.64070886,0.000040786712,0.003510031,0.00063115545,0.00018501228,0.0015186213,0.0030859609,0.00017836376,0.00153438,0.00006558051],"about_ca_topic_score_codex":0.0011168949,"about_ca_topic_score_gemma":0.0019719752,"teacher_disagreement_score":0.0016735841,"about_ca_system_score_codex":0.00046688257,"about_ca_system_score_gemma":0.0007970527,"threshold_uncertainty_score":0.008850813},"labels":[],"label_agreement":null},{"id":"W3126845260","doi":"10.1016/j.lungcan.2021.01.025","title":"Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Neutropenia; Internal medicine; Regimen; Incidence (geometry); Febrile neutropenia; Granulocyte colony-stimulating factor; Gastroenterology; Randomized controlled trial; Radiation therapy; Lung cancer; Chemotherapy; Surgery; Oncology","score_opus":0.01929891310890295,"score_gpt":0.36019842857951406,"score_spread":0.3408995154706111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126845260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98543036,0.0062299254,0.0007362924,0.00068231777,0.0004861743,0.0023836591,0.0018556414,0.00010937363,0.0020861863],"genre_scores_gemma":[0.9921928,0.0012168864,0.000775808,0.000585207,0.00031264988,0.0019324099,0.0013933409,0.00003404663,0.0015569426],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99744093,0.0018225027,0.000094844465,0.000287581,0.00012927281,0.00022484254],"domain_scores_gemma":[0.99758244,0.0009078578,0.00055562507,0.00031409317,0.00017067735,0.00046934147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034892508,0.0017556912,0.0036989334,0.00044169207,0.0005171714,0.0014949541,0.0012371141,0.002024446,0.0054582492],"category_scores_gemma":[0.0045263106,0.00050211675,0.0045370683,0.00066183304,0.0016307032,0.0012138285,0.0007265,0.00393022,0.0008632742],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99156296,0.0008051718,0.00044510418,0.00026740198,0.0008113788,0.000014128117,0.000016743763,0.00026241984,0.0007200597,0.00005275731,0.00033364465,0.0047082254],"study_design_scores_gemma":[0.9300114,0.06307186,0.0036852723,0.0000634218,0.001231522,0.0000460439,0.0000312646,0.0003660808,0.00053639064,0.00031727672,0.0006237839,0.000015732392],"about_ca_topic_score_codex":0.0018653787,"about_ca_topic_score_gemma":0.0026445754,"teacher_disagreement_score":0.0054582492,"about_ca_system_score_codex":0.0014833658,"about_ca_system_score_gemma":0.0020268008,"threshold_uncertainty_score":0.01845318},"labels":[],"label_agreement":null},{"id":"W3130089277","doi":"10.1016/j.lungcan.2021.02.030","title":"MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Roche; Merck; AstraZeneca","keywords":"Medicine; Discontinuation; Crizotinib; Internal medicine; Oncology; Lung cancer; Targeted therapy; Population; Chemotherapy; Cancer","score_opus":0.01069406291528424,"score_gpt":0.3345778876241834,"score_spread":0.32388382470889915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130089277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855724,0.005015266,0.0005790442,0.0013251938,0.00016294993,0.00015090914,0.00056715874,0.00004130512,0.006585748],"genre_scores_gemma":[0.9951155,0.000950842,0.00041893442,0.0005239577,0.00009027301,0.000048797847,0.00083088956,0.000010177111,0.0020106684],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99991715,0.000010480174,0.0000067750193,0.000022881288,0.000014848838,0.000027832757],"domain_scores_gemma":[0.9998574,0.00003528731,0.000018601811,0.0000070710103,0.000015667747,0.000065972425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014907098,0.00021319327,0.0006121317,0.00014925319,0.00027902357,0.0002973523,0.00014070762,0.00038077374,0.001274069],"category_scores_gemma":[0.00027294093,0.00006677253,0.00034504934,0.00022228343,0.0001459125,0.00018375093,0.00012045962,0.0006499577,0.00016247547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04382607,0.0038659382,0.28793734,0.0006609647,0.0007751807,0.053183287,0.00052534003,0.0059886617,0.12088367,0.0008636627,0.014609802,0.4668801],"study_design_scores_gemma":[0.0027699242,0.02961273,0.8575211,0.00018893414,0.0010291395,0.054504365,0.0005993462,0.007324445,0.016651688,0.0013349284,0.028385943,0.00007745498],"about_ca_topic_score_codex":0.00092999084,"about_ca_topic_score_gemma":0.003106299,"teacher_disagreement_score":0.001274069,"about_ca_system_score_codex":0.0005706175,"about_ca_system_score_gemma":0.00028383464,"threshold_uncertainty_score":0.004262209},"labels":[],"label_agreement":null},{"id":"W3134321408","doi":"10.1016/j.lungcan.2021.02.019","title":"A reply to “Lung cancer outcomes: Are BMI and race clinically relevant?”","year":2021,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Race (biology); Lung cancer; Oncology; Internal medicine","score_opus":0.02857701456576859,"score_gpt":0.3799848214228085,"score_spread":0.3514078068570399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134321408","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020723473,0.0005279221,0.000033395023,0.98455334,0.014117014,0.000008223351,0.00007981614,0.000006630417,0.00046646208],"genre_scores_gemma":[0.00089510594,0.0003090213,0.000060584243,0.9747762,0.022588812,0.000025837813,0.000035087654,0.000007898279,0.0013014522],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920879,0.0024979776,0.0014921711,0.0010292873,0.0015122865,0.0013803802],"domain_scores_gemma":[0.9676453,0.020439321,0.0023127527,0.0007277451,0.0044802506,0.0043946616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009269419,0.0013631963,0.0031792207,0.0015480923,0.0074031255,0.0059957155,0.0032386035,0.093433395,0.00801323],"category_scores_gemma":[0.062646925,0.0017995404,0.0023554147,0.001726358,0.003986789,0.004733953,0.0037586063,0.08479537,0.0075466763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063727566,0.000030708034,0.0021164634,0.00006295089,0.000039344966,0.000770383,0.00023547464,0.00003549786,0.00008347882,0.000836621,0.9920706,0.0036548323],"study_design_scores_gemma":[0.00040131607,0.00015546376,0.0093624545,0.0017112092,0.00027455343,0.0021675574,0.0028391848,0.0007947691,0.00032807264,0.010900505,0.970786,0.00027896292],"about_ca_topic_score_codex":0.016660696,"about_ca_topic_score_gemma":0.02603945,"teacher_disagreement_score":0.093433395,"about_ca_system_score_codex":0.0058467174,"about_ca_system_score_gemma":0.009618456,"threshold_uncertainty_score":0.04902196},"labels":[],"label_agreement":null},{"id":"W3135006396","doi":"10.1016/j.lungcan.2021.02.036","title":"Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; Toronto Western Hospital; Southlake Regional Health Center; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Radiosurgery; Incidence (geometry); Lung cancer; Internal medicine; Proportional hazards model; Oncology; Concomitant; Toxicity; Radiation therapy","score_opus":0.01833466819261894,"score_gpt":0.3719808780207105,"score_spread":0.3536462098280916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135006396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935173,0.003023675,0.00011796788,0.0004951041,0.00006906297,0.000008426311,0.0002809104,0.0000077979485,0.0024797986],"genre_scores_gemma":[0.99873835,0.00040506994,0.00003226197,0.000103922874,0.000046077952,0.000003830822,0.0003357696,0.00000324687,0.00033142196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994623,0.000113775466,0.00005853309,0.00007013448,0.00012415503,0.00017119544],"domain_scores_gemma":[0.9987507,0.0003271967,0.0005068935,0.00004201419,0.00012381925,0.00024937245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005599623,0.00019833543,0.0004516827,0.00028876885,0.00027806356,0.0005934951,0.0003565562,0.00046656645,0.0018993502],"category_scores_gemma":[0.0036027213,0.00007147202,0.0013383235,0.00036819087,0.00029599297,0.00051441963,0.00040418722,0.00070015807,0.00019340854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006478204,0.00044106602,0.90203995,0.0001982631,0.0016230431,0.0007846645,0.00018345626,0.0023303502,0.0017637651,0.00032727845,0.0017328464,0.08209711],"study_design_scores_gemma":[0.00004636339,0.0017209974,0.99515355,0.000049251452,0.0004987789,0.0006124341,0.00018715103,0.0005769355,0.00021515206,0.00032246226,0.0006000175,0.000016845277],"about_ca_topic_score_codex":0.0067748926,"about_ca_topic_score_gemma":0.021025531,"teacher_disagreement_score":0.0067748926,"about_ca_system_score_codex":0.0009582868,"about_ca_system_score_gemma":0.00070011074,"threshold_uncertainty_score":0.013470948},"labels":[],"label_agreement":null},{"id":"W3143892312","doi":"10.1016/j.lungcan.2021.03.017","title":"Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stage (stratigraphy); Adenocarcinoma; Lung cancer; Radiology; Confidence interval; Radiation therapy; Cancer; Nuclear medicine; Internal medicine","score_opus":0.005371146779315362,"score_gpt":0.26998970909895226,"score_spread":0.2646185623196369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143892312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817846,0.009358176,0.001584148,0.00008896936,0.00010151652,0.000098085504,0.005654342,0.000060014474,0.0012701812],"genre_scores_gemma":[0.9940282,0.00089049945,0.0003908185,0.00010468204,0.000063842665,0.00009139651,0.003997074,0.00004061455,0.00039291722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99322355,0.0021074186,0.0008202522,0.0024546003,0.00057972973,0.0008144512],"domain_scores_gemma":[0.9922389,0.0023076313,0.0025299108,0.0014008759,0.0010702492,0.00045254276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045050364,0.0017430002,0.003473512,0.0027213334,0.0006369772,0.0023513273,0.0014143694,0.0014687497,0.0019476144],"category_scores_gemma":[0.008399798,0.0013673843,0.008738897,0.0055837077,0.00066887855,0.0012845382,0.001859662,0.0010140989,0.00036643827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043492485,0.000058256122,0.9535668,0.0005760909,0.03452815,0.00019479434,0.00046160506,0.00064816436,0.00048529715,0.00007448074,0.001117486,0.0039396062],"study_design_scores_gemma":[0.00022718486,0.0005063063,0.97909045,0.00012307403,0.017401883,0.00023773352,0.00084541016,0.0006222405,0.00013458308,0.00006635402,0.0006907361,0.00005410217],"about_ca_topic_score_codex":0.022863662,"about_ca_topic_score_gemma":0.02415883,"teacher_disagreement_score":0.022863662,"about_ca_system_score_codex":0.00096025266,"about_ca_system_score_gemma":0.00095021015,"threshold_uncertainty_score":0.045461178},"labels":[],"label_agreement":null},{"id":"W3153040841","doi":"10.1016/j.lungcan.2021.04.005","title":"Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors – The Ontario experience","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Toronto General Hospital; University of Toronto; University Health Network; Women's College Hospital; Cancer Care Ontario; Princess Margaret Cancer Centre; Brock University","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Population; Cancer registry; Cancer; Risk assessment; Categorical variable; Environmental health; Internal medicine; Statistics","score_opus":0.01835187791511211,"score_gpt":0.3005128474192939,"score_spread":0.2821609695041818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153040841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98656195,0.00039103354,0.0004463384,0.0020424193,0.000032358774,0.000054928394,0.00059892837,0.000010909694,0.009861187],"genre_scores_gemma":[0.99498135,0.00037526354,0.0005761308,0.00019826645,0.000016517895,0.000017554674,0.00054288295,0.000019068471,0.0032730366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827075,0.00043621173,0.00007571416,0.00015492187,0.0007727876,0.00028955142],"domain_scores_gemma":[0.99237484,0.0016366306,0.00077313825,0.00054776884,0.0027105266,0.0019572077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033647607,0.0002997052,0.00044472085,0.00044131707,0.0020872094,0.0011341668,0.00076853053,0.0004711499,0.0018571456],"category_scores_gemma":[0.010009553,0.00028223768,0.00068563607,0.0012876476,0.0008728182,0.00062919466,0.0008685622,0.00071604614,0.0002760484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061936467,0.00018284917,0.9604356,0.00002928425,0.00011136104,0.00028178576,0.0026013223,0.0012739261,0.00028078197,0.0005231699,0.0072742607,0.026386198],"study_design_scores_gemma":[0.000084012325,0.0001484593,0.9873974,0.000030160902,0.00007033813,0.00015252586,0.002108448,0.0030473114,0.00015563432,0.00024006765,0.006529758,0.00003581996],"about_ca_topic_score_codex":0.9646226,"about_ca_topic_score_gemma":0.98572737,"teacher_disagreement_score":0.035377383,"about_ca_system_score_codex":0.018956883,"about_ca_system_score_gemma":0.023681069,"threshold_uncertainty_score":0.13754249},"labels":[],"label_agreement":null},{"id":"W3155565607","doi":"10.1016/j.lungcan.2021.04.006","title":"Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Oncology; Immune checkpoint; Internal medicine; Disease; Prophylactic cranial irradiation; Immune system; Immunotherapy; Cancer; Immunology","score_opus":0.005355088471290016,"score_gpt":0.25745019468544217,"score_spread":0.25209510621415215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155565607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930895,0.0047850357,0.00012014594,0.00014067262,0.000038998274,0.000013280356,0.00028835452,0.000007860341,0.0015161713],"genre_scores_gemma":[0.99869055,0.00048067354,0.000029393184,0.000055751712,0.000024279845,0.000006021208,0.0003277588,0.0000020653677,0.00038343656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979454,0.000036657395,0.000022178476,0.000040738032,0.000036410125,0.00006958601],"domain_scores_gemma":[0.9993119,0.00016408971,0.00024530734,0.00005726799,0.000068624795,0.00015287564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046742917,0.00012761843,0.00060991966,0.0001917583,0.00021691994,0.0004019473,0.00023448678,0.00023201005,0.0011791426],"category_scores_gemma":[0.0013861344,0.00006495621,0.00055834476,0.00025811887,0.00016335251,0.00036175209,0.00020073297,0.0005751857,0.00015954077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05934951,0.0011645259,0.64734185,0.00040048864,0.001953663,0.0009800073,0.0003429585,0.002804273,0.018140113,0.00024429584,0.0015050248,0.26577333],"study_design_scores_gemma":[0.00055820943,0.01605264,0.97384113,0.000049152328,0.0011844096,0.0011943668,0.00013978059,0.0008793763,0.0029619208,0.00021435712,0.0029041292,0.000020454165],"about_ca_topic_score_codex":0.0015440389,"about_ca_topic_score_gemma":0.0031512938,"teacher_disagreement_score":0.0015440389,"about_ca_system_score_codex":0.0005037863,"about_ca_system_score_gemma":0.0004361751,"threshold_uncertainty_score":0.003944576},"labels":[],"label_agreement":null},{"id":"W3157516959","doi":"10.1016/j.lungcan.2021.04.022","title":"Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Lung cancer; Pooled analysis; Oncology; Internal medicine; Cancer; Demography; Intensive care medicine; Immunotherapy; Meta-analysis","score_opus":0.004109893966680977,"score_gpt":0.2502025030859512,"score_spread":0.24609260911927022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157516959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97886115,0.009839816,0.000388792,0.00019393447,0.000039933864,0.000089705136,0.009850567,0.000028968263,0.0007071926],"genre_scores_gemma":[0.98919374,0.0015058988,0.00024794438,0.00014549831,0.000029833322,0.000051741114,0.008568647,0.000011460294,0.00024522594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956013,0.0011845217,0.0004878883,0.0010458935,0.0010480717,0.00063222036],"domain_scores_gemma":[0.99415946,0.0010558144,0.0021345618,0.0005539827,0.0015111377,0.0005850805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005612742,0.0010876262,0.0021372035,0.0029751572,0.0009399895,0.0020822573,0.001388202,0.0009009762,0.0011200636],"category_scores_gemma":[0.0064396155,0.0005404405,0.005843123,0.004558119,0.00059599045,0.00054901955,0.0012988867,0.0006867436,0.00013178337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026412928,0.000039944527,0.97063047,0.00024835978,0.020420585,0.00012676572,0.00012945704,0.0008869483,0.00013491928,0.00006205935,0.0010953625,0.0035836687],"study_design_scores_gemma":[0.00029107978,0.00022637646,0.98896945,0.00012842841,0.007137123,0.00018317827,0.00028804987,0.0013250529,0.00008035679,0.000036667985,0.0012921066,0.00004211738],"about_ca_topic_score_codex":0.71264637,"about_ca_topic_score_gemma":0.73389286,"teacher_disagreement_score":0.28735363,"about_ca_system_score_codex":0.00948187,"about_ca_system_score_gemma":0.0074992194,"threshold_uncertainty_score":0.5780918},"labels":[],"label_agreement":null},{"id":"W3159640992","doi":"10.1016/j.lungcan.2021.04.025","title":"Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Cohort; Radiation therapy; Systemic therapy; Chemotherapy; Hazard ratio; Mesothelioma; Surgery; Internal medicine; Cancer; Breast cancer; Pathology","score_opus":0.08764534016131116,"score_gpt":0.4213575770566978,"score_spread":0.33371223689538665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159640992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899095,0.00031040172,0.00005170847,0.00010760539,0.000010407785,0.000028541535,0.00008931697,0.000005454166,0.00040556208],"genre_scores_gemma":[0.9994635,0.00013915454,0.00007725397,0.00007388686,0.000030407145,0.000012097977,0.000096640244,0.0000022214383,0.00010481499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984322,0.0005444222,0.00014575294,0.0002109134,0.00023187643,0.00043481684],"domain_scores_gemma":[0.9956364,0.00082824065,0.0011274802,0.00016277086,0.00051924447,0.0017259194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014806434,0.00027450518,0.0006361867,0.0009427853,0.0009387786,0.001441439,0.0007035405,0.0006215812,0.0024034053],"category_scores_gemma":[0.004195628,0.00019442903,0.0005018122,0.0013358403,0.0006051764,0.0006660114,0.001603954,0.00061063044,0.00034487736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0155126685,0.0027002248,0.9033773,0.00032589774,0.00039198046,0.0008388433,0.0021677485,0.0013905525,0.00430477,0.00034721024,0.00090337364,0.0677394],"study_design_scores_gemma":[0.00046425423,0.007775126,0.9860254,0.000046659443,0.00017172673,0.00046324762,0.0027843248,0.0005154208,0.00091920665,0.000063740204,0.0007417947,0.000029014836],"about_ca_topic_score_codex":0.008859234,"about_ca_topic_score_gemma":0.018026538,"teacher_disagreement_score":0.008859234,"about_ca_system_score_codex":0.0032463525,"about_ca_system_score_gemma":0.0028568099,"threshold_uncertainty_score":0.023554027},"labels":[],"label_agreement":null},{"id":"W3165571064","doi":"10.1016/j.lungcan.2021.05.021","title":"A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Trillium Health Centre; University Health Network; University of Toronto; St Joseph's Health Centre; Princess Margaret Cancer Centre; Markham Stouffville Hospital; Queen's University","funders":"Novartis Pharmaceuticals Canada; Princess Margaret Cancer Foundation; Array BioPharma","keywords":"Medicine; Pemetrexed; Carboplatin; KRAS; Internal medicine; Oncology; MEK inhibitor; Lung cancer; Neuroblastoma RAS viral oncogene homolog; Adverse effect; Rash; Trametinib; Chemotherapy; Cancer; Colorectal cancer; MAPK/ERK pathway; Kinase; Cisplatin","score_opus":0.012106317204449145,"score_gpt":0.34483031731766367,"score_spread":0.3327240001132145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165571064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997027,0.0028464613,0.00044730114,0.00053807703,0.00031541518,0.0022212355,0.0010363933,0.000104079365,0.0025208017],"genre_scores_gemma":[0.9840679,0.0037967516,0.001723523,0.000933507,0.00021277583,0.0022555953,0.002394194,0.00004343457,0.0045722914],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997104,0.00010016092,0.000013274755,0.000064359214,0.00002524435,0.00008662735],"domain_scores_gemma":[0.99948704,0.00006710263,0.00005326927,0.000036930298,0.000030284604,0.00032539802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010047499,0.0014172196,0.0025304614,0.00048908027,0.00049734314,0.0011513754,0.0010285131,0.0012610003,0.0045017633],"category_scores_gemma":[0.00070982095,0.00079611863,0.0017527305,0.0005000784,0.0008209825,0.0009447924,0.00032958444,0.0040744967,0.0010222245],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7933124,0.09621749,0.0022110245,0.0010236459,0.0016535646,0.00022211931,0.00021564009,0.002737478,0.03297499,0.00032685237,0.0037483333,0.06535647],"study_design_scores_gemma":[0.5885312,0.3982514,0.005999054,0.00003539182,0.0006220279,0.0002146531,0.00007964671,0.0011036621,0.0026834763,0.00019044454,0.002253996,0.000035079207],"about_ca_topic_score_codex":0.0024556967,"about_ca_topic_score_gemma":0.0065062293,"teacher_disagreement_score":0.0045017633,"about_ca_system_score_codex":0.0011268529,"about_ca_system_score_gemma":0.0018573763,"threshold_uncertainty_score":0.015059888},"labels":[],"label_agreement":null},{"id":"W3169556370","doi":"10.1016/j.lungcan.2021.06.002","title":"The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; William Osler Health System; Humber Polytechnic; Dalhousie University; University of Toronto; Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Intensive care medicine","score_opus":0.017649542354702362,"score_gpt":0.3591299504094271,"score_spread":0.34148040805472474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169556370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009949663,0.9983941,0.00014633987,0.00046767484,0.00019400661,0.0000035162068,0.000024730018,0.0000084081885,0.0006617083],"genre_scores_gemma":[0.00068195496,0.99790275,0.00020730015,0.00047427905,0.00024585525,0.000005432002,0.000039384548,0.0000018842178,0.0004410862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978274,0.000050122337,0.000024698584,0.000031707685,0.000085210326,0.00002549748],"domain_scores_gemma":[0.9995036,0.00029172006,0.00005251224,0.000009666067,0.000103419254,0.00003905975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078212365,0.0006284285,0.0016283753,0.0013183804,0.00018758088,0.0011768854,0.0007520882,0.0009568649,0.0038319975],"category_scores_gemma":[0.0011239466,0.00019005238,0.00059655873,0.0012090143,0.00037644187,0.0012787045,0.00058642484,0.0024652083,0.0013485696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101241065,0.000057888774,0.000114144284,0.011927737,0.00008155175,0.00010556419,0.000027244507,0.00044252153,0.0014858011,0.0030435603,0.03302532,0.94958746],"study_design_scores_gemma":[0.00005860426,0.00020530958,0.000754886,0.0050318013,0.00020580969,0.000739952,0.000048924845,0.00025944406,0.00042934343,0.0027321554,0.98951364,0.000020023474],"about_ca_topic_score_codex":0.0007425277,"about_ca_topic_score_gemma":0.0025682906,"teacher_disagreement_score":0.0038319975,"about_ca_system_score_codex":0.0006105513,"about_ca_system_score_gemma":0.0008845255,"threshold_uncertainty_score":0.01281935},"labels":[],"label_agreement":null},{"id":"W3183328865","doi":"10.1016/j.lungcan.2021.07.007","title":"Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; London Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; SABR volatility model; Meta-analysis; Confidence interval; Radiation therapy; Internal medicine; Lung cancer; Observational study; Systematic review; Surgery; Oncology; MEDLINE","score_opus":0.09116733073286165,"score_gpt":0.45274710486949943,"score_spread":0.3615797741366378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183328865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036790606,0.9950518,0.00026643442,0.000110055866,0.000110786896,0.00013291017,0.0004481934,0.00001666454,0.00018418694],"genre_scores_gemma":[0.14027785,0.85578835,0.0012725471,0.0010834401,0.00017390447,0.0003876723,0.0005707037,0.00002866985,0.00041682873],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964585,0.0014287457,0.001061421,0.00049025303,0.00037081432,0.00019036002],"domain_scores_gemma":[0.99506336,0.0032479728,0.0010782283,0.0001818239,0.00034071575,0.00008787349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005269321,0.0022737202,0.012747714,0.0036495656,0.00049300474,0.002363713,0.0017796431,0.0022042382,0.0045912936],"category_scores_gemma":[0.012391269,0.0013597911,0.026751772,0.0055227946,0.00065491913,0.0016170718,0.0015474793,0.0018772564,0.0004402108],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001860417,0.000031232335,0.0036509705,0.4511517,0.52796465,0.00012812867,0.00010964841,0.0004550844,0.000331197,0.0001266956,0.0009121005,0.0132780345],"study_design_scores_gemma":[0.0007212855,0.00013657325,0.0032345017,0.02040505,0.97323066,0.00007879025,0.00005852504,0.00009069896,0.0000696568,0.0001436673,0.0018054672,0.00002517469],"about_ca_topic_score_codex":0.010532763,"about_ca_topic_score_gemma":0.036064915,"teacher_disagreement_score":0.012747714,"about_ca_system_score_codex":0.002295392,"about_ca_system_score_gemma":0.0027376749,"threshold_uncertainty_score":0.027867138},"labels":[],"label_agreement":null},{"id":"W3192563092","doi":"10.1016/j.lungcan.2021.08.003","title":"Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; University of Saskatchewan; Dalhousie University; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Calgary Laboratory Services; University of Manitoba; University of Calgary; Spinal Cord Injury BC; Canada's Michael Smith Genome Sciences Centre; Sunnybrook Health Science Centre; Ottawa Hospital; University Health Network; McMaster University Medical Centre; Health Sciences Centre; London Health Sciences Centre; Health Sciences North; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; University of Toronto","funders":"Pfizer Canada","keywords":"ROS1; Immunohistochemistry; Medicine; Crizotinib; Lung cancer; Fluorescence in situ hybridization; Cancer research; Pathology; Cancer; Oncogene; Adenocarcinoma; Internal medicine; Biology; Gene; Cell cycle; Genetics","score_opus":0.03611358999379091,"score_gpt":0.40586751162549994,"score_spread":0.36975392163170906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192563092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.894623,0.0027027961,0.001428094,0.015699293,0.0005741325,0.0021122254,0.048474576,0.00011707057,0.034268897],"genre_scores_gemma":[0.97102803,0.0013227235,0.0028626465,0.0054271524,0.00017085405,0.00088310114,0.0111214975,0.00006136631,0.007122525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973111,0.00042696702,0.00010036176,0.00031636792,0.00088160357,0.00096364616],"domain_scores_gemma":[0.99584454,0.00036585212,0.0008701749,0.00020734406,0.0011834649,0.0015285962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001818878,0.0004286301,0.0005515279,0.00064226147,0.0023010122,0.0010200945,0.0017020693,0.0010197748,0.0044556647],"category_scores_gemma":[0.004881026,0.00036242022,0.0010244001,0.0018910698,0.0005257329,0.00044108368,0.001160727,0.0014300682,0.00030209686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034397976,0.0007951536,0.8680466,0.0003351817,0.0006206592,0.00019549232,0.00051038404,0.00078033184,0.0011111832,0.0031025503,0.07377846,0.047284182],"study_design_scores_gemma":[0.001155001,0.0005433382,0.97921705,0.00023236989,0.00041167243,0.00009207439,0.0009216576,0.0006450692,0.00031083854,0.00031633815,0.01610371,0.000050754807],"about_ca_topic_score_codex":0.9576309,"about_ca_topic_score_gemma":0.9844611,"teacher_disagreement_score":0.042369127,"about_ca_system_score_codex":0.026927982,"about_ca_system_score_gemma":0.066898055,"threshold_uncertainty_score":0.19537705},"labels":[],"label_agreement":null},{"id":"W3198449529","doi":"10.1016/j.lungcan.2021.08.014","title":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; University of Toronto; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Crizotinib; Medicine; Alectinib; Bradycardia; Anaplastic lymphoma kinase; Internal medicine; Oncology; Adverse effect; Lung cancer; Heart rate","score_opus":0.07416902445756512,"score_gpt":0.44421100264302055,"score_spread":0.3700419781854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198449529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038096453,0.9945142,0.00033270475,0.00011800892,0.00012669191,0.00014086234,0.00068340474,0.000016572167,0.00025796078],"genre_scores_gemma":[0.12736149,0.86802495,0.0013183196,0.0012395137,0.000229606,0.0004119022,0.00087042665,0.000033736815,0.0005099943],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99674976,0.0011765023,0.0010692782,0.0004845201,0.0003483802,0.00017155241],"domain_scores_gemma":[0.9942591,0.0039501013,0.0011528635,0.00019357531,0.00034592717,0.00009832041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045505185,0.002123639,0.012701038,0.0022883834,0.00045708084,0.002403491,0.0016899632,0.0020113545,0.006540117],"category_scores_gemma":[0.01295125,0.0011717437,0.02431816,0.0041563665,0.00054847926,0.001553693,0.0014739591,0.0020743674,0.00061800383],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026345148,0.000033454766,0.0039081005,0.48958305,0.4876822,0.00015080532,0.000084104555,0.0003601892,0.00028099117,0.00013767314,0.0012096845,0.013935142],"study_design_scores_gemma":[0.0010174437,0.00016423309,0.0047593694,0.022022365,0.9690475,0.00011177539,0.000054724704,0.00009712067,0.00007797043,0.00019150539,0.0024239426,0.000032004704],"about_ca_topic_score_codex":0.006550982,"about_ca_topic_score_gemma":0.022650287,"teacher_disagreement_score":0.012701038,"about_ca_system_score_codex":0.0015796159,"about_ca_system_score_gemma":0.0022666298,"threshold_uncertainty_score":0.024065733},"labels":[],"label_agreement":null},{"id":"W3201631634","doi":"10.1016/j.lungcan.2021.09.003","title":"Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Computational biology; Cancer research; Biology","score_opus":0.09481768416690141,"score_gpt":0.3480119460773508,"score_spread":0.2531942619104494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201631634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000064107,0.9970241,0.00021380048,0.001682994,0.0002717006,0.0000040745604,0.000013036815,0.0000068685104,0.0007193079],"genre_scores_gemma":[0.0005285437,0.99812585,0.00026649702,0.0006107122,0.00026745946,0.0000057097527,0.0000138667565,0.0000018047454,0.00017956806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931335,0.00020684677,0.00011020744,0.00009109372,0.00023712724,0.00004135377],"domain_scores_gemma":[0.99735296,0.0017458348,0.00019653214,0.000059346574,0.0005578523,0.00008743145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020857747,0.00064277253,0.0012467187,0.00221306,0.00039103604,0.001536223,0.0010120859,0.0015681784,0.0019262157],"category_scores_gemma":[0.0032946905,0.00027405616,0.00076057855,0.0022228484,0.0011214996,0.0023861933,0.0009791147,0.0028561186,0.0010443128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030944153,0.000033941422,0.00025365216,0.018234972,0.000073578165,0.00017792618,0.000121410805,0.0004082212,0.00050380477,0.006929523,0.031089485,0.9421425],"study_design_scores_gemma":[0.000009822582,0.000067462286,0.00068875274,0.0109817255,0.00009769821,0.0012446209,0.00014897823,0.00012202067,0.00022190709,0.005326354,0.9810681,0.000022515442],"about_ca_topic_score_codex":0.0019392642,"about_ca_topic_score_gemma":0.0035950302,"teacher_disagreement_score":0.00221306,"about_ca_system_score_codex":0.0011338325,"about_ca_system_score_gemma":0.0025244686,"threshold_uncertainty_score":0.011030793},"labels":[],"label_agreement":null},{"id":"W3215059890","doi":"10.1016/j.lungcan.2021.11.011","title":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Sierra Oncology; MacroGenics; BeiGene; Janssen Pharmaceuticals; Merck KGaA; Sanofi; TG Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Gemcitabine; Tolerability; Internal medicine; Lung cancer; Nausea; Adverse effect; Oncology; Gastroenterology; Cancer","score_opus":0.006218265558364029,"score_gpt":0.29263375914906253,"score_spread":0.2864154935906985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215059890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965346,0.0009949328,0.00027780843,0.00019157406,0.00003456414,0.00096298347,0.000399591,0.000038990063,0.00056503894],"genre_scores_gemma":[0.99320483,0.001166881,0.0013746877,0.00033958867,0.000078780846,0.0009432515,0.0017227284,0.00002393477,0.0011453502],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995491,0.0002467863,0.000023155551,0.00007772514,0.000045821376,0.00005734411],"domain_scores_gemma":[0.99932575,0.000117274714,0.00017234453,0.000049257225,0.000042954234,0.00029230892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013979798,0.0013403778,0.001819382,0.00035387473,0.00032521656,0.0005697957,0.0005476048,0.0008219339,0.0025134927],"category_scores_gemma":[0.0009075903,0.00048692303,0.0007790227,0.00037634932,0.0006293569,0.00060494547,0.00028120173,0.0025561445,0.00063251925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5695775,0.11648568,0.01920329,0.0010871176,0.0015613998,0.000786951,0.0005056594,0.0040773214,0.15872492,0.00015988642,0.0032329487,0.1245973],"study_design_scores_gemma":[0.26077366,0.6958844,0.032144353,0.000027046162,0.00037221954,0.0006034697,0.000054198517,0.0014020825,0.006776999,0.000086062355,0.0018472522,0.000028211023],"about_ca_topic_score_codex":0.0006946493,"about_ca_topic_score_gemma":0.0023994902,"teacher_disagreement_score":0.0025134927,"about_ca_system_score_codex":0.000756386,"about_ca_system_score_gemma":0.0013073363,"threshold_uncertainty_score":0.008408487},"labels":[],"label_agreement":null},{"id":"W4205367336","doi":"10.1016/j.lungcan.2021.12.019","title":"Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Anaplastic lymphoma kinase; Internal medicine; Cohort; Oncology; Clinical endpoint; Alectinib; Progressive disease; Lung cancer; Chemotherapy; Clinical trial","score_opus":0.016814873006195555,"score_gpt":0.3132456634977558,"score_spread":0.29643079049156024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205367336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5331998,0.043775223,0.005409996,0.22192001,0.107804686,0.00035071772,0.03646294,0.0009013462,0.050175287],"genre_scores_gemma":[0.8020949,0.00998681,0.0030527057,0.050661832,0.06956363,0.00015559366,0.011088538,0.00017823222,0.053217966],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99967945,0.00006772714,0.000044819975,0.00006907493,0.00008726453,0.000051765033],"domain_scores_gemma":[0.99839646,0.00080557005,0.00022184785,0.000050993676,0.00020476071,0.00032043242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038284078,0.00034545685,0.00033206533,0.00041969313,0.00020934387,0.0006493027,0.00027469604,0.0013723379,0.005859775],"category_scores_gemma":[0.0022176385,0.00010422437,0.00027213333,0.00032214183,0.00017433426,0.00039444133,0.00013964274,0.001012139,0.0020924718],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012728389,0.0005280827,0.15436082,0.0008770129,0.00045992876,0.017220072,0.00017003472,0.0007722541,0.022440694,0.00100224,0.5496408,0.2397997],"study_design_scores_gemma":[0.0012647648,0.0070011667,0.5187151,0.0003318511,0.0007686136,0.03697612,0.00033820336,0.0033497626,0.02596768,0.0025386913,0.40257537,0.00017277461],"about_ca_topic_score_codex":0.00033537397,"about_ca_topic_score_gemma":0.00049533,"teacher_disagreement_score":0.005859775,"about_ca_system_score_codex":0.00029884977,"about_ca_system_score_gemma":0.00026455824,"threshold_uncertainty_score":0.019602835},"labels":[],"label_agreement":null},{"id":"W4210511187","doi":"10.1016/j.lungcan.2022.01.020","title":"Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Takeda (Canada); University Health Network","funders":"Swiss Cancer Research Foundation","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Nivolumab; Immunotherapy","score_opus":0.012730693498659464,"score_gpt":0.3251160578730218,"score_spread":0.3123853643743623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210511187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961421,0.0015528386,0.00008905622,0.0002485172,0.000018411209,0.000006104303,0.0005585964,0.000004827906,0.0013796304],"genre_scores_gemma":[0.99885,0.00024850975,0.000018833363,0.000055551274,0.00001579554,0.0000030882145,0.000500024,0.000003568626,0.00030461498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994943,0.00007836281,0.000060772418,0.00008617377,0.00007430224,0.0002059859],"domain_scores_gemma":[0.99869126,0.00023833838,0.0006312825,0.000045076005,0.0001125292,0.00028154027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040160812,0.0001423151,0.00034835708,0.0005505586,0.00031285078,0.00070769293,0.0003253201,0.00048185085,0.0021196725],"category_scores_gemma":[0.0024313962,0.00011291995,0.0006406057,0.00085901597,0.0002496378,0.0006290933,0.00047942335,0.0006268065,0.0002521562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005350507,0.000058662474,0.99199873,0.000018788978,0.00008646013,0.00011034063,0.000051502502,0.00019502775,0.000431616,0.00005937033,0.00029863912,0.006155748],"study_design_scores_gemma":[0.000010153269,0.00013944997,0.99841464,0.000013796559,0.000046111367,0.00027873155,0.00026391406,0.00022975219,0.00010365475,0.0001421898,0.00035226837,0.000005355042],"about_ca_topic_score_codex":0.0035727085,"about_ca_topic_score_gemma":0.008080434,"teacher_disagreement_score":0.0035727085,"about_ca_system_score_codex":0.00055721763,"about_ca_system_score_gemma":0.00044225072,"threshold_uncertainty_score":0.007103801},"labels":[],"label_agreement":null},{"id":"W4210525122","doi":"10.1016/j.lungcan.2022.01.013","title":"Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Prospective cohort study; Lung cancer; Chemotherapy; Cohort; Oncology; Gastroenterology; Radiation therapy; Cancer; Circulating tumor DNA","score_opus":0.015472865041570472,"score_gpt":0.3147946030324561,"score_spread":0.29932173799088563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210525122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983333,0.0010042982,0.011738335,0.00024487142,0.000102157246,0.0011424175,0.00063845544,0.00025132683,0.0015451831],"genre_scores_gemma":[0.98866755,0.0007978282,0.0051337047,0.00023906193,0.00005118115,0.00067551614,0.0011471799,0.00010566669,0.0031823139],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990994,0.00045404246,0.000036116435,0.0001488733,0.00008733166,0.0001743976],"domain_scores_gemma":[0.99934417,0.00023564689,0.00007615278,0.00017014904,0.00007326433,0.00010066192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018190632,0.00080003706,0.0005475729,0.00031359433,0.00044328332,0.00062545936,0.0005319744,0.00095347856,0.0036912602],"category_scores_gemma":[0.0009205035,0.00030541705,0.0006833324,0.00023884076,0.0007497961,0.00042070658,0.00035311698,0.0014007865,0.0008091458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004989519,0.004966892,0.0014010743,0.00013773172,0.00006639476,0.00018710249,0.00013658172,0.0003572983,0.97660756,0.00013956128,0.00045985245,0.010550328],"study_design_scores_gemma":[0.00073275575,0.095203914,0.00743532,0.00001505826,0.00019854898,0.0011142179,0.00012690894,0.0014721295,0.88893974,0.00012129616,0.004610529,0.000029532703],"about_ca_topic_score_codex":0.001091186,"about_ca_topic_score_gemma":0.0011595152,"teacher_disagreement_score":0.0036912602,"about_ca_system_score_codex":0.00038086504,"about_ca_system_score_gemma":0.0006059535,"threshold_uncertainty_score":0.012348473},"labels":[],"label_agreement":null},{"id":"W4210665852","doi":"10.1016/j.lungcan.2022.01.023","title":"Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Afatinib; Medicine; Pembrolizumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Population; Carcinoma; Epidermal growth factor receptor; Surgery; Gastroenterology; Cancer; Gefitinib; Immunotherapy; Clinical trial","score_opus":0.0071702449301228755,"score_gpt":0.3156310337756659,"score_spread":0.30846078884554307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210665852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99359435,0.0012428423,0.0004021881,0.00024927623,0.0000782073,0.0029151726,0.0006237525,0.00006254375,0.000831775],"genre_scores_gemma":[0.9893561,0.0011271458,0.0016353698,0.0006972146,0.00015516792,0.0034408688,0.0018764733,0.000022932561,0.0016886351],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994912,0.00023606893,0.00002806045,0.00009282651,0.00004711065,0.00010470761],"domain_scores_gemma":[0.99916315,0.00009027494,0.00016317336,0.00006263488,0.00005218926,0.00046856565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019247707,0.0015319254,0.0025940137,0.00042406458,0.00042590793,0.0011746477,0.0010420663,0.0012779027,0.003440897],"category_scores_gemma":[0.0008293687,0.00075062254,0.0014770469,0.0004225576,0.0009113581,0.0008567705,0.00044619266,0.0029807296,0.0010737083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74793226,0.10979683,0.014166387,0.0010388026,0.0020942264,0.00036613166,0.00044188448,0.0020913247,0.04436988,0.00020817046,0.0030084958,0.074485585],"study_design_scores_gemma":[0.6201012,0.36448705,0.011090648,0.000022437465,0.00033122418,0.0002287238,0.000041638606,0.0006141639,0.0017409286,0.000079969795,0.0012410186,0.00002088141],"about_ca_topic_score_codex":0.0008245725,"about_ca_topic_score_gemma":0.0023827108,"teacher_disagreement_score":0.003440897,"about_ca_system_score_codex":0.00096044573,"about_ca_system_score_gemma":0.0021561165,"threshold_uncertainty_score":0.011510909},"labels":[],"label_agreement":null},{"id":"W4214550380","doi":"10.1016/j.lungcan.2022.02.009","title":"Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Australian Government","keywords":"Medicine; Lung cancer; Quality-adjusted life year; Quality of life (healthcare); Lung cancer screening; Cost effectiveness; Intensive care medicine; Cost–benefit analysis; Baseline (sea); Actuarial science; Risk analysis (engineering); Oncology","score_opus":0.2596218530954964,"score_gpt":0.5800838968781026,"score_spread":0.3204620437826062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214550380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011145364,0.99729556,0.001812839,0.00030568556,0.00006750535,0.000029963092,0.00007191165,0.0000063406305,0.00029874084],"genre_scores_gemma":[0.005018331,0.98902893,0.0050135762,0.0004018698,0.00021783308,0.000100888086,0.00009040893,0.000012929793,0.000115204304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98701406,0.0075461715,0.0020487662,0.0009429723,0.002255361,0.00019274876],"domain_scores_gemma":[0.9272088,0.06771236,0.002411996,0.0006698146,0.0018192487,0.00017775015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026571669,0.002881996,0.009447809,0.006993241,0.0003415556,0.0044822716,0.003767813,0.0023851127,0.0048917686],"category_scores_gemma":[0.06123003,0.0015330022,0.0075364774,0.008619186,0.0015133042,0.003583868,0.0019517202,0.0049184225,0.0006206695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004895648,0.00012629859,0.0011611347,0.1577435,0.0077055325,0.000104064704,0.00011867213,0.0063010557,0.00022867192,0.019495828,0.0063918,0.8001338],"study_design_scores_gemma":[0.0008979487,0.0011889876,0.010103624,0.41822207,0.049747434,0.0024695084,0.00049710507,0.015392625,0.00183199,0.12554833,0.37348872,0.00061165326],"about_ca_topic_score_codex":0.0044268663,"about_ca_topic_score_gemma":0.0054721595,"teacher_disagreement_score":0.026571669,"about_ca_system_score_codex":0.0037092557,"about_ca_system_score_gemma":0.0046474696,"threshold_uncertainty_score":0.14052612},"labels":[],"label_agreement":null},{"id":"W4221131077","doi":"10.1016/j.lungcan.2022.03.003","title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"United Therapeutics Corporation","keywords":"Irinotecan; Topotecan; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Randomized controlled trial; Chemotherapy; Cancer; Adverse effect; Colorectal cancer","score_opus":0.032677582691871036,"score_gpt":0.39410300744961657,"score_spread":0.36142542475774553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221131077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853896,0.00364347,0.000830879,0.00082702504,0.0011151377,0.0035879086,0.0014472889,0.00014855669,0.0030101298],"genre_scores_gemma":[0.9814719,0.0023291819,0.0019084142,0.0018983579,0.000604058,0.0044209147,0.0021179984,0.000070368005,0.005178799],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99894327,0.000619287,0.000042417807,0.00015371847,0.000068068235,0.00017324538],"domain_scores_gemma":[0.99833715,0.000539737,0.0002920732,0.00016615426,0.00009586402,0.0005690108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025309885,0.0021458024,0.004084206,0.0005078043,0.0007035519,0.0016495829,0.0015233236,0.0019899446,0.008340904],"category_scores_gemma":[0.0020712467,0.0009612559,0.0030151242,0.0006002388,0.0016452334,0.0013790749,0.00059455953,0.00527744,0.0011814164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9891922,0.0041741272,0.0002053314,0.00013926036,0.0006828621,0.000015799473,0.000022786875,0.0002685123,0.0010232109,0.00007184565,0.00040697592,0.0037970103],"study_design_scores_gemma":[0.958862,0.038733434,0.0008551178,0.000012461395,0.00041784177,0.000014756122,0.000017989969,0.0003024096,0.0002489253,0.0001351642,0.0003886458,0.000011390366],"about_ca_topic_score_codex":0.0037515054,"about_ca_topic_score_gemma":0.007854243,"teacher_disagreement_score":0.008340904,"about_ca_system_score_codex":0.0020768761,"about_ca_system_score_gemma":0.0026117172,"threshold_uncertainty_score":0.02790308},"labels":[],"label_agreement":null},{"id":"W4235340419","doi":"10.1016/s0169-5002(04)00142-4","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial*1","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Performance status; Progressive disease; Gastroenterology; Surgery","score_opus":0.0281149032536593,"score_gpt":0.36894898323737196,"score_spread":0.3408340799837127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235340419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985713,0.005255714,0.00055211043,0.0013098423,0.00046467778,0.0027440188,0.0013598297,0.000099567085,0.0025012468],"genre_scores_gemma":[0.97622097,0.0060983812,0.0025829338,0.0015529464,0.00039192932,0.003396056,0.0029750573,0.00005259726,0.006729249],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995461,0.00023103462,0.000020357384,0.000074552256,0.000025219679,0.00010259571],"domain_scores_gemma":[0.9994037,0.0001419851,0.00009544818,0.000043239048,0.000026622549,0.00028911693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013518732,0.0018117774,0.0029968726,0.0003741948,0.00057427364,0.0010822013,0.00089227717,0.0017183585,0.0038733464],"category_scores_gemma":[0.0011711947,0.00067030033,0.0018078112,0.0005283547,0.0010094484,0.0008672229,0.00035313042,0.004706342,0.00086771353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9058054,0.026093101,0.0017626445,0.0006239476,0.0010998514,0.00009937268,0.00013748773,0.0016155749,0.0060218573,0.000271478,0.0040258854,0.052443344],"study_design_scores_gemma":[0.80900985,0.18347026,0.003286104,0.00004444106,0.0004433576,0.00009305972,0.00003511288,0.00045565036,0.00076700794,0.0001599223,0.0022100154,0.000025234627],"about_ca_topic_score_codex":0.0014795201,"about_ca_topic_score_gemma":0.005131939,"teacher_disagreement_score":0.0038733464,"about_ca_system_score_codex":0.0009449008,"about_ca_system_score_gemma":0.0017855053,"threshold_uncertainty_score":0.012957633},"labels":[],"label_agreement":null},{"id":"W4238393566","doi":"10.1016/s0169-5002(12)00159-6","title":"Contents","year":2012,"lang":"de","type":"paratext","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.026331870780195915,"score_gpt":0.3486145025486761,"score_spread":0.32228263176848015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238393566","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013272176,0.0018419448,0.0011812603,0.004151269,0.0053324318,0.00034329243,0.034891352,0.0010093814,0.94992197],"genre_scores_gemma":[0.002609956,0.0014560582,0.0008441714,0.00094136776,0.0017105716,0.00010538048,0.012879426,0.00028878922,0.9791642],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995877,0.000053633725,0.0000248242,0.000049989456,0.00023956595,0.00004443162],"domain_scores_gemma":[0.9973724,0.00057096744,0.00019172963,0.00015751137,0.0011421518,0.0005652886],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005142733,0.0004795602,0.0003591171,0.0033209738,0.0007774367,0.0028484236,0.00051352923,0.0006503124,0.5586082],"category_scores_gemma":[0.004260886,0.00018415891,0.00024982778,0.002657028,0.0003123084,0.001389444,0.00090056984,0.00096849253,0.3660648],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014404554,0.000024225195,0.00036589702,0.000073982614,8.3882867e-7,0.000013365837,0.000010493207,0.00006314294,0.00011133074,0.0016210534,0.94586074,0.051840477],"study_design_scores_gemma":[0.000004738916,0.000012159561,0.0022241387,0.00012742839,0.0000019089937,0.000057243873,0.00003929035,0.00009403017,0.00017939256,0.00093159894,0.9963252,0.0000029324167],"about_ca_topic_score_codex":0.0044693877,"about_ca_topic_score_gemma":0.0073086843,"teacher_disagreement_score":0.44139183,"about_ca_system_score_codex":0.0018580845,"about_ca_system_score_gemma":0.0021135993,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4246311091","doi":"10.1016/s0169-5002(00)80318-9","title":"Population-based outcome for small cell lung cancer (SCLC): Impact of standard management policies in British Columbia (BC)","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Outcome (game theory); Lung cancer; Population; Internal medicine; Demography; Environmental health","score_opus":0.03030715759910746,"score_gpt":0.3688329795743873,"score_spread":0.33852582197527986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246311091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901702,0.0010938573,0.00009914418,0.0020627882,0.000044324122,0.00002457438,0.004063471,0.000023580898,0.0024179714],"genre_scores_gemma":[0.99747854,0.0003003696,0.000054887714,0.00021308109,0.000010259876,0.0000125483375,0.0014040209,0.000005096494,0.0005212645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816376,0.0004011631,0.00013367238,0.00020463375,0.00043286316,0.00066398527],"domain_scores_gemma":[0.9965559,0.00031163212,0.0005463465,0.00014263189,0.0012517622,0.0011917051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015828083,0.00025469298,0.00049166306,0.0008768038,0.0010600181,0.0012714765,0.001403,0.0010797946,0.0013891424],"category_scores_gemma":[0.005794898,0.00022574047,0.00063492614,0.0022021877,0.0007461857,0.00057857437,0.001342535,0.0013740256,0.00018106452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003650803,0.00014184059,0.9888293,0.000025818628,0.00010790816,0.000065288965,0.00019483022,0.00079891895,0.00007361674,0.00017302469,0.0027880291,0.006436324],"study_design_scores_gemma":[0.0000148628715,0.000050144827,0.9985454,0.000012365791,0.000040225426,0.000024159286,0.00038023177,0.00046333132,0.00002853373,0.00006635575,0.0003669068,0.000007609622],"about_ca_topic_score_codex":0.95829624,"about_ca_topic_score_gemma":0.9720426,"teacher_disagreement_score":0.04170376,"about_ca_system_score_codex":0.022911085,"about_ca_system_score_gemma":0.01795563,"threshold_uncertainty_score":0.16623235},"labels":[],"label_agreement":null},{"id":"W4280569448","doi":"10.1016/j.lungcan.2022.05.008","title":"Race &amp; sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Race (biology); Lung cancer screening; Computed tomography; Cancer; Internal medicine; Lung; Oncology; Radiology","score_opus":0.020984149981019433,"score_gpt":0.3855254398027715,"score_spread":0.36454128982175205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280569448","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038515046,0.9492297,0.000173884,0.00436773,0.0005429091,0.00006686541,0.0025984247,0.000007213995,0.0044981823],"genre_scores_gemma":[0.14836401,0.84489995,0.0005192299,0.0028745886,0.0007000582,0.0000839938,0.001584222,0.000008065207,0.00096588314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995751,0.00006440281,0.000115265175,0.00007134285,0.000108278095,0.00006567343],"domain_scores_gemma":[0.9979214,0.001007269,0.0006374291,0.000031533207,0.0002699727,0.00013247845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008152999,0.00017552904,0.0004559737,0.0028111034,0.00031485225,0.00078596245,0.00030637567,0.0005693837,0.0034487038],"category_scores_gemma":[0.0042367624,0.00023260099,0.0010388349,0.0040669013,0.0002148281,0.00077438046,0.0005801569,0.00055904686,0.00019436136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024546465,0.00019837955,0.4495873,0.042282853,0.002095014,0.00056006486,0.0010642038,0.00017479066,0.0003463391,0.004076844,0.052329972,0.4470389],"study_design_scores_gemma":[0.00006273995,0.00012339822,0.72568107,0.07236809,0.0050659487,0.0021648018,0.0037974874,0.0002602414,0.00019643265,0.0010153604,0.18920228,0.00006219201],"about_ca_topic_score_codex":0.029485535,"about_ca_topic_score_gemma":0.062755756,"teacher_disagreement_score":0.029485535,"about_ca_system_score_codex":0.000783528,"about_ca_system_score_gemma":0.002941849,"threshold_uncertainty_score":0.058627784},"labels":[],"label_agreement":null},{"id":"W4280617886","doi":"10.1016/j.lungcan.2022.05.003","title":"Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Simon Fraser University","funders":"","keywords":"Medicine; Lung cancer screening; Population; Lung cancer; Cohort; Demography; Metric (unit); Risk assessment; Quality-adjusted life year; Cost effectiveness; Environmental health; Internal medicine; Risk analysis (engineering)","score_opus":0.06972541836701968,"score_gpt":0.457082574985871,"score_spread":0.38735715661885134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280617886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967501,0.00008694835,0.0002070757,0.000034670076,0.00000839605,0.00003820774,0.0023806817,0.000005709621,0.0004882922],"genre_scores_gemma":[0.99722785,0.000028168148,0.00011517341,0.000034819164,0.000005110182,0.000048937163,0.0021526902,0.0000016126064,0.00038568053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994404,0.00021232595,0.000058911497,0.00010782497,0.00008502515,0.00009555979],"domain_scores_gemma":[0.9991935,0.0002674712,0.0002719451,0.000070060145,0.000103094055,0.000093932686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010188401,0.0003061891,0.0006662529,0.00069347525,0.0003263552,0.00066617416,0.0003418408,0.00047919105,0.0022804888],"category_scores_gemma":[0.004158123,0.00016577507,0.0012628783,0.0011361489,0.00019029516,0.00068928924,0.0005071544,0.00073631806,0.0002524114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001739858,0.00029252894,0.9912539,0.00005124799,0.00075108797,0.000093953895,0.00016593601,0.0004957791,0.0003291743,0.00014673061,0.0006879552,0.003991834],"study_design_scores_gemma":[0.00007134308,0.00032058783,0.99705434,0.000006662693,0.0001986907,0.00012716616,0.00034383935,0.0013739507,0.00006332448,0.00015224879,0.00027696742,0.000010836073],"about_ca_topic_score_codex":0.008694559,"about_ca_topic_score_gemma":0.007981113,"teacher_disagreement_score":0.008694559,"about_ca_system_score_codex":0.00040479316,"about_ca_system_score_gemma":0.00031174943,"threshold_uncertainty_score":0.01728791},"labels":[],"label_agreement":null},{"id":"W4281390999","doi":"10.1016/j.lungcan.2022.05.012","title":"Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Crizotinib; Lung cancer; Hazard ratio; Confidence interval; Clinical endpoint; Oncology; Population; ALK inhibitor; Adverse effect; Cancer; Gastroenterology; Clinical trial","score_opus":0.0043017809103495,"score_gpt":0.3100869242154153,"score_spread":0.3057851433050658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281390999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888648,0.008286543,0.0002846929,0.00041897225,0.00011126684,0.00022344418,0.000969808,0.00002724959,0.0008132603],"genre_scores_gemma":[0.995739,0.0014346476,0.00020641062,0.00045944154,0.00011357213,0.00021483091,0.001362153,0.000018844432,0.0004512311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99886924,0.00050689426,0.00013275006,0.00022167515,0.00009696302,0.00017248641],"domain_scores_gemma":[0.9989611,0.00037393183,0.0002707653,0.00015266919,0.00007436316,0.00016716591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003105208,0.0015417235,0.0035621554,0.0005500813,0.00032766772,0.0014876086,0.0005854716,0.00092952355,0.0013890046],"category_scores_gemma":[0.002131287,0.00040962565,0.0083706,0.0008643307,0.00070919207,0.0012129268,0.000709403,0.0020431285,0.00025523335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77790314,0.0011383333,0.08910194,0.002129122,0.07288786,0.00027321174,0.0002918362,0.003041589,0.007104322,0.00023298095,0.0024555265,0.04344022],"study_design_scores_gemma":[0.40721458,0.06100317,0.35795918,0.00048740843,0.15263797,0.001075192,0.0010324904,0.006127495,0.0035740272,0.0024163665,0.0061544226,0.0003177555],"about_ca_topic_score_codex":0.0008946519,"about_ca_topic_score_gemma":0.0036261983,"teacher_disagreement_score":0.0035621554,"about_ca_system_score_codex":0.00082063436,"about_ca_system_score_gemma":0.0008059934,"threshold_uncertainty_score":0.016422093},"labels":[],"label_agreement":null},{"id":"W4282933212","doi":"10.1016/j.lungcan.2022.06.009","title":"Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Prevention of Organ Failure","funders":"Bristol-Myers Squibb","keywords":"Medicine; Chemotherapy; Lung cancer; Internal medicine; Oncology; Randomized controlled trial; Meta-analysis; Confidence interval; Surrogate endpoint","score_opus":0.0538948238228783,"score_gpt":0.37835719499216597,"score_spread":0.32446237116928767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282933212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054998463,0.9931242,0.00045356294,0.00010268042,0.00012696847,0.00011635314,0.000400108,0.00002176143,0.00015454442],"genre_scores_gemma":[0.24267313,0.75198525,0.0020951391,0.001034341,0.00027999785,0.00045780052,0.0009304725,0.000043424752,0.0005004766],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941619,0.0026117407,0.0016794921,0.0007850914,0.00056615734,0.00019572033],"domain_scores_gemma":[0.9887398,0.008420284,0.001731314,0.00040538862,0.00055400754,0.00014915717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0092835175,0.002759463,0.017114507,0.0029976692,0.0004463062,0.0028724927,0.0020469655,0.0022060291,0.0034862526],"category_scores_gemma":[0.020895291,0.0015540355,0.03994771,0.004107073,0.00069381733,0.001809663,0.0016034135,0.0028206056,0.00039911855],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023024052,0.00003100848,0.004537509,0.21271889,0.76920986,0.00007476418,0.000061015802,0.00049803645,0.00022195162,0.00008159174,0.00044890377,0.0098140435],"study_design_scores_gemma":[0.0005480208,0.00015049447,0.0034273423,0.006611755,0.9880613,0.00004924723,0.000029319554,0.00012868705,0.00006065207,0.00010886183,0.00080325315,0.000021002474],"about_ca_topic_score_codex":0.0062050577,"about_ca_topic_score_gemma":0.01799131,"teacher_disagreement_score":0.017114507,"about_ca_system_score_codex":0.0020825902,"about_ca_system_score_gemma":0.0021263063,"threshold_uncertainty_score":0.049096525},"labels":[],"label_agreement":null},{"id":"W4283714926","doi":"10.1016/j.lungcan.2022.06.014","title":"Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"Varian Medical Systems","keywords":"SABR volatility model; Medicine; Ablative case; Radiation therapy; Lung cancer; Concomitant; Radiology; Internal medicine","score_opus":0.0944734411297645,"score_gpt":0.4420928949961969,"score_spread":0.34761945386643245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283714926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030367666,0.99884194,0.000053570915,0.0003322808,0.00019014288,0.000002142526,0.000009209386,0.000002465421,0.0005379808],"genre_scores_gemma":[0.0003015726,0.998701,0.00013809501,0.0003610632,0.00020535536,0.0000034601296,0.000013687584,7.7294106e-7,0.00027500428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969363,0.00007759403,0.00004982635,0.000048078386,0.00010664916,0.000024301633],"domain_scores_gemma":[0.9992368,0.0004606015,0.000086585154,0.000013526705,0.00016885155,0.000033569235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012401432,0.00087233935,0.0017787565,0.0022429724,0.00029691067,0.0014876929,0.0010183235,0.0014966107,0.004289491],"category_scores_gemma":[0.0013834825,0.00031950866,0.0008525606,0.0018956846,0.00059101457,0.0017436526,0.00063949183,0.0021224318,0.0014622235],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010645311,0.000055598543,0.00016576132,0.03866286,0.0001351642,0.00024250356,0.00007586054,0.00066874863,0.001154348,0.0062297885,0.047839988,0.904663],"study_design_scores_gemma":[0.000035072793,0.000112026224,0.00083655,0.013570761,0.0002630314,0.0010599528,0.000086462285,0.00014658553,0.00018833157,0.0029544774,0.98072225,0.000024473502],"about_ca_topic_score_codex":0.0028031573,"about_ca_topic_score_gemma":0.007184768,"teacher_disagreement_score":0.004289491,"about_ca_system_score_codex":0.00091857207,"about_ca_system_score_gemma":0.0020706435,"threshold_uncertainty_score":0.014349759},"labels":[],"label_agreement":null},{"id":"W4285403511","doi":"10.1016/j.lungcan.2022.07.008","title":"The changing landscape of pneumonitis in non-small cell lung cancer","year":2022,"lang":"en","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Lung cancer; Pneumonitis; Radiation Pneumonitis; Hypersensitivity pneumonitis; Lung; Oncology; Internal medicine","score_opus":0.005636140618514189,"score_gpt":0.3081479833239252,"score_spread":0.302511842705411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285403511","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028229606,0.019696992,0.000102677885,0.0523522,0.9264965,0.000013366157,0.000049660066,0.000048815567,0.0012115701],"genre_scores_gemma":[0.00020371533,0.0072266525,0.000050822433,0.021136306,0.9686964,0.000009961055,0.000017003815,0.000015754944,0.0026433996],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941351,0.001481718,0.0007695127,0.00062507327,0.0026340573,0.00035463728],"domain_scores_gemma":[0.9742934,0.013550099,0.0012973385,0.0005084903,0.0071574203,0.0031931926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010014209,0.0041539785,0.0051603722,0.0035440659,0.0028806783,0.009106413,0.0041860826,0.020795284,0.010347696],"category_scores_gemma":[0.026923846,0.0015264796,0.003441118,0.0016307645,0.0027475345,0.0063775787,0.0019944164,0.030394891,0.007031701],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004669295,0.000011666304,0.00003066196,0.00035281642,0.000034628345,0.00008683625,0.000010804188,0.0000210703,0.00003737663,0.00032167506,0.9926825,0.006363308],"study_design_scores_gemma":[0.00017139569,0.00007476784,0.0004488985,0.0012714474,0.00019366226,0.00048613382,0.000073376184,0.00029025605,0.00010669221,0.0020359391,0.99480444,0.000042966814],"about_ca_topic_score_codex":0.0030463573,"about_ca_topic_score_gemma":0.009198756,"teacher_disagreement_score":0.020795284,"about_ca_system_score_codex":0.0048005334,"about_ca_system_score_gemma":0.0034638925,"threshold_uncertainty_score":0.052960813},"labels":[],"label_agreement":null},{"id":"W4287448591","doi":"10.1016/j.lungcan.2022.07.018","title":"PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Cytology; Medicine; Histology; Internal medicine; Lung cancer; PD-L1; Biomarker; Oncology; Cancer; Pathology; Gastroenterology; Immunotherapy; Biology","score_opus":0.05902054763603569,"score_gpt":0.4145764070750323,"score_spread":0.3555558594389966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287448591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022674,0.99927455,0.000057967078,0.00014951796,0.00006341709,0.0000043348005,0.000019149122,0.000002321163,0.00020197663],"genre_scores_gemma":[0.005186726,0.993454,0.00030905218,0.0004593318,0.00019133807,0.000016323931,0.000090059904,0.0000014038632,0.00029178464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99970764,0.00007347377,0.00005372647,0.00006189708,0.0000782448,0.000024892519],"domain_scores_gemma":[0.9991892,0.00049849175,0.00012891434,0.000012352576,0.00014576639,0.00002524409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011070304,0.000731195,0.0020978795,0.0010455229,0.00012434374,0.0011737619,0.00080580555,0.00086036394,0.0013255614],"category_scores_gemma":[0.0020760135,0.00032677673,0.0011210045,0.0010248511,0.00029128534,0.00067159394,0.00048797874,0.0016475203,0.00054985506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032123565,0.000058888378,0.0021753313,0.014901638,0.0006044154,0.000072011455,0.000024680676,0.00038977945,0.0006815284,0.00056104,0.008488884,0.9717206],"study_design_scores_gemma":[0.00070150447,0.00146045,0.03654133,0.037762646,0.0084547335,0.003026925,0.00024636163,0.0019568622,0.0030252945,0.0039830264,0.9026739,0.00016695644],"about_ca_topic_score_codex":0.0013260072,"about_ca_topic_score_gemma":0.0033045292,"teacher_disagreement_score":0.0020978795,"about_ca_system_score_codex":0.0005810908,"about_ca_system_score_gemma":0.000974216,"threshold_uncertainty_score":0.0058546662},"labels":[],"label_agreement":null},{"id":"W4296676807","doi":"10.1016/j.lungcan.2022.08.023","title":"EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; William Osler Health System; AstraZeneca (Canada); London Health Sciences Centre; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Centre; Canada Research Chairs; Western University","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Cohort; Adjuvant therapy; Oncology; Population; Lung cancer; Stage (stratigraphy); Retrospective cohort study; Disease; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.006545336997180896,"score_gpt":0.2823730039069236,"score_spread":0.2758276669097427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296676807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871586,0.00078955083,0.00008431737,0.00063784776,0.000017371454,0.000023174518,0.008765044,0.0000130016615,0.0025111889],"genre_scores_gemma":[0.9973506,0.00034129326,0.00005523852,0.00008732451,0.000004836507,0.0000059555728,0.0016968771,0.000003957917,0.0004539052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993343,0.00003489757,0.0000617331,0.000119495286,0.00016130734,0.00028833223],"domain_scores_gemma":[0.99832755,0.00008514442,0.0003530394,0.00004554611,0.00064933446,0.0005394017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031771592,0.0002471313,0.00034018114,0.0010002942,0.0015372275,0.0012216775,0.0010958804,0.00056048046,0.0025504346],"category_scores_gemma":[0.0016902102,0.00033671904,0.0006633875,0.0034980092,0.0006975124,0.00047533002,0.0006986055,0.00084170786,0.00023929002],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040457944,0.000015518028,0.9979367,0.000014383619,0.00003075607,0.000048255395,0.0001519631,0.00009018357,0.00006817626,0.00006200756,0.00059793907,0.0009437089],"study_design_scores_gemma":[0.000006060652,0.000011985441,0.9980039,0.000020003386,0.000025238922,0.00008214813,0.0010187373,0.00026329074,0.000037166807,0.000025077645,0.000497479,0.000008900888],"about_ca_topic_score_codex":0.9921199,"about_ca_topic_score_gemma":0.99481934,"teacher_disagreement_score":0.023425687,"about_ca_system_score_codex":0.023425687,"about_ca_system_score_gemma":0.023407385,"threshold_uncertainty_score":0.16996604},"labels":[],"label_agreement":null},{"id":"W4308432482","doi":"10.1016/j.lungcan.2022.11.004","title":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Nausea; Internal medicine; Quality of life (healthcare); ALK inhibitor; Oncology; Nursing","score_opus":0.017987614608198272,"score_gpt":0.3551372383528579,"score_spread":0.3371496237446596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308432482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361527,0.0030133002,0.00019548982,0.0002216591,0.00005644994,0.0008346997,0.0013119171,0.000029216046,0.0007219306],"genre_scores_gemma":[0.99366343,0.0009531124,0.0006704359,0.0003677552,0.00007976987,0.0012353543,0.0024486005,0.000010335433,0.0005712556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99879956,0.00075775845,0.000065178334,0.00013479234,0.00014685489,0.000095991876],"domain_scores_gemma":[0.99808806,0.000593341,0.00068032433,0.00013339623,0.00014997726,0.00035477313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028048332,0.000749655,0.0016221784,0.00022029884,0.00029191808,0.0006510805,0.0006087425,0.00079899566,0.0028852404],"category_scores_gemma":[0.0029200395,0.00030224925,0.002444012,0.00025385077,0.00054712663,0.0004371002,0.0003381538,0.001591645,0.0002354472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9526607,0.0027735957,0.009300279,0.00081586966,0.0034752705,0.00003295165,0.00008033583,0.0017306602,0.0032442051,0.0000874353,0.0016541454,0.024144517],"study_design_scores_gemma":[0.7759609,0.14519903,0.0675908,0.00008889284,0.0043033864,0.0001350784,0.00006241374,0.0027888871,0.0015862081,0.00022284623,0.0020078185,0.0000536463],"about_ca_topic_score_codex":0.0019511703,"about_ca_topic_score_gemma":0.005939107,"teacher_disagreement_score":0.0028852404,"about_ca_system_score_codex":0.0011347887,"about_ca_system_score_gemma":0.0015147245,"threshold_uncertainty_score":0.01483351},"labels":[],"label_agreement":null},{"id":"W4309342023","doi":"10.1016/j.lungcan.2022.11.009","title":"Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Observational study; Epidermal growth factor receptor; Chemotherapy; Medical record; Cancer","score_opus":0.05358302492849484,"score_gpt":0.38799351964314566,"score_spread":0.3344104947146508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309342023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954419,0.001089564,0.00020499408,0.00010967772,0.00002078563,0.000013618998,0.0022965914,0.000004947734,0.0008180089],"genre_scores_gemma":[0.99732924,0.00033361462,0.00010428471,0.00011082834,0.000019474914,0.0000160805,0.001896875,0.000007566775,0.00018203852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808854,0.00046076902,0.00027585583,0.00063927047,0.00020795323,0.00032766405],"domain_scores_gemma":[0.9935701,0.001218137,0.0033443468,0.0007314763,0.00045661474,0.0006793617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012774398,0.00045612044,0.0006920004,0.0009160365,0.0005707393,0.0013035187,0.0009341447,0.0010443476,0.0020350514],"category_scores_gemma":[0.0050193444,0.0006108548,0.0016268517,0.003336111,0.0005596976,0.0011862128,0.00091299164,0.0016597892,0.0003012507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020657916,0.000047651607,0.99865365,0.000018263358,0.0002872757,0.00004188206,0.000049162452,0.00004461712,0.000076008626,0.000025230247,0.00013817186,0.00041140337],"study_design_scores_gemma":[0.000023636923,0.00010526685,0.99857044,0.000024069514,0.00022875424,0.00023945089,0.00028755542,0.00015349181,0.000041165065,0.000040115032,0.00027407322,0.000011963631],"about_ca_topic_score_codex":0.01150297,"about_ca_topic_score_gemma":0.01145596,"teacher_disagreement_score":0.01150297,"about_ca_system_score_codex":0.0006172777,"about_ca_system_score_gemma":0.0006392889,"threshold_uncertainty_score":0.02287203},"labels":[],"label_agreement":null},{"id":"W4309942201","doi":"10.1016/j.lungcan.2022.11.017","title":"The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Population; Proportional hazards model; Epidermal growth factor receptor; Clinical trial; Cancer","score_opus":0.010252541598297648,"score_gpt":0.318615882465887,"score_spread":0.3083633408675894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309942201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94284236,0.008087551,0.0006856445,0.018994765,0.0004379481,0.00016609626,0.011247331,0.00010011686,0.017438255],"genre_scores_gemma":[0.9918677,0.0019757762,0.00048226007,0.001326355,0.00006241822,0.000020077923,0.0017022399,0.000018817016,0.0025444387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997092,0.0004323716,0.00013738062,0.00025956612,0.0010163883,0.0010621861],"domain_scores_gemma":[0.9942287,0.00047338285,0.00049325795,0.00011323854,0.0027411662,0.0019501864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018488783,0.00035662742,0.000515629,0.0010975396,0.0021115076,0.00217756,0.0021081867,0.00081354793,0.0020912157],"category_scores_gemma":[0.0055452455,0.00033010772,0.0009329155,0.0027290145,0.0010387157,0.00044435877,0.0012614081,0.0013557568,0.00016093497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032263345,0.00013590237,0.9646072,0.000118088894,0.00021395966,0.00033972092,0.00042110047,0.0019587257,0.00025258597,0.0010746607,0.009985943,0.020569492],"study_design_scores_gemma":[0.00004898346,0.00008379015,0.9920047,0.000120896235,0.00015262049,0.00017567968,0.0017781974,0.0017873682,0.00010807881,0.00019475701,0.0035162522,0.000028629733],"about_ca_topic_score_codex":0.99795973,"about_ca_topic_score_gemma":0.9988777,"teacher_disagreement_score":0.99795973,"about_ca_system_score_codex":0.07726521,"about_ca_system_score_gemma":0.120874316,"threshold_uncertainty_score":0.560601},"labels":[],"label_agreement":null},{"id":"W4313398502","doi":"10.1016/j.lungcan.2022.12.011","title":"Economic impact of using risk models for eligibility selection to the International lung screening Trial","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Brock University; Simon Fraser University; BC Cancer Agency; University of British Columbia; University of Calgary; Vancouver Coastal Health","funders":"Terry Fox Research Institute","keywords":"Medicine; Socioeconomic status; Quality-adjusted life year; Demography; Lung cancer screening; Cost effectiveness; Risk assessment; Environmental health; Internal medicine; Population; Lung cancer","score_opus":0.036244475782754484,"score_gpt":0.4078666064544207,"score_spread":0.3716221306716662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313398502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6652414,0.01378351,0.21885325,0.04751275,0.0026684478,0.0030328853,0.007979128,0.0012214162,0.039707173],"genre_scores_gemma":[0.9780602,0.0009622645,0.013237923,0.0019203702,0.00035330496,0.0004935322,0.0011434249,0.00009943978,0.0037294896],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.963347,0.03403345,0.00044399253,0.00082134554,0.00064552523,0.0007087038],"domain_scores_gemma":[0.7620274,0.22831415,0.0034324515,0.003637085,0.0012056493,0.0013832584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.061406232,0.0017183095,0.004045842,0.0010837152,0.000519705,0.0036724797,0.0019640145,0.0031846594,0.009066463],"category_scores_gemma":[0.14006749,0.0010310968,0.0036734706,0.001268031,0.0010596702,0.0025574556,0.0016073136,0.005769763,0.00061191886],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046004992,0.0013236958,0.01917386,0.00092459854,0.0041718725,0.00050133915,0.00016587197,0.8151004,0.00024623543,0.03175626,0.013409765,0.06722117],"study_design_scores_gemma":[0.00585912,0.0013845798,0.0036628775,0.00023803538,0.003065404,0.00013782017,0.000097171054,0.9272005,0.000257492,0.05560098,0.0024337333,0.000062231],"about_ca_topic_score_codex":0.007155061,"about_ca_topic_score_gemma":0.0052437396,"teacher_disagreement_score":0.061406232,"about_ca_system_score_codex":0.0023915533,"about_ca_system_score_gemma":0.0036260844,"threshold_uncertainty_score":0.32475114},"labels":[],"label_agreement":null},{"id":"W4315650998","doi":"10.1016/j.lungcan.2023.01.006","title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Prevention of Organ Failure","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Internal medicine; Oncology; Population; Lung cancer; Hazard ratio; Atezolizumab; Docetaxel; Cancer; Confidence interval; Immunotherapy","score_opus":0.07048827422576923,"score_gpt":0.39530272533794564,"score_spread":0.32481445111217644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315650998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0116896685,0.98524195,0.0010495714,0.00028541422,0.00020039368,0.00038086929,0.00073340687,0.000034068824,0.000384712],"genre_scores_gemma":[0.43275586,0.5578536,0.0038070667,0.0014109045,0.00038002254,0.0017319261,0.0015012705,0.000053123236,0.00050630467],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9877001,0.006771574,0.0026846996,0.0013812257,0.0011988356,0.0002636495],"domain_scores_gemma":[0.9792839,0.015004848,0.0036382584,0.0006266068,0.0011972118,0.00024906802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018953843,0.0022985088,0.015276379,0.005176407,0.00043258612,0.0030292273,0.0018940658,0.0019448227,0.002794467],"category_scores_gemma":[0.03537698,0.0012526081,0.036900785,0.00494585,0.00068286853,0.0016261828,0.0014281403,0.0017458666,0.00027621767],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002920518,0.000026192834,0.0025014712,0.15306374,0.83177274,0.000049305527,0.000045732813,0.00058833166,0.00017340986,0.00009614543,0.0002575042,0.00850488],"study_design_scores_gemma":[0.00066278834,0.00024157263,0.0021423898,0.008930363,0.98679966,0.000044657987,0.000022078862,0.00022954673,0.00007452227,0.00015748916,0.0006801628,0.000014682215],"about_ca_topic_score_codex":0.0048668603,"about_ca_topic_score_gemma":0.009417472,"teacher_disagreement_score":0.018953843,"about_ca_system_score_codex":0.0026857045,"about_ca_system_score_gemma":0.0026743207,"threshold_uncertainty_score":0.10023874},"labels":[],"label_agreement":null},{"id":"W4319240035","doi":"10.1016/j.lungcan.2023.02.002","title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Instituto de Salud Carlos III; Institut Du Cancer de Montréal; Sociedad Española de Oncología Médica; Terry Fox Foundation","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Immunotherapy; Oncology; Lung cancer; Progression-free survival; Cancer; Surgery; Gastroenterology; Breast cancer","score_opus":0.007287272378358274,"score_gpt":0.3189931669307253,"score_spread":0.311705894552367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319240035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938364,0.0049676457,0.0001525752,0.0005605891,0.00010911007,0.000035163554,0.0017985856,0.000013054425,0.0029795996],"genre_scores_gemma":[0.99516004,0.0005600639,0.000038865837,0.00025356715,0.00008293964,0.00002128283,0.0031575651,0.0000049902883,0.00072069967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963,0.000063734544,0.00003186303,0.00008520819,0.00006852785,0.0001207572],"domain_scores_gemma":[0.9988493,0.00022195502,0.00045527186,0.000047555335,0.00010487012,0.00032106973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005543552,0.00021134382,0.0006714813,0.00030809827,0.00030990003,0.00087616575,0.00038327917,0.00058861834,0.0016916275],"category_scores_gemma":[0.0019640874,0.00009321835,0.0017679073,0.00039430417,0.00016473432,0.0009086663,0.0004624554,0.001237282,0.0001920172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014601767,0.00062842184,0.92996347,0.0002828299,0.0014648135,0.0004482425,0.00018795344,0.0019441423,0.0010312331,0.00031146855,0.003626731,0.045509048],"study_design_scores_gemma":[0.0002914883,0.0024109627,0.99266654,0.00008369762,0.00064755906,0.0004203396,0.00020818561,0.0009093222,0.00026893706,0.0003364491,0.0017345088,0.000021964921],"about_ca_topic_score_codex":0.0025200155,"about_ca_topic_score_gemma":0.0058703283,"teacher_disagreement_score":0.0025200155,"about_ca_system_score_codex":0.0010464176,"about_ca_system_score_gemma":0.0005714254,"threshold_uncertainty_score":0.0075923204},"labels":[],"label_agreement":null},{"id":"W4323664765","doi":"10.1016/j.lungcan.2023.03.002","title":"Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Surrey Memorial Hospital; Sunnybrook Health Science Centre; Surrey Place Centre; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; University Health Network; Health Sciences Centre; St. John’s Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Radiation therapy; Lung cancer; Immunotherapy; Oncology; Stage (stratigraphy); Intensive care medicine; Consensus conference; Internal medicine; Cancer","score_opus":0.0804489223633583,"score_gpt":0.39027321538339904,"score_spread":0.3098242930200408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323664765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004281862,0.56860006,0.0049302923,0.37880188,0.0084247235,0.0021005482,0.0057697496,0.0001935755,0.026897352],"genre_scores_gemma":[0.069644295,0.73007715,0.09588769,0.08113546,0.0027975144,0.0033769673,0.010154082,0.00014119208,0.0067857928],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9781154,0.0048168977,0.007078507,0.0014096583,0.007309753,0.0012697746],"domain_scores_gemma":[0.8849403,0.021834709,0.009230329,0.0012293749,0.07625137,0.0065138116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031264555,0.0013463796,0.0023054664,0.009908556,0.0038822722,0.0037154956,0.007864278,0.006483052,0.004106833],"category_scores_gemma":[0.08064258,0.0010447188,0.0049836384,0.009394401,0.002273598,0.002847859,0.003075478,0.0051964824,0.0012343444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023100314,0.00015249522,0.013239582,0.08401415,0.0012230693,0.00057417504,0.0028218525,0.0012093495,0.00094796275,0.005821986,0.463382,0.42638245],"study_design_scores_gemma":[0.0004174758,0.00011302606,0.0214543,0.20758708,0.0037818754,0.0006578768,0.0027737033,0.00094483065,0.0006583287,0.005790882,0.75550324,0.00031753175],"about_ca_topic_score_codex":0.5273359,"about_ca_topic_score_gemma":0.5956375,"teacher_disagreement_score":0.47266412,"about_ca_system_score_codex":0.030649384,"about_ca_system_score_gemma":0.16020828,"threshold_uncertainty_score":0.9508955},"labels":[],"label_agreement":null},{"id":"W4353095460","doi":"10.1016/j.lungcan.2023.107176","title":"Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Presentation (obstetrics); Adenocarcinoma; Pooled analysis; Internal medicine; Lung; Oncology; General surgery; Meta-analysis; Surgery; Cancer","score_opus":0.06036838018464324,"score_gpt":0.45720151292088185,"score_spread":0.3968331327362386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353095460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24702393,0.7436019,0.00089960167,0.00018579383,0.00010608195,0.00021347187,0.0067594876,0.000033656666,0.0011760328],"genre_scores_gemma":[0.83801484,0.15141535,0.0009263588,0.00033365123,0.00032338753,0.00042637886,0.008314599,0.000038706872,0.00020682164],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9931584,0.0014726209,0.0031630408,0.0011138889,0.0009428085,0.0001493148],"domain_scores_gemma":[0.98618525,0.0055058254,0.005741159,0.0009078948,0.0014025975,0.00025729768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004766888,0.00088404637,0.0039612483,0.009366971,0.0003362744,0.0017571946,0.0007030851,0.0008750695,0.0011509478],"category_scores_gemma":[0.013610161,0.00060153287,0.0060082558,0.009132107,0.0005412261,0.0010034838,0.0012380341,0.00033325877,0.0003159347],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004092949,0.000070841954,0.70382434,0.08032362,0.15194471,0.002220174,0.0006816632,0.0005514807,0.0019836414,0.00013062551,0.0024510557,0.051724933],"study_design_scores_gemma":[0.00055511034,0.00096916704,0.7153845,0.01589646,0.24116395,0.010982384,0.0012113514,0.00040292463,0.0007913487,0.0004304009,0.012052998,0.00015940543],"about_ca_topic_score_codex":0.0006625392,"about_ca_topic_score_gemma":0.0012664535,"teacher_disagreement_score":0.009366971,"about_ca_system_score_codex":0.00044834317,"about_ca_system_score_gemma":0.00047827035,"threshold_uncertainty_score":0.025209963},"labels":[],"label_agreement":null},{"id":"W4362716531","doi":"10.1016/j.lungcan.2023.107191","title":"Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"Viropharma","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Oncology; Confidence interval; Vinorelbine; Discontinuation; Population; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Chemotherapy; Surgery; Phases of clinical research; Cisplatin","score_opus":0.024040701422515128,"score_gpt":0.3758878505984089,"score_spread":0.35184714917589377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362716531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873289,0.008320479,0.0012610328,0.00009775864,0.00008600111,0.00035647812,0.0011269235,0.000020617876,0.0014018238],"genre_scores_gemma":[0.99654144,0.00096779555,0.00073665264,0.00007744044,0.000054615328,0.00025426273,0.001116447,0.0000073287147,0.00024384023],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98900676,0.008799808,0.0005950025,0.00062927976,0.000811857,0.00015725648],"domain_scores_gemma":[0.9804581,0.013054302,0.004258623,0.0012254106,0.0006307831,0.00037282915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011796578,0.00088131387,0.0016740472,0.0009289268,0.00014327257,0.0010298779,0.0007982662,0.0006499701,0.0023138763],"category_scores_gemma":[0.015957698,0.00030054472,0.0030804921,0.0006807593,0.0006067725,0.0007492247,0.00110364,0.0010141742,0.00028162028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6867517,0.0044227787,0.12454983,0.008013174,0.067341216,0.0001507429,0.0003018242,0.013179557,0.0047485,0.000946938,0.0009425143,0.0886512],"study_design_scores_gemma":[0.11617035,0.3940196,0.3739766,0.001048399,0.06656597,0.0012046848,0.00041683824,0.02319037,0.011774076,0.001589758,0.009804756,0.00023860951],"about_ca_topic_score_codex":0.0004007054,"about_ca_topic_score_gemma":0.000593473,"teacher_disagreement_score":0.011796578,"about_ca_system_score_codex":0.0009085663,"about_ca_system_score_gemma":0.00048571316,"threshold_uncertainty_score":0.06238699},"labels":[],"label_agreement":null},{"id":"W4376619319","doi":"10.1016/j.lungcan.2023.107247","title":"Germline EGFR c.2527G &gt; A (p.V843I) variant and familial lung cancer","year":2023,"lang":"de","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Germline; Epidermal growth factor receptor; Lung cancer; Proband; Medicine; Germline mutation; Missense mutation; Adenocarcinoma; Exon; Gefitinib; Somatic cell; Oncology; Cancer research; Internal medicine; Cancer; Mutation; Genetics; Biology; Gene","score_opus":0.012307176042524784,"score_gpt":0.3530358392758478,"score_spread":0.340728663233323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376619319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825692,0.00322371,0.00057322666,0.0014940412,0.00013887904,0.000017470233,0.0008429005,0.000044490924,0.01109606],"genre_scores_gemma":[0.9985625,0.00023089157,0.00010819886,0.00009574941,0.000047030353,0.0000020737352,0.00008811701,0.0000037514017,0.0008617131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998616,0.000020012165,0.000012352946,0.000039440787,0.00003164161,0.00003494623],"domain_scores_gemma":[0.99982905,0.00004015713,0.000048651153,0.0000117214495,0.000015472448,0.00005490949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014133342,0.0003997407,0.00027150929,0.00042762226,0.00064013666,0.00034149145,0.0002506595,0.0011162221,0.0056073903],"category_scores_gemma":[0.0006430822,0.00018830934,0.00036917342,0.00048775272,0.00029945842,0.00024078356,0.00019869524,0.0005380926,0.0005709137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017486722,0.00030342164,0.71403044,0.00017243721,0.00039247354,0.20906082,0.00034914294,0.0014479053,0.03295154,0.0026302766,0.008761699,0.028151082],"study_design_scores_gemma":[0.000085588785,0.00032130204,0.7036275,0.00017986888,0.00039153782,0.2789104,0.000322356,0.0026924568,0.0036356368,0.002468912,0.00731347,0.000050966533],"about_ca_topic_score_codex":0.0060580615,"about_ca_topic_score_gemma":0.0062380545,"teacher_disagreement_score":0.0060580615,"about_ca_system_score_codex":0.00033533765,"about_ca_system_score_gemma":0.0002613851,"threshold_uncertainty_score":0.018758595},"labels":[],"label_agreement":null},{"id":"W4379141408","doi":"10.1016/j.lungcan.2023.107259","title":"Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"AstraZeneca; Johnson and Johnson; Pfizer","keywords":"Medicine; Meta-analysis; Radiofrequency ablation; Microwave ablation; Lung cancer; Radiosurgery; Stage (stratigraphy); Subgroup analysis; Internal medicine; Randomized controlled trial; Oncology; Systematic review; Radiation therapy; non-small cell lung cancer (NSCLC); Radiology; Nuclear medicine; Ablation; MEDLINE","score_opus":0.18104766197304406,"score_gpt":0.39147298220618093,"score_spread":0.21042532023313687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379141408","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004763427,0.99288017,0.0005665194,0.00024068139,0.0001057139,0.00038822994,0.0007566046,0.000025872627,0.0002728508],"genre_scores_gemma":[0.19147672,0.80000204,0.0032710312,0.0011950197,0.00031044922,0.002054283,0.001296821,0.000035628855,0.00035796917],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9896778,0.005042544,0.0027670234,0.0010652555,0.0011647521,0.00028248085],"domain_scores_gemma":[0.9820347,0.012965662,0.0031734535,0.00053394656,0.0010975235,0.00019467941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013200436,0.0024410484,0.015211618,0.0075731687,0.00058975234,0.002687404,0.0020366828,0.002191419,0.0037032817],"category_scores_gemma":[0.028998481,0.0011930304,0.03339384,0.0091862995,0.00073717843,0.0016067207,0.001190436,0.0013785161,0.00030513358],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012914923,0.000028508177,0.004999997,0.44490346,0.5371141,0.00012935443,0.00007655955,0.0006355441,0.00023989208,0.00013646118,0.00069414143,0.009750572],"study_design_scores_gemma":[0.00046895054,0.00016833258,0.0040641185,0.031181814,0.962027,0.00010210851,0.00003720649,0.00022693528,0.00010192279,0.00019748263,0.0014049311,0.000019163514],"about_ca_topic_score_codex":0.007144165,"about_ca_topic_score_gemma":0.013998077,"teacher_disagreement_score":0.015211618,"about_ca_system_score_codex":0.0024860485,"about_ca_system_score_gemma":0.0037936284,"threshold_uncertainty_score":0.069811404},"labels":[],"label_agreement":null},{"id":"W4381547499","doi":"10.1016/j.lungcan.2023.107281","title":"Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"Department of Health and Social Care; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Radiosurgery; Meta-analysis; Lung cancer; Radiation therapy; Incidence (geometry); Pneumonitis; Dose fractionation; Oncology; Internal medicine; Radiology; Lung","score_opus":0.1080639109713676,"score_gpt":0.45644371223217445,"score_spread":0.34837980126080687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381547499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025035464,0.99367493,0.0011871625,0.0004792891,0.0001286767,0.0005604139,0.0010817909,0.000036091347,0.00034808705],"genre_scores_gemma":[0.11196578,0.8762399,0.005293963,0.0015089377,0.00025244526,0.0027003074,0.0016628448,0.00005389025,0.00032188164],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98452145,0.0067088343,0.004980312,0.0014793925,0.0019282528,0.00038174543],"domain_scores_gemma":[0.97151864,0.01974746,0.0051361546,0.00083835586,0.0025134336,0.00024595516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025242915,0.002556221,0.014985679,0.010350451,0.0005571746,0.0030864757,0.002770834,0.0022746096,0.0032662367],"category_scores_gemma":[0.047521364,0.0013596436,0.033014294,0.009760275,0.0007379076,0.0020467893,0.0014982625,0.0016110728,0.00035497942],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007243667,0.000019616986,0.004389398,0.60825074,0.3648613,0.00013640581,0.00011791953,0.0009218819,0.00022796667,0.00028308452,0.0017192261,0.018348075],"study_design_scores_gemma":[0.00043865654,0.00011992945,0.004742334,0.101360455,0.88758785,0.00014458434,0.00006991782,0.00040247434,0.00017630692,0.00050465757,0.0044165887,0.00003620218],"about_ca_topic_score_codex":0.00788363,"about_ca_topic_score_gemma":0.016229192,"teacher_disagreement_score":0.025242915,"about_ca_system_score_codex":0.003560272,"about_ca_system_score_gemma":0.0059909434,"threshold_uncertainty_score":0.13349885},"labels":[],"label_agreement":null},{"id":"W4381953305","doi":"10.1016/j.lungcan.2023.107284","title":"Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Randomized controlled trial; Guideline; Radiation therapy; Radiology; Lung cancer; Stereotactic radiotherapy; Dose fractionation; Oncology; Internal medicine","score_opus":0.14962560740118783,"score_gpt":0.4413805635659144,"score_spread":0.2917549561647266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381953305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001533706,0.98831624,0.001504448,0.0026522933,0.0004070423,0.0029724792,0.0015950119,0.00004493826,0.000973727],"genre_scores_gemma":[0.027971243,0.9459163,0.011331661,0.0043065683,0.00024196453,0.008182799,0.001612933,0.000032038322,0.0004044192],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9497546,0.018155525,0.02155216,0.0030475948,0.0069093406,0.0005808275],"domain_scores_gemma":[0.9060366,0.05179396,0.027554495,0.0019431716,0.012017202,0.00065465993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.045996245,0.0017444371,0.0068846447,0.01595955,0.0007676749,0.0028341447,0.0038953978,0.002382591,0.003044031],"category_scores_gemma":[0.12283888,0.001468477,0.007504864,0.015019805,0.0017707564,0.0033999358,0.0021158312,0.001476961,0.0004811686],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012812547,0.000013675008,0.0015660983,0.94140506,0.007954092,0.00006215427,0.0003513361,0.00023550668,0.00018136053,0.0006881953,0.0066613974,0.04075295],"study_design_scores_gemma":[0.00030870608,0.0000805978,0.0033841257,0.942274,0.03253626,0.00016353032,0.00021035007,0.00016223482,0.00015954605,0.0006417166,0.020047273,0.000031797208],"about_ca_topic_score_codex":0.011066977,"about_ca_topic_score_gemma":0.03448036,"teacher_disagreement_score":0.045996245,"about_ca_system_score_codex":0.007117886,"about_ca_system_score_gemma":0.026209127,"threshold_uncertainty_score":0.2432543},"labels":[],"label_agreement":null},{"id":"W4387981858","doi":"10.1183/13993003.congress-2023.pa3887","title":"Impact of COPD on lung cancer symptom burden: A population-based study","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"COPD; Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Population; Cancer; Retrospective cohort study; Cohort; Poisson regression; Physical therapy","score_opus":0.01939794815664339,"score_gpt":0.3946958386500647,"score_spread":0.3752978904934213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387981858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981925,0.0002818436,0.000072515046,0.000087535685,0.0000066239413,0.000028405373,0.0009084234,0.0000041876274,0.000417918],"genre_scores_gemma":[0.9991629,0.0001369494,0.000048033526,0.00005360229,0.000011587135,0.000017423987,0.00049236685,0.0000016532553,0.00007550035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892455,0.0002873224,0.00007969878,0.00027046428,0.0002542386,0.00018374731],"domain_scores_gemma":[0.99870145,0.0001666803,0.0004543984,0.00015053026,0.00020306544,0.00032383666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001143181,0.00038032787,0.00043393107,0.00091107073,0.00088769075,0.0010192144,0.0006989467,0.0010125784,0.001122894],"category_scores_gemma":[0.0023725077,0.0005283877,0.0007560347,0.0022419312,0.0005227804,0.00070287037,0.0007640259,0.0008979372,0.000241282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047535992,0.000031179654,0.9992393,0.000007819647,0.000083802406,0.000035277204,0.00007795274,0.000017069422,0.00005110028,0.000006702534,0.00010408106,0.000298155],"study_design_scores_gemma":[0.000009529323,0.000042593772,0.99956363,0.0000043390537,0.00002835607,0.000060316896,0.000120654906,0.00006186327,0.000004718801,0.0000056490876,0.00009522178,0.0000030252443],"about_ca_topic_score_codex":0.13907425,"about_ca_topic_score_gemma":0.15867686,"teacher_disagreement_score":0.13907425,"about_ca_system_score_codex":0.0013263437,"about_ca_system_score_gemma":0.0014876059,"threshold_uncertainty_score":0.27652955},"labels":[],"label_agreement":null},{"id":"W4388185745","doi":"10.1183/13993003.congress-2023.pa3890","title":"Has the covid pandemic influenced the diagnosis of patients with lung cancer?","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); Referral; Retrospective cohort study; Stage (stratigraphy); Quarter (Canadian coin); Cancer; Pediatrics; Disease; Internal medicine; Family medicine; Infectious disease (medical specialty)","score_opus":0.05877271174007154,"score_gpt":0.40868309182035584,"score_spread":0.3499103800802843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388185745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893684,0.0032967087,0.00009740424,0.0033278512,0.00017218296,0.000016736622,0.0015444872,0.0000047077256,0.0021715595],"genre_scores_gemma":[0.9974885,0.00091471535,0.00006583118,0.00031269243,0.0001422682,0.000012267765,0.0008208868,0.0000036501533,0.0002392218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99892825,0.00033697748,0.00010374852,0.00021962411,0.00011434519,0.00029707546],"domain_scores_gemma":[0.9961151,0.0009642324,0.0017904993,0.00014110631,0.00033282005,0.0006563089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00129538,0.00013627211,0.00022135601,0.00057639304,0.00049212534,0.00089537195,0.00042964445,0.00081926864,0.005049071],"category_scores_gemma":[0.006517943,0.00016049408,0.00042856982,0.0016719836,0.00047264824,0.00084417005,0.0006691808,0.00073689787,0.0004382214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110581765,0.000016234908,0.9971909,0.000027588974,0.000016328228,0.000053888263,0.00014161994,0.00002112677,0.000039128012,0.00003002828,0.00043687184,0.001915722],"study_design_scores_gemma":[0.0000022828833,0.000033803422,0.99858105,0.00003191696,0.000008477008,0.00008027726,0.00069818704,0.000029205778,0.000015485117,0.000015657493,0.0005007274,0.0000030833787],"about_ca_topic_score_codex":0.024677992,"about_ca_topic_score_gemma":0.026087476,"teacher_disagreement_score":0.024677992,"about_ca_system_score_codex":0.0009819574,"about_ca_system_score_gemma":0.0016453884,"threshold_uncertainty_score":0.04906869},"labels":[],"label_agreement":null},{"id":"W4388563714","doi":"10.1016/j.lungcan.2023.107419","title":"Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca España; AstraZeneca","keywords":"Medicine; Quality of life (healthcare); Disease; Stage (stratigraphy); Lung cancer; Clinical trial; Intensive care medicine; Scope (computer science); Physical therapy; Oncology; Internal medicine; Nursing","score_opus":0.6041392632226493,"score_gpt":0.5597146177118956,"score_spread":0.04442464551075376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388563714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007498375,0.99966,0.00004003216,0.00007838611,0.000035492783,0.00001889862,0.00003959529,0.0000013520972,0.000051201125],"genre_scores_gemma":[0.001509948,0.997846,0.00024831799,0.00024549823,0.000044270986,0.000040675317,0.000036726975,9.982655e-7,0.000027634256],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9974323,0.00082869036,0.00088560407,0.00029028518,0.00047509593,0.00008796526],"domain_scores_gemma":[0.9898135,0.00827259,0.0012066511,0.00008002714,0.00053026556,0.00009696563],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061939615,0.001239865,0.0068209497,0.0035255672,0.0002656423,0.0023243376,0.0016248695,0.001674857,0.0040388675],"category_scores_gemma":[0.014922281,0.00066356227,0.0049966034,0.0045201206,0.0006065938,0.0017820556,0.0013126826,0.0018868552,0.00035677382],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005213852,0.00006656169,0.00074728555,0.6207334,0.009098776,0.000052996085,0.00009534593,0.0003575403,0.0002750079,0.00092901156,0.0054584905,0.3616642],"study_design_scores_gemma":[0.0012530058,0.0008237688,0.011159381,0.7050724,0.08222762,0.00059727556,0.0003601454,0.0004986512,0.00044014896,0.002720957,0.19469792,0.00014868725],"about_ca_topic_score_codex":0.0033677695,"about_ca_topic_score_gemma":0.009194824,"teacher_disagreement_score":0.99380606,"about_ca_system_score_codex":0.0016282985,"about_ca_system_score_gemma":0.0038704793,"threshold_uncertainty_score":0.032757223},"labels":[],"label_agreement":null},{"id":"W4391818063","doi":"10.1016/j.lungcan.2024.107504","title":"Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don’t Put the Cart before the stereotactic Horse","year":2024,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Cart; Microwave ablation; Medicine; Stage (stratigraphy); Ablation; Horse; Lung cancer; Oncology; Internal medicine; Nuclear medicine; Biology; History","score_opus":0.012961014427310983,"score_gpt":0.29490520646762397,"score_spread":0.281944192040313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391818063","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060258695,0.00040367348,0.00008520987,0.97657007,0.0168209,0.000029306877,0.00013479478,0.000041047602,0.0053124204],"genre_scores_gemma":[0.0038197169,0.00050227495,0.00022853976,0.96092904,0.014145459,0.000053847012,0.00006953484,0.00003724382,0.02021428],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826884,0.00034198642,0.00016915177,0.00024635365,0.00050958013,0.00046410743],"domain_scores_gemma":[0.99713933,0.0010863052,0.00018095435,0.000069708985,0.0007783147,0.000745395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016110191,0.0008414994,0.0013953649,0.00069460797,0.0052441596,0.0032800073,0.0017386118,0.05178297,0.012164892],"category_scores_gemma":[0.010341194,0.0006138102,0.0015476149,0.0005271693,0.0016607036,0.002201976,0.0011397266,0.033352777,0.008541281],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079407924,0.000064318156,0.0007690266,0.000040733816,0.00001854321,0.0028575337,0.00011571627,0.00007566254,0.00020795564,0.0010038089,0.99106795,0.003699456],"study_design_scores_gemma":[0.0002378825,0.0001783383,0.0027710267,0.0003339028,0.00006068506,0.0030191496,0.0010838723,0.0008707357,0.0003217028,0.005502306,0.9855139,0.00010641706],"about_ca_topic_score_codex":0.01927217,"about_ca_topic_score_gemma":0.044731908,"teacher_disagreement_score":0.05178297,"about_ca_system_score_codex":0.005543778,"about_ca_system_score_gemma":0.0063226935,"threshold_uncertainty_score":0.040695608},"labels":[],"label_agreement":null},{"id":"W4391896363","doi":"10.1016/j.lungcan.2024.107506","title":"Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Queen's University","funders":"","keywords":"Medicine; Pemetrexed; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Surrogate endpoint; Cancer; Immunotherapy; Cisplatin; Progressive disease","score_opus":0.0039897269361011825,"score_gpt":0.26341521555037406,"score_spread":0.2594254886142729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391896363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987746,0.0005343404,0.00007624581,0.000031764073,0.0000035944784,0.0000324917,0.00024417,0.0000040960444,0.0002987266],"genre_scores_gemma":[0.9991387,0.00009083744,0.000104841616,0.000036107594,0.00000847617,0.000027283475,0.0004480895,0.0000015715071,0.00014406639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996406,0.00011979244,0.000039844865,0.00008881579,0.000079696605,0.000031328327],"domain_scores_gemma":[0.999223,0.0002572424,0.00030652212,0.000033637767,0.000052948406,0.00012664965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011153176,0.000244305,0.00043693584,0.00021536689,0.00015727317,0.0002918257,0.00025643123,0.00032390183,0.0018997334],"category_scores_gemma":[0.001287127,0.00014661235,0.00025358394,0.00026594868,0.00015258898,0.00028839245,0.00017691813,0.00044794905,0.00025352955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035624467,0.0012293828,0.91724515,0.00021199441,0.0006045279,0.00012427496,0.00008098094,0.00085641764,0.008255902,0.000044770142,0.00081358897,0.03490845],"study_design_scores_gemma":[0.0019465628,0.009527058,0.9825948,0.000023556802,0.0002941767,0.00065835135,0.000037265614,0.0018656749,0.0018391339,0.0000530965,0.0011507524,0.000009667277],"about_ca_topic_score_codex":0.00048947695,"about_ca_topic_score_gemma":0.0009116864,"teacher_disagreement_score":0.0018997334,"about_ca_system_score_codex":0.00040556412,"about_ca_system_score_gemma":0.0002306197,"threshold_uncertainty_score":0.0063551664},"labels":[],"label_agreement":null},{"id":"W4392382353","doi":"10.1016/j.lungcan.2024.107529","title":"Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Lung cancer; Population; T790M; Clinical trial; Oncology; Cohort; Cancer; Surgery; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.0368810711503858,"score_gpt":0.4325912659763442,"score_spread":0.3957101948259584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392382353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900682,0.0026089284,0.00019363084,0.001400793,0.00021745662,0.000089288886,0.0019933716,0.000009981478,0.0034184295],"genre_scores_gemma":[0.9954982,0.00047030902,0.000061518,0.00064251595,0.00015682768,0.000083041596,0.0023726367,0.0000035455364,0.00071128923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995357,0.00014378713,0.000041485993,0.00007918326,0.000058913458,0.0001410605],"domain_scores_gemma":[0.9992756,0.00014499022,0.00023169702,0.000040192044,0.000062424384,0.00024512727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085343554,0.0002859178,0.001068775,0.0001741774,0.00044312954,0.0010034096,0.0003282624,0.00083310687,0.0019727056],"category_scores_gemma":[0.001708213,0.000118268516,0.0023777743,0.0003809235,0.00035187122,0.0007346128,0.0004061431,0.0013289782,0.00025714198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24231881,0.0033112087,0.6208577,0.00081242423,0.0055772546,0.001014422,0.00031501963,0.005695767,0.0045438204,0.0023494412,0.02019499,0.093009144],"study_design_scores_gemma":[0.03831748,0.047080748,0.8861211,0.00027014507,0.005079706,0.0012171139,0.0005174939,0.0054524713,0.0012238321,0.0042842696,0.010312685,0.00012291077],"about_ca_topic_score_codex":0.0015670202,"about_ca_topic_score_gemma":0.002861659,"teacher_disagreement_score":0.0019727056,"about_ca_system_score_codex":0.0012045514,"about_ca_system_score_gemma":0.0007356002,"threshold_uncertainty_score":0.00873965},"labels":[],"label_agreement":null},{"id":"W4392859966","doi":"10.1016/j.lungcan.2024.107535","title":"A pragmatic guide for management of adverse events associated with lorlatinib","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Adverse effect; Clinical trial; Anaplastic lymphoma kinase; Concomitant; Tyrosine-kinase inhibitor; Intensive care medicine; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.027980821829533785,"score_gpt":0.4324065033874051,"score_spread":0.40442568155787134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392859966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011670594,0.73077244,0.048660897,0.15217115,0.013788668,0.0033707125,0.0030692767,0.002063851,0.04493584],"genre_scores_gemma":[0.007483291,0.7134491,0.15852825,0.07875019,0.0038412167,0.004664571,0.0029701723,0.00025898434,0.030054223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960461,0.0017218133,0.0010710423,0.0001714184,0.0008893091,0.00010029211],"domain_scores_gemma":[0.9945766,0.002519651,0.0007190142,0.00018107894,0.001725018,0.00027875288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052527064,0.0015169363,0.001976375,0.0025774303,0.00056441,0.0017608344,0.0026822265,0.004549805,0.010376096],"category_scores_gemma":[0.012884266,0.00078616623,0.0019288651,0.001688342,0.0008573679,0.0032598127,0.0012237396,0.006622943,0.009972312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009967406,0.00011278835,0.0002209342,0.013131665,0.00013729764,0.00048347257,0.000375769,0.0003759196,0.00085149094,0.0066807014,0.43034998,0.5471803],"study_design_scores_gemma":[0.000114837225,0.000060274895,0.00061173696,0.01591634,0.00009096622,0.00088027894,0.00016771122,0.00021128467,0.00014686084,0.005178756,0.9765826,0.000038329763],"about_ca_topic_score_codex":0.0022881723,"about_ca_topic_score_gemma":0.006751366,"teacher_disagreement_score":0.010376096,"about_ca_system_score_codex":0.0010825647,"about_ca_system_score_gemma":0.0049728346,"threshold_uncertainty_score":0.03471148},"labels":[],"label_agreement":null},{"id":"W4393340184","doi":"10.1016/j.lungcan.2024.107557","title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Center for Clinical Trials, Japan Medical Association","keywords":"Lenvatinib; Medicine; Hazard ratio; Internal medicine; Adverse effect; Confidence interval; Oncology; Clinical trial; Gastroenterology; Cancer; Thyroid cancer","score_opus":0.03466082282414185,"score_gpt":0.3378925740177667,"score_spread":0.30323175119362483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393340184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888902,0.007047444,0.00027519875,0.00058658974,0.000092091555,0.0001546519,0.0015522115,0.00003723437,0.0013644508],"genre_scores_gemma":[0.992027,0.0019073742,0.00039941256,0.0007665515,0.0001597962,0.00025980358,0.0035950579,0.0000200728,0.0008650066],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99918634,0.0004019672,0.00003831161,0.0001447699,0.00007855382,0.00015003223],"domain_scores_gemma":[0.99883777,0.0002740601,0.00033457013,0.0001312036,0.00007318985,0.00034916378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023974914,0.0010658939,0.001980562,0.00023456594,0.00039810204,0.0015120223,0.00060722604,0.000886823,0.0013938401],"category_scores_gemma":[0.002059986,0.00031126,0.002629752,0.00041429835,0.0005665454,0.0011951751,0.0004336532,0.0023692674,0.0004075904],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66619045,0.0065814806,0.10294802,0.0012551713,0.013751227,0.0007040544,0.0003696191,0.0060064523,0.01633912,0.000570927,0.009061095,0.17622235],"study_design_scores_gemma":[0.35181972,0.1954772,0.4041601,0.00045075317,0.015702957,0.002530853,0.00060393155,0.0056109526,0.004002627,0.002562765,0.01683892,0.00023915428],"about_ca_topic_score_codex":0.0006813905,"about_ca_topic_score_gemma":0.0026244724,"teacher_disagreement_score":0.0023974914,"about_ca_system_score_codex":0.001063453,"about_ca_system_score_gemma":0.0009660858,"threshold_uncertainty_score":0.012679279},"labels":[],"label_agreement":null},{"id":"W4394878299","doi":"10.1016/j.lungcan.2024.107733","title":"172 Stage and Survival of Screen Detected Small Cell Lung Cancer from the SUMMIT Study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Summit; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Cartography","score_opus":0.028990671029437663,"score_gpt":0.36243275310084566,"score_spread":0.333442082071408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394878299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928202,0.001277207,0.000047123227,0.00027433824,0.000036536625,0.000009412394,0.0043864218,0.0000050515623,0.0011436184],"genre_scores_gemma":[0.99467766,0.00031217994,0.000022782197,0.00008281298,0.000048772792,0.000016286236,0.0038067263,0.0000052716177,0.0010275138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993981,0.0002164356,0.000049358037,0.00009864,0.00009034518,0.00014718511],"domain_scores_gemma":[0.9983026,0.00037031804,0.00043018733,0.00020548246,0.0002929133,0.00039849197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012837803,0.0004354014,0.0005506171,0.00091318216,0.0006372875,0.000931048,0.0006658476,0.00072132493,0.0025320915],"category_scores_gemma":[0.0032766543,0.00033675515,0.0010754822,0.00142204,0.00027767415,0.0007100327,0.0007092269,0.000875758,0.0003901545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022316773,0.00008348896,0.9929721,0.00004097349,0.00040753407,0.00016485836,0.00017262877,0.00006782616,0.00043803197,0.00007390317,0.0016202264,0.0017268822],"study_design_scores_gemma":[0.000065535365,0.000116528754,0.9986493,0.000010346482,0.0002340575,0.00005778139,0.00019023479,0.00006959372,0.000061510844,0.00002177437,0.0005164499,0.00000690768],"about_ca_topic_score_codex":0.06250679,"about_ca_topic_score_gemma":0.07763135,"teacher_disagreement_score":0.06250679,"about_ca_system_score_codex":0.00078075315,"about_ca_system_score_gemma":0.00084856903,"threshold_uncertainty_score":0.12428594},"labels":[],"label_agreement":null},{"id":"W4394879017","doi":"10.1016/j.lungcan.2024.107603","title":"42 Evaluation of a novel simulator for linear and radial EBUS at University College London: The Lung Phantom","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ultrasound in Clinical Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Imaging phantom; Medicine; Simulation; Nuclear medicine; Computer science","score_opus":0.05356015067535775,"score_gpt":0.40550049936074173,"score_spread":0.351940348685384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394879017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7198909,0.0013427197,0.25077078,0.0019724367,0.0003896725,0.0013843088,0.0021913194,0.0046406607,0.017417131],"genre_scores_gemma":[0.8936549,0.0005183456,0.09494971,0.00040250894,0.000034795416,0.00031568832,0.001304858,0.00072680815,0.00809228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99952185,0.00016202114,0.000026007572,0.000055316872,0.0001894295,0.000045410256],"domain_scores_gemma":[0.9984035,0.00073037954,0.00007445077,0.00017120762,0.00043097365,0.00018948298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013801431,0.0005108509,0.00038347967,0.00031425364,0.00026437722,0.0010050826,0.0010503968,0.0013501997,0.006070898],"category_scores_gemma":[0.0036224702,0.00049037684,0.00033346214,0.0003929405,0.0003753114,0.0005519139,0.00072811113,0.0006117279,0.0012453034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045987396,0.00084595574,0.018189259,0.0010829224,0.00021933437,0.0027149175,0.0018471383,0.17426117,0.68331975,0.0027499348,0.007699324,0.10247155],"study_design_scores_gemma":[0.001197132,0.008637446,0.040960446,0.00028415563,0.00039119055,0.0079232035,0.0012412628,0.49221307,0.3687416,0.0009810932,0.07694613,0.00048324198],"about_ca_topic_score_codex":0.003743679,"about_ca_topic_score_gemma":0.0035782703,"teacher_disagreement_score":0.006070898,"about_ca_system_score_codex":0.0008253861,"about_ca_system_score_gemma":0.0013590157,"threshold_uncertainty_score":0.02030921},"labels":[],"label_agreement":null},{"id":"W4394879899","doi":"10.1016/j.lungcan.2024.107562","title":"1 Fast-tracking NSCLC Standard of Care Genomic Testing with a Formalin-free Fresh EBUS Pathway","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Tracking (education); Oncology; Radiology; Internal medicine","score_opus":0.0064031601652497615,"score_gpt":0.24919803156432999,"score_spread":0.24279487139908024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394879899","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21493801,0.020676274,0.4573971,0.017032888,0.004428928,0.0045971917,0.059434753,0.05657539,0.16491947],"genre_scores_gemma":[0.47129798,0.004786465,0.42113906,0.008451885,0.0011783334,0.0024638998,0.030042503,0.0028366859,0.05780317],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986815,0.00022092716,0.000082467974,0.00032929605,0.0005644651,0.0001213569],"domain_scores_gemma":[0.99862623,0.00044235986,0.00009847023,0.0002915438,0.00041522525,0.00012617171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016790264,0.00063246617,0.0004599456,0.0017995687,0.0004791965,0.001354828,0.0010622835,0.0013946255,0.024666402],"category_scores_gemma":[0.003659961,0.00063481845,0.0005132109,0.0005902551,0.00035324323,0.0010646796,0.0014792997,0.0010087576,0.014363644],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024209996,0.00020961426,0.089205384,0.0008290674,0.0001720667,0.0025855203,0.00028036998,0.0031623987,0.14950116,0.0052373894,0.16013646,0.58625954],"study_design_scores_gemma":[0.00040052467,0.0014846907,0.10281507,0.00094630884,0.00044267668,0.019604957,0.00037945405,0.028930504,0.28110963,0.008959059,0.5546766,0.000250516],"about_ca_topic_score_codex":0.0024652234,"about_ca_topic_score_gemma":0.0045000454,"teacher_disagreement_score":0.024666402,"about_ca_system_score_codex":0.00086666783,"about_ca_system_score_gemma":0.00102515,"threshold_uncertainty_score":0.082517326},"labels":[],"label_agreement":null},{"id":"W4396769086","doi":"10.1016/j.lungcan.2024.107819","title":"Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Amgen","keywords":"Medicine; Natural history; Retrospective cohort study; Real world evidence; Natural (archaeology); Internal medicine; Archaeology; History","score_opus":0.015157342278014005,"score_gpt":0.35070606231962614,"score_spread":0.3355487200416121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396769086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99885917,0.00016747644,0.000096190604,0.000028649027,0.0000020141763,0.000013172741,0.00059547264,0.0000031970221,0.00023460398],"genre_scores_gemma":[0.99926275,0.00006536384,0.000056831075,0.000020615009,0.000004076787,0.000009954631,0.000547475,0.0000013233495,0.00003170667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993661,0.00017160198,0.00011295522,0.00016586772,0.000103206316,0.000080285536],"domain_scores_gemma":[0.99744797,0.00026645375,0.0017168382,0.00016572629,0.00017912553,0.00022390114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058617734,0.00014683523,0.00026837407,0.00073419634,0.00035827537,0.00060197443,0.0003155822,0.0003407422,0.0007545897],"category_scores_gemma":[0.002253144,0.00018727976,0.00035063692,0.0010237035,0.00029467267,0.0006855214,0.00041016232,0.00040556295,0.0001868734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034622786,0.000014730548,0.9994342,0.0000034242416,0.00001665658,0.000047161724,0.000030777643,0.00002489684,0.000054371772,0.00000551998,0.000031483094,0.00030214703],"study_design_scores_gemma":[0.000004732053,0.00010748341,0.9983935,0.000005854043,0.000014440312,0.00062731653,0.0002613044,0.0002467656,0.000073256575,0.000013246398,0.00024729967,0.0000047345043],"about_ca_topic_score_codex":0.0034363414,"about_ca_topic_score_gemma":0.0037404348,"teacher_disagreement_score":0.0034363414,"about_ca_system_score_codex":0.0004082939,"about_ca_system_score_gemma":0.0003374976,"threshold_uncertainty_score":0.0068326592},"labels":[],"label_agreement":null},{"id":"W4396774318","doi":"10.1016/j.lungcan.2024.107816","title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Crizotinib; Medicine; ROS1; Meta-analysis; Oncology; Lung cancer; Fusion gene; Internal medicine; Cancer; Gene; Adenocarcinoma; Genetics","score_opus":0.04719019416161372,"score_gpt":0.4142573196791078,"score_spread":0.36706712551749404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396774318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024353955,0.9961449,0.00031273108,0.0001917837,0.00006700548,0.00019392507,0.000404636,0.000011958063,0.00023758812],"genre_scores_gemma":[0.123217925,0.8721071,0.0016544086,0.0009318931,0.00021458708,0.00074581604,0.000878561,0.00002730459,0.00022247147],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9895836,0.0041808677,0.0036353257,0.0010109411,0.0012848224,0.00030454],"domain_scores_gemma":[0.97876245,0.014568003,0.0042119217,0.0005217942,0.001697614,0.000238193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015461339,0.0027799425,0.017047442,0.009104181,0.000564837,0.0037970718,0.002145927,0.0019395652,0.0037822614],"category_scores_gemma":[0.030694757,0.0014067361,0.033210766,0.00866805,0.0007725879,0.0018839604,0.0015495798,0.0018028831,0.00037093766],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012894211,0.000025341222,0.0028087841,0.49115086,0.48873168,0.00010905617,0.000087030036,0.00044417434,0.00026786615,0.00015271292,0.00048732536,0.014445791],"study_design_scores_gemma":[0.00036962083,0.00017618704,0.0030326527,0.04280768,0.95050514,0.00013107927,0.000053090065,0.00014983061,0.00013810996,0.00024504296,0.0023669046,0.000024684983],"about_ca_topic_score_codex":0.005133059,"about_ca_topic_score_gemma":0.012110587,"teacher_disagreement_score":0.017047442,"about_ca_system_score_codex":0.002917669,"about_ca_system_score_gemma":0.0043118335,"threshold_uncertainty_score":0.081768334},"labels":[],"label_agreement":null},{"id":"W4396901941","doi":"10.1016/j.lungcan.2024.107822","title":"Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; London Health Sciences Centre; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pulmonologists; Hypersensitivity pneumonitis; Radiation therapy; Pneumonitis; Prednisone; Internal medicine; Intensive care medicine; Lung","score_opus":0.009975424873616748,"score_gpt":0.3474710461159723,"score_spread":0.33749562124235555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396901941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.756416,0.04784577,0.020274077,0.10896343,0.0019814847,0.005328844,0.000625587,0.000046263653,0.058518544],"genre_scores_gemma":[0.974242,0.006659865,0.012453965,0.0044590663,0.00020494527,0.0013649104,0.00021017408,0.000019740102,0.00038535224],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.88165724,0.0888241,0.013473173,0.0018400546,0.010561744,0.0036436764],"domain_scores_gemma":[0.8384617,0.11693254,0.0072101797,0.003417196,0.029625941,0.0043525347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.14961594,0.0004730884,0.0010493002,0.001952242,0.003136681,0.002589054,0.0018137125,0.0020308944,0.0017455592],"category_scores_gemma":[0.13204156,0.00036679546,0.0011423657,0.0018380973,0.0021263498,0.0019842007,0.0054216078,0.0031866082,0.00018663194],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025499556,0.0011100173,0.090794355,0.017022936,0.0016740841,0.0011350166,0.11706729,0.004251937,0.0035488321,0.015233849,0.02350202,0.7221097],"study_design_scores_gemma":[0.0015094358,0.0034823732,0.23186588,0.056024827,0.002694141,0.003635209,0.4487074,0.00915982,0.0047677676,0.030673876,0.20680033,0.0006789693],"about_ca_topic_score_codex":0.0034113177,"about_ca_topic_score_gemma":0.0052828193,"teacher_disagreement_score":0.14961594,"about_ca_system_score_codex":0.0053080446,"about_ca_system_score_gemma":0.019005284,"threshold_uncertainty_score":0.79125416},"labels":[],"label_agreement":null},{"id":"W4396979303","doi":"10.1016/j.lungcan.2024.107823","title":"Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Internal medicine; Cohort; Brain metastasis; Metastasis; Proportional hazards model; Lung cancer; Stage (stratigraphy); Cancer; Oncology","score_opus":0.009659942565585887,"score_gpt":0.2731270567589191,"score_spread":0.2634671141933332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396979303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567075,0.001008351,0.00018685679,0.00040299934,0.000026561316,0.00006773465,0.010812061,0.000021540021,0.0018032272],"genre_scores_gemma":[0.99201465,0.0007604918,0.00031115508,0.00027019755,0.000022530801,0.000045120018,0.0057307216,0.00002493906,0.00082008005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806625,0.00008227707,0.00013092058,0.0004671014,0.00046905506,0.00078445894],"domain_scores_gemma":[0.99667823,0.00016523019,0.0007507914,0.00021573008,0.001386789,0.00080322253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010348995,0.0009620572,0.00087874423,0.002734897,0.0048465156,0.0025965788,0.0025555487,0.0012071553,0.0038309402],"category_scores_gemma":[0.0030823364,0.0012201937,0.0015409801,0.007782796,0.0011938922,0.00095565635,0.0017249665,0.0016984264,0.00063178304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112335045,0.000035695048,0.9960653,0.000029837132,0.00013003024,0.00014268231,0.00049234886,0.00007835469,0.0001679936,0.000079086814,0.0014488945,0.0012175436],"study_design_scores_gemma":[0.000021765769,0.000032103337,0.9964922,0.000037745962,0.00008367857,0.00033333688,0.0014980981,0.00018375827,0.000046934503,0.000033313172,0.0012052204,0.00003173997],"about_ca_topic_score_codex":0.9805468,"about_ca_topic_score_gemma":0.98814976,"teacher_disagreement_score":0.02996033,"about_ca_system_score_codex":0.02996033,"about_ca_system_score_gemma":0.03437744,"threshold_uncertainty_score":0.21737844},"labels":[],"label_agreement":null},{"id":"W4399565974","doi":"10.1016/j.lungcan.2024.107848","title":"Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; London Health Sciences Centre","funders":"Amsterdam University Medical Centers","keywords":"Ablative case; Medicine; Radiology; Lung; Stereotactic radiotherapy; Radiation therapy; SABR volatility model; Radiosurgery; Medical physics; Nuclear medicine; Internal medicine","score_opus":0.050608393796494566,"score_gpt":0.369057012862431,"score_spread":0.3184486190659364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399565974","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64804214,0.20818883,0.059230532,0.018700825,0.0018767398,0.0005153178,0.0013676712,0.0007719314,0.061306026],"genre_scores_gemma":[0.9245371,0.046358522,0.020564051,0.0026122094,0.0022471552,0.00006445561,0.0006586195,0.0001279153,0.0028299924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984451,0.0004389602,0.00024866927,0.00013885454,0.00049767946,0.00023088027],"domain_scores_gemma":[0.9948085,0.002116579,0.00081250624,0.00025528925,0.0015149433,0.00049216184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022312042,0.0008854611,0.0010302062,0.0028099099,0.00041382527,0.0023225383,0.0014625214,0.0024168119,0.002614016],"category_scores_gemma":[0.010186082,0.0005545687,0.0006047667,0.0013581811,0.0009974783,0.0022667442,0.0006025577,0.0018221942,0.0013420563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012808079,0.00041233783,0.54193485,0.0015406962,0.00032973156,0.12560757,0.00076876546,0.0023749778,0.07495743,0.0023796458,0.0123249,0.2360883],"study_design_scores_gemma":[0.000076882505,0.00093917333,0.475869,0.0024190797,0.0006622338,0.41640753,0.0045841183,0.018226013,0.027959941,0.0059928605,0.046619684,0.00024350164],"about_ca_topic_score_codex":0.0030151715,"about_ca_topic_score_gemma":0.004419358,"teacher_disagreement_score":0.0030151715,"about_ca_system_score_codex":0.0005951214,"about_ca_system_score_gemma":0.0008554975,"threshold_uncertainty_score":0.0117999315},"labels":[],"label_agreement":null},{"id":"W4400112296","doi":"10.1016/j.lungcan.2024.107863","title":"Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Pathological; Adenocarcinoma; Lung; Oncology; Internal medicine; Adenocarcinoma of the lung; Pathology; Cancer","score_opus":0.02446286563237558,"score_gpt":0.35464468166086716,"score_spread":0.33018181602849156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400112296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981211,0.00030232302,0.00020550974,0.000050404375,0.00000945151,0.000008134527,0.00010537674,0.000008275908,0.0011894684],"genre_scores_gemma":[0.9994904,0.000060546627,0.00006724891,0.000014040662,0.0000049872096,0.0000040436134,0.00014837187,0.0000028403206,0.00020749537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971205,0.00009675716,0.00003855747,0.00003887085,0.000053355096,0.0000602572],"domain_scores_gemma":[0.9974948,0.0012409885,0.00046327926,0.00012518116,0.00022740522,0.00044839148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008774164,0.00014537353,0.00024400796,0.00036200535,0.00027381355,0.0008545459,0.00024019656,0.0005248867,0.002167068],"category_scores_gemma":[0.0036368594,0.00012455748,0.00017263541,0.00033366057,0.00041102266,0.0004707551,0.00030337373,0.000591143,0.00040628656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018706262,0.00014131698,0.9788165,0.000016885973,0.000043163993,0.00060475984,0.00009805597,0.0006620325,0.012761169,0.00015385289,0.00020884183,0.004622757],"study_design_scores_gemma":[0.00001638743,0.0010379166,0.98875356,0.000006812684,0.00006495419,0.0023304068,0.00028485616,0.002067618,0.004285628,0.00020502358,0.00093778106,0.0000090626345],"about_ca_topic_score_codex":0.00046683563,"about_ca_topic_score_gemma":0.00061742397,"teacher_disagreement_score":0.002167068,"about_ca_system_score_codex":0.00023215698,"about_ca_system_score_gemma":0.00019399698,"threshold_uncertainty_score":0.0072495937},"labels":[],"label_agreement":null},{"id":"W4400485995","doi":"10.1016/j.lungcan.2024.107861","title":"Asbestos-Related lung Cancer: An underappreciated oncological issue","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Sydney; Sydney Local Health District","keywords":"Asbestos; Lung cancer; Mesothelioma; Medicine; Asbestosis; Incidence (geometry); Environmental health; Cancer; Oncology; Pathology; Internal medicine; Lung","score_opus":0.03920343235166781,"score_gpt":0.43045564897653765,"score_spread":0.39125221662486986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400485995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008557876,0.9674442,0.00015799214,0.026516683,0.003723588,0.0000035496498,0.000100320605,0.0000136626695,0.0011841881],"genre_scores_gemma":[0.0076368107,0.9768022,0.00021297808,0.0050772643,0.009596888,0.0000030718752,0.0001239586,0.000010286103,0.00053657545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840957,0.00024999699,0.00026941736,0.00032274018,0.0006122357,0.00013607767],"domain_scores_gemma":[0.98646253,0.006788008,0.0015411542,0.00054039015,0.0039585265,0.00070933835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032745418,0.0005427925,0.001749134,0.0034115838,0.00078742544,0.0038559113,0.0011256482,0.0035301014,0.005493994],"category_scores_gemma":[0.0074110003,0.00034404176,0.000920176,0.005124436,0.0028337515,0.005718791,0.001386899,0.0041892403,0.0017766342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018123291,0.000068743204,0.007980183,0.019075505,0.00021503601,0.0009340649,0.00051744486,0.0002040484,0.0018216865,0.013313096,0.13765574,0.81803316],"study_design_scores_gemma":[0.000019861553,0.00012815972,0.017510405,0.012209945,0.00030853474,0.0059630168,0.0014554608,0.00017877598,0.00054220745,0.010110626,0.9515145,0.000058506877],"about_ca_topic_score_codex":0.004460879,"about_ca_topic_score_gemma":0.0060194945,"teacher_disagreement_score":0.005493994,"about_ca_system_score_codex":0.0014427087,"about_ca_system_score_gemma":0.0047153584,"threshold_uncertainty_score":0.018379271},"labels":[],"label_agreement":null},{"id":"W4401029773","doi":"10.1016/j.lungcan.2024.107900","title":"Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC","year":2024,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Neoadjuvant therapy; Chemotherapy; Cancer","score_opus":0.017030840922792504,"score_gpt":0.30625259375077823,"score_spread":0.28922175282798573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8192333,0.004146273,0.0017872667,0.14873394,0.0027374732,0.00008930869,0.0012628346,0.00015266964,0.021856863],"genre_scores_gemma":[0.9770996,0.0012765363,0.0008347227,0.014902611,0.0022742955,0.00002630891,0.00043092965,0.000025187446,0.0031298222],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998342,0.000022114282,0.000016557651,0.00003524798,0.00003138266,0.000060526458],"domain_scores_gemma":[0.9993932,0.00021923195,0.000059084312,0.000022649472,0.000094977564,0.0002108496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015867646,0.00024596957,0.000442307,0.00038278225,0.0011497774,0.00087141467,0.00033560695,0.0022423076,0.0011470191],"category_scores_gemma":[0.0018843479,0.00021242749,0.0004326401,0.0003784104,0.00031940907,0.00049299584,0.00027595472,0.0025736769,0.00045925405],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011136535,0.00017224893,0.24624865,0.00007141163,0.000057935016,0.6971218,0.000519633,0.0011647124,0.003915101,0.0010176201,0.028096136,0.020501077],"study_design_scores_gemma":[0.00013957036,0.0010362354,0.20214143,0.0001842473,0.00023157196,0.7317273,0.0022199226,0.012047678,0.0037299707,0.0053458214,0.041076943,0.00011926933],"about_ca_topic_score_codex":0.0031721324,"about_ca_topic_score_gemma":0.0039074915,"teacher_disagreement_score":0.0031721324,"about_ca_system_score_codex":0.001616072,"about_ca_system_score_gemma":0.0007922884,"threshold_uncertainty_score":0.011725485},"labels":[],"label_agreement":null},{"id":"W4401029882","doi":"10.1016/j.lungcan.2024.107898","title":"Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; London Health Sciences Centre; Brampton Civic Hospital; CancerCare Manitoba; Ottawa Hospital; University Health Network; Occupational Cancer Research Centre; Juravinski Cancer Centre; University of Ottawa; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Institutes of Health Research; Amgen Canada; Amgen","keywords":"Medicine; Oncology; Retrospective cohort study; Internal medicine; Cohort; KRAS; Center (category theory); Cancer","score_opus":0.005912470398139684,"score_gpt":0.28135253948923683,"score_spread":0.27544006909109714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99415034,0.0005242999,0.00005834918,0.00015486722,0.000008466602,0.000019715331,0.0045096925,0.000006326834,0.00056792394],"genre_scores_gemma":[0.9966864,0.00035339268,0.00007728385,0.00009306435,0.000008379739,0.000011139444,0.0025182061,0.00000697984,0.00024511918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990681,0.000061709005,0.000063344145,0.0002685015,0.000181922,0.00035649625],"domain_scores_gemma":[0.99813724,0.00011223062,0.0005957387,0.00011220365,0.0004999203,0.0005426443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000416881,0.00038743162,0.0005749722,0.0011011122,0.0014523289,0.0013837492,0.0011199717,0.0007328133,0.0015232177],"category_scores_gemma":[0.0014250042,0.00048572128,0.0007998019,0.0034619411,0.0006834968,0.00053779746,0.00080791424,0.0009766277,0.00025293103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096292555,0.000021745136,0.99845994,0.00000920438,0.00008145181,0.0000639594,0.00009443351,0.00004608132,0.00014005994,0.000026622329,0.00038890762,0.00057138136],"study_design_scores_gemma":[0.0000142830895,0.000027981017,0.99855036,0.000012925126,0.000052596213,0.00018364222,0.00051015936,0.00016295498,0.000040489464,0.000017937471,0.00041590867,0.000010652013],"about_ca_topic_score_codex":0.85086316,"about_ca_topic_score_gemma":0.90629816,"teacher_disagreement_score":0.14913684,"about_ca_system_score_codex":0.009399376,"about_ca_system_score_gemma":0.0104545625,"threshold_uncertainty_score":0.30003023},"labels":[],"label_agreement":null},{"id":"W4401281322","doi":"10.1016/j.lungcan.2024.107919","title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; International Society for Pharmacoepidemiology; Gilead Sciences; Sanofi; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Ceritinib; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.01174501105919376,"score_gpt":0.329370564327469,"score_spread":0.31762555326827524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401281322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931699,0.0022676922,0.0002616287,0.00022236623,0.000008093836,0.000015338557,0.003400017,0.00000980227,0.00064520404],"genre_scores_gemma":[0.99596894,0.00053440855,0.0002661218,0.00009835246,0.000014106159,0.000017935208,0.0030112877,0.0000033163956,0.00008561046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975077,0.0007796012,0.00044036738,0.0005704422,0.00056308,0.00013885388],"domain_scores_gemma":[0.9837104,0.0037886314,0.0109354155,0.00042355215,0.0006922114,0.00044977939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031842706,0.00014144022,0.0004109306,0.00069086335,0.00020698278,0.0007974542,0.0003771391,0.00029652592,0.00082176045],"category_scores_gemma":[0.009666651,0.00014115364,0.00053553627,0.0013742292,0.00019291017,0.0006056129,0.00031403592,0.0003930651,0.00016148512],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048900855,0.000046290686,0.9877487,0.00006958233,0.0001701648,0.000033352873,0.000056038774,0.00063289463,0.0002554276,0.000043460666,0.00033584537,0.010119301],"study_design_scores_gemma":[0.000050057493,0.00034807646,0.9943528,0.00006904133,0.00014784125,0.00038973382,0.00012833453,0.0022048564,0.0006019691,0.00011271231,0.0015834164,0.000011086899],"about_ca_topic_score_codex":0.003938444,"about_ca_topic_score_gemma":0.0064315177,"teacher_disagreement_score":0.003938444,"about_ca_system_score_codex":0.0010222509,"about_ca_system_score_gemma":0.00072351214,"threshold_uncertainty_score":0.01684028},"labels":[],"label_agreement":null},{"id":"W4401344824","doi":"10.1016/j.lungcan.2024.107916","title":"Exomic and epigenomic analysis of pulmonary blastoma","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Montreal Neurological Institute and Hospital; Université de Montréal; McGill University; University of British Columbia; University of British Columbia Hospital; Jewish General Hospital","funders":"","keywords":"Somatic cell; Medicine; Pulmonary Blastoma; Lung cancer; Germline; Missense mutation; Genetics; Cancer research; Lung; Pathology; Biology; Gene; Mutation; Internal medicine","score_opus":0.008681207880618616,"score_gpt":0.3146348541837301,"score_spread":0.3059536463031115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401344824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763984,0.0022470814,0.002839804,0.00020675504,0.000033084118,0.000025710857,0.004638765,0.000044560496,0.0023243667],"genre_scores_gemma":[0.9879255,0.00106924,0.0025919387,0.0002337573,0.000027143758,0.000040523923,0.0052891965,0.000029285904,0.0027934255],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998271,0.0000197372,0.000014145605,0.000054575215,0.000043897897,0.000040592142],"domain_scores_gemma":[0.9998197,0.00006596741,0.000036510108,0.000022098215,0.000029513936,0.0000262371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002476462,0.00016871902,0.0002261101,0.00092634285,0.0003024326,0.00041798584,0.00016747315,0.00027098146,0.0031424328],"category_scores_gemma":[0.0005427307,0.00011546109,0.00028262465,0.00088620425,0.00016192949,0.00016648204,0.0004553159,0.00029726868,0.0003571541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011433803,0.00006418689,0.1835507,0.00033219284,0.00041428348,0.002410436,0.00032575664,0.00056152116,0.77228916,0.00056404073,0.00105108,0.037293248],"study_design_scores_gemma":[0.000032512027,0.0001988925,0.9131096,0.000048551607,0.00048112782,0.005057961,0.00043446527,0.0015505778,0.06345829,0.00053451787,0.01507539,0.000018227563],"about_ca_topic_score_codex":0.00058883015,"about_ca_topic_score_gemma":0.0012250545,"teacher_disagreement_score":0.0031424328,"about_ca_system_score_codex":0.00011845135,"about_ca_system_score_gemma":0.00016905527,"threshold_uncertainty_score":0.010512531},"labels":[],"label_agreement":null},{"id":"W4401351374","doi":"10.1016/j.lungcan.2024.107921","title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"UCLH Biomedical Research Centre; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; University College London; Amgen","keywords":"Docetaxel; Medicine; KRAS; Oncology; Internal medicine; Mutation; Chemotherapy; Cancer; Genetics","score_opus":0.013747274052184733,"score_gpt":0.36173386110479955,"score_spread":0.3479865870526148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401351374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949639,0.0024152338,0.00014651376,0.00021834587,0.00008043549,0.00028452452,0.0006472837,0.000021299082,0.0012225123],"genre_scores_gemma":[0.9973212,0.00065331697,0.00020076451,0.00021429497,0.000057625522,0.0002885233,0.0008054495,0.0000037160391,0.00045516968],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99928373,0.0003420329,0.00005647045,0.00010922691,0.00012285865,0.00008569689],"domain_scores_gemma":[0.998992,0.0002680098,0.0003594689,0.000044666176,0.00005432253,0.0002815485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013971751,0.00046079123,0.000894112,0.00022611355,0.00021791978,0.0007015149,0.00039992674,0.0007538771,0.002317405],"category_scores_gemma":[0.0015174471,0.00019276197,0.0011165974,0.00030951027,0.00036249694,0.0005087529,0.00029300217,0.0015545128,0.00019863065],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82666844,0.011404536,0.019192416,0.0014551623,0.0021092508,0.00013110394,0.00014875644,0.0033112976,0.010518718,0.00023969261,0.0033832716,0.121437274],"study_design_scores_gemma":[0.3672555,0.47091064,0.13997881,0.00019596123,0.0025064098,0.00061497407,0.00013274049,0.0066714394,0.0045549185,0.00041149513,0.006667022,0.000100033474],"about_ca_topic_score_codex":0.0008514317,"about_ca_topic_score_gemma":0.0029414082,"teacher_disagreement_score":0.002317405,"about_ca_system_score_codex":0.00090752204,"about_ca_system_score_gemma":0.0007841113,"threshold_uncertainty_score":0.007752478},"labels":[],"label_agreement":null},{"id":"W4401481084","doi":"10.1016/j.lungcan.2024.107927","title":"Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"Association of Pathology Chairs; Mayo Foundation for Medical Education and Research; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison; Mayo Clinic","keywords":"Immunotherapy; Medicine; Immunohistochemistry; Oncology; Predictive value; Lung cancer; Lung; Internal medicine; Copy-number variation; Value (mathematics); Cancer research; Cancer; Gene; Biology; Genome","score_opus":0.0033432570704485676,"score_gpt":0.28164715645814914,"score_spread":0.27830389938770056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401481084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955063,0.0013523726,0.00029162268,0.00020399943,0.000033735636,0.0000098827,0.00013289189,0.000015443444,0.0024538497],"genre_scores_gemma":[0.99952805,0.000121558616,0.00005551561,0.000020012778,0.000027772037,0.0000030822964,0.000064908476,0.0000024618873,0.00017664171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996939,0.00009112251,0.000029988209,0.000052439456,0.00007374366,0.000058831203],"domain_scores_gemma":[0.9977684,0.0011486176,0.0005134138,0.00011548204,0.00018852799,0.0002655853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067766325,0.00020134098,0.00027294562,0.00063455774,0.0002548635,0.000589774,0.00035563132,0.00056455174,0.0022957004],"category_scores_gemma":[0.003355886,0.00014084924,0.00030790007,0.0004650867,0.00045555294,0.0005258281,0.00020110328,0.0006339013,0.00026711484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076779665,0.00004815375,0.990759,0.000010876931,0.000048472168,0.00017680152,0.000019712115,0.00039238765,0.0027770519,0.000054587414,0.00010076546,0.0048444537],"study_design_scores_gemma":[0.00001288583,0.00036281114,0.9943749,0.000006953021,0.00012149012,0.0010135755,0.0001437534,0.0018038292,0.0014826275,0.00018204273,0.0004906808,0.000004480055],"about_ca_topic_score_codex":0.00067453436,"about_ca_topic_score_gemma":0.0010691676,"teacher_disagreement_score":0.0022957004,"about_ca_system_score_codex":0.00029433126,"about_ca_system_score_gemma":0.0002406626,"threshold_uncertainty_score":0.0076798797},"labels":[],"label_agreement":null},{"id":"W4401539643","doi":"10.1016/j.lungcan.2024.107928","title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","year":2024,"lang":"id","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Sanofi Genzyme; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Jazz Pharmaceuticals; European School of Oncology; AstraZeneca; Novocure; Invitae; Silverback Therapeutics; Verily Life Sciences; Boston Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Chugai Pharmaceutical; Lung Cancer Research Foundation; Revolution Medicines; International Association for the Study of Lung Cancer; U.S. Department of Defense; Sanofi; Bristol-Myers Squibb; Pfizer; University of Miami; National Cancer Institute; Bayer; Mesothelioma Applied Research Foundation","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Mesothelioma; Internal medicine; Oncology; Pathology; Immunotherapy; Cancer","score_opus":0.014904383084671374,"score_gpt":0.3307358708547637,"score_spread":0.3158314877700923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401539643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806279,0.0066156974,0.00090599223,0.0015564378,0.0028647813,0.0023653803,0.0014134545,0.00013389818,0.0035164363],"genre_scores_gemma":[0.9885689,0.0016930709,0.00110963,0.0009914715,0.0007384571,0.0016781525,0.0009217427,0.000029265178,0.004269426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985715,0.00075404695,0.00010035299,0.00028887647,0.000077451135,0.00020773306],"domain_scores_gemma":[0.9983444,0.00061397406,0.0003607383,0.00016787245,0.000100220284,0.0004128223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023118057,0.0022652994,0.0046331096,0.00047142417,0.0005881464,0.0018453941,0.0017116397,0.0021732615,0.011776406],"category_scores_gemma":[0.0030235471,0.0012673234,0.0037831187,0.00041798205,0.0017275295,0.0019722907,0.0007576015,0.005666734,0.0016886467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9951403,0.0007958415,0.00011397505,0.0001778106,0.0008539545,0.000013433584,0.000010434763,0.00015106902,0.00050758576,0.00006114006,0.00017152126,0.0020028737],"study_design_scores_gemma":[0.9736075,0.023481654,0.0007327975,0.00002797741,0.0010720089,0.000016347038,0.000016871096,0.00036576123,0.00014380395,0.00016862838,0.0003538029,0.000012810372],"about_ca_topic_score_codex":0.0021331953,"about_ca_topic_score_gemma":0.0032229759,"teacher_disagreement_score":0.011776406,"about_ca_system_score_codex":0.0016115798,"about_ca_system_score_gemma":0.0012757661,"threshold_uncertainty_score":0.039396048},"labels":[],"label_agreement":null},{"id":"W4402105865","doi":"10.1016/j.lungcan.2024.107952","title":"New diagnostic and nonsurgical local treatment modalities for early stage lung cancer","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Modalities; Treatment modality; Lung cancer; Cancer; Radiology; Lung; Oncology; Internal medicine","score_opus":0.03839558299077461,"score_gpt":0.40817030628290907,"score_spread":0.36977472329213446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402105865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000057117075,0.9992767,0.000054984244,0.00010457597,0.00008387935,0.0000052088103,0.000021739963,0.0000034533264,0.00039233288],"genre_scores_gemma":[0.00047575278,0.9988794,0.000109877765,0.00018789938,0.000099737415,0.000006207386,0.000026844373,9.627549e-7,0.00021335226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980754,0.00004090464,0.000044568507,0.00004008655,0.000051551633,0.000015359414],"domain_scores_gemma":[0.9995197,0.00029077873,0.00008921267,0.000012077007,0.000065845066,0.000022273854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060879445,0.0008682933,0.0019506244,0.0025604921,0.00020354784,0.0008039254,0.0008075948,0.00074831,0.0059741423],"category_scores_gemma":[0.0011001461,0.00031788222,0.0010559588,0.002037151,0.0003834921,0.0011506069,0.0005574575,0.00168922,0.001264142],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010374048,0.000064889115,0.0001708409,0.044404123,0.00025359678,0.00007816611,0.000037347,0.00029311466,0.0006210859,0.0007891309,0.018954312,0.9342297],"study_design_scores_gemma":[0.00023053058,0.00053399324,0.0037375488,0.034051843,0.0027912655,0.0018215377,0.00013285103,0.0002914327,0.0006888327,0.0019890089,0.9536743,0.000056800036],"about_ca_topic_score_codex":0.0015111802,"about_ca_topic_score_gemma":0.00525456,"teacher_disagreement_score":0.0059741423,"about_ca_system_score_codex":0.000602676,"about_ca_system_score_gemma":0.0010424788,"threshold_uncertainty_score":0.019985497},"labels":[],"label_agreement":null},{"id":"W4403992066","doi":"10.1016/j.lungcan.2024.108000","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2024,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Cancer; Lung; Anaplastic lymphoma kinase; Oncology; Internal medicine; Receptor","score_opus":0.014557669215704791,"score_gpt":0.32902184021540215,"score_spread":0.31446417099969737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403992066","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007706011,0.0012492944,0.00026841016,0.09002363,0.89569145,0.000048224272,0.0031639389,0.00026037716,0.009217616],"genre_scores_gemma":[0.0038919605,0.006212356,0.0024715674,0.27800155,0.2868808,0.00037001155,0.006977479,0.0007664456,0.41442794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99593097,0.00062300556,0.00065221125,0.00055170024,0.0018542728,0.00038791387],"domain_scores_gemma":[0.97974485,0.00604488,0.0008057212,0.0008436955,0.011543521,0.0010173038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003846362,0.0018561735,0.0029475163,0.00372528,0.0022932813,0.0035374896,0.0027714162,0.007866053,0.07964113],"category_scores_gemma":[0.03873278,0.0012571753,0.0032337923,0.0025692973,0.001185382,0.0013793986,0.0014378047,0.009652296,0.055799644],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011036024,0.0000035818612,0.000023040875,0.000021098154,0.000004286526,0.000029059887,0.0000017676625,0.000017127504,0.000006713364,0.00008565003,0.9983735,0.001423053],"study_design_scores_gemma":[0.00010652397,0.00003612356,0.0018215728,0.00032167084,0.00007641598,0.0001628809,0.00003216946,0.00035944505,0.00014535044,0.0012182985,0.9956683,0.00005123413],"about_ca_topic_score_codex":0.07157055,"about_ca_topic_score_gemma":0.12626405,"teacher_disagreement_score":0.07964113,"about_ca_system_score_codex":0.006275434,"about_ca_system_score_gemma":0.0074413577,"threshold_uncertainty_score":0.26642615},"labels":[],"label_agreement":null},{"id":"W4404512668","doi":"10.1016/j.lungcan.2024.108034","title":"Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Weight gain; Intensive care medicine; Internal medicine; Body weight","score_opus":0.005804123158632089,"score_gpt":0.3434996721612806,"score_spread":0.3376955490026485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404512668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587893,0.0017052961,0.0005117142,0.00020999057,0.000017803804,0.000012204408,0.0008016253,0.000008757061,0.00085355924],"genre_scores_gemma":[0.9984547,0.0003985377,0.0002116536,0.00008138422,0.00001953838,0.0000060049006,0.0006798639,0.0000050557264,0.00014327755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998896,0.00028518104,0.00018399648,0.0002935988,0.00018236571,0.00015889983],"domain_scores_gemma":[0.997282,0.00056236563,0.0013283554,0.00038274445,0.00023502679,0.00020944602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001356274,0.00022269688,0.00040854892,0.00082827173,0.0004533393,0.0010034981,0.00037780716,0.00036146908,0.0012546136],"category_scores_gemma":[0.0033523492,0.00036904938,0.0008429142,0.0016343031,0.00031023464,0.0007113229,0.0004108233,0.00070147985,0.00018446101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021774464,0.000019145098,0.9967577,0.000016272023,0.00025504123,0.0002475759,0.00002833102,0.00005318712,0.00012514713,0.00006645176,0.00016983703,0.0020437366],"study_design_scores_gemma":[0.00002136471,0.000113092094,0.9952714,0.00003268771,0.0003635877,0.0021978153,0.00023859927,0.0006348434,0.00014326084,0.00013231393,0.0008353685,0.000015720198],"about_ca_topic_score_codex":0.0052042995,"about_ca_topic_score_gemma":0.007468617,"teacher_disagreement_score":0.0052042995,"about_ca_system_score_codex":0.0005459272,"about_ca_system_score_gemma":0.00057088595,"threshold_uncertainty_score":0.010348022},"labels":[],"label_agreement":null},{"id":"W4404704376","doi":"10.1016/j.lungcan.2024.108040","title":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Cancer Center, University of Colorado; National Institutes of Health; National Cancer Institute; Georgia Clinical and Translational Science Alliance","keywords":"Medicine; Osimertinib; Pemetrexed; Lung cancer; Oncology; Chemotherapy; Internal medicine; Cancer research; Cancer; Epidermal growth factor receptor; Cisplatin; Erlotinib","score_opus":0.0069943952562110025,"score_gpt":0.3123541077166042,"score_spread":0.30535971246039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404704376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992636,0.00031698248,0.000028716331,0.000019606065,0.0000030083536,0.0000073786214,0.00015247863,0.0000012954894,0.00020700342],"genre_scores_gemma":[0.9993438,0.00015046801,0.00003891179,0.000019436171,0.000010288046,0.0000077870045,0.0003578758,5.711268e-7,0.000070883674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99972814,0.00007439826,0.000030216373,0.000065797394,0.00005562918,0.00004566824],"domain_scores_gemma":[0.9993279,0.0001347933,0.00035390139,0.00004663737,0.00003133394,0.00010539574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009396658,0.0001932443,0.00036621335,0.00023648505,0.0002879784,0.000543609,0.00029189637,0.00030540657,0.00081748434],"category_scores_gemma":[0.0012687239,0.00013862939,0.0005767959,0.00033516923,0.00023430218,0.00045549407,0.00025780822,0.00043662605,0.00011408038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038840158,0.0001346554,0.98715115,0.000032210344,0.00014043135,0.00012291901,0.000056719215,0.00017172124,0.00069838186,0.000022173297,0.00010609862,0.007479483],"study_design_scores_gemma":[0.00024628214,0.003074437,0.99429023,0.000020812055,0.0001732912,0.0005313108,0.00007924783,0.00047904378,0.00043512753,0.000054579432,0.0006087484,0.000006793579],"about_ca_topic_score_codex":0.0010427962,"about_ca_topic_score_gemma":0.0022716627,"teacher_disagreement_score":0.0010427962,"about_ca_system_score_codex":0.0004542865,"about_ca_system_score_gemma":0.0004720062,"threshold_uncertainty_score":0.0049694777},"labels":[],"label_agreement":null},{"id":"W4405861407","doi":"10.1016/j.lungcan.2024.108066","title":"FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Chemotherapy; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.04779677523494436,"score_gpt":0.46264716297713754,"score_spread":0.4148503877421932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405861407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014838559,0.9738617,0.00061745243,0.0013161658,0.0010198202,0.0004062484,0.001668889,0.00010832417,0.006162865],"genre_scores_gemma":[0.06833165,0.91550344,0.0013474986,0.0047216043,0.00036230893,0.00050019094,0.0021460147,0.000041524094,0.007045691],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99987304,0.000042452586,0.000015622707,0.000020270822,0.000025368461,0.000023254912],"domain_scores_gemma":[0.9998567,0.00006934157,0.00003734495,0.00000370281,0.000014080638,0.000018883438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007292371,0.0007407004,0.0020686088,0.00038461553,0.00011633737,0.0007829074,0.00080410205,0.0007294439,0.007293489],"category_scores_gemma":[0.0007193691,0.00018358072,0.0022442162,0.00051472004,0.00014441319,0.00040722903,0.0002523301,0.002336276,0.0008760652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02463894,0.000726628,0.00050590566,0.05874557,0.007168221,0.00012674968,0.00008392684,0.0018083762,0.0036145467,0.0014321144,0.04793112,0.85321796],"study_design_scores_gemma":[0.2189548,0.041163713,0.015312967,0.038262747,0.05019545,0.0016811518,0.00031099308,0.0027876096,0.004557925,0.0047768326,0.6217929,0.00020289654],"about_ca_topic_score_codex":0.001671822,"about_ca_topic_score_gemma":0.0062022735,"teacher_disagreement_score":0.007293489,"about_ca_system_score_codex":0.0005564828,"about_ca_system_score_gemma":0.00080283714,"threshold_uncertainty_score":0.024399161},"labels":[],"label_agreement":null},{"id":"W4406061941","doi":"10.1016/j.lungcan.2025.108080","title":"Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); University Health Network; Systems, Applications & Products in Data Processing (Canada); Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; F. Hoffmann-La Roche","keywords":"Medicine; Lung cancer; Intensive care medicine; Natural language processing; Medical physics; Oncology; Computer science","score_opus":0.060318550680282884,"score_gpt":0.48930471986458773,"score_spread":0.4289861691843049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406061941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9186535,0.0021429353,0.056424245,0.0026455927,0.0005450443,0.0041610817,0.008595969,0.00044930508,0.0063823853],"genre_scores_gemma":[0.96565264,0.0003297944,0.023521459,0.0005572633,0.00022767718,0.0025636351,0.0067728683,0.000103646424,0.00027105442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8304647,0.109880835,0.027534071,0.011816003,0.018761888,0.0015425308],"domain_scores_gemma":[0.34347436,0.5134349,0.05579402,0.03973525,0.045836233,0.0017252483],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2018125,0.00082262227,0.0009717872,0.004938737,0.0011395264,0.0035156705,0.0016953327,0.0012743634,0.0017992894],"category_scores_gemma":[0.46185532,0.0005299869,0.0037367297,0.004597426,0.003178272,0.0025497903,0.004334071,0.0012584182,0.0008510266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028913745,0.00037608686,0.92563003,0.0012081169,0.0014398444,0.00016970649,0.0023384658,0.0032808464,0.0009010384,0.0009398295,0.0025919955,0.058232702],"study_design_scores_gemma":[0.00094696175,0.0027838608,0.9004292,0.00161597,0.0016445923,0.00095598353,0.003277971,0.05865235,0.0075334325,0.006697562,0.015237825,0.00022438247],"about_ca_topic_score_codex":0.0016514198,"about_ca_topic_score_gemma":0.0014224247,"teacher_disagreement_score":0.2018125,"about_ca_system_score_codex":0.0017489808,"about_ca_system_score_gemma":0.0034545134,"threshold_uncertainty_score":0.9843073},"labels":[],"label_agreement":null},{"id":"W4406834303","doi":"10.1016/j.lungcan.2025.108107","title":"Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Oncology; Lung cancer; Cancer; Internal medicine; Predictive value","score_opus":0.029400893027625805,"score_gpt":0.3756929050328241,"score_spread":0.34629201200519827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406834303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082412397,0.97722274,0.006143305,0.009483664,0.0013245351,0.00021871687,0.000246379,0.0001279495,0.0044086524],"genre_scores_gemma":[0.012589431,0.95818293,0.019703157,0.0061845076,0.0007570916,0.0004107605,0.0005800861,0.000023679848,0.0015683235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998444,0.00060873997,0.00022833147,0.00020631748,0.00035908874,0.00015350121],"domain_scores_gemma":[0.9962858,0.0020913605,0.00041066794,0.00011652425,0.0009214395,0.00017421706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056123645,0.0008034548,0.0014975665,0.0016035334,0.00023836504,0.0021306481,0.0019967526,0.0023067303,0.0046722353],"category_scores_gemma":[0.009244068,0.00029012488,0.0016868205,0.0009833495,0.0005593059,0.001861715,0.0013659664,0.0029111179,0.0016551409],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018284,0.00011406688,0.0005828086,0.01746974,0.00020834916,0.0001556183,0.00006422084,0.00093399215,0.00080024387,0.013658165,0.022772258,0.9430577],"study_design_scores_gemma":[0.00030268755,0.0005411519,0.0028815574,0.03885612,0.0014446063,0.0008813227,0.0002225141,0.001899392,0.0016990459,0.012706779,0.93849844,0.00006628473],"about_ca_topic_score_codex":0.0023198603,"about_ca_topic_score_gemma":0.0033281662,"teacher_disagreement_score":0.0056123645,"about_ca_system_score_codex":0.0015285675,"about_ca_system_score_gemma":0.007082878,"threshold_uncertainty_score":0.029681325},"labels":[],"label_agreement":null},{"id":"W4407001040","doi":"10.1016/j.lungcan.2025.108412","title":"EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Health records; Electronic database; Retrospective cohort study; Electronic health record; Real world evidence; Medical record; Database; Internal medicine; Health care","score_opus":0.0344460277777888,"score_gpt":0.48366972175411665,"score_spread":0.44922369397632783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407001040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938976,0.0006132621,0.00014533428,0.000095917305,0.0000060431057,0.000045492223,0.004805049,0.0000045093775,0.0003867228],"genre_scores_gemma":[0.9962218,0.00020473408,0.00015972953,0.00006381512,0.000006927907,0.00004752682,0.0032479074,0.0000025342767,0.00004500809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948887,0.0014716231,0.0013973046,0.0010324733,0.0008741808,0.00033565226],"domain_scores_gemma":[0.9813669,0.0039473413,0.011536802,0.0011122308,0.0013648578,0.0006719103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035553884,0.00023725924,0.00058657164,0.0021809787,0.0004981276,0.0013157022,0.0006940634,0.0005032454,0.0009390697],"category_scores_gemma":[0.011829157,0.00042858458,0.0007423713,0.005548862,0.0004269919,0.0013727294,0.0010873838,0.0006477605,0.00019944063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042773045,0.000021200683,0.9992692,0.0000234531,0.00007704885,0.000027339995,0.00005487215,0.000025890542,0.000019402738,0.000012649175,0.00010143133,0.0003246945],"study_design_scores_gemma":[0.000013635677,0.00006550057,0.9981906,0.00004116499,0.00007475722,0.00031090202,0.00054790446,0.00033830522,0.000049768616,0.000018669658,0.00034206922,0.000006816028],"about_ca_topic_score_codex":0.00992481,"about_ca_topic_score_gemma":0.012901421,"teacher_disagreement_score":0.00992481,"about_ca_system_score_codex":0.0009682701,"about_ca_system_score_gemma":0.0010744926,"threshold_uncertainty_score":0.019734085},"labels":[],"label_agreement":null},{"id":"W4407100100","doi":"10.1016/j.lungcan.2025.108418","title":"Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) − A promising approach to enhance physiological strength, improve body composition, and build upon current evidence","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; BC Cancer Agency","funders":"BC Cancer Foundation; University of British Columbia; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; British Columbia Lung Association","keywords":"Medicine; Lung cancer; Cancer; Current (fluid); Lung; Composition (language); Intensive care medicine; Physical medicine and rehabilitation; Physical therapy; Oncology; Internal medicine; Engineering","score_opus":0.008952557718701293,"score_gpt":0.3242286696104168,"score_spread":0.3152761118917155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407100100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8164731,0.08533658,0.019924354,0.025053302,0.0035519197,0.0009324237,0.001305488,0.00065915316,0.046763677],"genre_scores_gemma":[0.9505787,0.026606232,0.011817884,0.0029568274,0.001036407,0.0006471915,0.00082379434,0.000045655644,0.0054873605],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99973077,0.000090004716,0.000012465215,0.00004233707,0.000064151754,0.00006021748],"domain_scores_gemma":[0.99967337,0.0000977688,0.000057601246,0.000018745937,0.000043015094,0.00010953356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058782025,0.00041176743,0.0004631781,0.00029466144,0.00033106428,0.0008218282,0.00064764294,0.00055228465,0.0063187224],"category_scores_gemma":[0.0014020723,0.00007717715,0.00081237545,0.00018191576,0.00018791888,0.0006411863,0.0011179482,0.000870316,0.0008638362],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002013474,0.0066187023,0.029077735,0.004509628,0.0009614577,0.00013014597,0.00031223847,0.00387829,0.008630819,0.0024180613,0.009392465,0.93205696],"study_design_scores_gemma":[0.0033976093,0.078157194,0.53060985,0.01783072,0.004432307,0.0018643447,0.0039794007,0.014264324,0.019483034,0.027211767,0.29843718,0.00033231938],"about_ca_topic_score_codex":0.0014870564,"about_ca_topic_score_gemma":0.0041185943,"teacher_disagreement_score":0.0063187224,"about_ca_system_score_codex":0.00020101127,"about_ca_system_score_gemma":0.0007453493,"threshold_uncertainty_score":0.021138191},"labels":[],"label_agreement":null},{"id":"W4407607529","doi":"10.1016/j.lungcan.2025.108452","title":"Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mutation; Lung cancer; Oncology; Internal medicine; Lung; Cancer; Cancer research; Genetics; Gene; Biology","score_opus":0.002382273752439514,"score_gpt":0.26599251725522083,"score_spread":0.26361024350278134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407607529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99737346,0.00088301976,0.00012315634,0.00020936156,0.000048371185,0.0000048970014,0.00025952028,0.000011261369,0.0010867836],"genre_scores_gemma":[0.99936193,0.000112663096,0.000044863158,0.000033158856,0.000054872587,0.0000021429362,0.00021864046,0.0000024326062,0.0001692992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99963367,0.00008845694,0.000036450994,0.0000807443,0.000056025656,0.00010469457],"domain_scores_gemma":[0.9986638,0.00046359928,0.00036477114,0.00007585197,0.0000924778,0.00033954447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004366852,0.00042022497,0.0004644529,0.00056045054,0.00040468358,0.0007634695,0.0004530078,0.00068484654,0.0023362248],"category_scores_gemma":[0.0028856366,0.000169482,0.0007150951,0.00065342215,0.00037314513,0.00054648274,0.00044096741,0.0008232359,0.00031692328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081544253,0.00003748877,0.99332774,0.000010541289,0.00009870178,0.00047505728,0.000023192617,0.00020300689,0.00085170596,0.000045131037,0.00019267877,0.0039192582],"study_design_scores_gemma":[0.00002571857,0.00029824235,0.9950448,0.000011045143,0.0002552803,0.0017743537,0.00017964774,0.0012619293,0.00040845352,0.0002027049,0.0005235717,0.000014358811],"about_ca_topic_score_codex":0.0012367176,"about_ca_topic_score_gemma":0.0028435655,"teacher_disagreement_score":0.0023362248,"about_ca_system_score_codex":0.00031995494,"about_ca_system_score_gemma":0.00033099452,"threshold_uncertainty_score":0.00781548},"labels":[],"label_agreement":null},{"id":"W4407856069","doi":"10.1016/j.lungcan.2025.108441","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2025,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; ALK inhibitor; Tyrosine kinase; Tyrosine-kinase inhibitor; Kinase; Oncology; Internal medicine; Cancer; Genetics; Biology","score_opus":0.01313441767526678,"score_gpt":0.32763194866333406,"score_spread":0.31449753098806726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407856069","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007651535,0.0013162462,0.0002715122,0.08966377,0.8954028,0.000049561615,0.0032554632,0.0002583211,0.009705767],"genre_scores_gemma":[0.004142354,0.006161931,0.0025045935,0.28214207,0.28465602,0.00035094898,0.007249432,0.0007346181,0.41205812],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99573225,0.0006486784,0.0006871963,0.00058069656,0.0019508718,0.00040039906],"domain_scores_gemma":[0.97999305,0.0058613443,0.0008045656,0.00083423563,0.011469866,0.0010369467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003957175,0.0017552,0.0028568737,0.0035831379,0.0022201005,0.0035706144,0.0026181617,0.007754227,0.08189266],"category_scores_gemma":[0.03781098,0.0011778353,0.0031643196,0.0024843214,0.0011498404,0.0013502392,0.0013821936,0.009352448,0.056012437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011371987,0.0000036259391,0.000022849732,0.000021660962,0.000004201809,0.0000284551,0.000001775307,0.000016992693,0.000006637461,0.00009090751,0.9982868,0.0015047215],"study_design_scores_gemma":[0.000105501924,0.00003579001,0.001853934,0.00033957136,0.00007153761,0.00015697691,0.00003189109,0.00036723388,0.00014181479,0.0011721269,0.99567395,0.000049752955],"about_ca_topic_score_codex":0.06906793,"about_ca_topic_score_gemma":0.12811899,"teacher_disagreement_score":0.08189266,"about_ca_system_score_codex":0.0062057986,"about_ca_system_score_gemma":0.007370893,"threshold_uncertainty_score":0.27395827},"labels":[],"label_agreement":null},{"id":"W4408032112","doi":"10.1016/j.lungcan.2025.108175","title":"65 Referral Trends for Peripheral Nodule Biopsy Using Navigational Bronchoscopy at a Tertiary Centre in London","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bronchoscopy; Tertiary referral centre; Tertiary care; Nodule (geology); Referral; General surgery; Radiology; Peripheral; Biopsy; Surgery; Internal medicine; Family medicine","score_opus":0.015100993089419092,"score_gpt":0.3564217013608297,"score_spread":0.3413207082714106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669344,0.0013444615,0.00014576013,0.0013805524,0.00003507416,0.000041505835,0.00421218,0.00006644312,0.0060806386],"genre_scores_gemma":[0.9922214,0.000685855,0.00015582984,0.0006455057,0.000035206776,0.00003365602,0.0018681051,0.000026239495,0.0043281545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981494,0.00019795365,0.00045299105,0.00029456863,0.00029267848,0.00061246124],"domain_scores_gemma":[0.9960581,0.00040557154,0.0017232945,0.000069312,0.0006649654,0.0010788252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003748117,0.00019111088,0.00042079858,0.0016628347,0.00084663427,0.0018296306,0.0006769187,0.0011310272,0.012356858],"category_scores_gemma":[0.002796397,0.0005273884,0.00090960745,0.0029250514,0.00046111637,0.0010117538,0.001255851,0.0008557351,0.0021081134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017665864,0.000048982518,0.98534596,0.00023545108,0.00006949673,0.0022995486,0.0025910465,0.00025099947,0.0010582712,0.00025534144,0.0030278466,0.0046403254],"study_design_scores_gemma":[0.00000848644,0.000069974274,0.99342716,0.000094582516,0.000015429398,0.0009756032,0.0034791098,0.00016880449,0.00007222092,0.000030357794,0.0016353244,0.000022883383],"about_ca_topic_score_codex":0.2135457,"about_ca_topic_score_gemma":0.31857914,"teacher_disagreement_score":0.2135457,"about_ca_system_score_codex":0.005515736,"about_ca_system_score_gemma":0.0027701752,"threshold_uncertainty_score":0.42460543},"labels":[],"label_agreement":null},{"id":"W4408032342","doi":"10.1016/j.lungcan.2025.108168","title":"58 Operator outcomes and learning for robotic-assisted bronchoscopic biopsies of pulmonary nodules","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Operator (biology); Radiology; Artificial intelligence; Computer science","score_opus":0.01189381326130011,"score_gpt":0.3310439689725905,"score_spread":0.31915015571129035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962125,0.00036212773,0.0003571883,0.000339913,0.000045936617,0.000023960498,0.00027763442,0.000018328714,0.002362383],"genre_scores_gemma":[0.99775213,0.00021102677,0.0002379009,0.000110548666,0.00004019554,0.000018794874,0.00044590325,0.000013857203,0.0011696109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840873,0.00024989998,0.00017450523,0.00023309016,0.00049415923,0.00043962625],"domain_scores_gemma":[0.97861356,0.009511278,0.005601677,0.00068398117,0.0021636188,0.0034259383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021436808,0.0002809761,0.0003254225,0.0006520138,0.00064733316,0.0018070689,0.00067818817,0.00090000534,0.006184186],"category_scores_gemma":[0.023537239,0.00021169473,0.001598659,0.00043149907,0.00064148306,0.0021710321,0.0010623195,0.0012973301,0.0008887457],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001688277,0.0008002085,0.9471755,0.0000862283,0.00024978103,0.00022777398,0.0006780322,0.0012013988,0.0005000785,0.00019081606,0.0009980904,0.04620376],"study_design_scores_gemma":[0.000031261523,0.0013608414,0.9933587,0.00006785981,0.00015474508,0.00041161472,0.0011713177,0.00136818,0.0004229436,0.0006570669,0.00094059925,0.0000550084],"about_ca_topic_score_codex":0.003852555,"about_ca_topic_score_gemma":0.008618468,"teacher_disagreement_score":0.006184186,"about_ca_system_score_codex":0.0010278093,"about_ca_system_score_gemma":0.0015086074,"threshold_uncertainty_score":0.020688176},"labels":[],"label_agreement":null},{"id":"W4408064743","doi":"10.1016/j.lungcan.2025.108309","title":"200 Stage shift in lung cancers found during a screening study: Early detection is only half the battle","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Battle; Oncology; Internal medicine; Ancient history; History","score_opus":0.011095965016378002,"score_gpt":0.34747468509005724,"score_spread":0.33637872007367925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408064743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4251171,0.17363624,0.008900747,0.31606212,0.013516436,0.00021004985,0.0040696836,0.0007593683,0.057728264],"genre_scores_gemma":[0.8981036,0.030730676,0.0030481631,0.050427184,0.009146605,0.00005845715,0.002419662,0.000184776,0.0058809365],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974371,0.0007595021,0.0002520618,0.00039556687,0.0007957142,0.00036006127],"domain_scores_gemma":[0.9868912,0.0057886234,0.001632764,0.0007602927,0.002804874,0.0021221119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004015807,0.00030475156,0.0010101537,0.0008255454,0.0006479155,0.001964483,0.0007046141,0.0021042058,0.007299001],"category_scores_gemma":[0.018727265,0.00033425595,0.00086194015,0.0006858439,0.00066353515,0.0019082987,0.00071118533,0.0028938926,0.0018592974],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001712244,0.0004129177,0.40722215,0.0004798012,0.00028985998,0.00063847814,0.00025833817,0.00037498918,0.0033966866,0.0024245342,0.070122175,0.51266783],"study_design_scores_gemma":[0.00022655998,0.0014627903,0.8902281,0.002504386,0.00073964865,0.004098676,0.0014773313,0.0018087311,0.002016634,0.010490108,0.08480209,0.00014498495],"about_ca_topic_score_codex":0.0062720953,"about_ca_topic_score_gemma":0.00992332,"teacher_disagreement_score":0.007299001,"about_ca_system_score_codex":0.0011841919,"about_ca_system_score_gemma":0.0016269191,"threshold_uncertainty_score":0.02441758},"labels":[],"label_agreement":null},{"id":"W4408065122","doi":"10.1016/j.lungcan.2025.108334","title":"225 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Durvalumab; Regimen; Oncology; Chemoradiotherapy; Conventional PCI; Internal medicine; Radiation therapy; Cancer; Immunotherapy","score_opus":0.03159646343939662,"score_gpt":0.39573207681587,"score_spread":0.3641356133764734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408065122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924616,0.005576192,0.000088352106,0.00024732595,0.00010671283,0.00010240222,0.00042819066,0.000010721813,0.0009786004],"genre_scores_gemma":[0.99673104,0.0014864772,0.00012221033,0.00029366484,0.00009137379,0.000054092074,0.0006340711,0.0000027940866,0.0005841808],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99956006,0.00022415559,0.000032847824,0.00006255384,0.000035809047,0.00008445602],"domain_scores_gemma":[0.9994784,0.00011658803,0.00013705864,0.000055065248,0.00003263339,0.00018032469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088798895,0.00055440806,0.001248905,0.00015389103,0.00020429838,0.00096061593,0.00044135956,0.00042813437,0.0013637942],"category_scores_gemma":[0.00091096264,0.00021787385,0.0017118442,0.00027177448,0.00038055566,0.00048869115,0.00030812796,0.0013770032,0.00025171592],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.882997,0.0029267676,0.037012246,0.00064159394,0.008079928,0.00009742132,0.00007927249,0.0010344645,0.004067577,0.0003568431,0.0022157137,0.0604911],"study_design_scores_gemma":[0.5041981,0.18076666,0.27384317,0.0003784595,0.020280683,0.00045494878,0.00033259776,0.0037905497,0.004667104,0.001212774,0.009971686,0.00010327805],"about_ca_topic_score_codex":0.0028285244,"about_ca_topic_score_gemma":0.0055187475,"teacher_disagreement_score":0.0028285244,"about_ca_system_score_codex":0.00087638333,"about_ca_system_score_gemma":0.00077750377,"threshold_uncertainty_score":0.0063586235},"labels":[],"label_agreement":null},{"id":"W4408067390","doi":"10.1016/j.lungcan.2025.108178","title":"68 First year experience of Robotic-assisted bronchoscopy implementation for lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Flexible bronchoscopy; General surgery; Bronchoscopy; Radiology; Oncology","score_opus":0.01628290795756007,"score_gpt":0.40431128137201017,"score_spread":0.3880283734144501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408067390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854592,0.0017720348,0.0033898298,0.00054626283,0.00013353187,0.000101702004,0.0002957667,0.00022216896,0.008079581],"genre_scores_gemma":[0.9841234,0.0015466295,0.0031918618,0.00043247564,0.000094034025,0.0000621406,0.00062878133,0.00008094806,0.009839708],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988111,0.00024078335,0.000086098036,0.00014604916,0.00032639745,0.0003896171],"domain_scores_gemma":[0.9974685,0.0003668882,0.0002732056,0.0002144313,0.00038093788,0.001296042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001252019,0.0005009646,0.0003960025,0.0005298947,0.0010390556,0.0011575128,0.00091471476,0.0009040845,0.0066446685],"category_scores_gemma":[0.0041296594,0.000317176,0.0010611694,0.00035014655,0.0003981533,0.0007516766,0.0014524196,0.0011019553,0.002715307],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012487747,0.009904561,0.43549973,0.00081589224,0.0005442019,0.017321553,0.013602139,0.0039564525,0.016950585,0.0011004272,0.012368142,0.48668754],"study_design_scores_gemma":[0.00016116789,0.024047654,0.72371423,0.0006822115,0.0005038767,0.09279581,0.009192735,0.0057903095,0.01782263,0.00078334473,0.12403203,0.00047396493],"about_ca_topic_score_codex":0.0026064583,"about_ca_topic_score_gemma":0.005328514,"teacher_disagreement_score":0.0066446685,"about_ca_system_score_codex":0.0010213602,"about_ca_system_score_gemma":0.0016384302,"threshold_uncertainty_score":0.022228599},"labels":[],"label_agreement":null},{"id":"W4408266096","doi":"10.1016/j.lungcan.2025.108491","title":"Establishing survival benchmarks in the era of peri-operative immunotherapy","year":2025,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Peri; Internal medicine; Oncology; Intensive care medicine; Cancer","score_opus":0.012279643713661387,"score_gpt":0.3195714229083646,"score_spread":0.3072917791947032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408266096","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029481866,0.000590203,0.00009853099,0.9912176,0.006110646,0.000005684789,0.000022612148,0.000011971978,0.0016479912],"genre_scores_gemma":[0.005209914,0.00069825904,0.00035983216,0.96321225,0.02727738,0.000028620374,0.000028793918,0.000017437815,0.003167523],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275947,0.0025428466,0.00085222756,0.00056079426,0.0019765466,0.0013081478],"domain_scores_gemma":[0.97189224,0.015676804,0.0014172005,0.00058852375,0.0040465198,0.0063788258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008635185,0.0005605999,0.0012781286,0.0007103734,0.004396515,0.005437142,0.0018360477,0.05126485,0.005713384],"category_scores_gemma":[0.042076983,0.0005247751,0.0010183112,0.00066715776,0.0041594976,0.00490219,0.0033061614,0.045223765,0.004321784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082195846,0.000055201202,0.0014480416,0.00005682349,0.000012667093,0.0012828277,0.00016781564,0.00013337033,0.0003453993,0.007201947,0.9707537,0.018460067],"study_design_scores_gemma":[0.00013385572,0.00015590865,0.0033859797,0.00050813484,0.00003159162,0.0017219547,0.0011569238,0.0008590061,0.00045396524,0.03435438,0.95713305,0.000105120685],"about_ca_topic_score_codex":0.0061186794,"about_ca_topic_score_gemma":0.01409318,"teacher_disagreement_score":0.05126485,"about_ca_system_score_codex":0.0059963553,"about_ca_system_score_gemma":0.012367967,"threshold_uncertainty_score":0.045667708},"labels":[],"label_agreement":null},{"id":"W4408914861","doi":"10.1016/j.lungcan.2025.108495","title":"Natural history models for lung Cancer: A scoping review","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Natural history; Intensive care medicine; Oncology; Internal medicine","score_opus":0.050988583829570826,"score_gpt":0.42904347260279624,"score_spread":0.3780548887732254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408914861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004322516,0.9919911,0.004004573,0.0013538209,0.0002428954,0.0002845238,0.00042308174,0.000034571767,0.0012331659],"genre_scores_gemma":[0.0077644526,0.98496825,0.0050217444,0.00060534006,0.00020632047,0.00079160143,0.00037932585,0.000017436161,0.0002454988],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99194723,0.004070275,0.0020062444,0.00053937524,0.0012711181,0.00016590202],"domain_scores_gemma":[0.9114886,0.08048293,0.0035707476,0.0010652798,0.003181706,0.00021080545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017714497,0.002151377,0.0043788366,0.012759655,0.00076527806,0.004273024,0.0031804934,0.0032181065,0.0057067676],"category_scores_gemma":[0.08563324,0.0012679942,0.008338778,0.010579165,0.0011032253,0.0039874823,0.0021969436,0.0026713745,0.0009647277],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001789028,0.00008155131,0.0013814146,0.6046237,0.0045492025,0.00043041274,0.0007889287,0.010759981,0.00025599138,0.025964392,0.01489523,0.33609036],"study_design_scores_gemma":[0.000067738496,0.00020823181,0.001578318,0.7797934,0.011224858,0.00048387423,0.0005592993,0.0040919953,0.0003109093,0.02182245,0.17975032,0.00010855015],"about_ca_topic_score_codex":0.012146998,"about_ca_topic_score_gemma":0.012717312,"teacher_disagreement_score":0.017714497,"about_ca_system_score_codex":0.005514156,"about_ca_system_score_gemma":0.013337843,"threshold_uncertainty_score":0.093684375},"labels":[],"label_agreement":null},{"id":"W4409210105","doi":"10.1016/j.lungcan.2025.108530","title":"Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fonds de Recherche du Québec - Santé; Québec Consortium for Drug Discovery; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"Medicine; Adenocarcinoma; Oncology; Lung; Internal medicine; Adenocarcinoma of the lung; General surgery; Cancer","score_opus":0.011483084744082344,"score_gpt":0.29671027015768725,"score_spread":0.2852271854136049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409210105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900204,0.00028959173,0.00011734591,0.0001236723,0.0000024931246,0.000024580271,0.007769635,0.0000331862,0.0016190746],"genre_scores_gemma":[0.9910788,0.00028978992,0.00017820761,0.00007970287,0.0000055556334,0.000021511558,0.007400645,0.000018895522,0.00092702534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983292,0.0002903039,0.0001098975,0.00024591808,0.00074719964,0.00027755255],"domain_scores_gemma":[0.9973326,0.00034362957,0.000568132,0.0002092937,0.001153048,0.00039330055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001537773,0.00024069725,0.00036133558,0.0014801867,0.0005244171,0.0007294637,0.0006303801,0.0004592162,0.0007033692],"category_scores_gemma":[0.0030317483,0.00016493203,0.0005690327,0.001231428,0.0004950145,0.0002780715,0.0009352954,0.00022102786,0.0005410727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002706655,0.000023680255,0.9933878,0.00003533416,0.00003825612,0.000095237876,0.00037331204,0.00009891364,0.00030867197,0.000023856584,0.0006292751,0.004715058],"study_design_scores_gemma":[0.000006068285,0.00006738894,0.99853575,0.000009381165,0.00001531314,0.000114994546,0.0003151901,0.000075863725,0.00009549561,0.0000063158213,0.00075199053,0.0000062112895],"about_ca_topic_score_codex":0.42382163,"about_ca_topic_score_gemma":0.45935968,"teacher_disagreement_score":0.42382163,"about_ca_system_score_codex":0.0025456415,"about_ca_system_score_gemma":0.0024515046,"threshold_uncertainty_score":0.8427094},"labels":[],"label_agreement":null},{"id":"W4409251436","doi":"10.1016/j.lungcan.2025.108535","title":"Tumour dimension is a prognostic factor in thymic epithelial tumours: An update analysis from the ESTS thymic database: Tumour dimension in thymic tumours","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Dimension (graph theory); Thymic carcinoma; Pathology; Thymoma; Thymus Neoplasm; Oncology","score_opus":0.01155893071936104,"score_gpt":0.3063515068251497,"score_spread":0.2947925761057887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409251436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89366996,0.02700307,0.0011215936,0.0004251766,0.00008994291,0.0000472779,0.07559265,0.000046991518,0.0020033936],"genre_scores_gemma":[0.909045,0.0085563855,0.0012679283,0.00020907601,0.00013961043,0.000069351845,0.07992724,0.00005695931,0.00072847586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993717,0.00008782995,0.00017387162,0.00013380364,0.00017593292,0.000056863348],"domain_scores_gemma":[0.99631006,0.001382564,0.00097092433,0.0002919567,0.0007861544,0.0002583891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010011848,0.00024969157,0.0008868906,0.0019433905,0.00019410781,0.0012618924,0.0004474137,0.00030524822,0.0015767451],"category_scores_gemma":[0.0048724273,0.00014297139,0.00097256666,0.0035329387,0.00017338403,0.00079627376,0.0009890015,0.0003608645,0.00050043175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092843745,0.000017965773,0.96007234,0.0007677842,0.00092461804,0.00015245996,0.000164434,0.00030639797,0.0005273689,0.000100568264,0.004369374,0.031668205],"study_design_scores_gemma":[0.00004253743,0.000053009415,0.99177647,0.00018795638,0.0007402613,0.0008616714,0.00015358017,0.00029744706,0.00014990693,0.00007833514,0.0056428635,0.000015994903],"about_ca_topic_score_codex":0.0039124815,"about_ca_topic_score_gemma":0.008527123,"teacher_disagreement_score":0.0039124815,"about_ca_system_score_codex":0.00032387034,"about_ca_system_score_gemma":0.0005735311,"threshold_uncertainty_score":0.0077794194},"labels":[],"label_agreement":null},{"id":"W4409595460","doi":"10.1016/j.lungcan.2025.108551","title":"Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.; AstraZeneca; LUNGevity Foundation","keywords":"Medicine; Afatinib; Osimertinib; Oncology; Lung cancer; Internal medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.021994936969514413,"score_gpt":0.38232338040072067,"score_spread":0.36032844343120624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409595460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863833,0.00056295947,0.00010149372,0.000039199458,0.0000049114155,0.000018897337,0.000471444,0.0000052471155,0.000157524],"genre_scores_gemma":[0.99908805,0.00013965134,0.00010292316,0.000033174467,0.000012881816,0.000018046538,0.00051717466,0.0000031758123,0.00008487675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980324,0.0008316233,0.00023689715,0.0004130827,0.0002335222,0.00025243484],"domain_scores_gemma":[0.9951309,0.0013111026,0.0025696326,0.00025812956,0.00019720527,0.0005331348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037318678,0.0004895507,0.0009755354,0.0010138995,0.00030383887,0.0011425643,0.0006458619,0.0006024434,0.0013793829],"category_scores_gemma":[0.0037824735,0.00023041443,0.0026598955,0.0010795051,0.00042421182,0.00080034474,0.0008156453,0.0008063948,0.00018274973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065694794,0.0009905921,0.8901057,0.00035738695,0.0066726822,0.00026888936,0.00023483227,0.004645356,0.0022310459,0.000113598086,0.00086024404,0.027824873],"study_design_scores_gemma":[0.0023482316,0.021612741,0.9575483,0.000078408935,0.0051042745,0.0011213385,0.00033528803,0.009017364,0.001440055,0.00015705622,0.001168013,0.000068978945],"about_ca_topic_score_codex":0.0020407457,"about_ca_topic_score_gemma":0.003623341,"teacher_disagreement_score":0.0037318678,"about_ca_system_score_codex":0.0015808549,"about_ca_system_score_gemma":0.00063679507,"threshold_uncertainty_score":0.01973623},"labels":[],"label_agreement":null},{"id":"W4410255805","doi":"10.1016/j.lungcan.2025.108579","title":"Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Exon; Lung cancer; Cancer research; Oncology; Epidermal growth factor; Receptor; Mutation; Internal medicine; Gene; Genetics; Biology","score_opus":0.006628700707250518,"score_gpt":0.31542100738779666,"score_spread":0.30879230668054614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410255805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999038,0.00032183004,0.000049186157,0.000010604011,0.0000032691867,0.000041300093,0.00019881582,0.000004525741,0.00033258574],"genre_scores_gemma":[0.9993161,0.00009550965,0.000059522114,0.000016800434,0.0000062631884,0.0000392319,0.0002681277,0.000001672644,0.000196757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995158,0.00014442137,0.00004128723,0.00012669811,0.00010951348,0.000062252446],"domain_scores_gemma":[0.99909925,0.00020360424,0.00044585063,0.000051084102,0.0000916767,0.00010853209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009544266,0.00022661644,0.0004270544,0.00038229336,0.00035930632,0.00039660127,0.0002675369,0.00033855587,0.0014569021],"category_scores_gemma":[0.0015228884,0.00018292284,0.00047201794,0.00032112838,0.00019161466,0.00031215657,0.000290426,0.0005119431,0.00022854371],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018987855,0.00095576537,0.94344985,0.00025714806,0.00043127776,0.0003898394,0.0002873779,0.0002651264,0.0037752925,0.000044991764,0.00065124105,0.030504365],"study_design_scores_gemma":[0.0008920818,0.008232198,0.9855166,0.000045028068,0.00042690488,0.0012195754,0.00014727037,0.00079115585,0.0013278937,0.00008820751,0.0012971174,0.000015830627],"about_ca_topic_score_codex":0.0016808602,"about_ca_topic_score_gemma":0.0035455632,"teacher_disagreement_score":0.0016808602,"about_ca_system_score_codex":0.00047606206,"about_ca_system_score_gemma":0.00043007717,"threshold_uncertainty_score":0.0050475},"labels":[],"label_agreement":null},{"id":"W4410349213","doi":"10.1016/j.lungcan.2025.108583","title":"Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; AstraZeneca (Canada); Institut universitaire de cardiologie et de pneumologie de Québec; Dalhousie University; Université Laval; Queen Elizabeth II Health Sciences Centre; Université de Montréal; University of Calgary; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Ottawa Hospital","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Oncology; Internal medicine; Overall survival; Relevance (law); Cancer; Immunotherapy; Nivolumab","score_opus":0.008585620769715262,"score_gpt":0.2952468966671313,"score_spread":0.286661275897416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410349213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337876,0.0004032233,0.00004268448,0.0003316334,0.000009372593,0.00002396347,0.0048680706,0.000006342709,0.00093604816],"genre_scores_gemma":[0.99722326,0.00019639061,0.00006027285,0.000101812584,0.000008746157,0.000010409881,0.0020741103,0.00000310868,0.0003219017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993,0.00006102861,0.000040104584,0.00014820814,0.00015309092,0.00029748605],"domain_scores_gemma":[0.99862945,0.000093956325,0.00036837137,0.000066030545,0.0003999137,0.0004424387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039395245,0.0003867851,0.00041352576,0.00059591973,0.0012172074,0.0011709493,0.0009889446,0.00059170014,0.0014840651],"category_scores_gemma":[0.0017923205,0.000276386,0.0007608098,0.0023184316,0.00072883937,0.00048960646,0.0007184723,0.00090969977,0.00020805739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044836564,0.000043127515,0.9959269,0.000024379806,0.00011097668,0.00006041995,0.00015840183,0.00015894766,0.00013270888,0.00005789787,0.00073729694,0.0021405967],"study_design_scores_gemma":[0.00004978363,0.0000659726,0.99788433,0.000015806596,0.00010090376,0.00007870288,0.00061196,0.00032537078,0.00005269524,0.00003158892,0.0007689846,0.000013907936],"about_ca_topic_score_codex":0.9654168,"about_ca_topic_score_gemma":0.97743475,"teacher_disagreement_score":0.03458321,"about_ca_system_score_codex":0.024831755,"about_ca_system_score_gemma":0.020854693,"threshold_uncertainty_score":0.18016785},"labels":[],"label_agreement":null},{"id":"W4410764962","doi":"10.1016/j.lungcan.2025.108596","title":"Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"KRAS; Medicine; Mutant; Adenocarcinoma; Mutation; Cancer research; Lung cancer; Oncology; Internal medicine; Cancer; Genetics; Gene; Biology; Colorectal cancer","score_opus":0.01598881384185044,"score_gpt":0.38761122630906397,"score_spread":0.3716224124672135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410764962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987458,0.0002562002,0.00005931372,0.000032588887,0.000007660406,0.0000038098797,0.00029291312,0.0000035155406,0.00059827324],"genre_scores_gemma":[0.99937856,0.000053770236,0.000018455215,0.000011698584,0.000009939354,0.0000030005533,0.00031536678,0.0000018809585,0.00020734477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997309,0.0000316065,0.000030658943,0.0000807647,0.00003356742,0.00009253442],"domain_scores_gemma":[0.9994363,0.000074171134,0.00020668725,0.000041660947,0.000048450576,0.00019257783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031279292,0.00022582013,0.00031590066,0.0006810601,0.00037553112,0.000644452,0.00030258976,0.00047588017,0.0029807265],"category_scores_gemma":[0.0009752059,0.00015793696,0.0005380684,0.0005871055,0.00030883704,0.00052515464,0.00048537902,0.00042755745,0.00039257715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005437757,0.000027709204,0.9963521,0.0000090675485,0.000053825224,0.00025880744,0.00003726107,0.00006396562,0.0009477238,0.000045845627,0.00009952256,0.0015603538],"study_design_scores_gemma":[0.000007833128,0.00015806165,0.9974152,0.000004823954,0.000042394295,0.0012759761,0.0003432306,0.0002635772,0.00010221416,0.00010828499,0.0002726309,0.0000056912863],"about_ca_topic_score_codex":0.0016982356,"about_ca_topic_score_gemma":0.0033887282,"teacher_disagreement_score":0.0029807265,"about_ca_system_score_codex":0.00032675834,"about_ca_system_score_gemma":0.00026688748,"threshold_uncertainty_score":0.009971559},"labels":[],"label_agreement":null},{"id":"W4411176534","doi":"10.1016/j.lungcan.2025.108621","title":"Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Meta-analysis; non-small cell lung cancer (NSCLC); Internal medicine; Cancer; PD-L1; Immune system; Immunotherapy; Immunology; A549 cell","score_opus":0.07116806147672569,"score_gpt":0.35294685240541346,"score_spread":0.28177879092868774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411176534","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38397846,0.58789396,0.017147258,0.0008158631,0.0018123316,0.00040990775,0.0055566295,0.00042903284,0.0019566424],"genre_scores_gemma":[0.9775063,0.01693647,0.0025832618,0.00049953966,0.00020700811,0.00019501995,0.0013796488,0.00010150661,0.00059139595],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98688865,0.008005573,0.0014650696,0.002532802,0.0006084887,0.0004994925],"domain_scores_gemma":[0.98650837,0.009570441,0.0013816091,0.0016826671,0.00053760497,0.00031936084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017980509,0.003211385,0.011574346,0.0019224178,0.0006338508,0.002616272,0.0021380547,0.002481546,0.0027091638],"category_scores_gemma":[0.019622367,0.002290077,0.05219412,0.002624913,0.0008036531,0.0019108979,0.0015193549,0.0036917638,0.00039900097],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019149361,0.000029454786,0.016805843,0.0057180147,0.95246786,0.00008392738,0.00003781839,0.0016797261,0.0004871349,0.00011592796,0.0002491334,0.003175869],"study_design_scores_gemma":[0.0018039447,0.0005713461,0.0086900825,0.00025994805,0.9866556,0.000058133446,0.000030143678,0.0009422758,0.00015598602,0.00023066434,0.00057982013,0.000022106988],"about_ca_topic_score_codex":0.0059118145,"about_ca_topic_score_gemma":0.007664754,"teacher_disagreement_score":0.017980509,"about_ca_system_score_codex":0.0010847873,"about_ca_system_score_gemma":0.0008664052,"threshold_uncertainty_score":0.095091105},"labels":[],"label_agreement":null},{"id":"W4411682439","doi":"10.1016/j.lungcan.2025.108644","title":"Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de recherche du Québec","keywords":"Medicine; Lung cancer; SMARCA4; Oncology; Adenocarcinoma; Lung; Internal medicine; Cancer; Pathology; Epigenetics","score_opus":0.008851246903555158,"score_gpt":0.3533905978112096,"score_spread":0.3445393509076544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411682439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926595,0.0023244186,0.0010734767,0.00012711644,0.00002250725,0.000018824425,0.00030589857,0.000087912624,0.0033803484],"genre_scores_gemma":[0.99890137,0.00021798852,0.00028852,0.000021457136,0.000017278264,0.000003391478,0.00013838841,0.000008432196,0.00040324958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996567,0.000052078827,0.000037666978,0.000081470775,0.00008350499,0.000088541434],"domain_scores_gemma":[0.99909973,0.00019886604,0.00024781586,0.00017698343,0.000119659606,0.00015688196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029373498,0.0003035968,0.00032327833,0.0013244711,0.0003689716,0.00062759046,0.00036369442,0.00072929094,0.0037050874],"category_scores_gemma":[0.0013939701,0.00020229506,0.00023007854,0.00075968,0.0003868081,0.0002876085,0.00037586456,0.00040976744,0.0008955691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014378731,0.000076488446,0.63684124,0.00017025971,0.00010927882,0.056053463,0.0002631916,0.00025385452,0.27500856,0.00071981817,0.0005224694,0.028543456],"study_design_scores_gemma":[0.00003292435,0.00036242875,0.70239496,0.000041249466,0.0002060484,0.23308633,0.00042299315,0.0014257422,0.051813778,0.0007589294,0.009432373,0.00002223286],"about_ca_topic_score_codex":0.0006077871,"about_ca_topic_score_gemma":0.00068213616,"teacher_disagreement_score":0.0037050874,"about_ca_system_score_codex":0.00025777184,"about_ca_system_score_gemma":0.00023142237,"threshold_uncertainty_score":0.012394726},"labels":[],"label_agreement":null},{"id":"W4412434154","doi":"10.1016/j.lungcan.2025.108662","title":"Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Canadian Patient Safety Institute; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Intensive care medicine","score_opus":0.029684763254258697,"score_gpt":0.4571309382903152,"score_spread":0.42744617503605653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412434154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010317681,0.9936528,0.00041846427,0.0037783887,0.0005561602,0.000034595385,0.00008498221,0.00003244971,0.0013389445],"genre_scores_gemma":[0.0008669586,0.9908352,0.0017645714,0.004146605,0.0006614181,0.000081355065,0.00014813662,0.0000069464245,0.0014888032],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942684,0.00017350685,0.0001435157,0.00006251628,0.00015219786,0.00004150589],"domain_scores_gemma":[0.99916995,0.00044313268,0.00016140344,0.000009894177,0.0001543201,0.00006132515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011579891,0.001166379,0.0017409191,0.0017263102,0.00034545898,0.0016108558,0.00087522704,0.0020342215,0.0058959965],"category_scores_gemma":[0.0022768506,0.0004038448,0.001434357,0.0010575046,0.00024016152,0.0023724493,0.0010090586,0.0030519133,0.0023844752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010527946,0.00008126534,0.0002964729,0.024007164,0.00019245919,0.0001762901,0.00010125399,0.0003031628,0.0003160386,0.001589355,0.14423728,0.828594],"study_design_scores_gemma":[0.00015057594,0.00012953326,0.0012773756,0.03644536,0.00042777337,0.001271917,0.0001734673,0.00022546406,0.00012124598,0.0023501827,0.9573866,0.000040553026],"about_ca_topic_score_codex":0.0018329638,"about_ca_topic_score_gemma":0.0076080146,"teacher_disagreement_score":0.0058959965,"about_ca_system_score_codex":0.0010484268,"about_ca_system_score_gemma":0.0022983395,"threshold_uncertainty_score":0.019724071},"labels":[],"label_agreement":null},{"id":"W4412653243","doi":"10.1016/j.lungcan.2025.108672","title":"Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study)","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Society of Thoracic Surgeons","keywords":"Medicine; Oncology; Adenocarcinoma; Internal medicine; Adjuvant; Lung; Multicenter study; Cancer; Randomized controlled trial","score_opus":0.018883263490755635,"score_gpt":0.3849086370658569,"score_spread":0.36602537357510123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412653243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988662,0.00085335586,0.00005244348,0.000028127568,0.000006750211,0.000032299664,0.000081629,0.0000016619758,0.000077540666],"genre_scores_gemma":[0.99877995,0.0004824264,0.00013316992,0.00008398906,0.000048938786,0.000035706107,0.00035662943,0.0000020007844,0.00007718722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940836,0.00023423205,0.0000748882,0.00015075711,0.00006210807,0.00006964894],"domain_scores_gemma":[0.99906296,0.00010561649,0.00040365726,0.00012443027,0.00006399943,0.00023947649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021813575,0.000566729,0.0008381942,0.0003747697,0.0003085795,0.00046006287,0.0003900461,0.00049276,0.0005332151],"category_scores_gemma":[0.0011044161,0.00038917494,0.0013060524,0.00069280015,0.00032539768,0.0005118225,0.00045929977,0.00038565678,0.000117419666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027644644,0.0014802199,0.9435895,0.00023239682,0.0016554035,0.00024278059,0.00020217673,0.00027676983,0.005718617,0.00004678899,0.00039866794,0.018512158],"study_design_scores_gemma":[0.0051821517,0.016862022,0.9713368,0.00005587564,0.0027629405,0.00073776423,0.00016564075,0.0006398484,0.0008140117,0.000055518056,0.0013638999,0.000023547314],"about_ca_topic_score_codex":0.0010705766,"about_ca_topic_score_gemma":0.0019324631,"teacher_disagreement_score":0.0021813575,"about_ca_system_score_codex":0.00041251766,"about_ca_system_score_gemma":0.00059487554,"threshold_uncertainty_score":0.011536241},"labels":[],"label_agreement":null},{"id":"W4413050186","doi":"10.1016/j.lungcan.2025.108683","title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; KRAS; Chemotherapy; Adverse effect; Cancer; Population; Confidence interval","score_opus":0.006267195991771177,"score_gpt":0.3542312934856155,"score_spread":0.3479640974938443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413050186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866305,0.0073046694,0.00037381164,0.00052195723,0.00035259442,0.002145542,0.0010072365,0.000079105776,0.0015845073],"genre_scores_gemma":[0.989673,0.004237787,0.0006530346,0.00075474306,0.00025770432,0.0018311752,0.0012328499,0.000019034926,0.0013407383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99953604,0.00025111774,0.000032878153,0.00008379661,0.000039316277,0.00005684071],"domain_scores_gemma":[0.999271,0.00019276334,0.0002153439,0.00004341518,0.000049736176,0.00022765051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014144111,0.001206815,0.0023838151,0.00034064005,0.00029096752,0.0011152294,0.0005845936,0.0009199887,0.0041428884],"category_scores_gemma":[0.0011780917,0.00039267202,0.00213658,0.00039719837,0.0008022177,0.00068257574,0.000264695,0.0022618563,0.0005321603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97078115,0.00343666,0.001180348,0.0010359782,0.0018381602,0.000043312288,0.000047850797,0.0004488028,0.003160851,0.00007845446,0.0009329901,0.017015442],"study_design_scores_gemma":[0.92159194,0.07191684,0.0036995814,0.000055869277,0.001095485,0.000051118015,0.00002207016,0.0004066071,0.00042504587,0.00010743153,0.0006134469,0.00001469713],"about_ca_topic_score_codex":0.0008518456,"about_ca_topic_score_gemma":0.0038377012,"teacher_disagreement_score":0.0041428884,"about_ca_system_score_codex":0.000689741,"about_ca_system_score_gemma":0.0011462086,"threshold_uncertainty_score":0.013859332},"labels":[],"label_agreement":null},{"id":"W4413365072","doi":"10.1016/j.lungcan.2025.108717","title":"Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Mount Sinai Hospital; Public Health Ontario; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Juravinski Cancer Centre; William Osler Health System; University of Alberta; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Intensive care medicine","score_opus":0.023430912474930395,"score_gpt":0.39245221475810704,"score_spread":0.36902130228317664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413365072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033482058,0.9754106,0.00007276908,0.021672036,0.0018434655,0.0000028502934,0.000050351373,0.0000054682723,0.00090896874],"genre_scores_gemma":[0.0008543684,0.98143655,0.0002562185,0.01467116,0.0022134439,0.000009049399,0.0000657014,0.0000048830602,0.00048867014],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9980063,0.00048891624,0.0003665213,0.00023727192,0.00067084195,0.00023005718],"domain_scores_gemma":[0.99246275,0.0027065005,0.00062738964,0.000102726,0.003431014,0.00066958996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060269143,0.00083401793,0.0029111055,0.0030929896,0.0010220868,0.0038162644,0.002774511,0.005178865,0.0065189465],"category_scores_gemma":[0.011949934,0.00038903192,0.0015170447,0.004093591,0.0020258846,0.0036358414,0.0017563081,0.008320176,0.001539358],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019951131,0.00003050282,0.00028196632,0.025638647,0.00024724458,0.00027805532,0.00021191283,0.0004864794,0.00032043387,0.018447205,0.41097447,0.5428836],"study_design_scores_gemma":[0.000057152978,0.000026784992,0.00054163573,0.026926024,0.00023041813,0.0003128228,0.00020058326,0.000081277016,0.00005193887,0.004076317,0.96746683,0.000028235901],"about_ca_topic_score_codex":0.072463565,"about_ca_topic_score_gemma":0.16420087,"teacher_disagreement_score":0.9275364,"about_ca_system_score_codex":0.009759481,"about_ca_system_score_gemma":0.02654713,"threshold_uncertainty_score":0.14408356},"labels":[],"label_agreement":null},{"id":"W4414062917","doi":"10.1016/j.lungcan.2025.108748","title":"Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Lung cancer; Stage (stratigraphy); Mutation; Cancer; Lung","score_opus":0.010605903276625087,"score_gpt":0.32990914063305166,"score_spread":0.3193032373564266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414062917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983374,0.00036073595,0.000053139996,0.000041596566,0.000003422422,0.0000075236476,0.0009876186,0.000002375576,0.00020618078],"genre_scores_gemma":[0.998408,0.00011985179,0.00003822967,0.00003299884,0.0000055474056,0.000007447848,0.0013302903,0.0000031040381,0.000054470373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907815,0.00033158908,0.0000861517,0.00020508977,0.00014130933,0.00015784576],"domain_scores_gemma":[0.99821115,0.00034844075,0.00087912293,0.00014865429,0.0001789667,0.00023368788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012171767,0.00043194764,0.0006640282,0.001018418,0.0003599447,0.0009315228,0.0005375069,0.000658991,0.00065375544],"category_scores_gemma":[0.0025702543,0.00038102773,0.0011568216,0.002713301,0.0005699818,0.00090456655,0.000759553,0.00061616855,0.000141422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025684258,0.000027524287,0.9985808,0.000009999296,0.00022161726,0.00003341912,0.00002944702,0.00008849786,0.00007187706,0.0000073213496,0.000076951284,0.00059580535],"study_design_scores_gemma":[0.000024033292,0.00007987966,0.9992638,0.0000045933825,0.000113211536,0.00008765312,0.00013378882,0.00014436294,0.000030047231,0.000013400392,0.000100503144,0.000004781581],"about_ca_topic_score_codex":0.009208195,"about_ca_topic_score_gemma":0.013546071,"teacher_disagreement_score":0.009208195,"about_ca_system_score_codex":0.00068035105,"about_ca_system_score_gemma":0.000508234,"threshold_uncertainty_score":0.018309236},"labels":[],"label_agreement":null},{"id":"W4414598684","doi":"10.1016/j.lungcan.2025.108765","title":"Letter to the editor: What is the target nodule for robotic-assisted bronchoscopy?","year":2025,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Intuitive; Olympus","keywords":"Nodule (geology); Solitary pulmonary nodule; MEDLINE; Computed tomography","score_opus":0.01246357973591114,"score_gpt":0.3112382687688385,"score_spread":0.29877468903292737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414598684","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00096389966,0.0017127709,0.00013806742,0.964601,0.029220587,0.000015336758,0.00005508881,0.000026661828,0.0032666493],"genre_scores_gemma":[0.015178072,0.0031582545,0.0004450562,0.8498042,0.12282669,0.000040238796,0.000059955746,0.000045500787,0.008442011],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813396,0.00059020304,0.00023775964,0.00026921715,0.0004852082,0.0002837199],"domain_scores_gemma":[0.9956691,0.0021279135,0.0003300476,0.00011015124,0.0007942326,0.0009685441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016350121,0.0007330103,0.0013906903,0.0007147133,0.002474395,0.0027174074,0.0013916834,0.0336886,0.005335952],"category_scores_gemma":[0.016803127,0.00062760245,0.0010705659,0.0005377036,0.0016511328,0.0026799443,0.0008434283,0.023287809,0.0041759256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010822414,0.000049182585,0.001768634,0.00009368877,0.000029525638,0.017471699,0.00015143973,0.00020491239,0.00021942251,0.0015458671,0.97013545,0.008222016],"study_design_scores_gemma":[0.0002736599,0.00017623341,0.003860337,0.00074088713,0.00011197368,0.040475935,0.0011153436,0.0021267715,0.0005827501,0.011115285,0.9392639,0.00015688987],"about_ca_topic_score_codex":0.003441283,"about_ca_topic_score_gemma":0.0059316005,"teacher_disagreement_score":0.0336886,"about_ca_system_score_codex":0.0031247726,"about_ca_system_score_gemma":0.0034718784,"threshold_uncertainty_score":0.022671938},"labels":[],"label_agreement":null},{"id":"W4415817108","doi":"10.1016/j.lungcan.2025.108812","title":"Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Refractory (planetary science); Lung cancer; Platinum; Chemotherapy; Clinical trial","score_opus":0.15357206138554297,"score_gpt":0.4720203776983185,"score_spread":0.31844831631277554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415817108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005020957,0.9926878,0.00071259047,0.00021632598,0.00023864013,0.0002618483,0.00052361994,0.000037004527,0.0003011968],"genre_scores_gemma":[0.25178307,0.740124,0.003518721,0.0017840745,0.0003719421,0.000868306,0.0008686352,0.00006646428,0.00061478117],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.986421,0.008507636,0.0027163073,0.001078154,0.00091700075,0.00035994512],"domain_scores_gemma":[0.98172504,0.014119007,0.0023686797,0.0006444688,0.0008795824,0.00026314473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013783711,0.0030104264,0.01827757,0.004013586,0.00062614796,0.0032255368,0.0021727402,0.0022520414,0.0055775205],"category_scores_gemma":[0.04053715,0.001487824,0.031630296,0.0055898214,0.00092779857,0.0021225854,0.0023085624,0.0029661846,0.00043429027],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002286468,0.00001824138,0.001933261,0.2416345,0.7456156,0.000074687225,0.000055168308,0.00031633506,0.00015871323,0.00011192715,0.0005764096,0.0072186287],"study_design_scores_gemma":[0.0013598214,0.00013658013,0.001929037,0.012920447,0.98200274,0.000050569844,0.00003342673,0.00013563245,0.000050148894,0.00019411839,0.0011686095,0.000018914727],"about_ca_topic_score_codex":0.012408489,"about_ca_topic_score_gemma":0.033706024,"teacher_disagreement_score":0.01827757,"about_ca_system_score_codex":0.0030023241,"about_ca_system_score_gemma":0.003927361,"threshold_uncertainty_score":0.07289606},"labels":[],"label_agreement":null},{"id":"W4416017497","doi":"10.1016/j.lungcan.2025.108834","title":"MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Chemotherapy; Lung cancer; Disease; Cancer","score_opus":0.009759950064900491,"score_gpt":0.3044476110311205,"score_spread":0.29468766096622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416017497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097,0.00502533,0.00016654283,0.00060136634,0.0002489507,0.00014129617,0.0003862771,0.000041151387,0.0024189542],"genre_scores_gemma":[0.99706537,0.0011489685,0.00026087693,0.00028491588,0.000064621956,0.00008653437,0.0003036514,0.0000068791983,0.00077805767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99970347,0.00008753927,0.000020870437,0.00005952106,0.000026070911,0.0001024646],"domain_scores_gemma":[0.9997024,0.000081310565,0.00003914573,0.0000243711,0.000010014775,0.00014280129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007105106,0.00040452718,0.0015572038,0.00021901584,0.00027133874,0.000666798,0.00067426026,0.00062205235,0.0024876406],"category_scores_gemma":[0.00079462887,0.00018214434,0.00093145005,0.00025009183,0.00048946735,0.00069913565,0.00023475793,0.0018356275,0.0003111446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73642135,0.0069058556,0.008593152,0.0006446441,0.0015602629,0.0006620545,0.00019594702,0.00398394,0.013001335,0.0008083921,0.0049814265,0.22224157],"study_design_scores_gemma":[0.33300158,0.43455285,0.1576428,0.00045631448,0.0058468026,0.0033391656,0.00060162554,0.016516471,0.016466567,0.0030914557,0.028259449,0.00022495644],"about_ca_topic_score_codex":0.002593033,"about_ca_topic_score_gemma":0.010010721,"teacher_disagreement_score":0.002593033,"about_ca_system_score_codex":0.0014621635,"about_ca_system_score_gemma":0.0010183093,"threshold_uncertainty_score":0.010608792},"labels":[],"label_agreement":null},{"id":"W4416345611","doi":"10.1016/j.lungcan.2025.108840","title":"Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Western University; AstraZeneca (Canada); London Health Sciences Centre; Dalhousie University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Occupational Cancer Research Centre; CancerCare Manitoba","funders":"Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Immunotherapy; Small-cell carcinoma; Lung cancer; Overall survival; Stage (stratigraphy); Small Cell Lung Carcinoma","score_opus":0.028782662505763917,"score_gpt":0.3607694565274413,"score_spread":0.3319867940216774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416345611","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40251893,0.006019615,0.0001728008,0.0021303738,0.00012796037,0.00033962194,0.5782486,0.00005652214,0.010385574],"genre_scores_gemma":[0.77685887,0.0041088634,0.00061445055,0.0010462145,0.00008695096,0.00041630003,0.21361834,0.00002559166,0.003224315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979266,0.00015525531,0.0002611436,0.000358276,0.0007386846,0.0005600602],"domain_scores_gemma":[0.9939243,0.000317502,0.0011530617,0.0002530543,0.0032904877,0.0010616294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011680924,0.0006379645,0.0010188387,0.0031610844,0.0018985865,0.0013634071,0.0021876812,0.00089172,0.0056069302],"category_scores_gemma":[0.007582206,0.00044388397,0.0015902816,0.011655219,0.0004578372,0.0008053818,0.0012984526,0.0012396112,0.00056470087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007405208,0.00010464241,0.92249095,0.0006725869,0.0007520277,0.000089286295,0.00028403552,0.00042247435,0.00012210694,0.0006883425,0.066750735,0.00688225],"study_design_scores_gemma":[0.00011887233,0.00002577902,0.9930519,0.00018310046,0.00023270366,0.00005546015,0.0003298387,0.00025260105,0.000036031277,0.00007886808,0.0056088404,0.000026066631],"about_ca_topic_score_codex":0.9892833,"about_ca_topic_score_gemma":0.9944142,"teacher_disagreement_score":0.027070763,"about_ca_system_score_codex":0.027070763,"about_ca_system_score_gemma":0.053732615,"threshold_uncertainty_score":0.19641304},"labels":[],"label_agreement":null},{"id":"W4416398904","doi":"10.1016/j.lungcan.2025.108844","title":"Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Population; Lung; Survival analysis; Duration (music); Cell","score_opus":0.021190006092245132,"score_gpt":0.37352279612439293,"score_spread":0.3523327900321478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416398904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94422346,0.040151063,0.0030904624,0.0014194951,0.00023686688,0.00010869798,0.0018585909,0.00017190377,0.008739478],"genre_scores_gemma":[0.9796948,0.011511121,0.001083223,0.0002697349,0.00039383202,0.000047456015,0.0013158368,0.000026979833,0.0056570447],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999848,0.000035249173,0.000013630576,0.000038621565,0.000028516266,0.000035976776],"domain_scores_gemma":[0.9994267,0.00029468045,0.00007988819,0.000052574043,0.000096609605,0.000049487375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006995941,0.00017747452,0.00033319552,0.0003788921,0.0002049133,0.00055134477,0.00017937209,0.0003669901,0.0026356871],"category_scores_gemma":[0.0009529831,0.000116961055,0.0002487978,0.00044960593,0.00017725956,0.00050054,0.00021130714,0.00045209882,0.0006939354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021782149,0.001178555,0.19279653,0.0013454227,0.0002551889,0.003160553,0.0011044487,0.001639419,0.23844638,0.0022000936,0.012439306,0.52365196],"study_design_scores_gemma":[0.00027954127,0.021399464,0.68292946,0.00010978966,0.00084930996,0.014400028,0.0011624749,0.0040915646,0.15428731,0.0012971783,0.11908183,0.00011215051],"about_ca_topic_score_codex":0.0015342407,"about_ca_topic_score_gemma":0.001124602,"teacher_disagreement_score":0.0026356871,"about_ca_system_score_codex":0.00036058316,"about_ca_system_score_gemma":0.00033902904,"threshold_uncertainty_score":0.0088172555},"labels":[],"label_agreement":null},{"id":"W4416507772","doi":"10.1016/j.lungcan.2025.108850","title":"Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Activation Laboratories","funders":"Pfizer","keywords":"Lung cancer; Tyrosine-kinase inhibitor; Tyrosine kinase; MEDLINE; Personalized medicine; Cancer","score_opus":0.01354000152627287,"score_gpt":0.35769011416939617,"score_spread":0.3441501126431233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416507772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620986,0.000093291885,0.00032511735,0.0009977076,0.000057014808,0.00007924529,0.00022439014,0.0000049628447,0.0020084071],"genre_scores_gemma":[0.9979826,0.000063494685,0.00046431145,0.00047822684,0.000022602882,0.000121392324,0.00011178003,0.0000026829596,0.00075297087],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956006,0.0034453392,0.00014792869,0.0002555993,0.00018181176,0.00036876512],"domain_scores_gemma":[0.96593297,0.028644746,0.0024964903,0.0007058274,0.00031391816,0.0019060328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062902328,0.0004384088,0.0008101939,0.00024400097,0.00080650626,0.0023007768,0.00056714297,0.0017228664,0.011152709],"category_scores_gemma":[0.01880956,0.00045414793,0.0010847508,0.00031476247,0.0015912903,0.0011812965,0.00074733794,0.0022374569,0.00055253133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46506953,0.11359777,0.2493736,0.0006533886,0.0026655777,0.000887985,0.004848518,0.042908028,0.008108913,0.022772288,0.016576238,0.07253806],"study_design_scores_gemma":[0.09811966,0.1788453,0.34165853,0.0004087787,0.0035797085,0.0010314123,0.01920999,0.2887374,0.007062978,0.04332843,0.01700488,0.0010130858],"about_ca_topic_score_codex":0.0066782217,"about_ca_topic_score_gemma":0.007998918,"teacher_disagreement_score":0.011152709,"about_ca_system_score_codex":0.001524453,"about_ca_system_score_gemma":0.0016858716,"threshold_uncertainty_score":0.037309527},"labels":[],"label_agreement":null},{"id":"W4416637135","doi":"10.1183/13993003.congress-2025.oa2354","title":"Late Breaking Abstract - Risk prediction for lung cancer screening: a systematic review","year":2025,"lang":"","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Institute of Cancer Research; University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Guideline; Lung cancer; Calibration; Predictive modelling; Selection (genetic algorithm); Biomarker; Data extraction; Risk assessment; Systematic review","score_opus":0.01470574262890578,"score_gpt":0.3546844643734007,"score_spread":0.3399787217444949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416637135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008057469,0.9943245,0.0005058777,0.0012945981,0.00034027075,0.00031130374,0.0019408762,0.000030451532,0.00044632444],"genre_scores_gemma":[0.023077097,0.9703507,0.0015130867,0.0021469016,0.00047626867,0.0007131128,0.001422676,0.000022653418,0.00027743017],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9894721,0.0042898124,0.003365127,0.00085843797,0.0017855298,0.00022905383],"domain_scores_gemma":[0.9306199,0.055174943,0.008391445,0.0009087343,0.004508263,0.00039683082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012864625,0.0015415935,0.0063126204,0.007504619,0.00045699233,0.0030681605,0.0028409045,0.0019932438,0.011447257],"category_scores_gemma":[0.080552235,0.00081433903,0.008990814,0.0075431773,0.0006907794,0.0030155585,0.0014000189,0.0018676886,0.0010792715],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002090722,0.000016675183,0.002628045,0.9283357,0.012771129,0.000078283505,0.00009652969,0.00025791329,0.000057766967,0.0004115257,0.008332652,0.046804592],"study_design_scores_gemma":[0.00035309946,0.00013672345,0.007168618,0.90844035,0.057608046,0.00025715792,0.00013456716,0.00047560246,0.00010160666,0.0010352519,0.024243452,0.000045495082],"about_ca_topic_score_codex":0.008635479,"about_ca_topic_score_gemma":0.01823136,"teacher_disagreement_score":0.012864625,"about_ca_system_score_codex":0.0030293122,"about_ca_system_score_gemma":0.010300841,"threshold_uncertainty_score":0.068035424},"labels":[],"label_agreement":null},{"id":"W4416795272","doi":"10.1016/j.lungcan.2025.108858","title":"Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Lung cancer; Brain metastasis; Anaplastic lymphoma kinase; Tyrosine kinase; Tyrosine-kinase inhibitor; ALK inhibitor; ROS1","score_opus":0.009281889041171434,"score_gpt":0.3533143530854521,"score_spread":0.3440324640442807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416795272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372476,0.0017596569,0.00009636957,0.00032890713,0.00001621974,0.000006079683,0.0033915443,0.0000064695546,0.0006698765],"genre_scores_gemma":[0.9984511,0.00040961264,0.000031498595,0.000037388745,0.000016688447,0.000004341604,0.0009837493,0.0000015526034,0.000064022366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99947196,0.00015384224,0.000074527314,0.00011915838,0.00007665657,0.00010380045],"domain_scores_gemma":[0.99850816,0.00024429397,0.0008645261,0.00005178462,0.000122014775,0.0002092283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031533887,0.00015911447,0.00027398538,0.0005543372,0.00019791831,0.0006747613,0.0003266098,0.00053254166,0.0015534253],"category_scores_gemma":[0.0022285446,0.00018493421,0.00063300267,0.0010570046,0.0002856067,0.00064510305,0.00044610247,0.00070775126,0.00019008409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035829793,0.000026177724,0.9963791,0.00003651388,0.00017384482,0.0001099352,0.00003627291,0.00017933367,0.000114630784,0.000054568165,0.0004319788,0.002099383],"study_design_scores_gemma":[0.000009373833,0.000073567244,0.99836534,0.000013660101,0.000057635592,0.00041458406,0.00022012799,0.00040558047,0.000034052122,0.000057611524,0.0003409394,0.0000074700356],"about_ca_topic_score_codex":0.010072746,"about_ca_topic_score_gemma":0.015221657,"teacher_disagreement_score":0.010072746,"about_ca_system_score_codex":0.0006684249,"about_ca_system_score_gemma":0.00038161065,"threshold_uncertainty_score":0.020028234},"labels":[],"label_agreement":null},{"id":"W4417407062","doi":"10.1016/j.lungcan.2025.108875","title":"Corrigendum to “Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)” [Lung Cancer 210 (2025) 108840]","year":2025,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Western University; AstraZeneca (Canada); London Health Sciences Centre; Dalhousie University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Occupational Cancer Research Centre; CancerCare Manitoba","funders":"","keywords":"Cancer; Lung cancer; Stage (stratigraphy); Cell; Small-cell carcinoma","score_opus":0.03818360186285828,"score_gpt":0.3594488226258624,"score_spread":0.3212652207630041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417407062","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027801257,0.0024480768,0.00023862846,0.13446271,0.71536136,0.00028146573,0.11748488,0.0005841095,0.028860666],"genre_scores_gemma":[0.007595507,0.0073534395,0.0020321892,0.21336815,0.1355837,0.0013922387,0.13499527,0.000960773,0.4967188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993489,0.00070217135,0.0011652878,0.000698379,0.0030884123,0.00085678196],"domain_scores_gemma":[0.95095694,0.006541078,0.0016389446,0.0012596706,0.036889154,0.0027140572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045345277,0.0015299821,0.0027871246,0.005893306,0.0038276094,0.0041676983,0.0032396428,0.005930257,0.20436983],"category_scores_gemma":[0.05875568,0.0012499957,0.0025347483,0.006297545,0.0011366901,0.0012582048,0.0019615663,0.0051870155,0.07605082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000054752063,0.0000016637284,0.00004481492,0.000020385449,0.0000020026773,0.000006340408,0.0000013212145,0.0000042692704,0.0000011137844,0.000041009065,0.9993685,0.0005031537],"study_design_scores_gemma":[0.00023579368,0.000022193426,0.008339307,0.0007554394,0.00007723583,0.000071935574,0.00008453398,0.00019605223,0.00005522113,0.000476404,0.98961735,0.00006848885],"about_ca_topic_score_codex":0.6078252,"about_ca_topic_score_gemma":0.7318234,"teacher_disagreement_score":0.39217478,"about_ca_system_score_codex":0.015311112,"about_ca_system_score_gemma":0.028672816,"threshold_uncertainty_score":0.78896874},"labels":[],"label_agreement":null}]}